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Abstract 
 
Pseudomonas aeruginosa is a Gram-negative species of bacteria that is of high clinical 
importance and is on the ESKAPE list of pathogens, causing the most serious nosocomial 
infections World-wide. Current antibiotics in clinical use against P. aeruginosa include 
carbenicillin, cefepime, ceftazidime, and the fluoroquinoline ciprofloxacin. The multi-drug 
resistant (MDR) phenotype exhibits widespread resistance to β-lactams and antibiotics from 
multiple classes often need to be administered in conjunction with β-lactamase inhibitors.  
 
Penicillin binding proteins (PBPs) are essential for cell viability and are important antibiotic 
targets, with the Class A bifunctional PBPs synthesising the principle component of the 
bacterial cell wall, peptidoglycan. The focus of this project was to investigate the kinetics of 
transglycosylation and transpeptidation mechanisms with a view to improving our 
understanding of bacterial cell wall synthesis, maintenance and regeneration. 
 
In this project, the function of Class A PBPs 1A and 1B from Escherichia coli and P. 
aeruginosa, with particular focus on PBP1A has been investigated. Transglycosylation and 
transpeptidation have been probed from multiple angles using orthogonal assays and 
fluorescently-labelled and native lipid substrates, as well as Lipid II structural variants. P. 
aeruginosa PBP1A transglycosylase and transpeptidase activities are demonstrated 
continuously, and compared to the model organism equivalent, E. coli PBP1A. The continuous 
monitoring of activity gave insights into the possibility of two catalytic sites for 
transglycosylation: a donor and an acceptor site. Data was fitted to different kinetic models to 
elucidate the best fit for extracting meaningful kinetic parameters.  
 
The data acquired over the course of this project suggests that P. aeruginosa PBP1A and E. coli 
PBP1A exhibit similar functional behaviour to each other, with E. coli PBP1B showing distinct 
activity from PBP1A. PaPBP1B activity was not detected at a level required to kinetically 
characterise the enzyme and it is possible that this PBP has an as yet undetermined stimulatory 
cofactor. The assays developed and optimised in this thesis will pave the way for further in-
depth studies of P. aeruginosa PBP1A, which could be used to screen for putative inhibitor 
compounds and potentially identify certain characteristics required for antimicrobial efficacy. 
 
Over the past 4 years, major leaps in our knowledge of assay development, the transglycosylase 
and transpeptidase activities of Class A PBPs and substrate features and requirements for 
transglycosylase and transpeptidase donors and acceptors have thus far and will continue to 
unravel the unique and fascinating mechanistic intricacies of the bifunctionality of PBPs.  
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Chapter 1 Introduction 
 
1.1  Gram-Positive vs Gram-Negative Bacterial Cell Envelopes 
 
The exclusivity of the cell wall to bacteria has resulted in its exploitation as a valid 
target for antimicrobials, particularly β-lactams such as penicillin and cephalosporins. 
Antimicrobial inhibition of cell wall synthesis can be targeted to several steps in the 
pathway, by antibiotics including Fosfomycin, Cycloserine, Bacitracin, Vancomycin 
glycolipids and β-lactams. Increasing prevalence of antibiotic resistance has fuelled 
research into novel targets for antibacterial drugs. 
 
     1.1.1  The Gram-Positive Bacterial Cell Wall 
 
Gram-positive cells contain an inner cell membrane called the plasma membrane, which 
follows the most widely accepted model for membrane structure: the fluid mosaic 
model. The structure is dynamic and flexible, containing peripheral and integral 
membrane proteins. This membrane comprises of a phospholipid bilayer with 
hydrophilic surfaces and hydrophobic interior, with most bacterial membranes lacking 
sterols. It provides a selectively permeable barrier that keeps the cytoplasm separate 
from the external environment. The plasma membrane is the site for metabolic 
processes such as lipid synthesis, cell wall synthesis and harbours chemo-response 
receptor molecules (Silhavy et al., 2010). 
 
Surrounding the plasma membrane is a thick layer of the organic polymer 
peptidoglycan (Figure 1.1 a), a mesh-like structure that maintains structural integrity 
under osmotic stress and pressure. The cell wall of Gram-positive bacteria defines the 
cell shape and is made up of 90% peptidoglycan, as well as large amounts of teichoic 
acids that are not present in Gram-negative bacteria. As Gram-positive cells have no 
membrane outside of their thick peptidoglycan layer, they are more susceptible to 
antibiotics.  
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Figure 1.1  The Structural Architecture of (a) Gram-Positive and (b) Gram-Negative 
Bacterial Cell Envelopes (Adapted from Prescott, Harley & Klein’s Microbiology 7th Ed, 
2008). 
 
1.1.2  The Gram-Negative Bacterial Cell Wall 
 
This thesis is focused on the Gram-negative bacteria Escherichia coli and Pseudomonas 
aeruginosa. The Gram-negative bacterial cell envelope is thinner, less compact and 
more chemically complex than in Gram-positive cells. The cell envelope of Gram-
negatives is comprised of an outer membrane, a cell wall, and an inner (cytoplasmic) 
membrane (Figure 1.1 b). The outer membrane is a distinguishing feature of Gram-
negative bacteria, where the outer leaflet is composed of the glycolipid 
lipopolysaccharide and the inner leaflet contains phospholipids. The outer membrane 
serves as a semi-permeable molecular sieve preventing lysis-promoting molecules such 
as Penicillin G and lysozyme from entering the cell (Silhavy, et al., 2010). It comprises 
of a plasma membrane, a layer of peptidoglycan surrounding the plasma membrane and 
an outer cell wall. The peptidoglycan layer in Gram-negatives is extremely thin (~ one 
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layer thick) being only 5-10% of the cell wall, making them much more challenging for 
antibiotics to penetrate. Cross-linking in Gram-negative peptidoglycan is mostly by 
direct 3-4 cross-linking between adjacent peptide stems, whereas in Gram-positive 
peptidoglycan, peptides can be cross-linked by additional amino acids due to potential 
peptide stem side-branching (amidation). Modification of the peptide stem alters the 
efficacy of antibiotics, as well as transpeptidase specificity (Münch et al., 2015). The 
Gram-negative cell envelope has to have more advanced mechanisms to evade 
destruction by β-lactams as they have a thinner peptidoglycan layer compared to Gram-
positive bacteria. The β-lactam antibiotics penicillin and cephalosporins interfere with 
the cross-linking between peptides in peptidoglycan, compromising cell wall integrity. 
Gram-negative bacteria are known to have developed a higher resistance to antibiotics 
compared to Gram-positive bacteria, Pseudomonas spp. in particular (Miller, 2016). 
 
An outer membrane composed of lipids, lipoproteins and lipopolysaccharides (LPS) 
surround the thin layer of peptidoglycan, with no teichoic acids in Gram-negative cell 
walls. This outer membrane is more permeable than the plasma membrane as it is 
composed of large LPS molecules and porins, which form channels through which 
small molecules (600-700 Da) can pass (van den Berg, et al., 2015). LPS can be 
harmful and are classified as endotoxins, however, they are necessary as they prevent 
antibiotics from entering the periplasm in Gram-negative bacteria (Delcour, 2009). 
 
1.2  Targets for Antibiotics 
 
Antibiotics target major metabolic processes including folate synthesis, DNA and RNA 
synthesis, protein synthesis and cell wall biosynthesis (Walsh 2003), some of which are 
summarised in Table 1.1. 
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Table 1.1  A List of Antibiotics and their Mode of Action Against Metabolic Processes in 
Bacterial Cells. The first year of the commercial availability of each antibiotic class is shown 
and examples from each class are given, with the mode of action (not an exhausted list). 
Adapted from (Lewis, 2013). 
 
Year Antibiotic Class Examples Mode of Action 
1935 Sulphonamides 
Sulpadimethoxine, 
sulphamethoxazole 
Folate Synthesis: Blocks folate 
metabolism which is essential in 
DNA replication  
1940 β-lactams 
Penicillin, cephalosporins, 
carbapenems, monobactams 
Peptidoglycan biosynthesis: 
Mimics D-Ala-D-Ala 
peptidoglycan chain and inhibits 
cross-linking 
1944 Aminoglycosides Streptomycin 
Protein Synthesis: Bind to 30S 
ribosomal subunit and blocks 
translation  
1945 Tetracyclines Chlortetracycline 
Protein Synthesis: Bind to 30S 
ribosomal subunit and blocks 
translation  
1948 Phenicols Chloramphenicol 
Protein synthesis: Binds to 50S 
ribosomal subunit of ribosome and 
blocks translation.  
1949 Polymyxins Colistin 
Cell membrane: Permeabilises the 
cell membrane, allowing 
components to diffuse out  
1952 Macrolides Erythromycin A Protein Synthesis 
1958 Glycopeptides Vancomycin 
Peptidoglycan biosynthesis: Binds 
to the D-Ala-D-Ala peptide chain 
of peptidoglycan precursors  
1962 
Quinolones and 
Fluoroquiolones 
Ciprofloxacin. 
Cefotaxime, Nalidixic Acid 
DNA synthesis: Binds to DNA 
gyrase, blocking DNA replication  
1963 Rifamycins Rifampycin 
RNA Synthesis: Binds to RNA 
polymerase and prevents 
attachment to DNA  
1984 
β-lactamase 
inhibitors 
Clavulanic acid, 
Penicillanic acid sulfones 
Target β-lactamases 
1998 Streptogramins Quinupristin 
Protein synthesis: Binds to 50S 
ribosomal subunit of ribosome and 
blocks translation.  
2000 Oxazolidinones Linezolid Protein Translation 
2003 Lipopeptides 
Daptomycin (Cubicin) 
Cubist Pharmaceuticals 
Cell membrane: Binds to and 
depolarises the cell membrane  
2011 
Fidaxomicins; 
 
Fidaxomicin 
Binds to RNA polymerase and 
specifically targets C. difficile  
2012 Diarylquinolines; Bedaquiline Inhibits ATP-Synthase 
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     1.2.1  Protein Synthesis as an Antibiotic Target 
 
Protein synthesis in bacteria is unique from that in Eukaryotes, and is a complex and 
viable target for antibiotics. The ribosome is central to protein synthesis, made up of 
two subunits: a 30S and 50S that associate to form a 70S ribosome upon protein 
synthesis. Initiation, elongation and termination are all targeted by streptogramins, 
macrolides and phenicols, which target the 50S subunit. Aminoglycosides (E.g. 
Kanamycin A) target the 30S subunit and cause misreading of the mRNA, incorporating 
the incorrect amino acids. Tetracyclines bind to part of the rRNA in the 30S subunit and 
compete with tRNA for the acceptor binding site. Chloramphenicol and 
tetrahydropyrimidinones block translation, while Oxazolidinones (e.g. Linezolid) inhibit 
the ribosomal peptidyl transferase activity (Arenz & Wilson 2016). 
 
     1.2.2  DNA and RNA Synthesis 
 
The RNA polymerase initiation complex that precedes transcription can be disrupted by 
oxazolidinone drugs, and rifampicin also binds to the RNA polymerase initiation 
complex, inhibiting RNA synthesis. DNA gyrase is unique to bacteria/prokaryotes and 
is inhibited by the quinolone family. The fluoroquinolone ciprofloxacin A targets and 
inhibits the DNA synthesis enzymes Topoisomerase IV and DNA gyrase (Fournier et 
al., 2000). 
 
     1.2.3  Cell Wall Biosynthesis 
 
The exclusivity of the cell wall to bacteria has resulted in its exploitation as a valid 
target for antimicrobials, particularly β-lactams such as penicillin and cephalosporins. 
Antimicrobial inhibition of cell wall synthesis can be targeted to several steps in the 
pathway, by antibiotics including Fosfomycin, Cycloserine, Bacitracin, Vancomycin 
glycolipids and β-lactams. Increasing prevalence of antibiotic resistance has fuelled 
research into novel targets for antibacterial drugs, which is the focus of this body of 
research. A list of antimicrobial agents that target a variety of biosynthetic mechanisms 
in the bacterial cell wall are summarised in Table 1.2. 
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Table 1.2  A Summary of Antimicrobial Agents that Target the Bacterial Cell Wall 
 
Antimicrobial 
Agent 
Cell Wall Target 
                              Inhibitors of Muramyl-Pentapeptide Synthesis 
Fosfomycin The N-acetylmuramic acid component of the bacterial cell wall is derived 
from N-acetyl glucosamine by the addition of a lactic acid substituent 
derived from phospheenolpyruvate. The pyruvyl transferase enzyme 
involved is MurA and is inhibited by fosfomycin. 
 
D-Cycloserine The first three amino acids of the pentapeptide chain are added 
individually, but the terminal two residues D-alanyl-D-alanine are added as 
dipeptide. This dipeptide is produced by racemization of L-Ala to D-Ala 
and subsequent ligation by a D-ala-D-ala ligase (DDlb). Both of these 
reactions can be inhibited by D-cycloserine as it is a structural analogue of 
D-alanine. 
 
     Inhibitors of reactions occurring at or in the membrane 
Ramoplanin Ramoplanin is a lipoglycodepsipeptide active against Gram-positive 
bacteria. It inhibits the uptake of N-acetylglucosamine by growing cells 
with a resultant accumulation of UDP-MurNAc-pentapeptide. Inhibition is 
of N-acetyl-glucosaminyl-transferase (MurG) that adds N-acetyl 
glucosamine to the undecaprenyl-muramyl-pentapeptide. 
 
Bacitracin The lipid carrier involved in transporting the cell wall UDP-MurNAc 
pentapeptides across the membrane are C55 isoprenyl phosphates. In the 
transport process the lipid acquires an extra phosphate moiety and to 
continue in another cycle of transport it must be dephosphorylated. 
Bacitracin is a cyclic peptide that binds to the isoprenyl pyrophosphate and 
prevents dephosphorylation. 
 
                            Inhibitors of chain cross-linking and formation of the cell wall structure 
β-Lactams β-Lactams are based around a thiazolidine ring structure and mimic the D-
Ala-D-Ala stem peptide of peptidoglycan. To prevent the final cross-
linking reactions in peptidoglycan biosynthesis that gives the 
peptidoglycan sacculus its characteristic rigidity. β-Lactams specifically 
inhibit the transpeptidase domain of penicillin-binding proteins (PBPs) by 
acting as suicide substrates, which form inactive acyl-enzyme complexes. 
This results in the accumulation of a pool of inactivated PBPs incapable of 
catalysing transpeptidation with resulting cell lysis. 
 
Vancomycin Vancomycin targets lipid II, the substrate molecule for transglycosylase/ 
transpeptidase. The cup shaped vancomycin molecule binds with high 
affinity to the N-acyl-D-Ala-D-Ala termini of the uncross-linked 
pentapeptide by the use of five hydrogen bonds in its concave binding 
pocket. This steric hindrance prevents subsequent transglycosylase / 
transpeptidase activity. 
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1.3  Mechanisms of Antibiotic Resistance in Bacterial Pathogens 
 
Resistance mechanisms include the breakdown of β-lactams by β-lactamases, which are 
present in the periplasm of the Gram-negative cell envelope. Permeability of the outer 
membrane can be altered due to altered porins in the outer membrane, preventing access 
of β-lactams to the cell. Also, PBPs are showing increasing signs of reduced affinity to 
β-lactams in particular (Moya et al., 2009). 
 
     1.3.1  Reduced Antimicrobial Uptake and Active Export by Efflux Pumps  
 
For inhibition of DNA topoisomerases, RNA polymerase, protein synthesis and the 
cytoplasmic stage of peptidoglycan biosynthesis, navigation through the plasma 
membrane is required (two in the case of Gram-negatives) and then accumulation in the 
cytoplasm. The outer membrane in Gram-negatives provides a selective barrier to 
antimicrobials, excluding most hydrophobic molecules and macromolecules but the 
presence of hydrophilic porins allows slow absorption through the membrane (Kumar & 
Schweizer, 2005). Efflux pumps are found in all bacteria but most cannot respond to an 
antibiotic without specific mutations. Active efflux pumps and selective uptake work in 
synergy to reduce the ability of antimicrobials penetrating the cell wall. Gram-negative 
cells can reduce the permeability of their outer membrane and can also lower the 
antibiotic concentration near the targets using efflux proteins. P. aeruginosa spp does 
not contain the porin OprD, and also contains the active β-lactamase AmpC, which 
confers resistance to the β-lactam Imipenem (Ochs et al., 1999). P. aeruginosa 
absorption efficiency of drug molecules through outer membrane porins is 10-100 fold 
less than those in E. coli (Hancock and Speert, 2000). 
 
     1.3.2  Modification of the Antibiotic 
 
Two examples of antibiotic modification are enzymatic modification of 
aminoglycosides and hydrolysis of β-lactams by β-lactamases (Walsh, 2004). Many 
antibiotics have hydrolytically susceptible chemical bonds (e.g. esters and amides), 
whose integrity is essential to biological activity. Aminoglycosides inhibit translocation 
of the tRNA and functional groups can be irreversible attached to the antibiotic via N-
acetylation, O-phosphorylation or O-adenylation by the acetyl-, phosphoryl- and 
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adenyltranserases, respectively (Shaw, et al., 1993). Modification reduces their affinity 
to the ribosomal RNA. 
 
Amidase enzymes have evolved to cleave the β-lactam ring of penicillins and 
cephalosporins. Also, β-lactamases hydrolytically cleave the β-lactam ring using either 
an active site serine nucleophile or a nucleophilic water molecule (activated via a Zn2+ 
centre). The β-lactam ring mimics the terminal D-Ala-D-Ala of the peptide stem, acting 
as a pseudosubstrate. β-lactamases have a similar active site structure to the 
transpeptidases and they also hydrolyse the β-lactam ring, so the β-lactam can no longer 
act as a suicide substrate for the inhibition of PBPs (Philippon et al., 1989). The spread 
of β-lactamase genes has been increased by their integration in to mobile genetic 
elements – plasmids and transposons. Multi-drug resistance cassettes can confer 
resistance not only to β-lactams, but to aminoglycosides, macrolides, sulphonimides and 
chloramphenicol.  
 
     1.3.3  Modification of the Antibiotic Target 
 
Interaction of the β-lactam with a PBP involves a rapid transformation of a non-
covalent complex, blocking PBP function. Many PBPs have evolved with decreased 
antibiotic affinity including the transpeptidase S. aureus PBP2a, which confers 
resistance to Methicillin as its rate constant for transpeptidation is reduced 1000-fold 
(Lim & Strynadka, 2002). The glycopeptide antibiotic vancomycin has a concave 
binding pocket that is a heptapeptide core, forming five Hydrogen bonds with the D-
Ala-D-Ala terminus of the pentapeptide, stalling peptidoglycan synthesis. Resistance to 
vancomycin occurs in some strains including Vancomycin-Resistant Enterococci (VRE) 
due to the vanHAX and vanRE genes structurally altering the D-Ala-D-Ala target to D-
Ala-D-Lac (Walsh et al., 1996). Vancomycin binds to D-Ala-D-Lac with only four 
Hydrogen bonds, reducing affinity by 1000-fold and causing resistance. 
 
     1.3.4  The Emergence of Antimicrobial Resistant (AMR) Superbugs 
Penicillin was initially introduced in to clinical use in 1948 and the first resistant isolate 
was found in 1950. By the end of the 1950s, MDR strains of S. aureus were widespread, 
with MRSA being isolated in 1960 (Moellering 2012). In 2014, MRSA was responsible 
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for 80,000 infections, and 11,285 deaths in the USA (Centre for Disease Control, USA 
2014). The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter species) are the leading cause of nosocomial (hospital-acquired) infections 
throughout the world. Most of them are multidrug resistant isolates, which is one of the 
greatest challenges in clinical practice (Santajit & Indrawattana, 2016). Roughly 400 
deaths per year are attributed to these infections (Data from Centre of Disease Control, 
2013, USA). Some strains of MDR P. aeruginosa have been found to be resistant to 
nearly all antibiotics, including aminoglycosides, cephalosporins, fluoroquinolones, and 
carbapenems. 
1.4  Peptidoglycan as the Molecular Scaffold 
 
The bacterial cell is encompassed inside a cell wall that is essential for its viability. 
This sacculus is composed of multiple layers of a carbohydrate polymer peptidoglycan. 
Peptidoglycan (murein) is the principal constituent of the bacterial cell wall and is 
responsible for rigidity of the cell against internal osmotic pressure. The biosynthetic 
pathway of peptidoglycan is intricate with multiple complexes involved (Figure 1.2). 
Peptidoglycan a regular mesh-like structure of numerous glycan strands cross-linked for 
extra tensile strength (Barreteau, et al., 2008). During bacterial growth, the murein layer 
is continually being replenished at a very high rate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2  A Schematic of the Peptidoglycan Synthesis Pathway (Adapted from Pinho et 
al., 2013). Beginning with the Mur ligases in the cytoplasm, becoming associated with the 
periplasmic membrane, being ‘flipped’ across the membrane by FtsW / MurJ / RodA or a 
synergy of the two, before undergoing polymerisation by PBPs. 
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     1.4.1  Cytoplasmic Steps of Peptidoglycan Synthesis 
 
The biosynthesis of peptidoglycan is a multistep pathway of 11 steps, divided into 3 
main phases: (1) Formation of UDP-N-acetyl muramic acid (UDP MurNAc) (2) a 
pentapeptide chain is added sequentially to UDP MurNAc by four ATP-dependent 
amide bond ligases (Figure 1.3) (3) transport through the cytoplasmic membrane and 
incorporation into the growing peptidoglycan layer. 
 
 
 
 
 
Figure 1.3  The Cytoplasmic Steps of Peptidoglycan Biosynthesis. The four Mur ligases: 
Mur C, D E and F catalyse the sequential addition of the pentapeptide side chain to the D-lactyl 
group of UDP-MurNAc. 
 
Peptidoglycan is formed by polymerisation and cross-linking of a lipid II monomer into 
a mesh structure. Lipid II (undecaprenyl-P-P-MurNAc-[pentapeptide]-GlcNAc) is 
formed in the cytoplasmic phase and is ‘flipped’ to the other cytoplasmic surface via a 
‘flippase’ mechanism performed by either FtsW (Mohammadi et al. 2011), or MurJ 
(Sham et al., 2014), or a synergistic effort by both. The extracellular processing of the 
monomer Lipid II occurs, with the membrane-associated transglycosylation reaction, 
followed by transpeptidation. 
 
     1.4.2  Lipid-Linked Steps of Peptidoglycan Synthesis 
 
Peptidoglycan is comprised of alternating N-acetylglucosamine (NAG) and N-
acetylmuramic acid (NAM) residues linked by β1-β4 Carbon-bonds and serves as a 
protective layer unique to bacteria (Lovering, et al., 2007). Polymerisation of each 
glycan strand is catalysed by transglycosylation and cross-linking between glycan 
chains is catalysed by transpeptidation. In the case of bifunctional peptidoglycan 
synthases (more commonly referred to as Penicillin-Binding Proteins or PBPs), these 
two functions can be performed by one bifunctional PBP. N-acetylmuramic acid has a 
pentapeptide stem attached to its D-lactyl group that helps form the bridge between two 
glycan chains. The structure of the pentapeptide in Gram-negative bacteria is commonly 
MurD MurE MurF 
UDP-MurNAc !
!
UDP-MurNAc-L-Ala UDP-MurNAc-
Pentapeptide 
MurC 
L-Ala D-Glu 
! ! !
mDAP D-Ala-D-Ala 
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L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. The cross-linking bridge is formed between L-
alanyl-γ-D-glutamyl-meso-2,6-diaminopimelic acid of one glycan and the forth D-
alanine on the new glycan. The most common form of cross-linking extends between 
the residue at position 3 of one peptide stem (the acyl acceptor) to the D-Ala at the forth 
position of another peptide stem (the acyl donor), known as 3-4 cross-linkage (Lovering 
et al., 2012). mesoDAP contains both an L- and a D-stereocentre. In peptidoglycan, the 
L-stereocentre is incorporated into the peptide backbone, whereas the cross-linking side-
chain contains the D-stereocentre of mesoDAP. 
 
     1.4.3  The Mechanism of Transglycosylation 
 
Transglycosylation is the polymerisation of the monomer unit LII in to linear glycan 
strands, catalysed by the transglycosylase domain of Penicillin Binding Proteins (PBPs). 
The initial reaction in transglycosylation is the linking of two LII molecules together to 
form Lipid IV. After which, the successive addition of a single LII unit on to the 
growing end of the glycan chain forms an extended glycan chain (Figure 1.4). These 
two reactions are similar, differing only in the length of substrate used. The terms 
transglycosylation donor and acceptor differentiate between the growing chain (donor) 
and the incoming LII unit (acceptor). The transglycosylases are processive enzymes 
anchored to the membrane by a TM alpha-helix, which have a donor site where the 
growing glycan chain resides and an adjacent acceptor site for the incoming lipid II 
monomer.  As a result the enzyme active site is comparatively long and extended and 
must accommodate at least four sugar binding sites. Similar active site architecture is 
seen in lysozyme which also binds alternating N-acetyl-glucosamine and N-
acetylmuramic acid repeat units and there are structural similarities between the two 
(Lovering et al. 2012). The carrier lipid, undecaprenyl pyrophosphate is released with 
each addition of LII. Transglycosylation remains an important target mechanism for 
novel bacterial cell wall inhibitor design. 
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Figure 1.4  Transglycosylation: The Mechanism. The transglycosylase domain of Penicillin-
Binding Proteins (PBPs) catalyse the polymerisation of Lipid II in to elongated linear 
peptidoglycan polymers. The growing glycan chain attached to undecaprenyl pyrophosphate is 
the glycosyl donor substrate and is transferred to the 4-OH group of the GlcNAc unit of the 
incoming LII, which is the glycosyl acceptor substrate. β-1-4 C-linked N-acetylmuramic acid-N-
acetylglucosamine [(NAG-NAM)n] polymers are formed by transglycosylation.  
 
     1.4.4  Known Inhibitors of Peptidoglycan Transglycosylation 
 
The natural product moenomycin has been used for several decades in agriculture 
without reports for resistance (Butaye et al. 2003). The search for novel inhibitors 
targeting the same mechanism is required, with improved pharmacokinetic properties 
for human use. The structure, biosynthesis and chemical properties of moenomycin 
have been reviewed extensively (Ostash and Walker 2010). The latest advancements in 
inhibitors of transglycosylation include those based on moenomycin and its analogues, 
as well as analogues of lipid II. The lantibiotic mersacidin inhibits peptidoglycan 
synthesis at the level of transglycosylation (Brötz et al., 1997). 
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          1.4.4.1  Moenomycin: The ‘blueprint’ Transglycosylase Inhibitor and a  
                       Structural Tool 
 
The moenomycins are a family of glycolipid antibiotics naturally produced as a 
complex of related compounds by Streptomyces ghananensis with moenomycin A 
representing the major component with antimicrobial activity (Welzel 2005, Ostash & 
Walker 2010). The structure of moenomycin consists of a pentasaccharide of units B, C, 
D, E and F with a chromophore (unit A) and a C25 lipid chain connected to the F 
saccharide via a phosphoglycerate linker (Figure 1.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5  The Chemical Structure of Moenomycin A. The only known potent inhibitor for 
bacterial transglycosylases. The region highlighted in blue is the minimal inhibitory 
pharmacophore, which is often used as a scaffold for the design of new potential inhibitors.  
 
The C25 chain is required for antimicrobial action and the moenomycin structure 
resembles that of the Lipid IV product formed within the transglycosylase active site. 
Moenomycin has amphiphilic properties due to the hydrophilic nature of the A to F 
carbohydrate units, the phosphate group of the phosphoglycerate linker and the folded 
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hydrophobic domain formed by the lipid chain. Structure-activity relationships have 
been carried out on the moenomycin A molecule through selective degradation of the 
moenomycin structure and the synthesis of di- and trisaccharide analogues, resulting in 
an understanding of the minimal pharmacophore for moenomycin (Welzel et al., 1987, 
Yang et al., 2004, Ostash & Walker 2010). The degradation of moenomycin to chemical 
entities retaining the carbohydrate units C, E and F, inhibit transglycosylation and thus 
have antibacterial activity (Möller et al., 1993, El-Abadla et al., 1999). Degradation to 
retain the E and F carbohydrate units only still inhibits transglycosylase function but 
lacks antibacterial activity (Welzel et al., 1987). The C25 lipid chain is required to 
achieve full antibacterial activity of moenomycin, but is also the origin of its long half-
life and contributes to its poor bioavailability and incompatibility for human 
consumption (Ostash & Walker 2010). Decreasing the length of the lipid chain slowly 
reduces the inhibitory ability of moenomycin (El-Abadla et al., 1999), most likely due 
to loss of ability to anchor itself into the cytoplasmic membrane. Modifying or 
truncating the lipid chain of moenomycin improves pharmacokinetic properties but the 
loss of activity needs to be compensated by maintaining essential polar active-site 
contacts or by utilisation of other hydrophobic chemophores with acceptable properties.  
 
          1.4.4.2  The Binding of Moenomycin and Lipid II to Transglycosylases 
 
The two natural molecules known to bind to the transglycosylase domain of PBPs are 
moenomycin and lipid II. The structural differences between lipid II and moenomycin 
must be responsible for the inhibition of transglycosylase, as lipid is the natural 
substrate for transglycosylation and moenomycin is the most potent inhibitor. 
Understanding how these two molecules interact and bind to the transglycosylase 
domain is fundamental in pursuing structural analogues of these molecules for 
inhibition. The LII molecule has two phosphates, whereas moenomycin only has one 
phosphate. The acid group on the lipid chain of moenomycin binds to the cytoplasmic 
membrane and is thought to mimic the second phosphate group of the growing 
peptidoglycan strand (Kempin et al., 1995). 
 
Moenomycin A binds with high affinity to the transglycosylase domain of several Class 
A PBPs and is the most potent inhibitor of the transglycosylase function of PBPs with 
MICs in the region of 0.01-0.1 µg/mL (Welzel 2005). The mode of inhibition of 
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moenomycin is unique in that it directly (and reversibly) binds to the active site of the 
transglycosylase domain, preventing lipid II polymerisation.   Moenomycin first binds 
to the cytoplasmic membrane via its lipid chain, followed by selective binding to the 
sugar moiety to the donor site of the transglycosylase. The transglycosylase domain 
contains five motifs representative of the GT51 fold-family (Lairson et al., 2008) and are 
conserved among both mono- and bi-functional PBPs.  
 
Six residues in the transglycosylase domain have been identified as important in the 
interaction with moenomycin in Aquifex aeolicus PBP1A (Yuan et al., 2007, Yuan et 
al., 2008), and are likely to be conserved across other species. It is also thought that the 
C25 chain of moenomycin interacts with the transmembrane (TM) segment of E. coli 
PBP1B (Cheng et al., 2008), increasing the binding affinity 5-fold of moenomycin to 
the transglycosylase domain, highlighting the importance of the TM domain in 
transglycosylases for activity.  
 
The only structural information available at present for the interaction of lipid II with 
the transglycosylase domain is that derived from the X-ray crystal structure of S. aureus 
mono-functional glycosyltransferase with an analogue of Lipid II (Huang et al., 2012). 
Many inhibitors that bind to transglycosylases occupy the donor site, mimicking the 
elongating chain of polymerized lipid II (Lovering & Strynadka, 2008). Lovering and 
co-workers have proposed that moenomycin structurally mimics Lipid IV (Lovering, et 
al., 2007, Lovering & Strynadka, 2008), further supported in that Lipid IV and 
moenomycin are suggested to bind to the same site on the transglycosylase domain 
(Gampe et al., 2011) and that lipid IV may bind to E. coli PBP1B with a higher affinity 
than lipid II (Shih et al., 2011). 
 
          1.4.4.3  Moenomycin Analogues as Transglycosylase Inhibitors 
 
Finding that the moenomycin degradation products exhibit inhibitory activity against 
transglycosylases prompted a study in 1999 by Sofia et al, to develop a combinatorial 
library of 1300 analogues of the disaccharide core of moenomycin (Sofia et al., 1999). 
These disaccharide analogues explored modifications at C2 of the E ring and C3 of the 
F ring (the critical interaction points with the transglycosylase domain). Modifications 
included aromatic groups attached to the E and F rings and a lipid tail of 12 rather than 
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25 carbons. Three compounds showed particular promise TS30663, TS30153 and 
TS30888, with some being more active than the EF disaccharide (Table 1.3). These 
compounds were orders of magnitude less potent than the parent molecule 
moenomycin, but had IC50 values in the range of 10-15 µM (Goldman & Gange 2000). 
These putative inhibitors also exhibited activity against the moenomycin-resistant strain 
Entercoccus faecium, highlighting that simple degradation compounds show potency 
against clinically relevant pathogens. The IC50 values obtained are within a similar 
range to other cell wall inhibitors such as bacitracin, vancomycin and ramoplanin. 
These compounds showed differing activities against transglycosylases in different 
species, suggesting that they may target different subsets of the transglycosylases 
(Ostash & Walker 2005) as is also seen for β-lactams which show differing activities 
against PBPs in various species (Miller et al., 2004). 
 
A new member of the moenomycin group AC326-alpha was introduced in 2000 whose 
moenocinol chain is cyclic, giving a diumycinol chain. Branched chain lipids show 
more potent antibacterial activity than linear chained lipids. Putative inhibitors could be 
designed to mimic moenomycin and could exhibit antibacterial activity to cyclic lipid 
chains. Halliday et al., presented a class of compounds made by Alchemia in 2006, 
based on the disaccharide scaffold of Sofia et al., with a focus on maintaining the 
important transglycosylase binding regions. The hits had MIC values of 1-4 µg/mL, 
against a broad range of Gram-positive organisms (Sofia et al., 1999, Halliday et al., 
2006). One example compound from this class: ACL 19273, showed direct binding and 
inhibition of the transglycosylase domain, potentially binding to either the acceptor or 
donor site of the transglycosylase (Halliday et al. 2006). Inhibitors that bind to the 
transglycosylase acceptor site, which may be the case for these small disaccharides, are 
binding to the contrary site to where moenomycin binds. Determining whether 
inhibitors bind to the donor or acceptor site of the transglycosylase is important is 
elucidating their mode of action. 
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Table 1.3  A Summary of Analogues and Small Molecule inhibitors of Moenomycin and 
Lipid II, exhibiting inhibitory activity against the transglycosylase function in PBPs, with some 
compounds additionally showing modest antibacterial activity. !
Reference Compound Name 
 Moenomycin Analogue Inhibitors 
Sofia et al., 
1999 
 
 
 
 
TS30153 TS30663 
 
TS30888 
He et al., 
2000 
 
AC326-α 
Halliday et 
al., 2006 
 
ACL 19273 
Cheng et al., 
2010 
 
  
HTS-6 HTS-7 HTS-8 
Gampe et 
al., 2013 
 
Compound 10 
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 Lipid II Analogue Inhibitors 
Garneau et 
al., 2004 
 
Compound 5 
Cheng et al., 
2010 
 
Compound 24 
Huang et al., 
2012 
 
Analogue 3 
Huang et al., 
2012 
 
Compound 31 
Dumbre et 
al., 2012 
  
Compound 21 Compound 62 
Huang et al., 
2013 
 
 
Compound 19 Compound 20 
 
 
Compound 24 Compound 25 
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         1.4.4.4  Lipid II Analogues as Transglycosylase Inhibitors 
 
In the early 1990’s, efforts were focused on synthesizing transglycosylase inhibitors 
based on monosaccharide and disaccharide analogues of lipid II, but most were not very 
active (Hecker et al., 1990, Qiao & Vederas 1993, Brooks et al. 1995). A combination 
of mono- and disaccharide analogues of lipid II and moenomycin were synthesised by 
Garneau et al based on the active part of moenomycin and combining with structural 
features of lipid II (Garneau et al., 2004). A lipid II monosaccharide analogue, 
Compound 5, was designed to mimic the pyrophosphate of lipid II with a dicarboxylate 
group. Modest activity with just monosaccharide analogues was exhibited, with 28 % 
inhibition of transglycosylases at 100 µM (Garneau et al., 2004).  Clearly the potency of 
such compounds is weak and it may be that monosaccharide analogues do not have 
comparable complexity to moenomycin, to sufficiently inhibit transglycosylases 
(Derouaux et al., 2013). 
 
Lipid I and lipid II substrate analogues (both mono- and disaccharides) were 
synthesised by Dr. M. Terrak and co-workers (Terrak 2008, Dumbre, et al., 2012, 
Derouaux et al., 2013) to test the consequences of variations in the lipid chain length, 
the pyrophosphate and the length of the peptide stem. The disaccharide analogues were 
2-fold better inhibitors than their cognate monosaccharides and also as the length of the 
peptide stem increased from no peptide to L-Ala- D-Glu, to L-Ala- D-Glu- D-Lys, 
inhibition decreased. This was attributed to the presence of a peptide preventing high 
affinity binding between the GlcNAc and the transglycosylase. Analogues were tested 
to highlight important moieties for the future designing of substrate-based inhibitors 
with two hits: C16-phosphoglycerate-MurNAc-GlcNAc (Compound 21) and C16-
phosphoglycerate-MurNAc-(L-Ala- D-Glu)-GlcNAc (Compound 62). The most active 
being Compound 62, which showed both inhibitory activity against the transglycosylase 
as well as antibacterial ability.  
 
The role of the pentapeptide moiety in lipid II and its mode of interaction with the 
transglycosylase has been explored (Shih et al., 2012). Lipid II analogues with an 
assortment of peptide stems were synthesised to analyse their capabilities as 
transglycosylase substrates. Modifications include incorporating a fluorescent NBD 
label into position 3 of the peptide and incorporating a D-lactyl group at the hydroxyl 
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group of MurNAc. Surface Plasmon Resonance (SPR) binding studies were conducted 
to determine the binding affinity of these lipid II analogues to transglycosylase. The 
three main conclusions from this work were (1) the terminal D-Ala-D-Ala is not 
essential for substrate binding and does not significantly interact with the 
transglycosylase domain, (2) the fluorescent probe NBD on the ε-amino group of the 3rd 
position lysine does not affect binding affinity to transglycosylase and (3) the minimum 
structural requirement for the peptide moiety in lipid II as a transglycosylase substrate is 
D-lactyl-L-Ala. Further research has shown that only the D-lactyl in the MurNAc is 
required for the substrate binding to transglycosylase (Dumbre et al., 2012). 
 
          1.4.4.5  Prospects for New Transglycosylase Inhibitors 
 
Developing new drugs with antibacterial properties by inhibition of peptidoglycan 
transglycosylation is of current interest to both academia and the pharmaceutical 
industry. Currently most compounds discovered have greater potency against Gram-
positive bacteria than Gram-negatives, presumably due to easier access to the thicker 
peptidoglycan layer in Gram-positives. Progress on the development of transglycosylase 
inhibitors has been slow historically due to the complexity of the active site of the 
enzymes, lack of suitable assays for high throughput screening, provision of suitable 
substrates for such assays and the difficulties surrounding the reconstitution of activity 
of these membrane proteins. The availability of lipid II substrate from chemo-enzymatic 
and total chemical synthesis domains allows transglycosylases from various species to 
be studied along with a growing literature detailing molecular architecture interactions 
within the active site. Further understanding of substrate specificity will aid the design 
of future substrate analogues, common features of which are becoming apparent. 
 
The development of glycolipids and glycopeptides as putative transglycosylase 
inhibitors has shown that there are new prospects for the combinatorial biosynthesis of 
phosphoglycolipid antibiotics (Ostash et al., 2013) and there are new generation 
glycopeptides currently in clinical development that inhibit the transglycosylation 
process (Yim et al., 2014). In addition, research is on-going to determine the exact 
inhibitory mechanism of moenomycin on transglycosylases, with a drive towards 
finding novel inhibitory compounds with distinct structural features to moenomycin. 
Total synthesis of moenomycin A has been achieved (Taylor et al., 2006) and the 
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biosynthetic pathway of moenomycin variants can be theoretically generated which 
could help in the quest to design new compounds with better pharmacokinetics (Ostash 
et al., 2007).  
 
There is now the capability to synthesize structurally diverse substrates and to 
homogenate synthetic and biological compounds by either enzymatic modification of 
synthetic analogues or by chemical modification of biosynthetic intermediates. These 
capabilities enable the better comprehension of the role of lipid II in binding to the 
transglycosylase domain and help to optimise structures for the transglycosylase donor 
and acceptor sites. These sites have different requirements for lipid chain length, which 
is important for the processivity of the transglycosylase, with the donor site requiring a 
C20 lipid chain and the acceptor site tolerating shorter lipids (Perlstein et al., 2010), so 
there is a compromise between lipid chain length and antibiotic activity. Walker and 
coworkers have predicted that lipid II with four successive cis isoprene units in a 35-
carbon chain is the best transglycosylase substrate (Ye et al., 2001). Investigating the 
optimal substrate for transglycosylases such as lipid IV or longer as potential substrate 
inhibitors may be a worthwhile focus and could be fruitful for being able to closely 
mimic moenomycin, without the poor pharmacokinetics (Shih, et al., 2011). Despite the 
evolution of structurally diverse substrates, there is still more room to understand 
transglycosylase-substrate mimics.                                                       
 
There are now in the region of 15-20 structures of transglycosylase enzymes in the 
protein databank, with a small subset being below 2.5 Å resolution and thus reliable for 
structure based drug design efforts. Further knowledge of the catalytic mechanism and 
in-vivo regulation of transglycosylation activity may provide further insight into the 
chemistry of potential novel lead compounds required for effective chemotherapeutic 
intervention. With the growing awareness to the need for novel antimicrobials by both 
the public and policy-makers, the development of new approaches within academia and 
Pharma to design novel inhibitors is on the horizon. 
 
     1.4.5  The Mechanism of Transpeptidation 
 
Transpeptidation involves a donor substrate and an acceptor substrate, cross-linked to 
each other by the action of PBPs. The donor substrate is the incoming strand, and is 
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often a glycan chain polymer of multiple disaccharide subunits. The acceptor is an 
adjacent strand that forms a 3-4 cross-link with the donor strand, creating a mesh-like 
structure of high tensile strength. Transpeptidation occurs when the PBP recognises the 
D-alanyl-D-alanine dipeptide on the end of the pentapeptide stem, forming an acyl-
enzyme intermediate at the active site serine. The terminal D-alanine on the acceptor 
strand acts as a nucleophile and resolves the acyl-enzyme intermediate, releasing the 
terminal D-alanine and the PBP from the original donor strand. The cross-link is formed 
between the fourth D-alanine on the donor strand and the third mesoDAP residue on the 
acceptor strand (Figure 1.6). The acyl-enyme intermediate undergoes either aminolysis 
via a DD-transpeptidase to yield cross-linked peptidoglycan, or hydrolysis via the DD-
carboxypeptidase function of the enzyme, limiting cross-linking (Spratt, 2008) (DD-
carboxypeptidase function discussed in Section 1.4.6.1). 
 
Transpeptidation requires polymerised LII as its substrate and therefore the 
transglycosylase product is likely to have an influence on the transpeptidase active site. 
Certain HMW PBPs require simultaneous peptidoglycan synthesis or a pre-formed 
uncross-linked peptidoglycan polymer (Born et al., 2006). The level of cross-linking is 
lower in Gram-negative bacteria (25-50% cross-linked stem peptides), compared to 70-
90% in Gram-positive bacteria (Bugg, 1999). 
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Figure 1.6  A Schematic of the Transpeptidase Mechanism  The PBP is acylated and donates a proton from its active-site serine to the terminal D-alanine of the donor 
strand. An acyl-enzyme intermediate is formed and the terminal D-alanine is released from the donor. An acceptor strand deacylates the PBP, with the amine group on its 
third position mesoDAP residue acting as a nucleophile and donating a proton back to the active site serine of the PBP. The ester bond between the PBP and the donor strand 
is broken and the PBP is released, forming a 3-4 cross-link between residue 3 on the acceptor peptide stem (mesoDAP) and residue 4 on the donor peptide stem (D-alanine). !
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                  1.4.5.1  PBP Acylation 
 
As the PBP docks onto the donor strand, the position 4 D-alanine of the pentapeptide 
stem acylates the active site Serine. A proton is removed from this Serine and 
transferred to the amine group of the terminal D-Alanine on the donor strand. The 
peptide bond between the two D-alanines is broken and the terminal alanine is released, 
harbouring the proton donated from the PBP active-site serine. An acyl-enzyme 
intermediate is formed, linking the PBP to the penultimate D-alanine of the donor strand 
via an ester bond. Acylation occurs by nucleophilic attack of a serine residue onto the 
carbonyl carbon of the β-lactam ring or of the penultimate D-Ala of the pentapeptide 
substrate to form a covalent acyl-enzyme complex. The second order rate constant of 
acylation is widely used as a measure of the potency of an antibiotic. 
 
         1.4.5.2  PBP Deacylation 
 
For cross-linking to occur between two stem peptides, the terminal D-alanine of the 
acceptor peptide stem acts as a nucleophile. Its amine group attacks the acyl-enzyme 
ester bond, giving a proton back to the active-site serine in the PBP, releasing the 
complex, forming a peptide bond cross-link between the position 3 mesoDAP of the 
acceptor stem, and the position 4 alanine of the donor stem. The third amino acid in the 
peptide stem that contains the reactive amine for transpeptidation varies between 
bacterial species, but the overall mechanism is conserved. 
 
Deacylation occurs when an incoming amino group of a neighboring peptide, or a water 
molecule attacks the acyl-enzyme complex, breaking the acyl-enzyme bond and 
allowing release of the product. The kinetics of deacylation between PBP and β-lactam 
is a lot slower than deacylation between PBP and stem peptide (Nicola et al., 2010). !
DD-Transpeptidase enzymes belong to a group of enzymes called transferases because 
they transfer away the D-Ala from the terminal position of the pentapeptide: the PBP is 
transferred from the active site serine hydroxyl group and added to the amine leaving 
group. An acyl-enzyme intermediate is formed and the second substrate comes in and 
displaces the enzyme from the complex. Both of these steps are nucleophilic 
substitution (SN2) reactions. In the first step the -OH group of the active site serine 
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residue acts as the nucleophile and in the second step, the incoming substrate (D-DAP) 
is the nucleophile. The concentration of water is extremely high (55 M) compared to 
that of the acceptor (mM) and water is smaller and fits into the active site easier than the 
transpeptidase acceptor. However in the case of most transferases, they transfer the 
intermediate to the incoming second substrate rather than water because the active site 
has under-gone conformational change that closes the active site to water, and makes it 
more complementary to the substrate (”induced fit”). In DD-carboxypeptidation, water 
acts as the nucleophile rather than the D-DAP residue of the in-coming substrate 
(Section 1.4.6.1).  
 
The active site of transpeptidase domains contains an SxxK motif with a catalytic serine 
and base lysine, characteristic of the acyl-transferase superfamily of proteins (Goffin & 
Ghuysen, 1998). The first serine is the essential nucleophile and is spatially central in 
the catalytic active site, key to the acylation and deacylation steps (Figure 6.1). There 
are 3 conserved motifs in total with the other two being SxN or SxD, and KTG or KSG. 
The motifs occur at equivalent places and with roughly the same spacing along the 
polypeptide chains and they have spatial proximity to each other in the 3D structure 
(Goffin & Ghuysen, 2002). 
 
The discovery of antibiotics against class A HMW PBPs has been hampered by lack of 
mechanistic information about these enzymes. The mechanism of the reaction between 
a PBP enzyme and D-Ala-D-Ala in peptidoglycan are the same as the mechanism of the 
interaction between PBP and β-lactam antibiotics, as β-lactams mimic the D-Ala-D-Ala 
moiety (Section 1.4.7). The transpeptidase reaction of almost all PBPs is less stringent 
for the acceptor substrate and can use various D-amino acids (Pollock et al., 1972), 
allowing their incorporation (exchange) into peptidoglycan (Sauvage & Terrak, 2016). 
 
     1.4.6  Peptidoglycan Recycling and Maintenance 
 
Although transpeptidation is the final step in cell wall synthesis, the cell wall is 
dynamic and constantly being maintained, remodeled and regenerated to maintain 
integrity. Gram-negative bacteria have evolved an elaborate process for peptidoglycan 
recycling, initiated in the periplasm by lytic transglycosylases. Products of lysis 
(muropeptides) are transferred to the cytoplasm to continue recycling mechanisms. 
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Peptidoglycan recycling occurs during cell wall growth, maturation, maintenance and 
also in response to antibiotics. Lytic transglycosylases catalyse the fragmentation of the 
glycosidic bond between NAG and NAM residues. Upon transfer of muropeptides to the 
cytoplasm, it is reformed de novo via the peptidoglycan biosynthesis pathway, merging 
recycling, recovery and remodeling with biosynthesis.  
 
In Gram-negative pathogens, cell wall recycling has been linked to β-lactamase 
induction (Johnson et al., 2013). Muropeptides regulate β-lactamase induction, 
including AmpC β-lactamase and AmpG in P. aeruginosa specifically (Zhang et al., 
2010). Inhibitors of cell wall recycling could be combined with cell wall-targeting β-
lactams to overcome resistance, which could be necessary in AmpC β-lactamase hyper-
producing P. aeruginosa in cystic fibrosis (Mark et al., 2011). 
 
        1.4.6.1  The DD-Carboxypeptidase and DD-Endopeptidase Function of PBPs 
 
Transpeptidases and carboxypeptidases have similar mechanisms: transpeptidases 
contain two domains (HWM PBPs), while many carboxypeptidases contain one domain 
(LMW PBPs), but not all. The mechanism of DD-carboxypeptidases and transpeptidases 
is very similar, the only deviation being what acts as the nucleophile (Figure 1.7). The 
nucleophile in carboxypeptidation is water, releasing a tetrapeptide, whereas in 
transpeptidation the nucleophile is the third-position mesoDAP/Lys in the acceptor 
peptide stem. Transpeptidases and carboxypeptidases are known as Penicillin-binding 
proteins (PBPs). DD-Carboxypeptidases are enzymes that remove the terminal D-alanine 
from muramylpentapeptide and DD-endopeptidases hydrolyse the cross-links between 
glycan chains. The protein family of DD-peptidases have the same active site functional 
groups, a common protein fold and the SxxK motif. 
 
Transpeptidation occurs by the enzyme recognising the D-alanyl-D-alanine dipeptide on 
the end of the peptide stem, forming an acyl-enzyme intermediate at the active site 
serine and releasing D-alanine. This covalent acyl-enzyme intermediate is attacked by a 
nucleophile. In carboxypeptidation, the nucleophile is water and the tetrapeptide is 
released whereas in transpeptidation, the nucleophile is an amine from a stem peptide 
on an adjacent peptidoglycan polymer, and the cross-linked product is formed. 
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Figure 1.7  DD-Carboxypeptidation vs Transpeptidation. (a) The active site serine attacks 
the forth D-Ala residue (b) an acyl enzyme intermediate is formed in which the PBP active site 
effectively takes the place of the terminal D-Ala residue (c) the pentapeptide stem is hydrolysed 
to a tetrapeptide lacking the final D-Ala. In the case of carboxypeptidation, H2O acts as a 
nucleophile to attack the ester bond, releasing the tetrapeptide, uncross-linked to any acceptor 
(Thesis of T. B. Clarke, Warwick 2008). 
 
     1.4.7  Antibiotics Targeting Transpeptidation: The Structural Similarity of   
               β-lactams to D-Ala-D-Ala 
 
The interaction between β-lactams and transpeptidases are more extensively 
characterised than transpeptidation reactions involving natural substrates, as the 
substrates required to study transpeptidation are hard to make. The final two amino acid 
residues in the pentapeptide stem of peptidoglycan have structural similarity to that of 
β-lactams such as penicillin G, in particular, the CO-N bond in both species. When the 
PBP enzyme interacts with its usual substrate D-Ala-D-Ala, the D-Ala-D-Ala acylates 
the active site serine residue in the PBP, and allows the terminal D-Ala to serve as the 
leaving group. In contrast, when penicillin interacts with the active site serine, it leaves 
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the leaving group covalently tethered to the acyl-enzyme species on the PBP (Tipper & 
Strominger 1965). 
 
Penicillin is an acylated cyclic dipeptide of L-cysteine and D-valine and is viewed as an 
analogue to the acylated D-alanyl-D-alanine in the pentapeptide stem (Pratt, 1952). 
The structure of penicillin is similar to that of D-alanyl-D-alanine therefore can bind to 
the active site of the transpeptidase as a ‘pseudosubstrate’ and inhibit the activity of the 
PBP. The active site of the PBP is acylated by penicillin and then deacylates very 
slowly and subsequently cannot perform its cross-linking function. PBPs break the 
amide bond in the lactam ring of β-lactam antibiotics, where the penicillin moiety is 
transferred to a serine in the active site of the PBP (Ghuysen, 1991). The amide bond of 
the β-lactam ring of penicillin is the equivalent of the peptide bond in D-alanyl-D-
alanine (Figure 1.8). Nucleophilic attack on β-lactams by the active site serine residue 
of a PBP leads to the β-lactam ring opening, leaving the antibiotic covalently attached 
to the serine, blocking further transpeptidase activity and leads to cell death. β-
lactamase can hydrolyse 103 penicillin molecules/second, rapidly destroying the drug 
before it reaches it target enzymes (Walsh, 2000). 
 
 
 
 
 
 
 
 
Figure 1.8  The Structure of (a) Penicillin G (6-aminopenicillanic acid) and (b) the D-
alanyl-D-alanine end of the Peptidoglycan Strand. (Tipper & Strominger 1965). Variations of 
the penicillin acyl side chain improve activity against Gram-negative bacteria, particularly the 
aminopenicillins such as Amoxicillin and Ampicillin. Non-β-lactam inhibitors of 
transpeptidation include lactivicin analogues, being amongst the most potent. 
 
1.5  The Penicillin Binding Proteins 
 
Each bacterial species has a set of PBPs that are involved in the late stages of 
peptidoglycan synthesis and are targets for β-lactam antibiotics. PBPs are acyl-serine 
transferases, the actions of which are mediated by an active-site serine moiety. PBPs 
Acyl side chain 
Thiazolidine ring 
a  Penicillin G (6-aminopenicillanic acid) b  D-alanyl-D-alanine 
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catalyse the final stages of murein biosynthesis and help to modify and shape of 
peptidoglycan exoskeleton by removing the terminal D-alanine residue from 
pentapeptide stems (Vollmer et al., 2008). The morphology of a bacterial cell is 
dependent on the composition and synthesis of the peptidoglycan layer. PBPs modify 
the exoskeleton and work with cytoskeleton proteins to manipulate the structure, 
through specific protein localisations and interactions. PBPs are named for their affinity 
for penicillin, which mimics the peptide side chain structure and blocks cell wall 
synthesis. However, they could be more appropriately named as ‘Peptidoglycan 
Synthases’, as their role is mainly as the drivers behind bacterial cell wall biosynthesis. 
 
     1.5.1  Classification and Topology of PBPs 
 
Penicillin-Binding Proteins (PBPs) are initially classified according to molecular weight 
and are then further classified according to function. PBPs are initially divided into high 
molecular weight (HMW, Mr >60,000) and low molecular weight (LMW, <60,000) 
PBPs. HMW PBPs are further divided in to Class A PBPs (bifunctional) and Class B 
PBPs (monofunctional transpeptidases) (Figure 1.9 a). Generally, two HMW PBPs are 
necessary for the bacterium to survive, one Class A and one Class B. LMW PBPs are 
shapeless mutants (Popham & Young, 2003) and not essential for survival of the 
bacterial cell. The role of LMW PBPs serves more to recycle peptidoglycan in 
preparation for the incorporation of nascent peptidoglycan by HMW PBPs. 
Peptidoglycan synthesis and incorporation is mainly by HMW PBPs 1-3. HMW Class 
A bifunctional PBPs are the focus of this PhD (Figure 1.9 b), which carry out both 
transglycosylation and transpeptidation.  
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Figure 1.9  (a) The Classification of Gram-negative PBPs (using E. coli as the model). The 
topology of HMW Class A PBPs (blue) consist of a cytoplasmic tail, a transmembrane anchor, 
and two domains joined by a β-rich linker located on the outer surface of the cytoplasmic 
membrane where peptidoglycan synthesis takes place. The C-terminal of all HMW PBPs has a 
transpeptidase domain. LMW PBPs (red) are sometimes classified based on their migration 
through SDS-PAGE in to Classes A, B and C. Here they have been divided based on amino acid 
sequence alignment and knowledge of their structure and function (Massova & Mobashery, 
1998). Type 4 and Type 7 PBPs are DD-endopeptidases, Type 5 PBPs are strict DD-
carboxypeptidases and Type AmpH are of unknown function, except PBP4b has shown weak 
DD-carboxypeptidase activity (Vega & Ayala, 2006). (b)  A Schematic representation of the 
two Class A bifunctional PBPs: E. coli PBP1A and PBP1B. NB: The ODD domain (Outer 
Docking Domain) of E. coli PBP1A is located between the transglycosylase and the 
transpeptidase domains, whereas the UB2H domain in E. coli PBP1B is after the TM helix, 
prior to the transglycosylase domain. 
 
The E. coli genome has two major bifunctional Class A penicillin binding proteins, E. 
coli 1A and 1B. E. coli PBP1A serves to polymerise LII monomer units into polymers 
of a length of ~20 disaccharide units. All bacteria contain at least one PBP from each 
class. Gram-negative cocci tend to have one peptidoglycan-synthesising machinery i.e. 
the divisome at the septum, whereas Gram-negative rods have two: the elongation 
machinery in addition, so they have at least two Class A PBPs and two class B PBPs. 
Chlamydiae peptidoglycan is a particular case as it doesn’t have any class A PBPs. 
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There are even some bacteria without peptidoglycan and PBPs: Rickettsia, Mollicutes 
and Dehalococcoides. 
 
     1.5.2  Membrane Proteins as Drug Targets 
 
Membrane proteins include receptors, ion channels, transporters, and enzymes, and  
constitute a significant fraction (20 %-30 %) of the proteome (Fagerberg et al., 2010). 
However they are highly underrepresented, and make up less than 1% of all protein 
structures solved. As of January 2017, there were 1194 published reports of membrane 
protein structures (671 unique) solved by NMR or crystallographic techniques. 
 
     1.5.3  Using Detergents to Study Membrane Proteins 
 
Detergents are required for the solubility of membrane proteins and are needed to 
extract PBPs from their periplasmic associated environment. Despite Class A PBPs only 
having a single transmembrane (TM) domain, the transglycosylase domain is also 
embedded within the cytoplasmic membrane, to maintain a hydrophobic environment 
for its Lipid II substrate. Mainly non-ionic detergents are used to solubilise PBPs in this 
thesis. Non-ionic detergents are neutrally charged. The most common of the synthetic 
anionic surfactants are based on the straight chain alkylbenzene sulfonates, which 
produce electrically negative colloidal ions in solution. Cationic detergents produce 
electrically positive ions in solution. Amphoteric detergents are capable of acting either 
as anionic or cationic detergents in solution depending on the pH of the solution. 
 
     1.5.4  E. coli PBP1A 
 
E. coli PBP1A is a bifunctional PBP with both transglycosylase and transpeptidase 
functionality. Its structure has not been solved crystallographically yet, but the 
transglycosylase domain of Aquifex aeolicus PBP1A structure was solved in 2007 
(Yuan et al., 2007). The A. aeolicus transglycosylase domain has also been crystallised 
in complex with Moenomycin (Fuse et al., 2010). E. coli PBP1A is likely to follow a 
similar structural pattern to H. influenzae PBP1A which was crystallised in December 
2016 (Minasov et al., 2017). The structure of E. coli PBP1A is likely to consist of an N-
terminal single α-helical TM domain, a transglycosylase domain, an Outer Docking 
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(ODD) Domain and a C-terminal transpeptidase domain. E. coli PBP1A interacts with 
the cell-elongation-specific Class B monofunctional transpeptidase PBP2 in vivo and 
localises mainly to the cylindrical wall of the cell, helping with cell elongation. It helps 
govern cell shape and inactivating PBP2 in E. coli causes cells to lose their rod shape 
and grow as enlarged spheres that eventually die unless compensatory mutations or 
conditions. PBP2 also binds to the outer-membrane lipoprotein LpoA, where the 
lipoprotein also helps in cell elongation. LpoA is attached to the outer-membrane and 
hangs down in to the periplasm to interact with PBP1A. The ODD domain of E. coli 
PBP1A and LpoA are restricted to γ-proteobacteria.  
 
     1.5.5  E. coli PBP1B 
 
E. coli PBP1B is a major Class A bifunctional PBP that has been heavily studied over 
the past quarter century, as it is the workhorse of peptidoglycan synthesis, synthesising 
glycan chains de novo. E. coli PBP1B consists of five domains: (i) an N-terminal TM α-
helix (residues 64-87) (ii) a UvrB domain 2 Homolog (109-200) (iii) a membrane-
associated transglycosylase domain (203-367) (iv) a linker region connecting the 
transglycosylase and transpeptidase domains (391-443) (v) a C-terminal transpeptidase 
domain (444-736).  
 
The X-ray crystal structure of E. coli PBP1B was solved in 2009 by Sung et al. The 
single α-helix TM region functions as both a signal sequence for secretion and a stop 
transfer signal that serves as a membrane anchor. It stabilises the PBP-membrane 
interaction, but stable protein-membrane interaction is not critical for normal function 
of E. coli PBP1B. Removal of the TM domain does not affect the structure of the 
transglycosylase domain in the binding site (Sung et al., 2009). The function of 
transglycosylases is similar to that of lysozyme (Terrak et al., 1999), in that lysozyme 
cleaves the β1-4 glycosidic bond between GlcNAc and MurNAc peptidoglycan units, 
which are initially generated by transglycosylases. The 2009 crystal structure shows the 
transglycosylase domain to be located at a site near to where the cell membrane would 
be, in relation to the overall structure of the enzyme. If this structural model is accurate, 
it would support the theory that the proximity of the enzyme to the membrane would 
assist in its interaction with the membrane bound substrate (Sung et al., 2009). The 
recent crystal structures of transglycosylase domains in complex with moenomycin and 
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various β-lactams have highlighted essential interactions but their significance in 
structure based drug design efforts (King et al., 2016). 
 
The transglycosylase domain is mostly α-helical and is responsible for polymerising LII 
in to linear glycan strands. It is part of a group of glycosyl transfer proteins ordered by 
sequence homology in to the CAZY (carbohydrate-active enzymes) classification of 
enzymes. Peptidoglycan glycosyl transfer proteins are in family 51 (GT51), 
characterised by five conserved motifs and the use of LII. 80 % of the CAZY database 
are bifunctional PBPs and 20 % are monofunctional. The transglycosylase domain is 
comprised of two regions - a larger globular ‘head’ and a smaller, flexible ‘jaw’ region, 
separated by a cleft (Lovering et al., 2007). The globular head subunit has homology to 
lysozyme and the flexible jaw has high hydrophobicity and interacts with the lipid 
bilayer and the lipidic substrate. Positioning of the two subunits forms a cleft lined with 
residues that are conserved, shown in E. coli PBP1B (Terrak et al., 2008), S. aureus 
MGT and A. aeolicus PBP1A, with several similar structural features between members 
of the TG51 family (Lovering et al., 2008) (Figure 1.10a). These residues are clustered 
in to five motifs (Figure 1.10 b and c), with the first three motifs residing in the cleft. 
The cleft contains the catalytic residues, with motifs 1 and 3 harbouring the two 
conserved glutamic acid residues and motif 2 being involved in substrate recognition. 
Motifs 4 and 5 play a structural role in the cleft.  
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Figure 1.10  The Conserved Motifs in the TG51 Structural Family, with this E. coli PBP1B 
Domain Bound to Moenomycin A, Residing in the Catalytic Cleft. (a) The alignment of the 
five conserved TG51 motifs in Gram-negative species (b) The full transglycosylase domain and 
α-helix of E. coli PBP1B, the beginning of the linker region between the transglycosylase and 
transpeptidase domains is in purple TM α-helix = cyan, transglycosylase domain = red the five 
conserved motifs are shaded as follows: Motif 1 = yellow, motif 2 = orange, motif 3 = pink, 
motif 4 = blue, motif 5 = violet. (c) The active site cleft of the transglycosylase domain. 
Conserved residues include the catalytic glutamates E233 in motif 1 and E290 in motif 3 
(Terrak et al., 2008). (d) The E. coli PBP1B transpeptidase domain (blue) containing the β-
lactam ligand, ampicillin (yellow), bound to the catalytic active site Serine 510 (magenta). 
(King et al., 2016). 
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The amino acids tryptophan and tyrosine are found at higher frequency at a lipid-water 
interface in membrane proteins (Yau et al., 1998) and were found at the bottom of the 
transglycosylase domain, indicating that it is partially embedded in the lipid bilayer. 
The residues in the transglycosylase domain that interact with transglycosylase 
inhibitors such as Moenomycin and are also conserved between other transglycosylases 
are critical in antibiotic drug design. 
 
The UvrB Homology (UB2H) domain interacts with the MltA protein. It also interacts 
with the lipoprotein LpoB along with the transpeptidase domain, which stimulates its 
cross-linking ability. E. coli LpoB and the UB2H domain of E. coli PBP1B are further 
restricted within γ-proteobacteria to the enterobacteria (Typas et al., 2010) and so are 
not present in Pseudomonas spp species. PBP1B-LpoB may work in parallel with the 
Tol-Pal complex to aid membrane constriction. 
 
Three-dimensional structures of the four proteins of interest in this thesis: E. coli and P. 
aeruginosa PBP1A and PBP1B have not been solved yet, apart from the full-length E. 
coli PBP1B protein (King et al., 2017, Sung et al., 2009) (Figure 1.11 b). The 
transpeptidase domain of P. aeruginosa PBP1A has been crystallised with a 
sideromimic conjugated compound in its transpeptidase serine active site (Starr et al., 
2014). The transglycosylase domain is missing due to intrinsic flexibility and tryptic 
cleavage. No structures at all have been solved for E. coli PBP1A or P. aeruginosa 
PBP1B. There is a total of two Class A PBPs from species other than E. coli and P. 
aeruginosa, for which structures have been resolved: the transglycosylase domain only 
of the bifunctional PBP1A from the thermophilic species Aquifex aeolicus (Yuan et al., 
2007) and the full-length bifunctional PBP1A from the Gram-negative Haemophilus 
influenzae (Minasov et al., 2017) (Figure 1.11 a). 
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Figure 1.11  The Crystal Structures of the Two Gram-Negative Class A Bifunctional PBPs 
(PBP1A and 1B). (a) H. influenzae PBP1A and (b) E. coli PBP1B. In E. coli PBP1B, the 
enzyme resides in the periplasmic space between the inner and outer membranes of E. coli cells, 
with the transmembrane α-helix anchoring the PBP to the membrane. The transglycosylase 
domain is at the N-terminal and the transpeptidase domain is at the C-terminal. The 
transglycosylase active site glutamic acid residue is at position 233 and the transpeptidase active 
site is residue 510. Cyan = TM domain, red = transglycosylase domain, orange = ODD domain 
in HiPBP1A, yellow = UB2H domain in EcPBP1B, blue = transpeptidase domain. H. influenzae 
PBP1A has been crystallised without its TM domain. PDBs: 3VMA & 5HL9 for EcPBP1B 
(Sung et al., 2009, King et al., 2017) and 5U2G for H. influenzae (Minasov et al., 2017) (The 
5U2G structure was deposited on to the Protein Data Bank (www.rcsb.org) in December 2016, but the 
associated article has not yet been published, thus the domain colouring of HiPBP1A in (a) has been estimated 
at this time). 
 
     1.5.6  P. aeruginosa as a Clinically Important Pathogen 
 
Pseudomonas aeruginosa was chosen as a species to study, as it is a Gram-negative of 
high clinical relevance with a major resistance problem. The P. aeruginosa enzymes 
earlier in the peptidoglycan synthesis pathway has been mostly characterised, but its 
PBPs have not. There is a need for high-through-put assays that could be used for 
screening, therefore part of the project was to investigate different assay methods for 
PBPs. 
 
P. aeruginosa is one of the most common Gram-negative micro-organisms isolated 
from nosocomial isolates in recent years. It commonly causes hospital-acquired 
infections (HAIs) including pneumonia, bloodstream, urinary tract and surgical-site 
infections. More than 6,000 (13%) of the 51,000 health care-associated P. aeruginosa 
infections that occur in the U.S. each year are multi-drug-resistant (MDR) (Rossolini et 
b  E. coli PBP1B 
 
a  H. influenzae PBP1A 
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al., 2014). The associated PBPs could play a crucial role in β-lactam resistance in MDR 
Gram-negative bacteria. P. aeruginosa colonises on the surface of medical equipment in 
surgical theatres and infects patients during surgery; this pathogen also infects the 
wounds of burns victims, and persistently occupies the lungs of Cystic Fibrosis patients. 
It is an opportunistic pathogen for which treatment options are limited, but include 
broad-spectrum β-lactams (carbapenems) and is of increasing concern in clinical 
situations. Some Gram-negative organisms including P. aeruginosa have mechanisms 
for evading the action of β-lactam antibiotics including the acquisition of β-lactamases, 
provoking the emergence of MDR strains. 
 
        1.5.7  P. aeruginosa PBP1A 
 
Pseudomonas aeruginosa have a full compliment of PBPs as E. coli, including the 
Class A PBPs 1A and 1B, three Class B enzymes (PBP2, PBP3, and PBP3a: 
orthologues of the corresponding enzymes in E. coli) and the Class C PBPs 4 and 5. 
PaPBP3 shares 42% sequence identity with the corresponding protein in E. coli and has 
been identified as the primary target of a number of β-lactams used to treat 
pseudomonal infections, including the cephalosporin analogues cefsulodin (Gotoh et al., 
1990) and ceftazidime (O’Callaghan et al., 1980), piperacillin (Godfrey et al., 1981), 
and the parenteral carbapenem, doripenem (Davies et al., 2008). PBP1A follows the 
same structural format as E. coli PBP1A: The TM helix followed by a domain of 
unknown function, known in E. coli PBP1A as the ‘ODD’ domain. This is followed by 
a transglycosylase domain, linked by a β-rich linker to a transpeptidase domain. The 
interface between the transglycosylase and transpeptidase domains comprises of 6 
sequential β-strands, with two serving as a linker between the two domains. The 
transpeptidase domain has a similar fold to other transpeptidases and serine β-
lactamases. Within the transpeptidase domain, there is an oligosaccharide/ nucleotide-
binding (OB) fold, as in A. baumanii (Han et al., 2011). The crystal structure of the 
transpeptidase domain of PaPBP1A was solved in 2014 (PDB: 4OON) with a 
sideromimic-conjugated compound bound to its transpeptidase domain (Starr et al., 
2014), achieved after proteolysis with trypsin. The construct crystallised was the full-
length PBP minus the N-terminal TM domain: residues 36-822, to a resolution of 3.20 
Å. The transglycosylase domain cannot be seen in the crystal structure due to intrinsic 
flexibility and tryptic cleavage. 
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     1.5.8  P. aeruginosa PBP1B 
 
Very little is published on Pseudomonas aeruginosa PBP1B, including any structural or 
functional information. It has been assumed thus-far that this enzyme behaves similarly 
to E. coli PBP1B and is likely to have a similar structure, with the main difference being 
that there is no LpoB protein present in Pseudomonas species and the LpoB protein is 
thought to have evolved along with the UB2H domain, as in E. coli PBP1B. Therefore it 
is also unlikely that PaPBP1B has a UB2H like that in E. coli. 
 
     1.5.9  P. aeruginosa Resistance to β-Lactams 
 
Many β-lactam antibiotics are used in combination with β-lactamase inhibitors, as there 
is such widespread β-lactam resistance. Pseudomonas aeruginosa cells exhibit 
resistance to β-lactams through over-expression of AmpC and OprD, as well as efflux 
pumps. Six P. aeruginosa nosocomial isolates were studied for resistance mechanisms, 
all of which lacked OprD and over-expressed AmpC, and five of them showed modified 
PBP profiles such as diminished expression of PBP1A and modified binding affinities 
to β-lactams (Moya, et al., 2012). Ceftaroline (a cephalosporin B-lactam) has a broad-
spectrum activity against Gram-positive pathogens and several Gram-negative 
pathogens, with the notable exceptions of P. aeruginosa (and extended spectrum β-
lactamase (ESBL)-producing Enterobacteriaceae). Current antibiotics active and in use 
against Pseudomonas aeruginosa infections include the carbenicillin, the 
cephalosporins cefepime and ceftazidime and the fluoroquinolone ciprofloxacin.!
 
     1.5.10  Proteins that Interact with PBPs 
 
PBP1B in particular makes a series of important protein-protein interactions (PPIs) that 
are important in cell metabolism providing a network of interactions.  PBP1A is 
involved in adding new sugar units to the peptidoglycan sacculus during cell elongation. 
PBP1B localises to the septum of a bacterial cell during cell division, forming a 
complex machinery of enzymes as part of the Z-ring, the driving force behind 
constriction of the cell wall. Both of these activities require a plethora of enzymes to 
work together to coordinate these fundamental processes (Figure 1.12). Cell division 
proteins such as FtsN interact with PBP1B, building a network of protein interactions 
! 39 
that work together to polymerise peptidoglycan including during enlarging of the 
sacculus during cell division. FtsN interacts with E. coli PBP1B (Müller et al., 2007) as 
well as PBP3 (FtsI) (Bertsche et al., 2006) and FtsW (Fraipont et al., 2011; Derouaux et 
al., 2013, Derouaux et al., 2008). FtsN is thought to initiate cell division and divisome 
assembly, being the final component in the divisome complex (van der Ploeg et al., 
2013). FtsW was recently shown to impair the polymerisation and peptide cross-linking 
of PBP1B (Leclerq et al., 2017). PaPBP3 is essential for growth in P. aeruginosa (Chen 
et al., 2017) and has an essential role in cell division in both P. aeruginosa and E. coli. 
The β-lactams ceftazidime, ceftolozane and Imipenem all target PaPBP3 and Imipenem 
targets PaPBP2 in addition to PaPBP3.  
 
 
 
 
 
 
 
 
 
 
Figure 1.12  The ‘Divisome’ machinery and ‘Elongasome’ complexes involved in both (a) 
Cell Elongation and (b) Cell Division (Adapted from Banzhaf et al., 2012). Cell wall synthesis 
has recently been thought to be mediated by Shape, Elongation, Division, Sporulation (SEDS)-
family proteins working within the cytoskeletal machines. The SEDS family of proteins 
represent a diverse set of peptidoglycan synthases, which exhibit weak similarity to O-antigen 
ligases involved in synthesis of LPS in Gram-negative bacteria (Cho et al., 2016 & Meeske et. 
al., 2016). 
 
     1.5.10.1  The LpoA and LpoB Lipoproteins 
 
Lpo proteins are associated with the outer-membrane and protrude down in to the 
periplasmic space, interacting with the PBPs. LpoA or LpoB are absolutely required for 
in vivo and in vitro activity of PBP1A and PBP1B, respectively. This has been proven 
in E. coli thus far (Typas et al., 2010, Paradis-Bleau et al., 2010), and each Lpo 
lipoprotein stimulates its transpeptidase function. The structures of E. coli LpoA and 
LpoB were solved by solution NMR in 2014 by Jean et al., 2014, and Egan et al., 2014, 
PBP 1B: Cell Division PBP 1A: Elongation 
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respectively. LpoA stimulates transpeptidase activity, which in turn stimulates 
transglycosylation. LpoB stimulates transglycosylase activity, stimulating 
transpeptidase activity in-turn. γ-proteobacteria regulate peptidoglycan synthesis by co-
evolving interacting proteins and their PBP docking domains (Typas et al., 2010). 
 
Little is known about the role of the N-terminal domain of LpoA, but structurally it is 
rich in α-helicies (H1-H12) with helix-turn-helix tetra-tripeptide repeat (TPR)-like 
motifs, adopting a TPR-like fold. LpoA interacts with the PBP1A ODD domain, 
stimulating both transglycosylase and transpeptidase domain activity, through 
conformational change. The C-terminus of LpoA has two extended flexible, 
unstructured regions that do not interact with PBP1A. As of consequence of this 
flexibility, it is not very stable and the ODD domain of PBP1A is also not very stable. 
There is very little flexibility between the N and C termini of LpoA, owing to a rigid 
linker between the two domains. The full LpoA protein is a long elongated shape and 
spans the entire outer membrane through the periplasm. 
 
LpoA and LpoB are unrelated in amino acid sequence and have very different molecular 
weights. LpoA is 700 amino acids long (>70 kDa) and LpoB is 200 amino acids long 
(20 kDa). LpoA and PBP1A are involved in the elongosome, LpoB and PBP1B are 
involved in the divisome, with YbgF (recently renamed CpoB in E. coli) being involved 
in outer membrane invagination, as part of the Tol-Pal complex (Gray et al., 2016). 
YbgF coordinates PBP1B and TolA during outer membrane constriction and cell 
division. YbgF forms a trimer in solution and modulates the activity of PBP1B via its 
interaction with LpoB, with LpoB and YbgF sharing the UB2H domain of EcPBP1B 
(Krachler et al., 2010). 
 
1.6  Underexploited Targets for Antimicrobials 
 
Peptidoglycan transglycosylases are under-exploited as antimicrobial drug targets, 
despite their key and clear role in an area of bacterial metabolism that is a validated 
target for a number of existing antibiotics. Moreover, since most pathogens have at least 
two transglycosylase activities required for peptidoglycan biosynthesis that utilise the 
same mechanism, resistance to novel compounds would require simultaneous and 
multiple compensatory mutations. 
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Antimicrobial peptides are an alternative avenue to explore; they are less vulnerable to 
bacterial resistance than conventional antibiotics (Lohner, 2017). It takes 30 passages of 
P. aeruginosa in a sub-MIC peptide to increase its resistance by 2-4 fold (Marr et al., 
2006). The lack of diversity in the sequence and targets of conventional antibiotics 
renders them more susceptible to resistance. Peptides have multiple targets so can cause 
cell lysis via various mechanisms, whereas conventional antibiotic target a specific 
enzyme or function in the cell. A class of antimicrobial peptides called structurally 
nano-engineered antimicrobial peptide polymers (SNAPPS) exhibit sub-µM activity 
against Gram-negatives, including ESKAPE and colistin-resistance MDR pathogens, 
showing toxicity against Acinetobacter baumannii in vivo (Lam et. al., 2016). 
 
Some of the most promising opportunities for antibiotic discovery and development are 
(i) antibiotic compounds that were discovered decades ago but left unexplored because 
of their limited therapeutic prospects and (ii) adjuvants that act synergistically with 
existing antibiotics to overcome established mechanisms of antibiotic resistance (Farha 
& Brown, 2013). 
 
1.7  Strategies for Novel Antibiotic Discovery 
 
Improvements in protein structure-activity relationships determination has enabled 
rational drug design, as well as robotic liquid handling has encouraged high through put 
screening of biochemical assays. The development of ‘big data’, improved data storage 
and manipulation capabilities, coupled with improved genome-mining strategies such as 
Genome Wide Association Study (GWAS) and metagenomics is aiding in identifying 
precise deletions that may prevent the drug target from being susceptible to current 
resistance mechanisms (Brown & Wright, 2005).  
 
Bacterial proteases that are responsible for the cell’s stress response and pathogenicity 
have been ear-marked as underexplored targets with potential (Culp & Wright 2016). 
Also an antibiotic resistance platform (ARP) that contains a set of resistance elements 
has recently been developed that can be used for both the identification of antibiotic 
adjuvants and for antibiotic dereplication (natural product screening) and identifying 
inhibitors of resistance (Cox et al., 2017). 
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Yeast-2-hybrid and bacterial-hybrid experiments are being used to generate networks of 
genetic interactions, which can be used to predict functional interactions, drugs targets 
or combinations of drugs that inhibit interacting proteins (Babu et al., 2011). A network 
of chemical and genetic interactions that resist disruption can be built using antibiotic 
adjuvants (non-antibiotic compounds that enhance or suppress antibiotics). These 
interaction networks offer new target for adjuvants (Brown, 2016). 
 
Microbes in the environment target cell wall synthesis by a variety of ways, making 
natural products the best sources of antibiotic. Natural products dominate the history of 
antibiotics, especially those produced by microorganisms. Although it is challenging to 
chemically synthesise natural product derivatives in the laboratory as they are 
chemically complex. Synthetic compounds are traceable (unlike natural products) and 
are easier to scale-up. A successful example being synthetic fluoroquinolones, but very 
little has been generated this was in the past 3 decades. Screens of natural products 
identify bioactive (but already known) compounds, screens of synthetic libraries find 
potent ligands that have poor bioactivity (Brown, 2016). One solution is the 
development of synthetic libraries with the chemical diversity and properties of natural 
products (Kim et al., 2014). It is also important to avoid resistance by using 
combination therapy, i.e. synergistic combinations (Worthington & Melander, 2013). 
Teixobactin was ineffective against wild type P. aeruginosa  and E. coli, however, an E. 
coli  strain with a defective outer-membrane had an MIC of 2.5 µ g/ml, suggesting that 
outer membrane-permeabilising adjuvants may increase the potency of Teixobactin 
against Gram-negatives, including P. aeruginosa (Lamers & Burrows, 2016). 
 
         1.7.1  Recent Developments in Compounds Against MDR P. aeruginosa 
 
Currently, the only clinically approved PBP1b specific β-lactam is cefsulodin, in which 
clinical utility is restricted to Pseudomonas aeruginosa (Sarkar et al., 2012). The 
monobactam Aztreonam in conjunction with the β-lactamase-inhibitor Avibactam was 
not lethal towards the β-lactamase-producing P. aeruginosa (Testa et al., 2015). 
However, a novel siderophore cephalosporin (S-649266) showed superior in vitro 
activity over its β-lactam comparators against MDR P. aeruginosa (Kohira et al., 2016). 
Synergy was also observed between the siderophore sulfactam BAL30072 and 
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carbapenems against both MDR Enterobacteriaceae and P. aeruginosa isolates 
(Mushtaq et al., 2013). The aminoglycoside Plazomicin demonstrated synergistic in 
vitro activity with carbapenems against P. aeruginosa and A. baumannii isolates 
(Walkty et al., 2014) but Eravacycline, like tetracycline, showed limited activity against 
P. aeruginosa (Sutcliffe et al., 2013). 
 
      1.7.2  Recently Approved Antimicrobials 
 
Zerbaxa is a combination product containing ceftolozane, a cephalosporin antibacterial 
drug, and tazobactam, a beta-lactamase inhibitor. Zerbaxa is used to treat complicated 
urinary tract infections, including kidney infections. It is used in combination with 
metronidazole to treat intra-abdominal infections like Avycaz. Developed by Cubist, 
(now Merck) clinically available 2014. 
 
Dalvance (USA) / Xydalba (Europe) is a lipoglycopeptide belonging to the same class a 
vancomycin, one of the few treatments against MRSA. Developed by Allergan, 
clinically available May 2014. 
 
Sivextro is an oxazolidinone-class antibiotic used to treat acute bacterial skin infections, 
developed by Cubist (now Merck), clinically available June 2014. 
 
Avycaz is a combination of ceftazidime, a cephalosporin, and avibactam, a β-lactamase 
inhibitor, to treat complicated intra-abdominal infections, used in combination with metronidazole. Developed by Allergan, available February 2015. 
 
Zinplava (bezlotoxumab) treats recurrent Clostridium difficile infections in patients 
receiving antibacterial treatment. Developed by Merck, approved October 2016. 
 
     1.7.3  Teixobactin - The Latest Discovery 
 
Most antibiotics are natural products derived from microbes in the soil and Teixobactin 
is no different. Teixobactin is natural product antibiotic isolated by Ling et al., in 
Boston, USA in 2015. The chemical was found in soil and has shown to be active 
against tuberculosis, septicemia, C. difficile and could potentially be available in the 
! 44 
next 5 years. An electronic chip was used to grow microbes in soil and isolate the 
naturally produced chemical compound from an uncultured soil microorganism similar 
to Aquabacteria. The compound exhibited antimicrobial ability, binding to both Lipid II 
and Lipid III. This novel technique allows compounds to be isolated from soil, 
harbouring microorganisms that do not grow under ‘normal’ laboratory conditions. It is 
currently believed that bacteria will not become resistant to Teixobactin for at least 30 
years as it targets lipid molecules as well as having multiple methods of attack. Trials 
thus far have revealed no side effects in mice. This antibiotic is being scaled-up ready 
for clinical trials in humans (Ling et. al., 2015). Teixobactin was ineffective against 
wild type P. aeruginosa and E. coli; however, an E. coli strain with a defective OM had 
an MIC of 2.5 µ g/ml, suggesting that OM permeabilising adjuvants may increase the 
potency of teixobactin against Gram-negatives, including P. aeruginosa. 
 
1.8  Antimicrobial Resistance (AMR) Public Policy  
 
The World Health Organisation (WHO) have published reports named ‘The Evolving 
Threat of Antimicrobial Resistance’ (2012) and ‘AMR: Global Report on Surveillance’ 
(2014), which both discuss better tracking and monitoring of antibiotic use, reducing the 
use of antibiotics in animal husbandry and improving infection prevention in hospitals 
(WHO Report, 2014). Recommendations from the UK Chief Medical Officer’s 2013 
Annual Report echoed many of the political commitments outlined in the 2012 WHO 
Report, such as widening education on antibiotics, challenging the irresponsible use of 
antibiotics, tightening the laws in agriculture to avoid over-use for the sake of 
prevention, improving data recording to retrieve true observations on prescription 
statistics and to encourage the investment in innovative solutions (Chief Medical 
Report, UK 2013). The Economist James O’Neill released a report on the socio-
economic impact of AMR (J. O’Neill Report, May 2016). The problem of AMR needs 
to be confronted through collaboration from multiple funding bodies, including WHO, 
NHS, DEFRA, Food Standards Agency as well as agricultural bodies. In 2007 the 
European Centre for Disease Prevention Control (ECDC) began an annual ‘Antibiotic 
Awareness Day’ each November to raise the profile of the scale of the problem. The 
European Commission is set to publish a ‘New Action Plan’ to combat antimicrobial 
resistance in 2017. In the USA, the FDA introduced the GAIN (Generating Antibiotics 
Incentives Now) Act, which extends by five years the exclusivity period during which 
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antibiotics can be sold without generic competition. This additional period of 
exclusivity increases the potential for profits from new antibiotics by allowing the 
Pharma industry more time to recoup investment costs. 
 
1.9  Thesis Aims and Outlines 
 
To further investigate the transglycosylase function of Class A bifunctional PBPs, using 
E. coli Class A PBPs as the model organism for which to compare to P. aeruginosa 
PBPs. Very little literature has been published on P. aeruginosa PBPs, possibly as they 
may have proven challenging to isolate and purity and additionally due to the 
pathogenicity of the P. aeruginosa PA01 strain generating caution. The transpeptidation 
activity of these PBPs will also be analysed using previously known techniques as well 
as novel assay developments and optimisation. The known interacting partner proteins 
to PBPs will also be investigated as to their stimulatory or inhibitory impact on the 
transglycosylase and transpeptidase function of P. aeruginosa PBPs.    
 
The main aim of this thesis is to develop spectrophotometric assays to enable the rapid, 
kinetic characterisation of the PBP transglycosylase and transpeptidase activities, whilst 
concomitantly establishing conditions in which these activities can be detected. The 
assays used to characterise these activities will be developed extensively. Enabling such 
assays to be used in a high-throughput manner will aid the screening of potential 
inhibitor compounds to elucidate future antimicrobial candidates.  
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Chapter 2 
Materials and Methods 
 
2.1  Chemical Reagents and Buffers 
 
All chemical reactions were sourced from the following, unless otherwise stated: Avanti 
Polar Lipids, Alabaster, AL, USA, Affymetrix (formerly Anatrace); Maumee, Ohio, 
USA, Calbiochem, USA, Fisher Scientific USA, GE Healthcare; Little Chalfont, 
Buckinghamshire, UK, Integrated DNA Technologies, Coralville, Iowa, USA, 
Invitrogen Life Technologies Ltd., Paisley, UK, New England Biolabs (UK) Ltd; 
Hitchin, Hertfordshire, UK, Promega Corporation; Madison, Wisconsin, USA, Sigma-
Aldrich Company Ltd.; Dorset, UK.  
  
All buffers were prepared in MilliQ purified water. Buffers for chromatography and 
spectrophotometric measurements were also filtered using a 0.2 mm filter. pHs were 
determined using a WPA pH meter CD720 with pH 4.0, pH 7.0 and pH 10.0 buffer 
standards supplied by Hanna Instruments. For chromatography, buffers were filtered 
prior to use with a 0.2 µm filter. 
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2.2  Growth and Maintenance of Bacteria 
 
2.2.1  Bacterial Strains 
 
Table 2.1 Bacterial strains used for cloning and protein overexpression. 
Competent 
Cell Line E. 
coli Strain 
Genotype Reference 
TOP10  
F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 deoR recA1 araD139 Δ (ara-leu)7697 galU 
galK rpsL (StrR) endA1 nupG 
Grant et 
al., (1990) 
DH5-α 
F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG 
Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK 
- mK+), λ– 
Hanahan, 
1985 
BL21 (λDE3)  
F- ompT hsdSB (rB- mB-) gal dcm rne131 (λDE3) 
An E. coli strain with DE3, a λ prophage carrying the 
T7 RNA polymerase gene and lacIq. Transformed 
plasmids containing T7 promoter driven expression are 
repressed until IPTG induction of T7 RNA polymerase 
from a lac promoter. 
Lopez et 
al., (1999) 
C41 (λDE3) 
Derivative of E. coli BL21(λDE3) : F- ompT hsdSB (rB- 
mB-) gal dcm (λDE3). Contains at least one 
uncharacterized mutation - prevents cell death 
associated with expression of toxic recombinant 
proteins. 
Miroux & 
Walker 
(1996) 
C43 (λDE3) Derivative of C41 (λDE3) obtained using F
- ATPase 
subunit gene, contains no plasmid. 
Miroux & 
Walker 
(1996) 
 
2.2.2  Preparing Chemically Competent Cells 
 
The cell line was streaked on to an LB-agar plate using a sterile loop and a single 
colony was selected for overnight culture. 125 mL of Luria Broth in a 500 mL glass 
conical flask was inoculated with 1.25 mL of the overnight culture. 20 mM MgSO4 was 
added to stimulate transformation efficiency. All buffers were filter-sterilized (F/S) and 
stored at 4 °C before using. The culture was grown at 37 °C, shaking at 800 RPM, until 
reaching OD 0.4-0.6 (making sure not to exceed OD0.6). The cell suspension was 
transferred to four ice-cold, sterile centrifuge tubes (competent cells are very 
temperature sensitive and must be kept at 4°C at all times). The tubes were spun at 
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4,500 ×g for 10 minutes at 4 °C in rotor JA 25.5. The pellets were resuspended in 50 
mL (or 0.4 × the original culture volume) of ice-cold TFB1 buffer (30 mM potassium 
acetate pH 5.8, 10 mM CaCl2, 50 mM MnCl2, 100 mM RbCl, 15% glycerol and was 
adjusted to pH 5.8 using F/S IM acetic acid) and all four suspensions were combined 
and left on ice for 5 minutes. The cells were spun again at 4,500 ×g at 4°C for 10 
minutes and the pellet was resuspended in 5 mL (or 1/25 × original culture volume) of 
ice-cold, F/S TFB2 buffer (10 mM MOPS or PIPES pH 6.5, 75 mM CaCl2,10 mM 
RbCl, 15% glycerol, adjusted to pH 6.5 using F/S 1M KOH). The cells were incubated 
on ice for 1 hour, before being pipetted at 4 °C in to 100 × 50 µL aliquots in 1.5 mL 
Eppendorf tubes. The tubes were flash frozen in liquid Nitrogen and stored at -80 °C. 
The cells remained fully competent for ~3 months. 
 
2.2.3  Bacterial Transformation 
 
An aliquot of chemically competent cells were thawed on ice for 15 minutes. The 
competent cells were inoculated with 100 ng plasmid DNA and left on ice for 30 
minutes. The cells were heat shocked at 42 °C for 45 seconds and placed back on ice for 
2.5 minutes. 300 µL SOC (Super Optimal broth with Catabolite repression) was added 
to the transformation and incubated at 37 °C, shaking for 1 hour. 100 µL was spread on 
to an LB-agar plate and incubated overnight at 37 °C. 
 
2.2.4  Bacterial Electroporation 
 
An electrical field is applied to the cells to increase the permeability of the membrane, 
allowing the DNA to be introduced into the cell, which was used to insert plasmid DNA 
into P. putida competent cells. 25 µL of P. putida competent cells were incubated with 
100 ng DNA on ice for 30 minutes, in an electroporation cuvette before electroporation 
in a BioRad GenePulser at 250 V, 100 Ω, and 25 µF. 
 
2.2.5  Bacterial Growth Media 
 
LB  
 
1 % (w/v) tryptone, 0.5 % (w/v) NaCl, 0.5 % (w/v) yeast extract. 
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2YT 
 
1.6 % (w/v) tryptone, 1 % (w/v) yeast extract, 0.5 % (w/v) NaCl, adjusted to pH 7.0. 
 
Auto Induction Media 
 
Auto-inductive media was based on the an autoinduction method by Studier (2005), 
containing a combination of ZY media, NPS solution, 5052 solution and 1 mM MgSO4. 
The ZY media 1 % (w/v) N-Z amine, 0.5 % (w/v) yeast extract. NPS solution was 25 
mM ammonium sulphate, 50 mM potassium dihydrogen phosphate and disodium 
hydrogen phosphate, commonly made as a 20-fold (20 x) stock solution. 5052 solution 
was mixture of 0.5% (v/v) glycerol, 0.05% (w/v) glucose and 0.2% (w/v) 훼-lactose, 
commonly made as a 50-fold (50 x) stock solution. 
 
LB-Agar plates 
 
Comprised of LB media with 1.5 % (w/v) bacto-agar, heated to melt the agar, and 
cooled sufficiently to add antibiotic, before pouring 17 mL media in to each plate. 
 
2.2.6  Preparation of Glycerol Stocks 
 
3 mL LB + antibiotic was cultured overnight at 37 °C. 0.5 mL of the overnight culture, 
with 0.5 mL of sterilized 100 % (v/v) glycerol were mixed and flash frozen and stored 
at -80 °C. 
 
2.3  Molecular Biology Techniques 
 
    2.3.1  Polymerase Chain Reaction 
 
The polymerase chain reaction (PCR) was used predominantly to amplify genes for 
cloning in to expression vectors. Genes would commonly be screened across a variety 
of conditions (with and without MgCl2 and DMSO) using High Fidelity (HF) Phusion 
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polymerase (Thermo Fisher Scientific), Phusion HF buffer, dNTPs, forward an reverse 
primers and template (complementary) DNA. The primers (oligos) were specific to the 
gene and contained a restriction site and template DNA were species specific. Four 
master mixes were made up with and without MgCl2 and DMSO, adding the 
polymerase last to each master mix (Table 2.2). An Eppendorf Thermocycler was used 
for PCR, with the conditions outlined in Table 2.3. 
 
Table 2.2  PCR Reaction Mixtures for HF Phusion Polymerase 
 - MgCl2 
- DMSO 
µL 
+ MgCl2 
µL 
+ DMSO 
µL 
+ MgCl2 
+ DMSO 
µL 
5 × Phusion HF buffer 24 24 24 24 
10 mM dNTPs 2.4 2.4 2.4 2.4 
10 µM Forward primer 6 6 6 6 
10 µM Reverse Primer 6 6 6 6 
50 mM MgCl2 2.4 2.4 2.4 2.4 
Template cDNA (5-50ng) 2.4 2.4 2.4 2.4 
100% DMSO - - 6 6 
Phusion DNA Polymerase 1.2 1.2 1.2 1.2 
H2O (up to 120 µl) 78 75.6 72 69 
 
 
 
 
Table 2.3  The PCR program used for Phusion DNA Polymerase 
Stage Number of 
cycles 
Temperature Time 
Initial Denaturation 1 98 °C 30 seconds 
Primer Annealing !  25 
98 °C 10 seconds 
50 - 60 °Ca 30 seconds 
72 °C 30 seconds 
Primer Extension 1 72 °C 10 minutes 
a The annealing temperature was set to a gradient from 50 °C to 60 °C across the plate 
 
PCR products were analysed by 0.8% or 1.0& agarose gel, depending on the size of the 
amplified gene. Upon successful amplification of the gene by PCR, the gene was either 
excised from the agarose gel and the Agarose removed using a Qiagen Gel Extraction 
Clean-Up Kit, or the PCR products were cleaned up using a Qiagen PCR Clean Up Kit. 
The DNA yield was quantified by Nanodrop. 
 
25 µL 
60°C 
25 µL 
50°C 
25 µL 
56°C 
25 µL 
54°C 
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   2.3.2  DNA Quantification 
 
Nanodrop technology was used to quantify DNA ND-1000 spectrophotometer 
(Thermo Scientific) using 1.0 µL samples. 
 
   2.3.3  Agarose DNA Electrophoresis 
 
Agarose solution was prepared by dissolving 0.8 % or 1.0 % (w/v) of high-melting 
point agarose (Sigma-Aldrich) in to 1 x Tris-acetate-EDTA (TAE) buffer (40 mM Tris 
acetate, 1 mM EDTA), by heating in the microwave for 60 seconds. 1 µL of a 10 mg/ml 
stock of Ethidium bromide was mixed in to the molten agarose. Molten agarose was 
poured in to a gel cassette and left for 15 minutes to set, before being submerged in 1 x 
TAE buffer. Samples were supplemented with DNA loading dye and loaded in to the 
wells. Electrophoresis was conducted at 110 Volts for 35 minutes. Gels were analysed 
upon a trans-illuminator through a UV filter. 
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2.3.4  DNA Cloning 
 
A summary of a typical DNA cloning protocol is summarised in the schematic below. 
 
 
 
 
 
 
 
 
1 µg of PCR product DNA along with 1 µg of the destination vector was digested with 
the appropriate restriction enzymes, at the optimum temperature(s) for the restriction 
enzymes (usually 37 °C) for between 1 and 3 hours. The protocol provided with the 
specific restriction enzymes was followed. The vector (only) was treated with 1 µL of 
SAP (Shrimp Alkaline Phosphatase) for 30 minutes at 37 °C to remove the terminal 
phosphates from the digested vector ends and prevent them re-ligating back together. 
Digestion products were analysed by agarose gel and extracted from the gel and cleaned 
up using a Qiagen Gel-Extraction Kit and the yield was quantified by Nanodrop. A 
ligation reaction included a 1:10 molar ratio of vector : gene insert, with ATP, T4 DNA 
ligase and ligase buffer. Controls without vector were included. Ligation reactions were 
left overnight (3 hours minimum) at room temperature (20 °C).  
 
!Primer!Design! !Gene!amplification!by!PCR! !Clean!up!PCR!products!
Digest!PCR!products!with!restriction!enzymes!!Clean!up!digestion!products!Digest!target!vector!with!the!same!restriction!enzymes!
SAP?treat!vector!(to!remove!phosphates!at!termini)!!
!Clean!up!vector!digest!by!gel!extraction! Set!up!ligations!of!vector!and!gene!insert!in!a!1:10!molar!ratio!
Transform!TOP10!competent!cells!with!ligation!reaction!
!Select!colonies!and!set!up!O/N!cultures!Screen!colonies!for!correct!insert!by:!PCR!amplification!(DreamTaq)!Colony!PCR!Restriction!Digestion! Send!for!sequencing!for!final!confirmation!
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Table 2.4  Typical Vector : Insert Ligation Reactions 
 
 Negative Controls  
 
Vector Only 
Vector + Insert 
(No DNA Ligase) 
Vector + Insert 
(With DNA Ligase) 
Insert - - 3X µM 
Vector X µM X µM X µM 
ATP 1 mM 1 mM 1 mM 
Ligase - 1 µL 1 µL 
Ligase buffer 1x 1x 1x 
water Up to 25 µL Up to 25 µL Up to 25 µL 
 
Aliquots of TOP10 competent cells were inoculated with 4 µL of each ligation reaction 
and transformed and plated onto LB-agar with the antibiotic selection of the plasmid 
vector being used for cloning. Colonies from the plate with vector, insert and DNA 
ligase were screened for potential positive clones.  
 
2.3.4.1  Screening for Positive Clones 
 
Screening methods for potential clones was done in one of three ways: conducting PCR 
on plasmid DNA extracted from the colonies, colony PCR (introducing the bacterial 
colony in to the PCR mixture as a DNA template, or by restriction digest. Colonies 
were selected from the vector+insert+DNA ligase LB-agar plate and amplified by 
growing in 3 mL LB + antibiotic for 5 hours minimum. The DNA was extracted from 
each culture using a DNA mini-prep kit (Qiagen). PCR could be performed on these 
plasmid preps. using one vector-specific primer and one gene-specific primer to ensure 
that the gene is present within the plasmid, and in the correct orientation. Alternatively, 
colonies from the vector+insert+DNA ligase LB-agar plate can be used as the DNA 
template for colony PCR by picking the colony with a tip-end and dipping it into PCR 
reaction mixtures. Another method for colony screening is doing a restriction digest of 
the extracted plasmid DNA potential clones, using one restriction enzyme that the 
enzyme was cloned into the vector with, and a vector-specific restriction site, often XbaI 
in pET vectors (Novogen), which is located upstream of the multiple cloning site 
(MCS). Potentially successful clones were sequenced by GATC Sequencing Services 
often using T7 primers (specific to pET vectors). 
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2.3.5  DNA Sequencing 
 
80-100 ng.µL-1 plasmid DNA and 5 pmol.µL-1 primer (often vector specific T7 
promoter or terminator of the pET vector or the primers used for the original PCR 
amplification of the target gene) were used for each sequencing reaction in a final 
volume of 10 µL. Reactions were submitted to GATC Biotech (Germany), and 
results were analysed using ApE Plasmid Editor (ApE) software. 
 
2.3.6  Site-Directed Mutagenesis 
 
Wildtype genes in their respective plasmid vectors (e.g. pET28::PaPBP1A) was used as 
the template for site-directed mutagenesis, following the protocol of the QuikChange II 
Site-Directed Mutagenesis Kit (Stratagene). Clones containing the correct mutation (a 
change of the catalytic active site residue via a single or double base change) were 
confirmed by DNA sequencing. 
 
2.4  Recombinant Protein Expression in E. coli 
 
2.4.1  Over-expression of P. aeruginosa PBP1A and E. coli PBP1A 
 
EcPBP1A was expressed in 6 x baffled flasks of 750 mL 2xYT media in each flask. 
C222222222222ultures were grown at 37 °C until they reached OD 0.6-0.7. Cultures 
were induced with 0.05 mM ITPG (Born et al., 2006) and the temperature for 
expression reduced to 25 °C for 5 hours, or 18 °C overnight; both methods gave an 
equally high expression-level of viable, active EcPBP1A. Cultures were pooled in to 1L 
centrifuge flasks and spun for 12 minutes at 4,000 x g at 4 °C in the Beckman JLA 
8.1000 rotor. Cell pellets were weighed and resuspended in 3 mL resuspension buffer 
(25 mM Tris.HCl pH 7.5, 100 mM MgCl2, 100 mM NaCl) per gram of cell pellet. Cells 
were lysed according to section 2.4.4. 
 
2.4.2  Over-expression of P. aeruginosa PBP1B and E. coli PBP1B 
 
The E. coli PBP1B gene was previously cloned into plasmid DML924 (conferring 
kanamycin resistance), which encodes a Hexa-Hig tag on the N-terminal end of the 
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protein. The construct was transformed into E. coli expression strain BL21 (DE3). An 
overnight culture was grown to inoculate 10 x 400 mL LB in 2.5 L baffled flasks. 50 
µg/mL kanamycin and 0.2 % (final concentrations) glucose were added to select for 
the plasmid and encourage optimum expression, respectively. Cultures were grown at 
37 °C until OD578 reached 0.7, upon which the cultures were induced to a final 
concentration of 1 mM IPTG. Cells were grown for a further 5 hours at 37 °C and then 
put on ice for 10 minutes before being centrifuged at 8,000 x g for 20 minutes. 
 
2.4.3  EcPBP1B and PaPBP1B Expression Cell Line Trials 
 
Alternative cell lines to BL21(DE3) were transformed and cultures of 200 mL were 
grown to OD600 0.7. Upon reaching OD600 0.7, the 200 mL culture was divided in to 
two, using 100 mL as a non-induced control and the other half was induced to 1 mM 
IPTG. The membrane fractions were harvested and run on two 10% SDS-PAGE gels. 
One gel was stained with Coomassie, the other gel was transferred to PDVF membrane 
and blotted with anti-His antibodies. 
 
2.4.4  Large-Scale Bacterial Cell Lysis for the Preparation of Crude Cell Lysates 
 
Bacterial cells were resuspended in 3 mL of resuspension buffer per gram of wet cell 
pellet weight and 2.5 mgs lysozyme per mL of cell suspension. 1 mg DNAaseI was 
added along with 1 mM PMSF and 1 µM of both leupeptin and pepstatin protease 
inhibitors. The resuspension was left to stir at 4 °C for 30 minutes before passing 
through a cell disrupter (Constant Systems Ltd). Cells were passed through the cell 
disrupter three times to complete the cell lysis process at 30,000 kpsi and 4 °C. Lysed 
cells were spun at 24,000 x g in the Beckman JA 25.50 rotor, for 40 minutes to pellet 
cell debris.  
 
2.4.5  Harvesting the Membrane Fraction  
 
The supernatant from the 24,000 x g spin containing cell cytosol was spun in a 
Beckman Coulter Optima L-90K Ultracentrifuge at 40,000 RPM using the Ti-45 
(Titanium, max speed 45K RPM) rotor for 1 hour at 4 °C. The membrane pellet was 
scraped off the side of the centrifuge tube using a metal spatula and resuspended in to 
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resuspension buffer (without detergent) using a 1 mL Jencon glass homogenizer (cat# 
361-039/P and 361-089).   
 
2.4.6  Membrane Protein Solubilisation 
 
The resuspended membrane pellet was supplemented with detergent (e.g. CHAPS, 
Triton-X-100 or DDM) to a suitable concentration for solubilisation, usually ~10xCMC. 
The suspension was left rocking/rolling at 4 °C for 4 hours to allow complete 
solubilisation. The length of solubilisation: the longer the better for more extraction of 
the desired protein, but longer than 4 hours can be detrimental to enzyme activity, 
personal communication, Dr. Andrew Quigley). The solubilised suspension was 
centrifuged at 40,000 RPM in the Ti-45 rotor for 1 hour at 4 °C to pellet any insoluble 
material. The supernatant was then incubated with loose resin, either Ni2+ bound 
chelating metal affinity resin, or TALON metal affinity resin (Co2+ metal ions 
(Clontech)). 
 
2.5  Protein Purification 
 
2.5.1  Purification of Class A PBPs 
 
E. coli PBP1A was purified loosely based on the protocol in Born et al., 2006, with 
minor optimisation. After solubilisation in detergent (e.g. TritonX-100 or CHAPS) and 
removal of unwanted insoluble material by centrifugation (section 2.4.6), the solubilised 
fraction was incubated with loose Ni2+-bound chelating metal affinity resin for 1 hour 
on rollers at 4 °C. The slurry was poured in to an empty syringe barrel, used as a 
column. The resin was washed with 2x 40 mL of buffer with 5 mM imidazole. 5 mL 
aliquots of increasing imidazole concentration were made: 20 mM, 50 mM, 100 mM, 
150 mM, 200 mM, 250 mM, 300 mM, 350 mM, 400 mM, 450 mM, 500 mM to elute 
the protein over a 50 mL gradient. Samples of each were run on 10% SDS-PAGE for 
analysis (section 2.6.1). 
 
2.5.2  Immobilised-Metal-Affinity Chromatography (IMAC) 
 
The protein has a hexa-His tag on its N-terminal, which readily binds to nickel metal 
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resin. The solubilized protein was incubated with the resin, rocking at 4 °C for 1 hour. 
The resin was transferred to the column and washed with 10 x 5 mL of extraction buffer 
+ 15 mM imidizole, followed by elution with 3 x 5 mL of extraction buffer + 400 mM 
imidazole. The eluted fractions were dialysed multiple times before cleaving the his-tag 
with 2U / mL of thrombin. The protein was dialysed into a low-salt and low pH buffer 
(10 mM sodium acetate pH 5.0, 10 mM MgCl2, 0.02% NaN3, 10% glycerol, 100 mM 
NaCl) ready to for loading on to the Source S column on the AKTA. The jump in buffer 
pH from pH 7.5 to pH 5.0 is important relative to the pI (isoelectric point) of the 
protein, to ensure that the protein is negatively charged for binding to the Ni2+ beads. 
 
2.5.3  Ion Exchange Chromatography: Source S Column 
 
The protein was loaded onto the column and any contaminating proteins were washed 
away with 10 column volumes of Buffer A (10 mM sodium acetate pH 5.0, 10 mM 
MgCl2, 0.02 % NaN3, 10 % glycerol, 100 mM NaCl, 0.2 % TritonX-100). The protein 
was eluted at a flow rate of 1 mL / minute, over a 65 mL continuous gradient from 100 
% Buffer A to 100 % Buffer B (10 mM sodium acetate pH 5.0, 10 mM MgCl2, 0.02 % 
NaN3, 10% glycerol, 2 M NaCl, 0.2 % TritonX-100). Eluted protein was dialysed into 
the appropriate buffer for long-term storage (10 mM soodium acetate pH 5.0, 10 mM 
MgCl2, 0.02% NaN3, 10% glycerol, 500 mM NaCl, 0.2 % TritonX-100) and stored at -
80 °C in 50 µL aliquots. 
 
2.6  Protein Analysis and Detection 
 
2.6.1  SDS-PAGE 
 
SDS-PAGE employs a multi-phasic buffer system with differing pH to cause separation 
according to molecular weight. The samples are loaded into very narrow starting zones, 
which along with the discontinuities, determines the subsequent sharpness of the 
separations and is responsible for the very high resolving power of the multi-phasic 
buffer system. The advantage of this system is that large volumes of dilute protein 
samples can be applied to the gel without loss of resolution of their component 
polypeptides. The pH of the Tris.HCl buffer used in the stacking gel has a different pH 
to the Tris.HCl buffer used in the resolving gel, which have been specifically selected 
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so that the proteins migrate at a pace between that of the leading Cl- ions and of the 
trailing glycinate ions. When the current is applied, a boundary is formed where the 
proteins collect in the stacking gel and then move according to molecular mass in the 
resolving gel. Lots of negatively charged SDS molecules bind to the hydrophobic 
regions of proteins, disrupting non-covalent bonds and cause unfolding. The intrinsic 
charge of the protein is masked, causing them to migrate to the cathode when the 
voltage is applied. Sample preparation involved measuring the protein concentration of 
each sample using Bio-Rad, to quantify against a standard curve, so as to set up samples 
with 25 µg of protein. If too much protein is loaded onto a gel, it can smear and 
individual bands are hard to define. For volumes of substances to make up the resolving 
and stacking gels, refer to tables in Appendix. Gels were run at 180 Volts for 50 
minutes. 
 
2.6.2  Western Blotting 
 
Western blotting procedures have been optimised to reduce background and decrease 
experiment time, using the method outlined here.  
 
SDS-PAGE, Transfer and Overnight Block  
 
Proteins were resolved by SDS-PAGE (10% acrylamide for HMW proteins) or Native 
PAGE against either High Molecular Weight Calibration Standards (Amersham) or His-
tagged protein markers (Benchmark or MagicMark XP, Invitrogen) and the resulting gel 
was washed in transfer buffer (Transfer Buffer (1L) 5.8 g Tris base, 2.9g glycine, 200 
mL MeOH, 0.05% SDS (500 mgs) (for membrane proteins and those > 80 kDa). 
Polypeptides were transferred from the gel to a PVDF membrane (Hybond-P, GE 
Healthcare) at a constant voltage of 120V in transfer buffer for 90 minutes, using a 
BioRad electroblotting kit. Before transfer, the membrane was activated by placing in 
methanol for 5-10mins, washing with deionised water then adding to transfer buffer for 
2mins.  After transfer, membranes were blocked in 50mL of 10% Milk powder in TBS 
containing 0.1% Tween-20 (TBST-T) and rocked for 1 hour at room temperature before 
being left stationary (but rocked if possible) in the cold room O/N.  
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Antibody Incubations  
 
Wash the milk away with 50mL of TBS-T for 15min. The TBS-T wash step was 
repeated twice more. Primary Incubation: 20mL of TBS-Tween containing 5% milk, 
add 20µL of anti-his IgG mouse monoclonal antibody (Roche - binds to either His 
terminus) or 8µl anti-His IgG mouse monoclonal (N-terminal preferential antibody – 
Sigma H1029), and leave to shake for one hour. Follow with three 20mL TBS-T wash 
steps of 15 mins each. Secondary Incubation: 20mL of TBS-T containing 5% milk, add 
10µl of anti-mouse IgG conjugated to horseradish peroxidase derived from sheep 
(Sigma, A5906) was added and left to shake for two hours before three further TBS-T 
wash steps. For the final wash step, membranes were left to rock overnight at RT to 
reduce the background of unbound proteins.  
 
Development 
 
For developing – in the dark room, 5mL of western blotting reagent 1 (GE Healthcare) 
and 5mL of western blotting reagent 2 (GE Healthcare), or more recently – 2 mL of EZ-
ECL Solution A and 2 mL Solution B were added to the membrane and allowed to 
develop for 2 minutes (preferably in the dark). The developed membrane was held by 
tweezers to drip excess developing solution onto a tissue, and placed is a cassette lined 
with cling-film. Exposure time to x-ray films (Super-RX NIF, Fujifilm) varied from 30 
seconds and 5 minutes, but sometimes up to 30 minutes. Observed bands resulted from 
electrochemical luminescence (ECL) from proteins embedded in the membrane.  
Latterly, instead of developing using Fuji Film, a chemi-illuminescence detector was 
used to analyse the Western Blot PVDF Membrane. 
 
2.6.3  Protein Concentration Determination 
 
2.6.3.1  BioRad Assay 
 
The BioRad assay was used to measure the protein concentration of soluble protein 
samples of unknown concentration and was carried out as described by the BioRad 
protocol. The concentrated BioRad reagent was diluted 1 in 5 with ddH2O and 1 mL 
aliquoted in to plastic cuvettes. A standard curve was performed on each occasion, 
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using the sample volume of the protein sample of unknown concentration added as 
Bovine Serine Albumin (BSA), typically 1.5 µL. Each cuvette was inverted 3 times 
using parafilm as a cuvette ‘lid’, before measuring the absorbance at 595 nm. Protein 
samples were done in triplicate. 
 
2.6.3.2  BCA Assay 
 
A BCA (bicinchoninic acid) assay was used to measure the protein concentration of 
membrane protein samples of unknown concentration and was carried out as described 
by the Pierce protocol. BSA protein standards were made in 0.25 mg/mL increments 
from 0 to 2 mg/mL BSA. Reagents A and B were mixed at a 50:1 ratio, a volume 
sufficient for 9 x BSA standards plus the number of samples to test in triplicate). 1 mL 
of mixed BCA reagents was aliquoted into plastic cuvettes. 2 µL of each BSA standard 
was added to a cuvette, along with 2 µL protein sample of unknown concentration, 
always done in triplicate. Addition of protein samples was done accurately but with 
haste, as the colour change of the BCA reagents once mixed together, is time (and 
temperature) dependent. Parafilm was secured over the top off a cuvette and the cuvette 
was inverted three times to mix the protein sample with the reagent. Reactions were left 
to incubate at 37 °C in a static incubator for exactly 30 minutes. Absorbancies were 
measured against a blank (1 mL BCA A+B, + 2 µL water, i.e. 0 mg/mL BSA) at 562 
nm using a using a Jenway 6306 UV-visible spectrophotometer. Protein concentrations 
were calculated based upon the standard curve. The working range for the assay is 
between 20 and 2000 µg/mL. 
 
2.7  Compound Synthesis 
 
2.7.1  UDP-MurNAc-Pentapeptide Synthesis 
 
Method adapted from Lloyd et al. (2008). 2 mL reaction volumes were used containing 
50 mM HEPES pH 7.5, 10 mM MgCl2, 200 mM PEP, 50 mM KCl, 10 mM 
dithiothreitol, 10 mM UDP-GlcNAc, 30 mM L-Ala, 30 mM D-Glu (or 100 mM D-Gln), 
30 mM L-Lys, 30 mM D-Alanyl-D-Ala, 200 µM NADPH, 6 mM ATP, 25 mM 
isocitrate, 40 units isocitrate dehydrogenase (Sigma-Aldrich), 500 units of pyruvate 
kinase (Sigma-Aldrich), 300 µg MurA, 2000 µg MurB, 750 µg MurC, 1000 µg MurD, 
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1250 µg MurE and 1500 µg MurF. The synthesis was incubated at 37 °C overnight, 
before dilution with 5 mL sterile water, and filtration with a Vivaspin® centrifugal 
concentrator (10 kDa cut-off) to remove proteins. Non-canonical pentapeptides such as 
UDP-MurNAc-L-Ala-γ-D-Glu-mesoDAP-D-AzaTrp-D-Ala and UDP-MurNAc-L-Ala-γ-D-
Glu-mesoDAP-D-Trp-D-Ala were synthesised in the same way as described here, with 
extra MurF, as the terminal dipeptides were synthesised prior to incorporation in to the 
pentapeptide by MurF. 
 
2.7.2  UDP-MurNAc Pentapeptide Purification 
 
20 mg of UDP-MurNAc pentapeptide (L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala) was 
desalted on the Source 30Q column with Buffer A 10 mM Sodium Bicarbonate pH 9.0, 
Buffer B 250 mM Sodium Bicarbonate. 2 mL fractions were collected. A Nessler’s 
reagent test was conducted on the first and final fraction of the peak to test the amount 
of ammonium remaining in the eluted pentapeptide intermediate after the de-salting 
process. 500 µL of the sample to be tested was added to 500 µL of Nessler’s reagent and 
the absorbance at A425nm was measured after mixing. The obtained values were 
compared against a standard curve. Both fractions had the same absorbance reading and 
contained small traces of ammonium. Fractions of the major peak were pooled and the 
yield of purified pentapeptide was quantified (section 2.7.3) as 4.5 mgs. Purified 
pentapeptide can be converted in to LII, or can be labelled with a fluorophore prior to 
lipid synthesis. 
 
2.7.3  Pentapeptide Quantification 
 
The concentration of UDP-MurNAc-pentapeptide synthesised was calculated by 
measuring the absorbance of the solution at 260 nm using a Jenway 6306 UV-visible 
spectrophotometer, where the uracil moiety of the pentapeptide has an extinction 
coefficient of 10,000 M-1cm-1. 
 
2.7.4  Labelling UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala with   
          Fluorescamine 
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A 42-fold molar excess of fluorescamine (53 mgs) was dissolved in acetone (an equal 
volume to the pooled fractions of pentapeptide) and added to the pentapeptide for 
labeling at room temperature overnight with a magnetic stirrer in a round-bottomed 
flask, covered in foil. The acetone was removed fully by rotary evaporation and the 
reaction was neutralized with Tris.HCl pH 9.0. A 500 µL sample was injected onto a 1 
mL Q-Sepharose column, and eluted over a 20 mL gradient from 10 mM to 1 M 
ammonium acetate pH 7.6 collecting 1 mL fractions. Each eluted peak was freeze-dried 
separately. The exact mass of UDP-MurNAc-L-Ala-D-Glu-(Nε-Fluorescamine)-
mesoDAP-D-Ala-D-Ala is 1472.43 and the molecular weight = 1473.24 Da. 
 
2.7.5  Pentapeptide Dansylation: UDP-N-actylmuramyl-L-Ala-γ-D-Glu-(Nε-  
        dansyl)-mesoDAP-D-Ala-D-Ala (Dansyl-labelled UDP-MurNAc-pentapeptide) 
 
A Source 30Q column (26 x 120 mm) on an AKTApurifier 10 was used to purify UDP-
MurNAc-pentapeptide by anion exchange chromatography. Following purification, all 
ammonium acetate was removed before labelling with dansyl chloride by passing it 
through a Superdex Peptide column in sodium bicarbonate. The presence of any 
ammonium prevents access to the ε-amine group on the DAP of the pentapeptide and 
can discourage dansyl labelling. The removal of ammonium acetate is important to 
allow successful dansylation. After desalting, the pentapeptide was quantified and 
incubated for one hour in the dark with a 42 molar excess of dansyl chloride. The 
reaction was set up in a round-bottomed flask with a magnetic stirrer, in the dark, at 
room temperature, with dansyl chloride dissolved in an equal volume of acetone as 
pentapeptide. The dansyl group reacts instantaneously with the ε-amine group of the 
DAP. After one hour of incubation, the acetone was removed by rotary evaporation. 
 
To separate the desired dansylated-pentapeptide from any unlabelled pentapeptide and 
unreacted dansyl chloride, the product was first centrifuged to remove any insoluble, 
precipitated material. The supernatant was purified by gel filtration on a Sephadex G25 
column (80 × 3 cm), using a peristaltic pump and water as the solvent, at a flow-rate of 
1 mL/min, collecting 5 mL fractions. The entire column and collection tubes were 
covered in foil to purify the labelled-pentapeptide in the dark. Labelled-pentapeptide 
eluted from the column first as it is the largest compound, closely followed by un-
labelled pentapeptide. Unreacted dansyl chloride (dansic acid) eluted last as it is 
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smaller. The absorbance of the eluted fractions was measured at 340 nm, the excitation 
wavelength of the dansyl group. Fractions containing the labelled-pentapeptide were 
lyophilized over-night. The powder was dissolved in water to 1 mg/mL stock solution. 
Mass spectrometry was performed to confirm synthesis of the labelled compound. 
 
2.7.6  Removal of the UDP Group from UDP-Pentapeptides 
 
0.1 M HCl was added to the pentapeptide carefully until pH 1.0 was achieved and 
boiled at 99 °C for 30 minutes to destabilise the phosphodiester linkage between the 
UDP-group and the pentapeptide. The sample was neutralised to pH 7.5 with NaOH. 
 
2.7.7  The Synthesis of Lipid II 
 
The method of preparation was based upon that published (Breukink et al., 2003). To 
make LII, 4.8 µmol undecaprenyl phosphate (Larodan) was dried down under a stream 
of nitrogen gas before being resolubilised in a buffer with detergent. The buffer 
contained 50 mM HEPES (pH 7.6), 1 mM MgCl2 and 1 % TritonX-100 (w/v). To this, 
48 µmol UDP-GlcNAc and 12 µmol UDP-MurNAc pentapeptide was added, for a final 
volume of 2 mL. The final component was M. flavus membrane vesicles (to a final 
membrane protein amount of 10.5 mg). This mixture was gently mixed at room 
temperature for 3 hours. Following incubation, the reaction was stopped with 3.5 mL 6 
M pyridine acetate (pH 4.2) and the synthesised lipids extracted into 3.5 mL solvent (n-
butanol). This was centrifuged at 4,500 g for 10 minutes and the top phase (n-butanol) 
extracted and mixed with an equal volume of water, before centrifugation, as before. 
The top phase was taken, the solvents evaporated and stored at -80 °C until purification.  
 
2.7.8  The Purification of Lipid II 
 
The synthesised lipids were purified by anion exchange, using a DEAE Sephacel 
column. A 20 mL glass pipette was used, with a glass wool plug at the bottom and filled 
with 3 mL of DEAE Sephacel resin. The resin was charged with 5 CV of 1 M 
ammonium acetate, then washed with 5 CV water. The running solvent was a mixture 
of chloroform, methanol and water (in the ratio 2:3:1), and the eluting solvent was the 
same but with ammonium bicarbonate added. The dried lipid sample was resuspended 
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in 6 mL of the running solvent. The resin was equilibrated with 10 CV of the running 
solvent and the resuspended lipids were loaded. The column was developed through 4 
CV washes of the running solvent, with incremental increases in ammonium 
bicarbonate additive, from 0 mM - 300 mM in 50 mM steps, with a further 500 mM and 
1000 mM wash. All of the wash and the loading flow-through samples were collected in 
glass vials and analysed by TLC (section 2.7.9). Samples containing the lipid of interest 
were combined and dried down by rotary evaporation and freeze-drying. 
 
2.7.9  Thin Layer Chromatography 
 
Samples of the LII purification elutions were analysed by TLC. 1.5 mL of eluted 
samples were dried down in a dessicator. The dried samples were resuspended in 20 µL 
of running solution. The running solvent was a mixture of chloroform, methanol, water 
and ammonia (in the ratio of 88:48:10:1). A TLC silica plate was prepared by pencil 
marking a line 1.5 cm from one end with spots 2 cm apart along its length. Lipid 
samples were carefully loaded in 2 µL aliquots and dried between loadings to maintain 
small spot sizes. The running solvent was added to a glass TLC tank to a depth of 1 cm 
and the dried TLC plate was added and developed at room temperature. The plate was 
removed when the solvent reached a few cm from the top and the plate was placed in an 
iodine vapour chamber until stained. Once stained, an image of the plate was promptly 
taken by camera or scanner as iodine staining is not permanent.  
 
2.7.10  Lipid II Quantification  
 
A 50 µL lipid samples and 50 µL chloroform/methanol/water 2:3:1 (v/v) were dried 
down and resuspended in 50 µL 50 mM HEPES, 10 mM MgCl2, 30 mM KCl, 1.5 % 
(w/v) CHAPS, pH 7.6. One of the lipid samples and the blank were treated with: 50 µL 
1 M HCl, boiled for 30 min, centrifuged at 3,000 x g for 5 min, and readjusted to pH 
7.6. The inorganic phosphate hydrolysed from the lipids was quantified using a 
phosphate release assay. The phosphate release assay contained 50 mM HEPES, pH 7.6, 
10 mM MgCl2, 200 µM MESG, 1U PNP and 1 unit inorganic pyrophosphatase (IPP). 
The absorbance was monitored at 360 nm before addition of 10 µL lipid sample. The 
concentration of the lipid was calculated from the amount of phosphate released from 
the acid-hydrolysed lipid compared to the blank sample. The extinction coefficient of 
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the change in absorbance at A360nm by 1 M Pi is 10,000 M-1cm-1 caused by the 
phosphorolysis of MESG. 
 
     2.7.11  Preparing Samples for Mass Spectrometry 
 
50 µL samples were prepared for mass spectrometry, using 50 % acetonitrile and 50 % 
ddH2O. Mass estimates were obtained by negative ion electrospray ionisation mass 
spectrometry (ESI-MS), either in the Chemistry Department facility or by Dr. Adrian 
Lloyd in Life Sciences. 
 
2.8  Enzyme Activity Assays 
 
     2.8.1  Tris-Tricine Polyacrylamide Gel System 
 
Assays of a 15 µL volume were set up to assay the transglycosylase activity of purified 
E. coli PBP1B. In most cases, 65 µM LII and 65 µM Dansylated LII were mixed 
together in a glass vile and the solvents (Chloroform and Methanol) in which the Lipid 
are dissolved were evaporated by N2 gas. The dried LII wasresuspended in the 
appropriate volume of assay buffer to result in the total final concentration of 130 µM 
LII (65 µM Dansylated and 65 µM non-dansylated) in each 15 µL assay. The optimized 
assay buffer is 10 mM HEPES pH 7.5, 3 mM MgCl2, 150 mM NaCl, 0.18% TritonX-
100. 2.3 mM Penicillin G was also added to inhibit any transpeptidase activity. 6 µM E. 
coli PBP1B was added to each assay and was the final component to be added before 
being gently mixed by pipetting. Reactions were left at 37 °C for 45 minutes before 
terminating the reaction at 60 °C for 10 minutes. Samples were centrifuged at 13,000 
RPM for 5 minutes to pellet all protein in the assay. The supernatant was transferred to 
new tubes for avoid loading any protein on 14 to the gel. Loading buffer (100 mM 
Tris.HCl pH 8.8, 4% SDS, 40% glycerol) was added to each sample. 
 
This gel system was first used and published by Schagger & von Jagow in 1987 and has 
more recently been used by Susanne Walker’s lab (Barrett et al., 2007) and Thierry 
Vernet and Andre Zapun (Hellassa et al., 2012). A 37.5 part acrylamide : 1 part 
bisacrylamide stock is used to achieve the correct final acrylamide percentages (9 % 
acrylamide, 2.6 % cross-linker) to separate the glycan lipid chains. No stacking gel is 
! 66 
required and the comb is inserted directing into the resolving gel. A blank sample is 
loaded into one of the lanes to monitor the electrophoresis progress, which consists of 
assay buffer, loading buffer and bromo-phenol blue. Bromophenol blue is not used in 
any of the assay samples as the dye can interfere with their separation and resolution. 
This gel system involves a dual buffer system, which is non-continuous. Anode buffer: 
0.1 M Tris.HCl pH 8.8, Cathode buffer: 0.1 M Tris.HCl pH 8.25, 0.1 M Tricine, 0.1 % 
SDS. Gels are run at 110 Volts, 50 mAmps, for 1 hour. Gels are imaged under UV light 
and the dansylated LII is visible. 
 
     2.8.2  BOCILLIN Assay 
 
Fluorescently labelled penicillin with BODIPY, commonly referred to as BOCILLIN 
FL can bind to the transpeptidase domain of PBPs. A 3 x molar ratio of BOCILLIN-FL 
to PBP was incubated at 37 °C in the dark for 1 hour. Protein loading dye was added to 
the sample, but they were not heat-denatured before analysis by SDS-PAGE. Results 
were visualised in the GelDoc (Syngene) using a short pass (SP) Y520 filter. Adjusting 
the histogram, to avoid capturing a saturated image, amended over-exposure and 
saturation. Densitometry could then we used to more quantitatively compare intensity 
and binding.  
 
     2.8.3  A Continuous Fluorescence Assay for Transglycosylase Activity 
 
An assay was developed by Schwartz et al. in 2002, in which the transglycosylase 
activity of E. coli PBP1B is monitored continuously. This assay may also be suitable for 
other bifunctional PBPs. The principle behind the assay involves N-acetyl-Muramidase 
which breaks down polymers of LII that have been polymerized by PBP. The dansyl 
fluorophore attached to position 3 of the pentapeptide (mesoDAP) in LII is released 
from a lipidic to an aqueous environment upon the breakdown of polymers into 
monomers by N-acetyl-Muramidase. This change in environment surrounding the 
fluorophore results in a decrease in fluorescence, indirectly representing the 
polymerisation of LII. The assay has been developed and adapted for use in a plate 
reader in 25 uL, to allow the potential for more high-throughput screening. All assays in 
the plate reader are carried out in 96-well, black, fluorescence compatible, NUNC 
plates, with excitation and emission of dansyl 340 and 520 nm. All assays were 
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conducted at 30 °C and specific buffers used are given in each case in the figure legend. 
 
     2.8.4  The Spectrophotometric Phosphate Release Assay for Transglycosylase  
              Activity 
 
This assay is a phosphate (Pi) release assay based on the dephosphorylation of the by-
product of transglycosylation, undecaprenyl pyrophosphate (C55-PP), by PgpB. In the 
presence of free inorganic phosphate, PNP (purine-nucleoside phosphorylase) converts 
MESG (absorbance maximum at 330 nm) to ribose-1-phosphate and 7-methyl-6-
guanine (absorbance maximum at 355 nm). Inorganic phosphate consumption is 
proportional to the formation of 2-amino-6-mercapto-7-methylpurine, which has a peak 
absorbance wavelength of 355 nm. As there is minimal background absorbance at 355 
nm from un-reacted substrate, the formation of reaction products can be followed by an 
increase at this wavelength. The concentration of LII input in to the polymerisation is 
directly proportional to the amount of undecaprenyl pyrophosphate (C55-PP) formation 
(assuming polymerisation went to completion), which is proportional to the amount of 
free phosphate generated from dephosphorylation of C55-PP by PgpB. 
 
Discontinuous LII Polymerisation Assay 
 
The polymerisation of Lipid II was set up in a 0.5 mL Eppendorf, to a final volume of 
15 uL. The desired concentration of DAP/Lys LII (usually was dried down in a 0.5 mL 
Eppendorf with a gentle stream of N2 gas. The LII was resuspended in 5 µL of 0.1% of 
DDM by vortex and a short spin in a microcentrifuge. 3 µL of 5x polymerisation assay 
buffer (100 mM Tris.HCl pH 7.6, 50 mM MgCl2) is added to the LII substrate. The of 
E. coli PBP is added last, made up to 15 µL with EcPgpB storage buffer. The 
polymerisation is placed in a PCR machine pre-set to 30 °C for up to 1 hour (or 
completion of polymerisation). Polymerisation is terminated by heating to 60 °C for 10 
minutes, the heat-inactivated enzyme precipitates and is spun down in a microcentrifuge 
for 5 minutes. The soluble products in the supernatant (14 µL, including undecaprenyl 
pyrophosphate transglycosylation by-product) are transferred to a quartz cuvette 
containing the components for the continuous phosphate detection assay in the 
Spectrophotometer. 
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Continuous Inorganic Phosphate Detection Assay 
 
Upon incorporation of a LII monomer in to a growing glycan chain through the 
enzymatic activity of a transglycosylase enzyme, the polyprenyl lipid tail (undecaprenyl 
pyrophosphate, UPP) is cleaved and released as a by-product. The outer-most phosphate 
on UPP can be cleaved by a phosphatase (e.g. PgpB) and quantified 
spectrophotometrically. A quartz cuvette comprised of 5 x assay buffer (100 mM 
Tris.HCl pH 7.6, 50 mM MgCl2), 600 µM MESG, 0.4 Units PNP, up to 20 µL PBP, 
made up to 20 µL with EcPgpB enzyme storage buffer (20 mM Tris.HCl pH 7.5, 1 mM 
MgCl2, 2 mM BME, 0.5 M NaCl, 10 % glycerol, 0.5 mM (3 x CMC) DDM) and finally 
14 µL of the discontinuous polymerisation. The absorbance was measured at A355nm at 
37 °C for 10-30 minutes. The spectrophotometric PNP/MESG coupling system used in 
this assay is illustrated in Figure 5.1. 
 
     2.8.5  Continuous Spectrophotometric Assay for D-Alanine Release 
 
An assay used to discriminate between the two peaks involved D-amino acid oxidase, 
Horse Radish Peroxidase (HRP) and Amplex red. As this assay is selective for D-amino 
acids only, one peak should show activity and the other peak should not. The principle 
behind the assay is that in the presence of D-Amino Acid Oxidase (DAAO) enzyme, the 
D amino acid (D-azatryptophan) is deaminated, releasing the by-products ammonia and 
hydrogen peroxide. In the presence of HRP, hydrogen peroxide is reduced to oxygen, 
which breaks down Amplex red and causes a colour change, detected at a maximum of 
A555nm. Assays were performed in a Cary 100 Spectrophotometer (Varian) at 37 °C. 
 
     2.8.6  The Continuous Transpeptidase Spectrophotometric Assay 
 
To measure the transpeptidase activity of Penicillin-Binding Proteins, 50 mM 
BisTrisPropane pH 8.5, 20 mM MgCl2, 0.1% TritonX-100, 10 mM (or 50 uM) Amplex 
Red, 3.5 Units DAAO, 5.8 U HRP, 0.008 mgs E. coli LpoB, donor: 20 mM Lys-LII in 
0.1% TritonX-100. A baseline reading was measured for a few minutes, before adding 
the PBP and finally the acceptor: 20 uM MurNAc pentapeptide. The assay was 
monitored at 555 nm, at 30degC, for 30-40 minutes. 
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     2.8.7  MurF Assay for Dipeptide Incorporation 
 
5 x assay buffer, 1 mM DTT, 0.2 mM NADH, 2 mM PEP, 1 mM ATP, 1 uL MurF, 1 
uL, Pyruvate kinase lactate dehydrogenase, 1 uL UDP MurNAc tripeptide, 1 mM 
dipeptide, 1 mM ATP. 1mM of the Dazatryp dipeptide was sufficient to do kinetics with 
and do the synthesis with. SpMurF was better for the azaTryp dipeptide. The assay was 
conducted by initiating the reaction with PaMurF, ATP, and the dipeptide of interest for 
incorporation. 
 
     2.8.8  D-Ala-D-X Ligase (VanA) Assay 
 
To determine whether the D-Ala-D-X ligase VanA, would incorporate D-tryptophan or 
D-azatryptophan in to the second subsite of the dipeptide formed, a continuous, coupled, 
spectrophotometric assay was used to test the axtivity of VanA (Daib, 1988). In the 
presence of ATP, VanA normally ligates D-Ala to D-Lactate. Upon the activity of 
VanA, ATP is hydrolysed forming ADP + Pi. In the presence of pyruvate kinase, PEP is 
converted to pyruvate, which is subsequently converted to lactate in the presence of 
lactate dehydrogenase. NADH is concurrently oxidised to NAD+. This oxidation is 
observed as a reduction in absorbance at 340 nm.  
 
2.9  Techniques for Protein Structure Analysis 
 
     2.9.1  Circular Dichroism Spectroscopy 
 
Circular dichroism is a technique that can be used to determine protein secondary 
structure in solution and the extent of α-helicity, β-sheet and random coil. Circular 
dichroism is defined as the difference in absorption of left and right circularly polarized 
light (Correa & Ramos, 2009). When plane polarized light enters a chiral molecule it is 
resolved into two perpendicular vibrating waves that propagate at different velocities. 
Circular dichroism can be measured by the difference in absorbance of the material for 
circularly polarized light, ΔA, where ΔA = (AL-AR). This difference in absorption is 
easily converted to ellipticity units, θ, and typically spectra are generated by the CD 
spectropolarimeter as a function of θ (in millidegrees) against wavelength (nm). 
Millidegree units are converted into standard Mean Residue Ellipticity (MRE) units 
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(mdeg cm2 dmol-1), which incorporate mean residue weight, protein concentration in 
mg/mL, path length in cm and amino acid sequence length.  
 
CD spectra were measured using a Jasco 815 spectropolarimeter at room temperature 
and using a 1.0 mm path-length quartz circular cuvette, roughly the size and shape of a 
£1 coin. All spectra were recorded at room temperature between 190-260 nm, using a 
data pitch of 0.2 nm, bandwidth of 2 nm, scanning speed of 100 nm/min, response time 
of 1 second, and either 16 or 32 accumulations. Specific protein concentrations buffers 
used are given in the text. 
 
     2.9.2  Protein Crystallisation 
 
Sparse matrix screening was trialled with PBP1A proteins, including the commercially 
available MemStart and MemGold, in which conditions have been optimised for 
membrane proteins. Sitting drop crystal trays were set up with 100 µL precipitant per 
reservoir at 18 °C. 200 nL protein mixed with 200 nL precipitant using the Mosquito 
robot and trays checked after 24 and 48 hours initially. 
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Chapter 3 
 
The Cloning, Expression and Purification of  
PBPs and their Associated Proteins 
 
3.1  Introduction 
 
The cloning, expression and purification of a vast array of Class A PBPs along with 
their associated proteins was pivotal to the success of this project. This chapter outlines 
the groundwork in put to achieve a wide plethora of proteins available to assay in the 
following chapters. 
 
3.2  Experimental Aims 
 
• Clone, express and purify Class A PBP genes along with the associated proteins 
for high-through-put expression 
• Optimise protein expression levels 
• Screen for the optimal detergent(s) for extraction and purification of 
membranous and membrane-associated proteins 
• Purify the proteins to homogeneity / monodispersity 
• Conduct initial X-ray crystallography trials of Class A PBPs 
 
3.3  The Cloning, Expression and Purification of PBPs 
 
A list of all the DNA constructs used in this body of work are described in Table 3.1. 
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Table 3.1  A Comprehensive Library of all PBP and PBP-associated DNA Constructs used 
Throughout this Project 
Construct Protein Fragment Tag (Protease) 
Restrictn 
Sites 
Anti 
biotic 
Selectn 
Cloned by 
E. coli PBP1A 
pET28::Ec 
pbp1a 
Full-length 1-850 
N-term His 
(Thrombin) 
NdeI / 
NotI 
Kan Amy O’Reilly 
pET28::Ec 
pbp1a - E86Q 
Full-length 1-850, with 
TG active site mutation 
E86Q 
N-term His 
(Thrombin) 
NdeI / 
NotI 
Kan Amy O’Reilly 
pET28::Ec 
pbp1a - 
S473A 
Full-length 1-850, with 
TP active site mutation 
S473A 
N-term His 
(Thrombin) 
NdeI / 
NotI 
Kan Amy O’Reilly 
E. coli PBP1B 
pET28(a)+:: 
Ecpbp1b 
γ isoform: ‘short’. 
Starts at M46 with an N-
term extension of 6 amino 
acids: GSHMASM46-N844 
N-term His 
(Thrombin) 
NheI / 
EcoRI 
Kan 
pDML924 
(Terrak et al., 
1999), Vollmer’s 
group, Newcastle 
University, UK. 
pET28(a)+:: 
Ecpbp1b - 
E233Q 
with TG active site 
mutation E233Q 
N-term His 
(Thrombin) 
NheI / 
EcoRI 
Kan 
SDM of 
Newcastle PBP1B 
construct by Amy 
O’Reilly 
pET28(a)+:: 
Ecpbp1b - 
S510A 
with TP active site 
mutation S510A 
N-term His 
(Thrombin) 
NheI / 
EcoRI 
Kan 
SDM of 
Newcastle PBP1B 
construct by Amy 
O’Reilly 
Vector::Ec 
pbp1b Δ106 
E. coli PBP1B, missing 
everything before the 
UB2H domain begins at 
Y107 
?? ?? ?? 
Dr. David Roper, 
University of 
Warwick 
P. aeruginosa PBP1A 
pET28::Pa 
pbp1a 
Full-length M1-F822 
N-term His6 
(Thrombin) 
NdeI / 
NotI 
Kan 
GenScript, E. coli 
codon-optimised 
pET28::Pa 
pbp1a E86Q 
Full-length M1-F822 with 
TG active site mutation 
E86Q 
N-term His6 
(Thrombin) 
NdeI / 
NotI 
Kan 
SDM of Genscript 
construct by Amy 
O’Reilly 
pET28::Pa 
pbp1a S461A 
Full-length M1-F822 with 
TG active site mutation 
S461A 
N-term His6 
(Thrombin) 
NdeI / 
NotI 
Kan 
SDM of Genscript 
construct by Amy 
O’Reilly 
P. aeruginosa PBP1B 
pET28:: Pa 
pbp1b Δ22 
W23-N774  
N-term His6 
(Thrombin) 
NdeI / 
NotI 
Kan Amy O’Reilly 
pET28:: Pa 
pbp1b Δ22 - 
E190Q 
W23-N774 with TG active 
site mutation E190Q 
N-term His6 
(Thrombin) 
NdeI / 
NotI 
Kan Amy O’Reilly 
! 73 
pET28:: Pa 
pbp1b Δ22 - 
S468A 
W23-N774 with TP active 
site mutation S468A 
N-term His6 
(Thrombin) 
NdeI / 
NotI 
Kan Amy O’Reilly 
pIX1016::Pa 
pbp1b 
Δ22 * 
W23-N774 Plasmid for 
expression in P. putida 
cells 
N-term His6 
 
HindIII / 
XbaI 
gento
mycin 
Amy O’Reilly 
Class B PBPs 
pSUMODave 
::Ecpbp2 
M1-H633, full-length 
His SUMO 
(TEV) 
BamHI / 
XhoI 
Kan 
Dr. Dean Rea, 
Roper Group, 
University of 
Warwick 
pET52b::Ec 
pbp3 Δ43 
W44-S588, No TM domain 
C-term His10 
(Thrombin) 
BamHI / 
SacI 
Amp Amy O’Reilly 
pET52b::Pa 
pbp3 - Δ34 
A35-G565, No TM domain 
C-term His10 
(Thrombin) 
BamHI / 
SacI 
Amp Amy O’Reilly 
PBP-Associated Proteins 
pTrcHis6::Ec 
pgpb 
M1-S254, Full length C-term His6 
NcoI / 
BglII 
Amp 
Gift from Dr. T. 
Touzé, Université 
Paris-Sud 
pAK147::Ec 
cpob Δ26 
(pET21d) 
Q27-M263, No TM domain C-term His6 
NcoI / 
XhoI 
Amp 
Prof. Colin 
Kleanthous’s 
group, University 
of Oxford 
pProEx HTa 
::Pa ybgf 
M1-R274, full-length 
N-term His6 
(TEV) 
NcoI / 
XhoI 
Amp 
Genscript, E. coli 
codon-optimised 
pET28b::Ec 
ftsn 
M1-G319, full-length 
C-term His6 
(Thrombin) 
NcoI / 
XhoI 
Kan 
Dr. Dean Rea, 
Roper Group, 
University of 
Warwick 
pET28d::Ef 
VanA 
M1-G343, full length 
N-term His6 
(Thrombin) 
?? Kan 
Dr. Sarah Baton, 
Roper Group, 
University of 
Warwick 
pSUMODave 
::Ec lpoa Δ27 
G28-S678 
His-SUMO 
(TEV) 
NcoI / 
XhoI 
Kan 
Dr. Dean Rea, 
Roper Group, 
University of 
Warwick 
pET28b::Pa 
lpoa Δ20 
A21-F604, no TM domain 
N-term His6 
(Thrombin) 
NdeI / 
NotI 
Kan Amy O’Reilly 
pProExHT::Ec 
lpob Δ21 
G22-Q213 His (TEV) 
NcoI / 
XhoI 
Amp 
Dr. Dean Rea, 
Roper Group, 
University of 
Warwick 
* All constructs are for expression in E. coli except for pIX1016::PaPBP1B23-774, which 
expresses in P. putida cells. 
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     3.3.1  The Cloning and Purification of E. coli PBP1A 
 
The EcPBP1A gene was amplified from E. coli chromosomal DNA by PCR (Figure 
3.1). 
 
 
 
 
 
 
 
Figure 3.1  PCR Amplification of Full-length E. coli PBP1A. PCR products analysed by 1.0 
% agarose gel. The four names in each section is an increase in annealing temperature from 50-
60 °C. Expected size: 2.56 kb. 
 
The PCR products were cleaned up and cloned in to the plasmid vector pET28 using the 
restriction digestion enzymes NotI and NdeI (Section 2.3.4). The pET28::E. coli PBP1A 
construct is the full length E. coli PBP1A protein with an N-terminal His6-tag (93,636 
kDa without the His6-tag). This construct was expressed and purified according to 
section 2.3.4 and 2.5.1. After elution from Ni2+-IMAC (Figure 3.2a), a second 
purification step by cation exchange using Sepharose S resin was employed to clean up 
the protein (Figure 3.2b).  
  
 
 
 
 
  
 
Figure 3.2  The Immobilised Metal Affinity Chromatography and Cation Exchange 
Purification of Full-length E. coli PBP1A. (a) 10% SDS-PAGE analysis of Ni2+-IMAC 
elutions (b) 10% SDS-PAGE analysis of the subsequent Sepharose Q Ion Exchange 
purification. FT: Flow-through, W: wash  
 
A second purification step was not always necessary after IMAC, but was employed on 
occasion if particularly clean protein was required, e.g. for X-ray crystallographic 
studies. 4 mg of pure protein per 750 mL of culture was routinely achieved. 
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     3.3.2  The Purification of E. coli PBP1B 
 
The pET28(a)+::EcPBP1b construct was a kind gift from Waldemar Vollmer 
(Newcastle University, UK.) which is the γ-isoform, also known as ‘short’ (the α-
isoform of EcPBP1B is 46 amino acids longer than the γ-isoform). This construct starts 
at Met46 and has an N-terminal extension of 6 amino acids: GSHMAS M46-N844 (89.48 
kDa without the His6-tag). This construct was expressed in BL21(λDE3) cells and 
purified according to sections 2.4.2 and 2.5.1 (Figure 3.3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3  SDS-PAGE Analysis of the Purification of E. coli PBP1B M46-N844, by Ni2+ 
IMAC gravity flow column, at 4 °C. A: Crude extract (supernatant from 25,000g spin) B: 
Cytoplasm phase (supernatant from 40K RPM spin) C: After 1 hour solubilisation in TritonX-
100 D: Soluble phase (supernatant after 44K RPM spin), incubated with Ni2+ resin) E: Flow-
through F: Column wash G: 50 mM Elution H: 100 mM Elution I: 150 mM Elution J: 200 mM 
Elution K: 250 mM Elution L: 300 mM Elution M: 350 mM Elution.  
 
In most cases, E. coli PBP1B was purified sufficiently enough after one pass through a 
Ni2+ column, as in Figure 3.3. The His6-tag was cleaved by thrombin protease and 
purified by cation exchange using SourceS resin (Section 2.5.3). 3 mg of pure protein 
per 750 mL of culture was routinely achieved. A second purification step was rarely 
used, but if necessary, a pre-packed SourceS column would be used to clean up the 
protein further before cleavage of the His6-tag with thrombin. 
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     3.3.3  The Cloning and Purification of Full-length P. aeruginosa PBP1A 
 
Pseudomonas aeruginosa PBP1a gene (gene locus PA5045) was amplified by PCR 
from genomic DNA (gDNA) using Phusion HF DNA polymerase under varying 
conditions (Section 2.3.1). The PCR products were a mixture of varying sizes, although 
the conditions with MgCl2 only appeared to generate a PCR product of the correct size 
for PaPBP1a (2.47 kb) (Figure 3.4a). Two fresh extractions of PA001 gDNA were 
purified from a mini-culture of P. aeruginosa PA001 using a Promega Wizard Genomic 
DNA Purification Kit and were tested as PCR template for PaPBP1a amplification, 
using the PCR conditions with MgCl2 (Figure 3.4b). 
 
 
 
 
 
 
 
Figure 3.4  The Amplification of Full-length P. aeruginosa PBP1A by PCR. Analysed by 
1.0 % agarose gel. (a) PCR in four different conditions, across an annealing temperature 
gradient (Section 2.3.1). (b) The most successful conditions from (a) were repeated with two 
new extracts of PA001 gDNA. PaPBP1A gene = 2.47 kb). 
 
The PCR products of PaPBP1a were not clean and using fresh PA001 template did not 
alter the result. The four DNA bands highlighted in (a) were extracted with a scalpel 
and cleaned up using a Qiagen Gel Extraction Clean-Up Kit. A sample of the extracted 
PCR product was analysed on agarose gel to analyse its purity and size, before being 
cloned in to expression vector pET28b(+) using the restriction enzymes NdeI and NotI. 
After multiple attempts, the cloning of PaPBP1a was unsuccessful and so full-length 
pET28b::PaPBP1a was cloned by GenScript, using am E. coli codon-optimised 
synthetic gene. pET28b::PaPBP1A was transformed in to the bacterial expression 
competent cells C43(λDE3) (Section 2.2.3) as this cell-line has been optimised for 
membrane protein expression and was the optimal cell line for PaPBP1B after 
expression trials (section 2.4.3). PaPBP1A was expressed according to Section 2.4.1 
and purified by gravity flow IMAC (Figure 3.5) at 4 °C across a step-wise imidazole 
gradient. 
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Figure 3.5  The Purification of pET28(b)::PaPBP1A1-822 by Ni2+ IMAC and SourceS 
Cation Exchange. (a) SDS-PAGE analysis of IMAC purification of PaPBP1A, eluted with 
increasing concentrations of imidazole (b) After His6-tag cleavage, the PBP was separated from 
it’s His6-tag and remaining Thrombin protease. PaPBP1A = 91.2 kDa.  
 
PaPBP1A was purified to homogeneity in two steps of purification, before and after 
His6-Tag cleavage. Purified PaPBP1A was subsequently used in enzymatic assays in 
Chapters 4, 5 and 6 and X-ray crystallography trials later in this chapter. 
 
     3.3.4  Cloning P. aeruginosa PBP1B 
 
The PaPBP1B W23-N774 gene was amplified by PCR using  (Figure 3.6a) using the 
primers in Appendix 1. The amplified PaPBP1B gene was cleaned up and it’s purity 
analysed by agarose gel (Figure 3.6b), alongside its destination vector. Upon cloning 
PaPBP1b in to pET28b, the ligation reactions were transformed in to TOP10 competent 
cells (Section 2.2.3) and two colonies harboring the potential PaPBP1b clone were 
cultured and the plasmid DNA extracted. Diagnostic PCR using Dream Taq DNA 
polymerase and T7 promoter and and reverse PaPBP1B oligo amplified a gene product 
of the same size as Pa pbp1b (2256 bp) (Figure 3.6c). 
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Figure 3.6  Amplification of PaPBP1B W23-N774 by PCR. (a) PCR using Accuprime Taq 
DNA polymerase (Invitrogen), with 4 µM MgCl2 (including that in the PCR buffer) and 3 % 
DMSO, across a sliding temperature gradient from 60 - 70 °C during annealing. Two PA001 
gDNA aliquots were used as template for amplification. The expected PCR fragment size = 
2256 bp (b) The purified PCR product and destination vector pET28b analysed by 1.0 % 
agarose gel. (c) Diagnostic PCR of two colonies (TOP10 cells) potentially containing the 
pET28b::PaPBP1b plasmid. Primers used for diagnostic PCR were the pET vector-specific T7 
forward primer and the PaPBP1B reverse primer initially used to amplify PaPBP1B, the DNA 
polymerase used was DreamTaq. 
 
PaPBP1B W23-N774 was successfully cloned into pET28b, which was tested for its 
optimum expression in a variety of cell lines, along with EcPBP1B for direct 
comparison. 
 
     3.3.5  Expression Trials with E. coli PBP1B and P. aeruginosa PBP1B 
 
Upon confirmation of the correct in-frame sequence, expression trials of EcPBP1B and 
PaPBP1B were done to identify the optimum bacterial cell line to express each protein 
(Section 2.4.3). Cells containing the expression plasmids were cultured with half being 
induced with IPTG and the other half remaining as an uninduced control. The isolated 
membrane fractions were analysed by SDS-PAGE and Western blot (Figure 3.7). 
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Figure 3.7  A Bacterial Cell-Line Expression Trial of PaPBP1B and EcPBP1B. The 
membrane fraction of IPTG-induced and non-induced cells were analysed by 10% SDS-PAGE 
and anti-His Western blot. Cells lines tested were BL21, BL21*R, C41, C43 and C43*R (a) 
EcPBP1B membranes from each cell line analysed by 10% SDS-PAGE (b) EcPBP1B 
membranes from each cell line analysed by anti-His Western blot (c) PaPBP1B membranes 
from each cell line analysed by 10% SDS-PAGE (d) PaPBP1B membranes from each cell line 
analysed by anti-His Western blot. C = non-induced control, I = induced to 1 mM IPTG upon 
reaching OD600 0.7. EcPBP1B = 89.48 kDa without the His6-tag, PaPBP1B = 83.05 kDa. 
 
BL21(DE3) and BL21*R(DE3) cell lines did not express PBP1B as well as the 
BL21(DE3) derivative cell lines C41, C43 and C43*R (all DE3 lysogens). These cell 
lines are optimised for membrane protein expression (Miroux & Walker 1996). 
C43(DE3) was chosen for the expression of EcPBP1B M46-N844 and PaPBP1B W23-N774. 
Upon selection of the optimum cell line, expressions at alternative temperatures and 
duration of expression were trialled (Figure 3.8).  
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Figure 3.8  Expression Temperature Trials for EcPBP1B and PaPBP1B. The membrane 
fraction of IPTG-induced and non-induced cells were analysed by 10% SDS-PAGE and anti-
His Western blot. Temperatures tested for optimum protein expression were 37 °C for 5 hours, 
25 °C overnight and 16 °C overnight. (a) EcPBP1B membranes from each cell line analysed by 
anti-His Western blot (b) EcPBP1B membranes from each cell line analysed by anti-His 
Western blot (c) PaPBP1B membranes from each cell line analysed by anti-His Western blot 
(d) PaPBP1B membranes from each cell line analysed by anti-His Western blot. C = control, I 
= induced. 
 
There was very little expression of either protein at 16 °C or 37 °C. Both EcPBP1B and 
PaPBP1B proteins were selected to be expressed for 18 hours overnight, at 25 °C to 
achieve optimal protein expression. 
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     3.3.6  P. aeruginosa PBP1B Detergent Screen 
 
A detergent screen of ionic, anionic and non-ionic detergents was conducted with P. 
aeruginosa PBP1B (Figure 3.9) to determine its solubility in different detergents and 
therefore which detergent would be preferable for maximum yield in further studies. 
The membrane fractions were isolated as in section 2.4.5, except on a smaller scale, 
using the benchtop Beckman T90K ultracentrifuge with the TLA 100.3 rotor and 2 mL 
samples instead of the large Ti45 rotor. Solubilisation was conducted as in section 2.4.6 
at 5-fold the CMC of each detergent. 
 
 
 
Figure 3.9  A Detergent Screen of P. aeruginosa PBP1B in a Variety of Ionic, Anionic and 
Non-Ionic Detergents. This screen highlights the extent to which each detergent solubilizes 
PaPBP1B, visualised by anti-His Western blot. Soluble and insoluble fractions of PaPBP1B are 
shown. 
 
TritonX-100 had the best solubilizing ability by far and is the detergent most commonly 
used in the literature to extract and solubilise Class A PBPs as well as for use in PBP 
assays. If needed, the protein could be extracted in an alternative detergent that is more 
compatible with the technique intended for the specific use of the protein e.g. DM does 
solubilise PaPBP1B to some extent and could be selected for crystallisation studies of 
the protein even though the amount of protein that is extracted by DM is not optimal 
compared to TritonX-100 so the yield of soluble protein extracted by DM is 
compromised relative to TritonX-100. 
 
     3.3.7  The Purification of PaPBP1B 
 
PaPBP1B was expressed for 18 hours at 25 °C in C43(λDE3) cells and was extracted 
into four different detergents: CHAPS, TritonX-100, LDAO and DDM. All batches 
were purified by gravity flow Ni2+ IMAC at 4 °C (Section 2.5.2) (Figure 3.10). After 
cleavage of the His6-tag by thrombin protease, a further purification step to remove the 
thrombin was by cation exchange using SourceS resin. 
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Figure 3.10  The Purification of pET28(b)::PaPBP1B W23-N774 in four detergents: 
CHAPS, TritonX-100, LDAO and DDM, by Co2+ IMAC. 10 % SDS-PAGE analysis of IMAC 
purification of PaPBP1B, eluted with increasing concentrations of imidazole. PaPBP1B W23-
N774 = 83.05 kDa once the His-tag has been cleaved.  
 
PaPBP1B was purified to homogeneity by IMAC followed by cation exchange. The 
ability of the PaPBP1B transpeptidase domain to bind to fluorescent penicillin was a 
quick test to determine correct folding of the protein.  
 
3.4  Initial Structural and Functional Characterisation of Purified PaPBP1A and     
       PaPBP1B 
 
     3.4.1  Labelling PaPBP1B with Fluorescent-Penicillin, BOCILLIN FLTM 
 
The binding of the PaPBP1B transpeptidase domain to boron-dipyrromethene 
(BODIPY)-labelled penicillin (referred to as BOCILLIN FLTM) was analysed to 
confirm correct folding of the transpeptidase domain (section 2.8.2). The proteins were 
incubated with a 3:1 molar ratio of BOCILLINTM to protein, incubated for 1 hour at 37 
°C, visualised by SDS-PAGE. BOCILLINTM is acylated by the active site serine 
forming a covalent complex, which can be observed by fluorescence detection 
following SDS-PAGE (Figure 3.11).! 
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Figure 3.11  BOCILLINTM-FL Labelling of PaPBP1B, EcPBP1B and PaMurF. (a) SDS-
PAGE analysis of two PBPs (both purified in TritonX-100) and one negative-control protein 
MurF, ± BOCILLINTM-FL, imaged on a UV transilluminator in a Syngene G:Box using a 
ShortPass filter (suitable for detecting the λEm of BODIPY at 512 nm) and GeneSnap software 
to avoid a saturated image.  
 
PaPBP1B appeared to bind to BOCILLINTM-FL upon incubation together and 
PaPBP1B does not indicate any fluorescence when not incubated with BOCILLINTM-
FL. The same can be said for EcPBP1B. The cytoplasmic ligase MurF, which does not 
have a transpeptidase domain, does not bind to BOCILLINTM-FL when incubated. The 
transpeptidase domains of PaPBP1B and EcPBP1B both appear to be folded correctly. 
 
     3.4.2  Circular Dichroism of PaPBP1A and PaPBP1B 
 
As a pre-requisite to functional spectrophotometric studies as well as structural 
macromolecular X-ray crystallisation, P. aeruginosa Class A PBPs were analysed by 
Circular Dichroism (CD) (section 2.9.1) to ensure the proteins were properly folded, 
and to compare secondary structure characteristics of both proteins. CD provides 
information about molecular conformation and protein stability. In the instance of 
proteins, there are spectral signatures characteristic of α-helical, β-sheet and random 
coil secondary structures, and fitting software can determine the relative percentages of 
each in the sample. PaPBP1A and PaPBP1B were analysed by CD spectroscopy to test 
for a native protein fold (Figure 3.12). 
(b) Coomassie stained 
Pa
PB
P1
B 
+ 
BO
CI
LL
IN
 
Pa
PB
P1
B 
+ 
BO
CI
LL
IN
 
Pa
PB
P1
B 
Ec
PB
P1
B 
+ 
BO
CI
LL
IN
 
Ec
PB
P1
B 
+ 
BO
CI
LL
IN
 
Ec
PB
P1
B 
M
ur
F 
+ 
BO
CI
LL
IN
 
M
ur
F 
+ 
BO
CI
LL
IN
 
M
ur
F 
(a) BOCILLINTM  
     fluorescence 
Pa
PB
P1
B 
+ 
BO
CI
LL
IN
 
Pa
PB
P1
B 
+ 
BO
CI
LL
IN
 
Pa
PB
P1
B 
Ec
PB
P1
B 
+ 
BO
CI
LL
IN
 
Ec
PB
P1
B 
+ 
BO
CI
LL
IN
 
Ec
PB
P1
B 
M
ur
F 
+ 
BO
CI
LL
IN
 
M
ur
F 
+ 
BO
CI
LL
IN
 
M
ur
F 
MurF 
! 84 
 
 
 
 
 
 
 
 
 
Figure 3.12  Circular Dichroism Analysis of P. aeruginosa PBP1A and 1B. Both proteins 
were solubilised in 1.5 mM CHAPS. Scans were made in the far UV range (190 - 260 nm) and 
all data was collected at 20 °C. Both PBPs were diluted in sodium phosphate buffer to a final 
PBP concentration of 0.1 mg/mL (1.1 µM and 1.2 µM respectively, in a 200 µL sample). 
 
Examination of the CD spectra in CHAPS detergent shows weak peaks at around 208 
nm and 222 nm, characteristic of a predominantly α-helical protein. Using the protein 
secondary structure prediction software PSIPred (Jones, 1999), the predicted α-helicity 
of PaPBP1A was 53.7 and 61.2 % for PaPBP1B derived from the protein sequences 
alone. 
 
3.5  Further Investigation in the quest for active PaPBP1B 
 
3.5.1  The Cloning and Expression of Shorter, ‘Soluble’ PBP1B from E. coli and    
          P. aeruginosa 
 
Shorter protein fragments of P. aeruginosa and E. coli PBP1B were cloned that lacked 
the majority of the membrane-associated N-terminal region, with the aim to achieve a 
higher protein expression yield due to the protein being more soluble in nature and 
would not require detergents for extraction from the membrane. The EcPBP1B protein 
fragment cloned and expressed was Y107-N844 and the PaPBP1B construct was Y65-N774 
with the initiating tyrosines being the first amino acid of the UB2H domain in PBP1B in 
both species. The PCR products of EcPBP1B Y107-N844 are in Figure 3.13a, with an 
expected size of 2214 bp. The chosen destination vector for PBP1B expression was 
pET22b as it carries an N-terminal pelB signal sequence for potential periplasmic 
localization. The majority of PBP1B resides in the bacterial periplasm, anchored to the 
! 85 
cytoplasmic membrane at its N-terminus. With the absence of N-terminal membrane 
associated regions in these designed constructs, the expressed protein may be free in the 
periplasmic space. Upon successful cloning in to plasmid pET22b, EcPBP1B Y107-N844 
was expressed in BL21(λDE3) cells. The cells were lysed by sonication and spun down 
to pellet any insoluble material, leaving soluble proteins from the cytosol in the 
supernatant. A sample of both the pelleted insoluble material and the soluble 
supernatant were run on SDS-PAGE for analysis of the solubility of EcPBP1B Y107-
N844 (Figure 3.13b). The same theory was applied to PaPBP1B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13  The PCR Amplification of EcPBP1B Y107-N844 and PaPBP1B Y65-N774 and 
Initial Solubility Expression Trial. PCR products were analysed by 1.0 % agarose gel 
and initial expression by 10 % SDS-PAGE. PCR of EcPBP1B107-844 (a) and PaPBP1B65-774 (c) 
was carried out as in section 2.3.1 using High Fidelity Phusion DNA polymerase in a range of 
conditions ± MgCl2 and DMSO, across an annealing temperature gradient of 50-60 °C. 
EcPBP1B gene size = 2214 kb and PaPBP1b = 2256 kb. The PCR products were pooled, cloned 
into pET22b and expressed in BL21 (λDE3) cells. (b) and (e) The soluble and insoluble 
fractions of both EcPBP1B107-844 (82.0 kDa) and PaPBP1B65-774 (78.4 kDa) were analysed by 
10% SDS-PAGE. (d) Diagnostic PCR of potential PaPBP1B Y65-N774 clones using the pET22b 
vector-specific T7 Forward primer, and the Pa1b reverse primer. !
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Both of these genes were successfully cloned in to pET22b and an expression analysis 
of the soluble versus insoluble phases revealed where the majority of the expressed 
proteins resided. Despite cleaving the N-terminal membrane-associated region, both 
proteins expressed predominantly in the insoluble phase. No further experiments were 
conducted with EcPBP107-844 as the M46-844 construct showed average expression yields 
and already exhibited good enzymatic activity. It was unknown what affect cleaving the 
first 106 residues from the N-terminus would have on the activity of EcPBP1B. 
However, the insoluble expression of PaPBP1B Y65-774 underwent a solubilisation 
experiment with TritonX-100 to see if PaPBP1B could be extracted from the membrane 
(section 2.4.6) (Figure 3.14a). Triton-X100-solubilised PaPBP1B Y65-N774 was 
purified by IMAC (Figure 3.14b). 
 
 
 
 
 
 
Figure 3.14  The Solubilisation and IMAC Purification of PaPBP1B Y65-774. (a) The 
solubilisation of PaPBP1B Y65-774 in 1% TritonX-100, with the insoluble and soluble fractions 
analysed by 10% SDS-PAGE (b) Ni2+ IMAC purification (gravity-slow column at 4 °C) of 
PaPBP1B Y65-774 analysed by 10% SDS-PAGE, FT: flowthrough, W: wash. (c) BOCILLINTM 
binding to the original PaPBP1B W23-774 and the shorter PaPBP1B Y65-774. 
 
PaPBP1B Y65-774 was successfully extracted from the membrane with TritonX-100 and 
purified by IMAC. The transglycosylase activity of PaPBP1B Y65-774 was analysed by 
continuous fluorescence monitoring (Schwartz et al., 2002), but was not active for 
transglycosylase activity. Incubating PaPBP1B65-774 with fluorescent penicillin 
(BOCILLINTM) indicated that the transpeptidase domain was folded correctly in an 
active conformation for both PaPBP1B constructs. 
 
     3.5.2  Cloning P. aeruginosa PBP1B in to a P. putida Expression Construct and     
               Homologous Protein Expression  
 
Catalytic activity of P. aeruginosa PBP1B had not been observed with the constructs 
cloned and heterologously-expressed in E. coli cells and purified thus far. Therefore, 
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cloning the gene in to a Pseudomonas-compatible expression vector and expressing the 
protein homologously was trialled. The PaPBP1B gene was amplified by PCR (section 
2.3.1) (Figure 3.15a) and cloned in to low-copy number vector pIZ1016 with restriction 
sites HindIII and XbaI. Diagnostic PCR amplification of potential 
pIX1016::PaPBP1B23-774 clones revealed that 5 out of 12 colonies contained the 
PaPBP1b gene (Figure 3.15c). These 5 clones were sequenced using vector-specific 
M13 forward primer and the reverse primer that was designed for original gene 
amplification. The gene was expressed in P. putida cells, the membrane fraction 
isolated and the over-expressed protein was extracted from the membrane with 0.2 % 
TritonX-100 and purified by IMAC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15  The Cloning of PaPBP1B23-774 in to the P.Putida Expression Vector pIZ1016 
(a) PCR amplification of PaPBP1B23-774 using the wildtype pET28b PaPBP1B construct as the 
template, in a combination of MgCl2 and DMSO conditions, across an annealing temperature 
gradient from 50-60 °C (b) Restriction digestion of PaPBP1B23-774 PCR product and the 
pIZ1016 vector using HindIII and XbaI (c) Diagnostic PCR amplification of 12 potential 
pIZ1016::PaPBP1B23-774 clones, using M13 (forward) primer with the reverse primer that was 
designed for original gene amplification. (d) Anti-His Western blot of pIZ1016::PaPBP1B23-774 
expression in a P. putida expression cell-line and IMAC purification, Mem = membrane 
fraction of P. putida cells over-expressing PaPBP1B, 100, 150 are the mM imidazole elutions. 
 
PaPBP1B was successfully cloned in to a vector compatible with expression in P. 
putida cell-lines and was cultured in a large-scale expression, with protein expression 
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induced by the addition of arabinose. The level of PaPBP1B expression was low, but 
pIZ1016 is a low-copy number plasmid. The protein was effectively extracted from P. 
putida membranes with TritonX-100 and purified by IMAC and visualised by anti-His 
Western blot (Figure 3.15d). A final yield of 0.56 mg of protein was achieved which 
was tested for transglycosylase activity using a continuous fluorometric assay (Schwartz 
et al., 2002), but no activity at all was detected. 
 
All four Class A PBPs of interest (E. coli PBP1A, E. coli PBP1B, P. aeruginosa PBP1A 
and P. aeruginosa PBP1B) have been cloned and purified, summarised in Figure 3.16 
with all four amplified gene products and IMAC purification SDS-PAGE analysis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16  A Summary of the Cloning and Purification of all Four Class A PBPs: 
EcPBP1A, EcPBP1B, PaPBP1A and PaPBP1B. (a) The PCR amplified products of all four 
genes (b) The IMAC purification of all four proteins, analysed by 10 % SDS-PAGE. 
 
3.6  Purification of PBP Catalytic Active Site Mutants 
 
3.6.1  Site-Directed Mutagenesis and Purification of E. coli PBP1A and PBP1B        
          Transglycosylase Active Site Mutants E86Q and E233Q Respectively 
 
Primers were designed to alter the transglycosylase catalytic active site of E. coli 
PBP1A and PBP1B from glutamate to glutamine (Section 2.3.6). The primers used are 
in Appendix 1. Upon confirmation of successful site-directed mutagenesis by DNA 
sequencing (section 2.3.5), the mutated genes were expressed in C43(DE3) cells 
(sections 2.4.1 and 2.4.2 respectively) and the protein purified by IMAC (section 2.5.3) 
(Figure 3.17). 
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Figure 3.17  The Purification by IMAC of E. coli PBP1A and 1B Transglycosylase  
Mutants. Fractions analysed by 10% SDS-PAGE. (a) E. coli PBP1A transglycosylase active- 
site mutant E86Q purification by Ni2+ IMAC (b) E. coli PBP1B transglycosylase active-site 
mutant E233Q.  
 
The transglycosylase active site mutants for the E. coli Class A PBPs were successfully 
engineered and purified. An experiment on how these catalytic active-site mutants 
expressed was conducted in the next section. These proteins analysed using a 
continuous fluorimetric transglycosylase assay in Chapters 4, 5 and 6 and compared 
against the wildtype function (section 4.7). The EcPBP1A transglycosylase active-site 
mutant (E86Q) was also tested for transpeptidase (in)activity in section 6.9.2.6. 
 
3.6.2  The Effect of Over-Expression of E. coli PBP Transglycosylase Catalytic   
          Active Site Mutants on Cell Culture Growth 
 
The impact of mutating the transglycosylase active site residue in E. coli PBPs upon the 
viability of the bacterial cell in cell culture was investigated. Meisel et al., established 
that induction of overexpression of transglycosylase and transpeptidase deficient 
EcPBP1B resulted in cell lysis (Meisel et al., 2003). This analysis has been extended to 
a parallel comparison of the overexpression of both class A bifunctional enzymes: 
PBP1A and PBP1B with transglycosylase active site mutations. The transglycosylase 
catalytic active site residue glutamate of EcPBP1A was mutated to the polar amino acid 
glutamine (E86Q) and the EcPBP1B transglycosylase active site glutamate was also 
mutated to glutamine (E233Q). These E. coli PBP transglycosylase active site mutants 
were grown separately and in triplicate, with the mean value plotted in (Figure 3.18), 
using the same protocol as wildtype protein expression. The cultures were grown 
overnight and the optical density (OD) of each culture was measured after 20 hours of 
growth (17.5 hours of protein expression).  
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Figure 3.18  The Growth Curves of the Expression of the Transglycosylase Active Site 
Mutants EcPBP1A and EcPBP1B, independently. C43(DE3) cells were grown at 37 °C and 
induced with 0.5 mM IPTG at OD600= 0.6-0.7 (grey dashed line). Upon induction the 
temperature was reduced for expression at 25 °C. 
 
The lysis phenotype was found in EcPBP1B only. Similar effects have been reported 
with a serine to cysteine (thiol) mutant of overexpressed class B, E. coli PBP3 
(transpeptidase only) (Broome-Smith et al., 1985). Upon the OD measurement of the 
cultures after 20 hours of growth, all cultures had remained constant since the previous 
measurement the night before, except for E. coli PBP1B transglycosylase active site 
mutant, whose density had increased. After induction of expression of the EcPBP1B 
E233Q mutant, the density of the culture plummeted from OD600=0.85 to 0.41 within 30 
minutes and remained low for the next 3.5 hours. Upon measuring the culture after 17.5 
hours of expression, the OD had returned to >2 absorbance units. The cell culture 
appeared to rescue and recover its phenotype and viability. 
 
      3.6.3  Site-Directed Mutagenesis and Purification of E. coli PBP1A and E. coli   
                PBP1B Transpeptidase Active-Site Mutants S473A and S510A,     
                respectively  
 
The primers used to mutate the active-site serine of E. coli PBP1A and 1B are in 
Appendix 1. These mutated constructs containing the altered base-pairs were expressed 
in C43(DE3) and purified by IMAC (Figure 3.19a). The ability of the transpeptidase 
mutant to bind BOCILLINTM was compared to that of the wildtype protein (Figure 
13.19b and c). 
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Figure 3.19  The Purification of E. coli PBP1A Active Site Mutant S473A and its Ability to 
Bind BOCILLINTM. (a) The purification of EcPBP1A transpeptidase active site mutant, 
analysed by 10% SDS-PAGE (b) SDS-PAGE of wildtype and transpeptidase active site mutant 
EcPBP1A incubated with BOCILLINTM FL, stained with coomassie (c) BOCILLINTM FL 
fluorescence of S473A mutant and EcPBP1A wildtype. PaMurF was included as a negative 
control, imaged on a UV transilluminator in a Syngene G:Box using a ShortPass filter (suitable 
for detecting the λEm of BODIPY at 512 nm) and GeneSnap software to avoid a saturated image.  
 
EcPBP1A S473A was successfully expressed and subsequently purified by IMAC. The 
wildtype transpeptidase domain bound to BOCILLIN, indicating a structurally native 
fold but the active site mutant did not bind to BOCILLIN, suggesting it was unable to 
bind to the alanine in the absence of the catalytic serine, as expected. 
 
The transpeptidase active-site mutant of EcPBP1B (S510A) was also confirmed by 
DNA sequencing, expressed, solubilised in TritonX-100 and purified by IMAC (Figure 
3.20a). The purified protein was incubated with BOCILLINTM to further confirm the 
absence of the active site serine in the transpeptidase domain (Figure 3.20c). 
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Figure 3.20  The Purification of E. coli PBP1B Transpeptidase Active-Site Mutant 
S510A and its Ability to Bind BOCILLINTM. (a) The purification of EcPBP1B 
transpeptidase active site mutant by IMAC, analysed by 10% SDS-PAGE (b) SDS-PAGE of 
wildtype and transpeptidase active site mutant EcPBP1A incubated with BOCILLINTM FL, 
stained with coomassie. (c) BOCILLINTM FL fluorescence of S510A mutant and EcPBP1B 
wildtype, imaged on a UV transilluminator in a Syngene G:Box using a ShortPass filter 
(suitable for detecting the λEm of BODIPY at 512 nm) and GeneSnap software to avoid a 
saturated image.  
 
The EcPBP1B transpeptidase active-site mutant S510A was successfully genetically 
modified within the wildtype construct and the purified transpeptidase-inactive protein 
failed to bind to BOCILLINTM, as expected.  
 
     3.6.4  Site-Directed Mutagenesis and Purification of P. aeruginosa PBP1A   
     Transglycosylase and Transpeptidase Active Site Mutants E86Q and      
     S461A, respectively. 
 
The transglycosylase and transpeptidase active-site mutants of PaPBP1A: E86Q and 
S461A were engineered into the PaPBP1A wildtype construct, confirmed by DNA 
sequencing, expressed, solubilised by TritonX-100 and purified by IMAC (Figure 
3.21). 
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Figure 3.21  The Purification P. aeruginosa PBP1A Transglycosylase E86Q Mutant and 
Transpeptidase S461A Mutant. (a) The purification of PaPBP1A transglycosylase active-site 
mutant by IMAC, analysed by 10% SDS-PAGE (b) The purification of PaPBP1A 
transpeptidase active-site mutant by IMAC, analysed by 10% SDS-PAGE.  
 
Both catalytic active-site mutants of PaPBP1A were successfully expressed and 
purified. The functionality of these catalytically inactive PaPBP1A active-site mutants 
(E86Q) and (S461A) were tested for transglycosylase activity in section 4.7 and 
transpeptidase activity in section 6.9.3.1. 
 
3.7  The Cloning and Purification of PBP-Associated Proteins 
 
     3.7.1  Cloning and Purification of P. aeruginosa and E. coli PBP3 
 
E. coli and P. aeruginosa PBP3 (FtsI) were cloned and purified for use in activity 
assays in the following chapters. PBP3 is a Class B monofunctional DD-transpeptidase 
and loss of PBP3 inhibits cell septation, causing cells to grow as elongated filaments. 
PaPBP3 is essential for growth in P. aeruginosa (Chen et al., 2017). Upon successful 
cloning of both PBP3 genes, constructs were expressed in BL21(DE3) cells, followed 
by IMAC purification (Figure 3.22). 
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Figure 3.22  The PCR Amplification and Purification of E. coli PBP3 and P. aeruginosa 
PBP3. (a) PCR amplification of full-length EcPBP3 (1.76 kb). PCR products were pooled, 
digested with BamHI and SacI, and cloned in to vector pET52b.  (b) Purified EcPBP3 (63.87 
kDa) (c) PCR amplification of full-length PaPBP3 (1.7 kb) (d) Purification of PaPBP3 (61.10 
kDa) by gravity-flow IMAC. 
 
     3.7.2  E. coli CpoB and P. aeruginosa YbgF  
 
YbgF coordinates PBP1B and TolA and also modulates the activity of PBP1B via its 
interaction with LpoB, coordinating cell wall biosynthesis during division and the 
apparatus for constricting the outer membrane. A E. coli CpoB (formally YbgF) 
plasmid was a kind gift from Prof. Colin Kleanthous, University of Oxford. pAK147 
full-length EcCpoB with a C-terminal His6 but lacking its signal peptide (1-26) was 
cultured and its protein purified according to Krachler et al., 2010. Initially the 
insoluble and soluble phases of the cell extract were analysed to determine the location 
of EcYbgF, before purifying by IMAC (Figure 3.23). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23 The Expression and Purification of E. coli CpoB (formally EcYbgF). (a) 
Expression of EcCpoB, analysing the insoluble and soluble fractions of the cell lysate (b) 
Chromatogram of the purification profile of EcCpoB, purified by IMAC using a pre-packed 5 
mL HisTrap column on an AKTA 10/100 system (GE Healthcare) in a cold cabinet at 4°C (c) 
12 % SDS PAGE analysis of EcCpoB27-263 (25.448 kDa). 
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EcCpoB expressed highly in the soluble phase of the bacterial cells and was easily 
purified by IMAC using an ÄKTA Purifier. The P. aeruginosa equivalent of EcCpoB 
(PaYbgF) was expressed and purified by gravity-flow IMAC (Figure 3.24). 
 
 
 
 
 
 
 
 
Figure 3.24  The Expression and Purification of full-length P. aeruginosa YbgF.  
(pProEx::PaYbgF) (a) Expression of PaYbgF, analysing the insoluble and soluble fractions of 
the cell lysate (b) 12 % SDS PAGE analysis of full-length PaYbgF (29.10 kDa). 
 
Both E. coli CpoB and P. aeruginosa were sufficiently expressed and purified for use in 
activity assays. 
 
     3.7.3  The Expression and Purification of Enterococcus faecium VanA 
 
EfVanA is a D-Ala-D-Lac ligase that requires ATP for activity and is known to make D-
Ala-D-X dipeptides (Bugg et al., 1991, which was required and used in a VanA-coupled 
assay in Chapter 6 (section 6.6.1). EfVanA was expressed and purified according to the 
thesis of Dr. S. Batson (Batson, 2010) (described in section 2.8.8) with the results in 
Figure 3.25. 
 
 
 
 
 
 
Figure 3.25  The Purification of E. faeccium VanA. (a) IMAC purification over a 5 mL 
HisTrap (b) Gel filtration of EfVanA (37.44 kDa). 
 
The specific activity of EfVanA was calculated as 6.4 x 10-3 mol/min/mg.   
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     3.7.4  The Expression and Purification of E. coli LpoA and LpoB  
 
E. coli LpoA stimulates the transpeptidase activity of E. coli PBP1A and was over-
expressed according to Jean et al., 2014 (Figure 3.26a), from a construct cloned by Dr. 
Dean Rea at The University of Warwick (pSUMODave::EcLpoA). E. coli LpoB was 
purified from a construct (pProEx::EcLpoB) also cloned by Dr. Dean Rea  and purified 
according to Paradis-Bleau et al., 2010 (Figure 3.26b). 
 
 
 
 
 
Figure 3.26 The Purification of E.coli LpoA and LpoB. The expected size of each was 72.8 
kDa and 20.2 kDa respectively. (a) The purification analysis of IMAC elutions of EcLpoA by 
10 % SDS-PAGE  (b) The purity analysis by 12 % SDS-PAGE of purified EcLpoB.  
 
E. coli LpoA was further purified by gel filtration and used to stimulate EcPBP1A 
transpeptidase activity in Chapter 6. The orthologous protein in P. aeruginosa, PaLpoA 
was also cloned and purified. 
 
     3.7.5  The Cloning and Purification of P. aeruginosa LpoA 
 
PaLpoA was amplified by PCR and cloned into pET28b using NcoI and NotI. The 
resulting expressed protein was purified by gravity-flow IMAC at 4 °C (Figure 3.27). 
 
 
 
 
 
 
 
 
Figure 3.27  The PCR Amplification of the PaLpoA Gene and Purification of PaLpoA 
Protein. (a)  PCR amplification of the PaLpoA gene, using Q5 DNA polymerase, with four 
PCR aliquots across an annealing temperature gradient from 55-65 °C, gene size 1815 bp (b) 
Purification of PaLpoA by Ni2+-NTA IMAC (65.63 kDa). 
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PaLpoA was tested for its ability to stimulate PaPBP1A in section 6.9.3.  
 
     3.7.6  The Expression and Purification of E. coli FtsN  
 
E. coli FtsN is an essential cell division protein that activates septal peptidoglycan 
synthesis and constriction of the cell and is a known binding-partner of EcPBP1B. The 
pET28b::FtsN construct was cloned by Dr. Dean Rea and was purified according to 
Yang et al., 2004, Figure 3.28. 
 
 
 
 
 
 
 
Figure 3.28  The Purification of E. coli FtsN. Purified by gravity-flow IMAC, 
analysed by 12 % SDS-PAGE (35.8 kDa) 
 
3.8  PBP X-Ray Crystallography 
 
     3.8.1  Initial X-Ray Crystallography Screens of E. coli PBP1A, P. aeruginosa   
               PBP1A and P. aeruginosa PBP1B 
 
Crystallisation screens were set up in 96-well Greiner plates using a Mosquito robot. 
Commercially-available crystallisation matrix screens that have been designed to target 
membrane protein crystallisation were tested with the three PBPs. MemStart and 
MemGold (48 and 96 conditions, respectively) were tested using the sitting drop 
method of crystallography (section 2.9.2). EcPBP1A, PaPBP1A and PaPBP1B were 
purified in LDAO and CHAPS, with CHAPS giving better results. A sitting drop of 200 
nL of protein was deposited into the mother liquor (100 µL per well) and all crystals 
were grown at 18 °C. Protein concentrations were between 8.1 and 12.0 mg/mL and all 
affinity His-tags were cleaved prior to crystal trials. Crystal structures of PBPs already 
solved are discussed in the introduction sections 1.5.4 and 1.5.5. Trays were set up in 
the apo- and ligand-bound proteins and monitored every 24 hours for the first week, 
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then every 48 hours for the following 3 weeks. All crystals were formed by the end of 
week two. Trays of E. coli PBP1A in DDM, LDAO and CHAPS were set up with and 
without Moenomycin, using the screen MemGold and MemStart. Photos were taken of  
the apo-enzyme EcPBP1A in CHAPS in MemGold (Figure 3.29). 
 
 
 
 
 
 
 
 
Figure 3.29  Crystallisation Screen of E. coli PBP1A, in its apo-enzyme form and co-
crystallised with its ligand Moenomycin  
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Figure 3.30  Crystallisation Screen of P. aeruginosa PBP1A, in its apo-enzyme form and 
co-crystallised with its ligand Moenomycin   
 
 
 
 
 
 
 
 
 
0.2 M Ammonium Sulfate 
0.02 M Sodium Acetate 
pH 4.0  
33 % v/v PEG 200 
 
0.1 M Sodium 
Chloride, pH 9.0 
0.05 M Bicine  
33 % v/v PEG 300 
 
 
0.2 M Lithium Sulphate, 
0.1 M Sodium Citrate  
pH 3.5   
28 % w/v PEG 400 
 
+ 
M
oe
no
m
yc
in
 
- M
oe
no
m
yc
in
 
0.1 M HEPES pH 7.5, 
11 % w/v PEG 3350 
 
0.1 M Sodium 
Acetate pH 7.0, 
0.1 M HEPES, 22 % 
w/v PEG 3000 
 
0.02 M Nickel II sulfate 
hexahydrate, 0.01 M 
HEPES pH 7.0, 33 % 
v/v Jeffamine M600 
 
 
MemGold 
0.3 M Lithium Sulfate 
pH 6.5, 0.1 M ADA, 
30 % (v/v) PEG 400 
0.1 M Ammonium 
Phosphate Dibasic 
pH 8.5, 0.1 M Tris,  
12 % w/v PEG 6000 
0.1 M Ammonium Sulfate 
10 % w/v PEG 8000 
+ 
M
oe
no
m
yc
in
 
MemStart 
! 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.31  Crystallisation Screen of P. aeruginosa PBP1B, in its apo-enzyme form and 
co-crystallised with its ligand Moenomycin 
 
It is unknown whether these initial crystals are true protein crystals or whether they are 
actually salt crystals or detergent crystals. In future crystal trials, it would be useful to 
check the monodispersity of the protein batch upon purification (e.g. by analysing its 
elution profile from a gel filtration column), before embarking on crystallisation studies. 
The homogeneous nature of the protein batch is of paramount importance to protein 
crystallography, particularly with the presence of detergent micelles with membrane 
proteins. One artefact of concentrating membrane proteins in VivaSpins is that it is not 
known how readily the detergent passes through the filter membrane and therefore 
whether the protein sample is concentrating uniformly with the detergent. It is possible 
that detergent could remain above the VivaSpin filter due to their ‘sticky’ and viscous 
nature thereby increasing the detergent concentration in the protein sample for 
crystallisation. The choice of detergent with respect to charge, micelle size and CMC is 
also critical for crystallisation and is protein-specific. 
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3.9  Discussion 
 
     3.9.1  The Lack of Activity of PaPBP1B 
 
The N-terminally shorter PaPBP1B and EcPBP1B proteins did not show much 
expression in the soluble phase of the ‘soluble vs insoluble’ expression trial (Figure 
3.13 b and e). On reflection, it is highly likely that these proteins may have expressed in 
the periplasm, as this is where the majority of the PBP1B protein resides in vivo, with 
the N-terminal TM domain anchored to the cytoplasmic membrane in the full-length 
protein. Future studies could include the isolation of the periplasmic fraction of these 
expressions, so that proteins in the periplasm can be visualised separately from those in 
the cytoplasm. The ‘proteome’ in the periplasm will be smaller than that of the 
cytoplasm and it is very possible that the yield of these periplasmic proteins will be low 
relative to a cytoplasmic expressed protein. Isolating the periplasmic phase may reveal 
high-level expression of these shorter, potentially soluble PBP proteins. The PaPBP1B 
Y65-774 construct was designed to yield a soluble, high-level expressing protein. As the 
expressed products required extraction from the membrane with detergent, there is no 
advantage to this construct over the full-length PaPBP1B cloned initially.  
 
Bacterial cells expressing the PaPBP1B protein with an N-terminal pelB signal 
sequence for localisation to the periplasm, could be isolated and extracted by osmotic 
shock to reveal the periplasm. 
 
PaPBP1B was expressed in P. putida but the purified protein yield was poor and did not 
exhibit any transglycosylase activity. Conditions need to be optimised for this enzyme, 
as each PBP is different and are notoriously difficult to show activity. 
 
     3.9.2  Over-Expression of the EcPBP1B Transglycosylase Mutant 
 
Over-expression of E. coli PBP1B transglycosylase active site mutant E233Q caused 
the optical density to fall upon induction by IPTG. One theory for this observation is 
that the high abundance of EcPBP1B proteins in the cell sequester known associated 
proteins of EcPBP1B, namely MltA (Vollmer et al., 1999), PBP3 (Bertsche et al., 
2006), FtsN (Muller et al., 2007), LpoB (Typas et al., 2010, Paradis-Bleau et al., 2010) 
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and FtsW (Egan et al., 2013), the latter of which is proposed to act as a LII flippase 
providing substrate for peptidoglycan formation. Removing essential components from 
protein complexes, disrupting vital protein-protein interactions (PPIs) that are required 
for coordination of cell wall biosynthesis with other processes.   
 
     3.9.3  PBP Crystallography Trials 
 
Detergent-solubilised membrane proteins do not often form ordered crystal lattices 
(Newby et al., 2009). Changing the pI of the proteins changes the crystallisation 
conditions of the protein, for example a his6-tag alters the pI of the protein, decreasing it 
by 0.5 Units, however a his6-tag can aid crystallisation. 
“X-ray crystallography is more of a religion than a science” Dr. Dom Bellini 2016.  
 
3.10  Conclusions 
 
A multitude of enzymes have been purified to homogeneity for use in this project, with 
certain proteins expressing better than others. Generally PBP1A expressed at a higher 
level than PBP1B. Although PaPBP1B did not show any activity, the enzyme expressed 
very well and was easily purified to homogeneity, good enough to justify initial crystal 
trial experiments. PaPBP1B was also cloned into a P. putida expression vector and 
expressed to a low level and purified.  
 
3.11  Future Work 
 
The circular dichroism of PaPBP1A and PBP1B demonstrated natively-folded protein, 
and in silico prediction algorithms predicted ~50-60% α-helicity. Comparing the 
wildtype PBP CD spectrum with the catalytic active site mutants would be interesting to 
demonstrate any change is protein fold. It would also be interesting to investigate the 
thermo-stability of the PBPs using CD and compare to this to a parallel experiment 
using Thermoflour. Optimisation of crystallography conditions is needed for further 
structural studies of PaPBP1A and PaPBP1B.  
 
The Pa5052 gene is the potential P. aeruginosa FtsN as it has genome synteny and 
predicted structural similarity. Cloning this gene would be interested to see if it exhibits 
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a function upon PaPBP1B, similar that of EcFtsN upon EcPBP1B. Expressing the 
PaPBP1B UB2H domain of PaPBP1B would also be of interest, in the quest to find an 
E. coli LpoB homologue in P. aeruginosa. Also, as EcPBP2 stimulates PBP1A in a 
similar way to LpoA, it is possible that a similar situation exists in P. aeruginosa, 
cloning PaPBP2 would be needed for this.  
 
The PaPBP1B construct used in this project was W23-N744. Testing the activity of the 
full-length protein may help in generating an active construct of this protein. Over-
expressing the current PaPBP1B W23-N744 construct in E. coli membranes and 
assaying the activity of PaPBP1B in a membranous environment would be interesting, 
as other proteins present in vivo that are usually removed upon purification may be 
aiding the activity of PaPBP1B.  
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Chapter 4 
The Kinetic Analysis of the Transglycosylation  
Activity of E. coli PBP1A and P. aeruginosa PBP1A 
 
4.1  Current Transglycosylase Assays in the Literature 
 
The kinetic activity of PBPs has been challenging due to the difficulty in obtaining and 
synthesising relevant and native substrates. This is compounded by the nature of PBPs 
and their integral association with the cell membrane. PBPs are stabilised in vitro using 
synthetic detergents that aim to mimic the cell membrane. Defining the amount of 
detergent to use to maintain PBP integrity and activity while still creating a native 
environment in which to assay the function of the PBP is one of the more challenging 
aspects of this project. The improved knowledge of synthesising lipid-linked 
intermediates has aided the study of transglycosylation (Schwartz et al., 2001, van 
Nieuwenhze et al., 2002, Breukink et al., 2003,). The mechanism of transglycosylation 
is illustrated in Figure 1.4, with the substrates and products involved in the mechanism 
being as follows:  
(GlcNAc-MurNAc)n-Un-P-P + Lipid II ! (GlcNAc-MurNAc)n+1 + Un-P-P. 
A myriad of assays aiming to detect and monitor transglycosylase activity have been 
developed over the last 20 years, summarised below. 
 
4.1.1  Thin Layer Chromatography Assays 
 
Thin layer chromatography was one of the earliest methods of separating out and 
visualising the products of transglycosylation (van Heijenoort et al., 1978, Di Guilmi et 
al., 2003). The labelled lipid II was incubated with a transglycosylase and the reaction 
products distinguished by thin layer chromatography (TLC). The lipid II substrate can 
be labelled either radioactively with 14C on the L-alanine at position 1 of the 
pentapeptide or the GlcNAc sugar ring (van Heijenoort et al., 1978), or alternatively the 
ε-amino group on the mesoDAP residue in the pentapeptide can be labelled with a 
fluorescent moiety including dansyl (Schwartz et al., 2002), NBD (van Dam et al., 
2007) and fluorescamine (Schwartz et al., 2001). After polymerisation, the polymerised 
products were run on TLC. Any material that remained at the origin (immobile 
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polymeric fragments) was digested with lysozyme before being separated by TLC and 
compared with monomer and dimer peptidoglycan fragments of known structure (van 
Heijenoort et al., 1978). TLC is not the only method of separating multi-length glycan 
polymers, polyacrylamide gel-based systems have also been employed to show 
processivity and activity. 
 
4.1.2  SDS-PAGE Analysis of Transglycosylation Products 
 
A polyacrylamide gel system (Tricine-sodium dodecyl sulfate-polyacrylamide) 
originally designed to separate large proteins of 1-100 kDa (Schägger & von Jagow, 
1987), has been exploited and adapted for the analysis of transglycosylation reaction 
products (Barrett et al., 2007, Helassa et al., 2012). The monomer substrate is radio- or 
fluorescently-labelled prior to polymerisation to enable detection. This technique was 
used to analyse the distribution of transglycosylase products following time-dependent 
incubations of E. coli PBP1B and A. aeolicus PBP1A with heptaprenyl-[14C]-Lipid II 
(Barrett et al., 2012, Yuan et al., 2007). The sensitivity of this assay is questionable and 
is qualitative rather than quantitative, however, it is a useful technique for overall 
visualisation of polymerisation results. The length of glycan chains in E. coli 
peptidoglycan is 10-40 disaccharide units (Vollmer, 2008) with chain lengths detected 
via this polyacrylamide separation technique ranging from the monomer Lipid II, 
through Lipid IV, detecting glycan chain lengths of approximately 30 and 50 
disaccharide units with E. coli PBP1A and E. coli PBP1B (Helassa et al., 2012). By 
general agreement, transglycosylases are processive rather than dispersive, catalysing 
multiple rounds of polymerisation without releasing the elongating glycan polymer 
(Yuan et al., 2007). Long glycan chains were detected without the accumulation of 
short chains, concurrent with the processive model of transglycosylation (Barrett et al., 
2007). 
 
4.1.3  HPLC Analysis of Transglycosylation Products  
 
The analysis and separation of polymerised products has also been conducted using 
high-pressure liquid chromatography - HPLC. Radio-labelled LII as well as 
fluorescently-labelled LII have both been used for this technique and can be 
polymerised (Bertsche et al., 2005 & Biboy et al., 2013). Fluorescently labelling the LII 
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can be done prior to polymerisation (Heaslet et al., 2009) or post-polymerisation 
(Schwartz et al., 2001), before HPLC analysis. The advantage to labelling post-reaction 
is that the fluorophore does not interfere transglycosylation progress. 
 
4.1.4  High-Through Put (HTP) Screening Assays Based on Moenomycin   
          Displacement 
 
High-through-put assays have used the displacement of moenomycin from the 
transglycosylase active site, as a screen for potential inhibitors (Cheng et al., 2008, 
Gampe et al., 2011). Cheng et al designed a highly sensitive fluorescence anisotropy 
assay using a fluorescein-labelled moenomycin. Fluorescence anisotropy properties 
decreased when competitively-binding compounds displaced the fluorescein-labelled 
moenomycin (Cheng et al., 2008). Gampe et al. developed a fluorescence polarisation 
assay, based upon displacement of a fluorescently-labelled minimal pharmacophore of 
moenomycin in an effort to identify low micromolar inhibitor binding. Although both of 
these assays by-pass the need for LII substrates, they rely upon chemically modified 
derivatives of the moenomycin pharmacophore (Gampe et al., 2011). 
 
4.1.5  Continuous Fluorescence Assays 
 
The first continuous, coupled assay of transglycosylase activity reported was based 
upon the increased quantum yield of fluorescence signal from a dansyl fluorophore 
when in a hydrophobic micellar environment (Schwartz et al 2002). The lipid II 
substrate is labelled with a fluorescent dansyl moiety attached to the ε-amino group of 
the mesoDAP residue in the pentapeptide stem. The polymerised products are 
hydrolysed by the presence of muramidase, which cleaves the glycosidic bond between 
GlcNAc and MurNAc sugars. Upon product digestion by muramidase, polymerisation is 
visualised by a decrease in fluorescence due to a shift from a lipidic to a soluble 
environment. This assay has been used extensively in this chapter, and is described 
further below. 
 
A novel FRET assay was developed to elucidate transglycosylase activity (Huang et al., 
2013) using LII analogues, including the pentapeptide chain being labelled with NBD. 
Structures of the hit compounds identified using this assay are in Table 1.3. Liu and 
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Wong also employed a nitrophenol LII analogue to characterise the transglycosylase 
function of S. pneumoniae PBP1b spectrophotometrically (Liu & Wong, 2006). The 
continuous fluorometric assay developed by Schwartz et al., using dansyl-labelled 
(dansylated) LII (Schwartz et al., 2002) forms the basis for the analysis of 
transglycosylase activity in Class A PBPs in this chapter. The advantages of this assay 
are that it is continuous, it is easy to set up, it is quantitative, it can be monitored in real 
time and is high-throughput.  
 
4.2  Experimental Aims 
 
• To use E. coli PBP1B as a model enzyme for the study of transglycosylation 
• Develop the continuous, fluorescence transglycosylation assay in to a high-
throughput plate reader format 
• Optimise the transglycosylase assay for E. coli PBP1A and P. aeruginosa 
PBP1A, including ionic strength, detergent and pH. 
• Kinetically characterise the Class A PBPs, defining the Km and Vmax for 
different substrates 
• Synthesise transglycosylase active-site mutants for the transglycosylase domain 
of the three Class A PBPs and test their transglycosylase activity 
• Characterise the effect of LpoA, LpoB, PBP2 and PBP3 on transglycosylation 
activity of E. coli PBP1B, E. coli PBP1A and P. aeruginosa PBP1A 
 
4.3   E. coli PBP1B as a Control Enzyme for the Study of Transglycosylation by     
       Class A Transglycosylase Enzymes 
 
4.3.1  A Continuous Fluorescence Assay for Transglycosylase Activity 
 
The assay developed by Schwartz et al. in 2002 in which the transglycosylase activity 
of E. coli PBP1B (EcPBP1B) was monitored continuously has been replicated and 
adapted for use for a variety of transglycosylases in the literature (Sung et al., 2009, 
Offant et al., 2010, Huang et al., 2012) and for other Class A PBPs in this thesis. The 
LII used for the substrate was fluorescently labelled by dansylation of the ε-amino 
group of the third position amino acid in the stem peptide. Upon successful synthesis of 
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UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala, a dansylation reaction was 
conducted to label the ε-amino group on the third-position DAP, before converting in to 
a lipid. The fluorescence signal followed in this continuous assay is the shift in spectral 
intensity of the dansyl moiety, at its emission optimum of 520 nm, due to its release 
from a lipidic to an aqueous environment upon the hydrolysis of polymers into 
monomers by N-acetyl-muramidase (Figure 4.1). This change in environment for the 
fluorophore causes a decrease in fluorescence, indirectly representing the 
polymerisation of LII. 
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Figure 4.1 The Continuous Fluorometric Assay for the Detection of Glycan Chain Polymerisation (Adapted from Schwartz et al., 2002). The monomer lipid II was 
used, with the fluorescent reporter, Dansyl, represented as ‘D’. N-acetyl-muramidase, mutanolysin, derived from a Streptomycete was used to hydrolyse the polymers and 
release the dansyl fluorophore from its lipidic environment. This change in environment alters the fluorometric properties of the dansyl fluorophore, reported as a decrease 
in fluorescence emission at 520 nm. The decrease in fluorescence continuously (indirectly) monitors the polymerisation of the monomer lipid II into glycan strands. !
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      4.3.2  Assay Scale-Up: From Fluorimeter to Plate Reader 
 
This fluorescence assay was initially recreated using the same enzyme as previously 
tried and tested in by Schwartz et al, EcPBP1B. Development began using a steady-
state fluorimeter with a Xenon light source and R1527 photomultiplier tube, with assays 
being conducted at a volume of 200 µL in a quartz cuvette. The natural progression was 
to transfer this assay in to a plate reader format, for high-throughput purposes to reduce 
the assay volume, consumption of dansylated LII and cost of reagents. The difference 
between the output from the fluorimeter compared to the plate reader is minimal 
(Figure 4.2). 
     
 
 
 
 
 
 
 
 
Figure 4.2  The Continuous Fluorometric Transglycosylation Assay in a Fluorimeter 
Compared to a Plate-Reader. The comparison between (a) a continuous fluorescence 
transglycosylation assay in a 200 uL assay volume in a quartz cuvette in the fluorimeter and (b) 
the same assay in a volume of 25 uL in a well of a 96-well plate. Both assays copied exactly the 
reaction conditions given in Schwartz et al., 2002. 50 mM HEPES, pH 7.5, 0.085% decyl PEG, 
10 mM MgCl2, 10% DMSO, 0.1 µg muramidase, 10 µM dans-DAP-LII, 50 nM EcPBP1B. 
 
The continuous assay is reproducible in both a fluorimeter and plate-reader format, so 
all subsequent assays were conducted using a Clariostar plate reader, with a reaction 
volume of 25 µL, using a 96-small-well plate (section 2.8.3). The transfer of this assay 
to a plate-reader was also published at this time (Helassa et al., 2012). A ‘proof of 
principle’ assay was conducted in the plate reader, with controls (Moenomycin is a 
potent inhibitor of transglycosylation and so was used as a negative control), illustrated 
in Figure 4.3.  
 
 
a" b"
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Figure 4.3 The Continuous Fluorometric Transglycosylase Assay - Proof of Principle assay 
with Positive and Negative Controls. 50 nM EcPBP1B, 10 µM dans-DAP-LII. (a) Assay 
buffer (50 mM HEPES, pH 7.5, 0.085% decyl PEG, 10 mM MgCl2, 10% DMSO) alone (b) 
buffer + 10 µM LII (c) buffer + 0.1 µg muramidase (d) buffer + LII + muramidase (e) buffer + 
LII + muramidase + 50 nM EcPBP1B + 50 µM Moenomycin (transglycosylation inhibitor) (f) 
buffer + LII + muramidase + E. coli PBP1B (g) buffer + LII + muramidase + EcPBP1B + 250 
µM ampicillin (transpeptidation inhibitor).  
 
The assay was initiated with the EcPBP1B enzyme in all cases in Figure 4.3, also, 
initiating the reaction with the substrate dansylated LII was tested to ensure that the 
reagent used to initiate polymerisation was independent of how the assay proceeded 
(data not shown).  
 
Figure 4.3 is a proof of principle experiment showing that LII substrate is only 
polymerised in the presence of the LII polymerase EcPBP1B, with the exception when 
EcPBP1B is in the presence of MoenomycinA, the potent transglycosylase inhibitor. 
The presence of ampicillin, which binds to the transpeptidase domain of the PBP, had 
no affect on the transglycosylase activity of EcPBP1B. A valid alternative to using N-
acetyl muramidase to break the glycosidic bonds in the glycan sugar backbone is hen 
egg white lysozyme. A comparison assay between the use of N-acetyl muramidase and 
lysozyme to hydrolyse the polymers was conducted, concluding that there is no 
difference between the efficiency of polymer breakdown or assay progression (data not 
shown).  
 
It has been well documented that the Class A PBP transglycosylases EcPBP1A (Barrett 
et al., 2007) and PBP1B (Schwartz et al., 2002) exhibit an initial polymerisation lag 
phase. In vitro, upon initiation of a transglycosylase reaction, glycan chains do not exist 
and the enzyme has to perform de novo polymerisation of LII forming a short polymeric 
glycan strand. In vivo, however, transglycosylases are ‘primed’ by a pre-existing 
polymerised precursor, providing a scaffold for elongation (Schwartz et al., 2002). 
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This fluorescence continuous assay can be successfully replicated with the model 
enzyme EcPBP1B and in a plate reader format. Subsequently, further Class A PBPs 
(EcPBP1A, PaPBP1A and PaPBP1B) were tested for transglycosylase activity using 
the same assay and initially the same assay conditions as those used for E. coli PBP1B. 
However the assay conditions needed to be optimised for EcPBP1A and PaPBP1A 
including the optimum detergent for activity, the optimum pH and ionic strength. 
 
4.4  The Kinetic Characterisation of Transglycosylation for the Model Enzyme E. 
coli PBP1B 
 
     4.4.1  Dependence of E. coli PBP1B Transglycosylase Activity on Enzyme  
               Concentration  
 
The dependence of EcPBP1B concentration on the initial rate of glycan chain 
polymerisation was tested to determine if there is a linear relationship between enzyme 
concentration and initial reaction rate. With EcPBP1B exhibiting a polymerisation lag, 
the initial rate of reaction was taken from the beginning of the linear phase of the 
reaction, usually 30 seconds after reaction initiation. The initial rate was measured over 
a time interval of 30 seconds, after the initial 30 second lag. A substrate concentration 
of 10 µM dans-DAP-LII was used to ensure that the initial velocity measured was 
independent of substrate concentration and that the initial rate of reaction (V0) was 
dependent on EcPBP1B enzyme concentration. The LII substrate used for all of these 
assays was dansylated on the pentapeptide as a means of detection. Enzyme dependence 
was conducted with two substrates of LII, with a variation in their prenyl chain length: 
dansylated-DAP LII C55 and dansylated-DAP LII C35 (Figure 4.4). C55 LII is the native 
carbon chain length, with C35 (a heptaprenyl lipid chain) being a variant with a shorter 
lipidic carbon tail and is a more soluble substrate due to its shorter lipid chain. A prenyl 
chain length of more than 20 carbon atoms is critical for the transglycosylase 
processivity of (Perlstein et al., 2010). Transglycosylases in E. coli membranes have a 
preference for C35 over their native C55 substrate in vitro, as the shorter lipid chain 
minimises the possibility of aggregation as observed with the undecaprenyl 
pyrophosphate in LII-C55 (Ye et al., 2001).  
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Figure 4.4  Dependence of E. coli PBP1B Transglycosylase Activity on Enzyme 
Concentration. • Dans-DAP-LII C55 and • dans-DAP-LII C35. The substrate concentration used 
in both cases was 10 µM LII. EcPBP1B was purified in TritonX-100 and 50 mM HEPES, pH 
7.5, 10 mM MgCl2, 10% DMSO, 0.1 µg muramidase, 10 µM Dans-DAP-LII. 25 µL reaction 
volume in a well of a 96-well plate. 
 
EcPBP1B has a linear relationship between enzyme concentration and initial reaction 
velocity, with both dans-DAP-LII C55 and dans-DAP-LII C35 substrates. This plot 
indicates that the amount of product formed is dependent upon enzyme concentration.  
 
     4.4.2  Michaelis-Menten Kinetic Constants 
 
The Michaelis Menten model demonstrates a measure of how well a substrate 
complexes with its enzyme (binding affinity). The Michaelis Mention equation relates 
reaction rate to substrate concentration [S]. Vmax is the maximum rate achieved at 
saturating enzyme concentration. Km is the Michaelis Menten constant defined as the 
substrate concentration at which the reaction rate is half Vmax. Scheme (1) is the rate 
equation from which the parameters Km, Vmax, Kcat and v0 are derived. 
 
 
 
Km, Kcat and the initial velocity V0, can all be found from a solution to the parent 
equation, by plotting experimental data on a Time vs [S] graph. Scheme 1 is based on a 
single substrate turnover with the assumption of steady-state kinetics and a single 
enzyme binding site. Km and Vmax can be inferred from a graph, which can be used to 
determine the V0 parameter. 
[E]!+![S]!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!![ES]!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!![E]!!!!+!!!![P]!K1! Kcat!+![S]!-![S]!K2!Scheme (1)!
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Km can be calculated by: 
 
 
Vmax can be calculated by: 
 
 
 
      4.4.3  The Kinetic Profile of E. coli PBP1B with dansDAP-LII C35 and C55   
                Polyprenyl Chain Lengths 
 
The dependence of EcPBP1B transglycosylase initial velocity on its substrate dans-
DAP-LII with C35 and C55 prenyl tails was characterised (Figure 4.5). 
 
 
 
 
 
 
 
 
 
Figure 4.5  The Initial Rate of Transglycosylation in EcPBP1B with Increasing dans-DAP-
LII Substrate Concentration, using two substrates with different polyprenyl chain lengths. 50 
nM EcPBP1B used. Reaction conditions: 50 mM HEPES pH 7.5, 10 mM MgCl2, 10% DMSO, 
0.1 µg muramidase, 10 µM dans-DAP-LII. Both data sets were fitted to the Michaelis-Menten 
equation, Equation 4.1 using GraphPad Prism 6. 
 
There is a hyperbolic relationship between the initial enzyme velocity (v0) and the 
substrate concentration, enabling the data to be fitted to the Michaelis-Menten equation 
(Equation 4.1) to determine Km and vmax by non-linear regression. The kinetic 
parameters for EcPBP1B with both dans-DAP-LII C35 and dans-DAP-LII C55 
(calculated using GraphPad Prism 6) are presented in Table 4.1. 
 
v0!=!! Km + [S]!!Vmax [S]!!Equation (4.1)  !
Km!=!! K1!Kcat + K2!Equation (4.2) !
Equation (4.3) ! Vmax = Kcat [ET] 
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Table 4.1  A Summary of the Vmax and Km data derived from the Michaelis-Menten 
equation for the two substrates dans-DAP-LII C35 and dans-DAP-LII C55. The data was 
fitted to Equation 4.1 by non-linear regression, enabling kinetic constants to be derived. 
 
Substrate vmax (RFU / sec) Km (µM) Vmax/Km (RFU/sec/µM) R2 
Dans-DAP-LII C35 15.3 ± 0.72 1.25 ± 0.23 12.2 ± 2.32 0.93 
Dans-DAP-LII C55 26.1 ± 5.10 4.49 ± 1.79 5.81 ± 2.58 0.97 
 
The Km for EcPBP1B with dans-DAP-LII C35 was lower than for the C55 substrate 
equivalent, suggesting that EcPBP1B has a higher affinity for the C35 substrate over the 
C55 substrate, also observed by Suzanne Walker and colleagues in Ye et al., 2001.  
 
4.5  Buffer Optimisation Screening with E. coli PBP1A and P. aeruginosa   
       PBP1A and PBP1B 
 
The assay buffer conditions used in Schwartz et al,, 2002 were used as a starting point, 
however the percentage of DMSO was thought of as extremely high and was reduced 
from that published (25 %) to 10 % as this high DMSO concentration may interfere 
with protein-protein interactions. DMSO was subsequently shown to prevent the 
interaction between E. coli PBP1B and E. coli LpoB (Dr. A. J. Egan PhD Thesis, The 
University of Newcastle, 2014). In order to further characterise the transglycosylase 
activity of both E. coli and P. aeruginosa PBPs, the impact of pH, ionic strength and 
detergent choice on the activity of these enzymes was assessed and optimised in the 
following sections. 
 
      4.5.1  Optimal Detergent(s) for Transglycosylase Activity of E. coli and P.   
                aeruginosa PBP1A 
 
PaPBP1A and EcPBP1A were extracted and purified into four different detergents: 
CHAPS, DDM, LDAO and TritonX-100 according to (sections 2.4.6 and 2.5.1, e.g. 
Figure 3.10), to test which detergent(s) the enzymes would be active and stable in 
(Figure 4.6). Three of these detergents are non-ionic and CHAPS is zwitterionic. The 
percentage and concentration of each detergent used for both extraction and purification 
is summarised in Appendix 1. 
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Figure 4.6  The Transglycosylase Activity of PaPPBP1A and EcPBP1A in LDAO, DDM, 
CHAPS and TritonX-100 (a) PaPBP1A (b) EcPBP1A. Each detergent was present at 3xCMC 
final concentration in the assay. Reaction conditions: 50 mM HEPES, pH 7.5, 10 mM MgCl2, 
10% DMSO, 0.1 µg muramidase, 10 µM Dans-DAP-LII, 100 nM PBP1A. 
 
PaPBP1A and EcPBP1A were both active in the detergents CHAPS and TritonX-100, 
but neither were active in LDAO or DDM. TritonX-100 was used for the remaining 
continuous assays, unless stated otherwise, as it is much cheaper than CHAPS and the 
two detergents showed little difference in PBP activity.  
 
An alternative protocol for getting EcPBP1A and PaPBP1A into each of the four 
detergents. The CHAPS-purified PBP1A proteins were reconstituted in to another 
detergent of choice. The CHAPS-purified PBP1A proteins were used because of the 
properties of CHAPS and its extremely high CMC (0.49 %) and so samples can easily 
be diluted below the CMC. The PaPBP1A and EcPBP1A (CHAPS) enzymes were 
diluted sufficiently to reduce the concentrations of CHAPS to below its CMC, 
substituting the lipidic environment for the new detergent in the storage buffer. 
Although the PBPs were originally extracted and purified in CHAPS, they were 
subsequently exchanged into TritonX-100, DDM or LDAO. The same results as above 
were seen, where both EcPBP1A and PaPBP1A were active when exchanged to 
TritonX-100 and when conserved in CHAPS, but were inactive when exchanged in to 
DDM or LDAO. 
 
      4.5.2  Testing Optimal Detergent(s) for P. aeruginosa PBP1B Activity 
 
PaPBP1B did not show transglycosylase activity in the conditions that EcPBP1A, 
EcPBP1B, and PaPBP1A had all shown activity. The enzyme was also extracted and 
a" b"
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purified separately in to each of the four detergents (CHAPS, DDM, LDAO and DPC) 
to test transglycosylase activity in each environment (Figure 4.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7  The Transglycosylase Activity of P. aeruginosa PBP1B after Extraction and 
Purification in to CHAPS, DDM, TritonX-100 and LDAO. (a) CHAPS (b) DDM (c) Triton-
X100 and (d) LDAO. Reaction conditions: 50 mM HEPES, pH 7.5,10 mM MgCl2, 10% 
DMSO, 0.1 µg muramidase, 10 µM dans-DAP-LII, 1 µM PaPBP1B.  
 
The only detergent in which PaPBP1B exhibited significant changes in fluorescence, 
compared with the control in the zwitterionic detergent, CHAPS (a), but much lower 
activity than EcPBP1A or PaPBP1A. PaPBP1B did not show enough activity to be able 
to continue any kinetic studies including determining its Km with LII. Optimising the 
activity of PaPBP1B will need further analysis as part of future work. 
 
       4.5.3  The Optimisation of pH for Transglycosylase Activity 
 
pH can have substantial affects on the activity of an enzyme: protein structure, 
ionization state of the catalytically active amino acid and the behaviour of the substrate. 
The catalytic residue of transglycosylation is Glu86 in both E. coli and P. aeruginosa 
PBP1A, whose side chain is negatively charged and has a pKa value between 4-7 
depending on surrounding environment, which is deprotonated at pH 6-9. Before testing 
PBP1A activity, the effect of pH on the emission maximum of the dansyl group was 
a" b"
c" d"
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assessed. The λmax of dans-LII remained unchanged at different pH. To test the effect of 
pH on the PBP1As, the initial velocity of transglycosylation was tested from pH 6.5 to 
9.5 (Figure 4.8).  
 
 
 
 
 
 
 
 
Figure 4.8  The Dependence of E. coli and P. aeruginosa PBP1A Transglycosylase Activity 
on pH. (a) The optimum pH for EcPBP1A and (b) PaPBP1A. The initial rate of 
transglycosylation was measured at different pH, using the continuous fluorometric 
transglycosylation assay. 50 mM buffer pH 6.5-9.5, 10 mM MgCl2, 10% DMSO, 0.1 µg 
muramidase, 10 µM dans-DAP LII C55, 100 nM PBP1A. The buffering agent used at pH 6.5 = 
CAPS, pH 7.0 = MOPS, pH 7.0 HEPES, pH 7.5 = HEPES, pH 8.0 = Tricine, pH 8.0 = 
BisTrisPropane (BTP), pH 8.5 = BTP, pH 9.0 = CHES, pH 9.5 = CHES. 
 
EcPBP1A has a pH maximum in HEPES at pH 7.5, with its transglycosylase activity 
varying in Tricine and BTP at pH 8.0. The conditions published in Schwartz et al., for 
the optimal assay conditions for EcPBP1B transglycosylase activity also concluded 
HEPES pH 7.5 (Schwartz et al., 2002). The ‘shoulder’ to the pH profile curve between 
pH 6.0 and 7.0 in (a) EcPBP1A is significant and is probably due to loss of 
transglycosylase activity as the Glu86 residue is protonated. This suggests that the pKa 
of this catalytic Glu86 residue in EcPBP1A is in the range of pH 6.5-7.0.  
 
With PaPBP1A, there is no major change in activity over pH 6.5-9.5 but the pH 
optimum is 7.0 in HEPES. All subsequent transglycosylase assays were conducted in 
HEPES pH 7.5 for EcPBP1A, and at pH 7.0 for PaPBP1A. 
 
      4.5.4  The Optimisation of NaCl Concentration for Transglycosylase Activity 
 
The concentration of sodium chloride and therefore the ionic strength in the assay could 
affect the activity of these Class A PBPs (Figure 4.9), as it has been shown that the 
b"a"
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presence of NaCl has an inhibitory impact on the activity of EcPBP1B (Adrian Lloyd, 
personal communication).  
 
 
 
 
 
 
 
 
 
 
Figure 4.9  The Transglycosylase Activity of E. coli and P. aeruginosa PBP1A at 
Increasing Ionic (NaCl) Concentration, from 0-250 mM NaCl. Assays were conducted in 50 
mM HEPES pH 7.0 for PaPBP1A, pH 7.5 for EcPBP1A, 10 mM MgCl2, 10 % DMSO, 0.1 µg 
muramidase, 10 µM dans-DAP LII C55, 0.5 µM PBP1A. 
 
The activity of these two PBPs was enhanced with increasing NaCl concentration, up to 
a maximum of 60 mM NaCl. Beyond this concentration, no additional PBP activity was 
observed. In all subsequent transglycosylation assays, a total NaCl concentration of 60 
mM was used. The data in Figure 4.9 was fitted to the Michaelis Menten Equation 4.1. 
 
4.6  The Kinetic Characterisation of Transglycosylation of E. coli PBP1A and P.    
       aeruginosa PBP1A and PBP1B 
 
      4.6.1  Dependence of E. coli PBP1A and P. aeruginosa PBP1A Transglycosylase   
                Activity on Enzyme Concentration  
 
As observed for EcPBP1B, a linear relationship between enzyme concentration and 
initial velocity was confirmed. It was observed that at a lower LII concentration (3 µM), 
linearity was only observed at > 0.6 µM enzyme Figure 4.10 (a), whereas when a 
higher LII concentration of 10 µM was used, a more typically linear relationship was 
seen Figure 4.10 (b). 
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Figure 4.10  The Dependence of Initial Rate of Transglycosylation on E. coli PBP1A 
Concentration at 3 and 10 µM dans-DAP-LII. The relationship between the initial reaction 
rate of transglycosylation, and EcPBP1A concentration. (a) 3 µM dans-DAP LII C55 and (b) 10 
µM dans-DAP LII C55. Reaction conditions: 50 mM HEPES pH 7.5, 10 mM MgCl2, 60 mM 
NaCl, 10 % DMSO, 0.1 µg muramidase, EcPBP1A was delivered to the assay in 0.02 % (v/v) 
TritonX-100.  
 
The plot obtained when using a lower substrate concentration suggests that as the 
EcPBP1A enzyme concentration in the assay increases to above 0.5 µM, a distinct 
change in enzyme activity occurred. This could indicate that the EcPBP1A dimerises > 
0.5 µM and the enzyme becomes more stable in a dimeric form. This difference in 
behaviour of the enzyme at different concentrations suggests either that substrate 
binding to the enzyme promotes an active conformation of EcPBP1A or it could suggest 
that as EcPBP1A dimerises upon reaching a threshold enzyme concentration and this in 
itself increases the turnover of the enzyme. In addition, it is highly possible that at these 
low concentrations of enzyme, the amount of detergent in the assay buffer reduces the 
frequency at which the PBP encounters and collides with its LII substrate, shielded by 
excess detergent. A further experiment reducing the amount of detergent to the absolute 
minimal amount would be ideal. EcPBP1B in Figure 4.4 shows a linear relationship 
between enzyme concentration and initial reaction rate, which obeys classical Michaelis 
Menten kinetics more so than EcPBP1A in Figure 4.10. 
 
The dependence of the initial rates of transglycosylation for PaPBP1A at two different 
substrate concentrations are compared below (Figure 4.11).  
 
 
 
a b 
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Figure 4.11  The Dependence of Initial Rate of Transglycosylation on P. aeruginosa 
PBP1A Concentration at 3 and 10 µM dans-DAP-LII. (a) 3 µM dans-DAP LII C55 and (b) 
10 µM dans-DAP LII C55. Reaction conditions: 50 mM HEPES pH 7.5 for E. coli, pH 7.0 for P. 
aeruginosa, 10 mM MgCl2, 60 mM NaCl, 10% DMSO, 0.1 µg muramidase, 3-10 µM dans-
DAP-LII C55, PaPBP1A was delivered to the assay in 0.02 % (v/v) TritonX-100. 
 
The curve shown when using a lower substrate concentration shows that as the 
PaPBP1A enzyme concentration in the assay increases to above 0.6 µM, the initial rate 
of reaction increases rapidly. The observed behaviour of PaPBP1A is similar that seen 
for EcPBP1A in Figure 4.10. 
 
4.6.2  The Kinetic Profile of E. coli PBP1A and P. aeruginosa PBP1A  
 
      4.6.2.1  The Kinetic Profile of E. coli PBP1A and P. aeruginosa PBP1A with  
                   dansDAP-Lipid II C55 and C35 
 
The kinetic characterisation of E. coli and P. aeruginosa PBP1A was determined with 
dans-DAP-LII C55, dans-DAP-LII C35 and dans-Lys-LII C55. The affinity of the 
transglycosylase domain of two Class A PBPs (E. coli and P. aeruginosa PBP1A) for a 
variety of LII substrates was tested in the continuous fluorometric assay. All substrates 
investigated were labelled with a dansyl group for fluorescence detection and all assays 
were conducted as in (section 2.8.3). 
 
It has been established that there is a linear relationship between E. coli PBP1A and P. 
aeruginosa PBP1A concentration and the initial transglycosylation rate. PBP1A 
concentrations used for E. coli and P. aeruginosa were selected where the relationship 
between v0 and enzyme concentration is linear. The ability of these PBP1A enzymes to 
b"a"
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utilise a variety of transglycosylase substrates from assessed, defining the Vmax and Km 
values for each enzyme and LII substrate combination. Kcat could not be calculated as 
the consumption of LII substrate could not be determined from change in fluorescence 
alone. The kinetic profiles of EcPBP1A and PaPBP1A with two LII substrates: dans-
DAP-LII C55 and dans-DAP-LII C35 is displayed in Figure 4.12.  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
Figure 4.12  The Dependency of E. coli and P. aeruginosa PBP1A upon LII Substrate 
Concentration (dans-DAP-LII C55 and dans-DAP-LII C35). The data was fitted to both the 
‘dual substrate’ equation and the Hill Equation (section 4.5.2.2), with Km and Vmax derived 
values summarised in Tables 4.2-4.5. (a) EcPBP1A with dans-DAP-LII C35 (b) PaPBP1A with 
dans-DAP-LII C35 (c) EcPBP1A with dans-DAP-LII C55 (d) PaPBP1A with dans-DAP-LII C55. 
Reaction conditions: 50 mM HEPES pH 7.5 for E. coli, pH 7.0 for P. aeruginosa, 10 mM 
MgCl2, 60 mM NaCl, 10% DMSO (v/v), 0.1 µg muramidase, 0-15 µM dans-DAP-LII, 0.75 µM 
PBP1A was delivered to the assay in 0.02 % (v/v) TritonX-100. Each value represents the mean 
± standard deviation of 3 reactions. 
 
The resulting kinetic profiles are sigmoidal rather than the usual hyperbolic curves 
exhibited in traditional Michaelis-Menten kinetics. The sigmoidal shape reflects low 
enzyme activity at low substrate concentrations, with a rapid increase in enzyme activity 
C" D"
A" B"
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at higher substrate concentrations until Vmax is achieved. An acceleration in v0 is seen 
from 5 µM LII substrate onwards, suggesting that there is a minimum concentration of 
LII required (as well as PBP1A ≥ 0.5 µM) for an initial rate to be observed. Therefore 
this initial lag-phase observed in Figure 4.12 is in part related to the low LII 
concentration. This sigmoidal shape could also suggest that there are two different 
substrates throughout glycan chain polymerisation: (1) The LII monomers being 
incorporated into the growing glycan chain and (2) the polymerized glycan strand 
waiting to accept a nascent LII monomer. The binding of one substrate to the enzyme 
affects the affinity to which the other substrate can interact.  
 
The poor fit of this data to the Michaelis Menten equation (Equation 4.1) indicates that 
this particular equation is an inappropriate model to fit the data to. Biochemical 
reactions with a single substrate often follow Michaelis Menten kinetics, however, 
Class A PBPs do not necessarily follow traditional Michaelis Menten kinetics as they 
can be described as having two substrates: a transglycosylase donor and acceptor 
substrate, which are both LII substrates. Alternative models were sought to fit this 
PBP1A kinetic data to, which considered two substrates separately for the 
transglycosylase domain during transglycosylation. The first substrate was the 
transglycosylase donor and the second substrate being the transglycosylase acceptor, 
defining values for two Km constants: Kma and Kmb. 
 
4.6.2.2  The Dual-Substrate Kinetic Equation and the Hill Equation 
 
In vitro, transglycosylases perform de novo synthesis of glycan chains and require two 
LII substrate molecules to bind in to the active site (Scheme 2). 
 
 
 
A kinetic equation that considers two substrates, can be derived from Scheme 2 
(assuming that rapid equilibrium kinetics exist, Km1 and Km2 are equilibrium constants 
and that the substrate(s) remain unchanged over the initial rate measurements, which are 
based on the formation of Lipid IV from two molecules of LII. Equation 4.4 considers 
both LII substrates, introducing a Km for both the transglycosylase donor and acceptor. 
The derivation of Equation 4.4 is in Appendix 2. 
[E]!+![S]!!!!!!!!!!!!!!!!!!!!!!!!!!!!!![ES]!!!!!!!!!!!!!!!!!!!!!!!!!!!!![ES2]!!!!!!!!!!!!!!!!!!!!!!!!!!!!![E]!!!!+!!!![P]!Km1! Km2! Kcat!+![S]!-![S]!(Scheme 2)       !
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Under initial conditions, a single turnover of the PBP1A transglycosylase domain 
involves two moles of the same substrate per mol of enzyme. The dual-substrate 
equation considers a donor and an acceptor substrate that are both the same thing, 
generating Km values for the acceptor and donor substrates separately. Under initial rate 
conditions, the majority of catalysis is likely to be the formation of Lipid IV: LII 
monomer + LII monomer. Over time, the donor substrate increases in length, constantly 
altering the donor substrate with the catalytic cycle. 
 
The kinetic data for E. coli PBP1B with dansDAP-LII-C35 and C55 in Figure 4.5 was 
fitted to the dual-substrate equation (Equation 4.4) in addition to the Michaelis Menten 
equation, however a poor fit to the dual equation was observed for E. coli PBP1B, 
therefore this model does not represent the data as closely as the Michaelis Menten 
equation. The PBP1A data was fitted to this ‘dual-substrate’ equation (Equation 4.4) 
and the extracted kinetic constants for each enzyme and LII substrate combination is 
summarised in Tables 4.2 to 4.5.  
 
The other equation sought to fit the kinetic data to was the Hill equation for 
cooperativity (Equation 4.5), where the binding of substrate molecule to one monomer 
of enzyme changes the affinity of another monomer (the enzyme must be dimer or 
tetramer).  
 
 
The Hill coefficient (h) is used as a measure of cooperativity and a h value of >1.0 
indicates positive cooperativity where the binding of one substrate molecule can induce 
structural or electronic changes that result in altered affinities for the vacant sites (Segel 
et al., 1993). The sigmoidal shape of the curves that fit the Hill equation exhibit, 
indicate that there are two different substrates throughout glycan chain polymerisation: 
(1) The LII monomers being incorporated into the growing glycan chain and (2) the 
polymerized glycan strand waiting to accept a nascent LII monomer. The binding of one 
substrate to the enzyme affects the affinity to which the other substrate can interact.  
 
v0 = ! Vmax [S]2 KmA KmB + KmB [S] + [S]2!Equation (4.4)  !
v0 =  S0.5 + [S]h!vmax [S]h!!Equation (4.5)  !
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        4.6.2.3  The Kinetic Profile of E. coli PBP1A and P. aeruginosa PBP1A with  
                     dansLys-Lipid II C55 
 
The kinetic profile of E. coli and P. aeruginosa PBP1a with dansLys-LII C55 was 
conducted for comparison with that of dansDAP-LII-C55. The Km for the native 
substrate for Gram-positive rather than Gram-negative PBPs was determined for E. coli 
and P. aeruginosa PBP1a in Figure 4.13. The data was fitted to both the ‘dual-
substrate’ equation and the Hill Equation, with Km and Vmax derived values summarised 
in Tables 4.2-4.5. The derived kinetic constants are summarised in Tables 4.2-4.5. 
 
 
 
 
 
 
 
 
 
 
Figure 4.13  The Dependency of E. coli and P. aeruginosa PBP1A upon dansLys-LII C55 
Substrate Concentration.  The data was fitted to both the ‘dual-substrate’ equation and the 
Hill Equation, with Km and Vmax derived values summarised in Tables 4.2-4.5. Values represent 
mean ± standard deviation of 3 reactions. The curve illustrated in this figure is the data fitted 
to the dual-substrate equation (a) EcPBP1A and (b) PaPBP1A with the non-canonical substrate 
dansLys-LII. Reaction conditions: 50 mM HEPES pH 7.5 for E. coli, pH 7.0 for P. aeruginosa, 
10 mM MgCl2, 60 mM NaCl, 10% DMSO (v/v), 0.1 µg muramidase, 0-20 µM dansLys-LII C55, 
0.75 µM PBP1A was delivered to the assay in 0.02 % (v/v) TritonX-100, n = 3. 
 
The sigmoidal kinetic profile suggests again that there are two substrates in this 
polymerisation, with monomer LII molecules being joined to other LII molecules 
initially, and subsequently glycan strands becoming the substrate for elongation with 
additional LII moieties. For EcPBP1A with dansLysLII (Figure 4.13a), the data was 
fitted to the dual-substrate equation (Eq. 4.4) with an R2 value of 0.87 but Prism 
identified the fit as ‘ambiguous’. However, when the data was fitted to the Hill equation 
(Eq 4.5) the R2 value was 0.94 and was deemed to be a more appropriate fit by 
GraphPad Prism (Table 4.2 and 4.3). P. aeruginosa PBP1A with dansLys-LII fitted to 
both equations but the fit to the Hill equation was optimal (Table 4.4 and 4.5). Vmax/Km 
A" B"
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and Vmax/S0.5 were calculated measures of catalytic efficiency and suggest that dansLII-
C35 is a preferred substrate over dansLII-C55, confirming the published finding that the 
shorter lipid chain minimises the possibility of aggregation as observed with the 
undecaprenyl pyrophosphate in LII-C55 in vitro (Ye et al., 2001). 
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Table 4.2  The Kinetic Parameters for E. coli PBP1A Transglycosylase Activity Fitted to 
the Dual-Substrate Equation. Data in Figures 4.12 and 4.13 was fitted to Equation 4.4. 
LII substrate Vmax (RFU/sec) Km (µM) 
Vmax / Km 
(RFU/sec/µM) 
R2 
dansDAP LII C55 17.48 ± 8.02 Ambiguous fit N/D - 
dansDAP LII C35 22.85 ± 10.52 
1: 9.92 ± 2.96 
2: 10.67 ± 3.37 
1: 2.30 
2: 2.14 
0.96 
dansLys LII C55 Ambiguous fit N/D N/D - 
 
Table 4.3  The Kinetic Parameters for E. coli PBP1A Transglycosylase Activity Fitted to 
the Hill Cooperativity Equation. Data in Figures 4.12 and 4.13 was fitted to Equation 4.5. 
LII Substrate 
Vmax 
(RFU/sec) 
S0.5 (µM) 
Vmax / S0.5 
(RFU/sec/µM) 
Hill 
Coefficient 
R2 
dansDAP LII C55 13.12 ± 0.97 6.97 ± 0.44 1.88 ± 0.18 3.19 ± 0.44 0.97 
dansDAP LII C35 38.66 ± 5.59 9.41 ± 1.40 4.11 ± 0.85 2.25 ± 0.32 0.96 
dansLys LII C55 66.21 ± 6.58 11.00 ± 0.99 6.02 ± 0.81 3.29 ± 0.50 0.94 
 
Table 4.4  The Kinetic Parameters for P. aeruginosa PBP1A Transglycosylase Activity 
Fitted to the Dual-Substrate Equation. Data in Figures 4.12 and 4.13 was fitted to Equation 
4.4. 
LII substrate 
Vmax 
(RFU/sec) 
Km (µM) 
Vmax / Km 
(RFU/sec/µM) 
R2 
dansDAP LII C55 17.47 ± 4.66 Ambiguous fit N/D  
dansDAP LII C35 25.57 ± 4.72 
1: 13.46 ± 2.40 
2: 11.86 ± 2.23 
1:1.90 
2: 2.16 
0.97 
dansLys LII C55 15.63 ± 1.60 
1: 7.64 ± 1.31 
2: 13.02 ± 2.89 
1: 2.05 
2: 1.20 
0.92 
 
Table 4.5  The Kinetic Parameters for P. aeruginosa PBP1A Transglycosylase Activity 
Fitted to the Hill Cooperativity Equation. Data in Figures 4.12 and 4.13 was fitted to 
Equation 4.5. 
LII Substrate 
Vmax 
(RFU/sec) 
S0.5 (µM) 
Vmax/S0.5 
(RFU/sec/ µM) 
Hill 
Coefficient 
R2 
dansDAP LII C55 16.48 ± 1.67 8.81 ± 0.97 1.87 ± 0.28 2.13 ± 0.22 0.98 
dansDAP LII C35 43.27 ± 3.90 10.60 ± 1.02 4.08 ± 0.54 2.48 ± 0.29 0.97 
dansLys LII C55 14.00 ± 5.12 12.60 ± 5.46 1.11 + 0.63 1.70 ± 0.36 0.92 
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The determined Km values of EcPBP1B transglycosylase domain for dansDAP-LII-C35 
vs. dansDAP-LII-C55 are 1.1 µM vs 4.5 µM, respectively, demonstrating a higher 
affinity towards the shorter (C35) prenyl chain lipid.  
 
Kinetic constants were determined for PBP1A from E. coli and P. aeruginosa, extracted 
by fitting the data to two equations (dual-substrate and Hill equations). The affinity for 
dansDAP-LII-C35 and slightly lower than that of dansDAP-LII-C55, with less deviation 
between the two compared to the difference in Km values between these substrates 
obtained for EcPBP1B. The S0.5 value (substrate concentration at half maximal rate) for 
EcPBP1A with dansDAP-LII-C55 was determined as 6.97 ± 0.44 µM when fitted to the 
Hill equation, compared to 9.41  ± 1.40 µM for dansDAP-LII-C35 indicating that E. coli 
PBP1A has a slight preference for LII with a C55-prenyl chain compared to LII with a 
C35-prenyl chain. 
 
Comparing the affinity of E. coli PBP1A for DAP vs Lys-LII demonstrated a preference 
for DAP-LII, which was expected as mesoDAP is the native substrate for Gram-
negative PBPs. The S0.5 values (determined by data fitting to the Hill equation) for 
EcPBP1A and dansDAP-LII was 6.97 ± 0.44 µM compared with 11.00 ± 0.99 µM for 
dansLys-LII. 
 
As for P. aeruginosa PBP1A, the results in Table 4.4 and 4.5 echo that of EcPBP1A 
with a preference for dansDAP-LII-C35. The S0.5 values obtained by fitting the data to 
the Hill equation were 8.81 ± 0.97 and 10.60 ± 1.02, respectively, suggesting a small 
preference for the native C55 substrate. There was very little difference in the S0.5 values 
between dansLys-LII-C55 and dansDAP-LII-C55. 
 
4.7  The Activity of Transglycosylase Active Site Mutants 
 
The three Class A PBPs that have thus far exhibited transglycosylase activity were 
mutated at their transglycosylase active site. The transglycosylase active-site mutants of 
E. coli PBP1A (E86Q), PBP1B (E233Q) and P. aeruginosa PBP1A (E86Q) were 
genetically engineered by site-directed mutagenesis, and the proteins were purified 
according to section 2.5.1. The transglycosylase activity of these catalytic active-site 
mutants were analysed using the continuous fluorometric assay (Figure 4.14). 
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Figure 4.14  The Transglycosylase Activity of PBP Transglycosylase Active-Site Mutants. 
EcPBP1A (E86Q), EcPBP1B (E233Q) and PaPBP1A (E86Q). Transglycosylase mutants are in 
pastel colours, wildtype PBP activities are in bold colours. 
 
All the wildtype PBPs exhibited their expected transglycosylase activity and the 
proteins with the mutated (glutamate to glutamine) transglycosylase active site did not 
demonstrate any ability to polymerise LII, further confirming the necessity of the 
glutamate for transglycosylase activity.  
 
4.8   The Effect of PBP-Associated Proteins on Transglycosylase Activity 
 
Recently there have been advancements in the knowledge of PB-associated proteins and 
how these proteins interact with, and stimulate PBP activity. The outer-membrane 
proteins LpoA and LpoB regulate peptidoglycan synthesis (Typas et al., 2010, Paradis-
Bleau et al., 2010). It was published that EcLpoA stimulates the transpeptidase activity 
of EcPBP1A, and EcLpoB stimulates both the transpeptidase and transglycosylase 
activities of EcPBP1B. This theory was tested with EcPBP1A and PaPBP1A. 
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       4.8.1  The Effect of E. coli LpoA, LpoB and P. aeruginosa LpoA upon the   
                 Transglycosylase Activity of PBP1A 
 
As EcLpoB stimulates EcPBP1B transpeptidase activity and EcLpoA stimulates both 
EcPBP1A transpeptidase and transglycosylase activities, the affect of PaLpoA on the 
transglycosylase activity of PaPBP1A was investigated and compared to that of E. coli 
(Figure 4.15). It is possible that the transglycosylase function of PaPBP1A is 
stimulated as a consequence of transpeptidase stimulation via LpoA binding to the ODD 
domain. 
 
 
 
 
 
 
 
 
Figure 4.15  The Effect of PaLpoA upon the Transglycosylase Activity of PaPBP1A (c), 
alongside (a) the affect of EcLpoA on EcPBP1A transglycosylase activity and (b) EcLpoB on 
EcPBP1B transglycosylase Activity. Reaction conditions: 50 mM HEPES pH 7.5, 10 mM 
MgCl2, 60 mM NaCl, 10% DMSO, 0.1 µg muramidase, 10 µM dansDAP-LII C55, 0.5 µM Ec/Pa 
PBP1A was used in each assay, 1.5 µM EcLpoA, 1.5 µM EcLpoB, 1.5 µM PaLpoA. 
 
EcLpoA stimulates the transpeptidase domain of EcPBP1A, but has no affect on 
transglycosylase activity (Lupoli et al., 2014), equally, PaLpoA does not show any 
stimulation of the transglycosylase activity of PaPBP1A. The effect of PaLpoA upon 
the transpeptidase activity of PaPBP1A is discussed in section 6.9.3. A dose-response 
curve of EcPBP1B to increasing concentrations of both EcLpoA and LpoB is illustrated 
in Figure 4.16. 
 
  
 
 
 
 
(a) 
(b) (c) 
! 131 
 
 
 
 
 
 
 
 
 
 
Figure 4.16  A Dose-Response of EcPBP1B Transglycosylase Activity to EcLpoB and 
EcPBP1A Transglycosylase Activity to EcLpoA. A titration of EcLpoA and LpoB outer 
lipoproteins with their cognate PBPs. Reaction conditions: 50 mM HEPES pH 7.5, 10 mM 
MgCl2, 60 mM NaCl, 10% DMSO, 0.1 µg muramidase, 10 µM dans-DAP-LII C55, 0.5 µM 
PBP1B used in each assay.  
 
EcPBP1B transglycosylase activity is stimulated with increasing concentrations of 
EcLpoB, however, EcPBP1A transglycosylase activity is not stimulated by the presence 
of EcLpoA. In Chapter 6, the transpeptidase activity of PaPBP1A, EcPBP1A and 
EcPBP1B are stimulated by the presence of PaLpoA, EcLpoA and EcLpoB 
respectively. 
 
      4.8.2  The Effect of E. coli PBP2 and FtsN on the Transglycosylase Activity of   
                Class A PBPs 
 
The monofunctional EcPBP2 was shown to stimulate the transglycosylase activity of 
EcPBP1A, and E. coli FtsN stimulates transglycosylase activity in EcPBP1B (Bertsche 
et al., 2005). This was extended to P. aeruginosa to see if EcPBP2 and/or EcFtsN had 
an effect on the transglycosylase activity of Pa Class A PBPs (Figure 4.17). E. coli 
PBP3 was shown to have no effect on the transglycosylase activity of EcPBP1B (Egan 
PhD Thesis, 2014), to which it interacts and PBP3 does not interact with EcPBP1A, so 
no PBPs were chosen to be tested with PBP3. The amount of TritonX-100 in the assay 
buffer was adjusted to compensate for the addition of TritonX-100 in the storage buffers 
of the PBP-associated proteins, to ensure a consistent final TritonX-100 concentration 
in each reaction, of 0.2 %. 
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Figure 4.17  The Effect of E. coli FtsN and PBP2 on PBP1A and PBP1B. Graphs labelled 
with specific proteins accordingly. Reaction conditions: 0.5 µM EcPBP2, 0.5 µM EcPBP3, 0.5 
µM PBP. 50 mM HEPES pH 7.5, 10 mM MgCl2, 60 mM NaCl, 10% DMSO, 0.1 µg 
muramidase, 10 µM dansDAP-LII-C55. 
 
The affect of EcPBP2 and EcFtsN on the transglycosylase activities of EcPBP1B were 
assayed for comparison with that of both EcPBP1A and PaPBP1A (Figure 4.17). The 
presence of E. coli PBP2 with EcPBP1B in a transglycosylase assay demonstrated little 
enhancement in the initial reaction rate of transglycosylation, with the amount of LII 
consumed plateauing to the same amount. In the presence of EcFtsN, however, a 2-3-
fold enhancement of transglycosylation by EcPBP1B was observed. For E. coli PBP1A, 
+ E. coli PBP2 + E. coli FtsN"
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the presence of EcPBP2 showed a 2-3-fold enhancement in transglycosylation activity 
but no enhancement in activity in the presence of FtsN. As for P. aeruginosa PBP1A, 
PaPBP1A transglycosylase activity was slightly increased by as much as 10-20% in the 
presence of E. coli PBP2, and PaPBP1A transglycosylase activity was not stimulated by 
E. coli FtsN. What is interesting is that EcPBP2 also had a slight stimulatory affect on 
its non-cognate PBP, EcPBP1B, at least upon the initial rate of transglycosylation. 
 
4.9  Discussion 
 
     4.9.1  Plate Reader versus Fluorimeter for Transglycosylase Activity  
               Measurement 
 
Using the plate reader to measure the fluorescence output of the continuous 
transglycosylase reaction rather than doing individual assays in a cuvette in a 
fluorimeter is beneficial for high-throughput screening and reduces material 
requirements. However, as a 96-well plate has a lower path length compared to the 1 cm 
path length of a cuvette, the background noise and light scattering increases in a plate 
well compared to a cuvette. The increase in assay noise from using a shorter assay path 
length is highlighted when analogous results from a 1 cm path length cuvette assay in a 
fluorimeter are compared with that from a much shorter path length in a plate reader. 
The advantage of reduction in assay volume from 200 µL in a cuvette to 25 µL in a well 
outweighs any issue with background noise, due to the more high-through-put nature of 
a 96-well plate, and the cost saving on the LII substrate. The major disadvantage of the 
plate reader is that the assay initiator, e.g. PBP enzyme is added externally by a multi-
channel pipette, and readings are taken when the 96-well plate is back inside the 
equipment. This misses the very initial rate of the reaction, and could be avoided if 
dispensers were used to add the enzyme to each well, removing the need to remove the 
plate from the reader. This is suitable if there is enough PBP enzyme to prime the 
dispenser lines beforehand and not run out of reagents half way through. Using 
dispensers places a higher demand on the use of enzyme, but if this can be afforded, it is 
preferable as it allows the easier capture of the initial rate of reaction. 
 
The linear regression curve should pass through the origin, as in the absence of enzyme 
the rate should also be zero. A suggestion for why the curve does not pass through the 
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origin could be an artifact of the assay technique itself. The assay is initiated in a 96-
well plate using a multi-channel pipette and upon initiation to plate is automatically 
returned to the plate reader machine and measurements are resumed. The very initial 
reaction rate is missed between final reagent addition and the first fluorescence 
measurement, which could justify why initial rates above zero are being observed at the 
initial fluorescence measurement, ‘time zero’. As all transglycosylation assays have 
been conducted in a uniform manner through this body of work, all assays are directly 
comparable to each other. 
 
The transfer of the spectrophotometric phosphate release assay in to a plate reader 
format would speed up the testing of the range of reaction conditions and would save 
reagents. The assay is very low-throughput at present in a cuvette. With more time, a 
plate reader format for this assay would be pursued. 
 
     4.9.2  Different Substrates Exhibit Different Levels of Fluorescence in the      
               Continuous Assay 
 
The kinetic profile of each PBP was characterised with a range of substrates, including 
dans-DAP-LII C35 and dans-DAP-LII C55 and the Lysine equivalents. The proportion of 
dansylation of C35 LII and C55 LII could be different to each other, as the length of the 
polyprenyl chain could interfere with the successful dansylation of the pentapeptide 
stem. The different levels of fluorescence between the different substrates need to be 
taken in to account in future studies.  
 
      4.9.3  Defining the Optimum pH of the Transglycosylase Activity of PBPs 
 
Upon testing the pH optimum of PaPBP1A and EcPBP1A, a biphasic profile was 
observed for P. aeruginosa PBP1A, which could indicate different orientations of either 
the PBP or the LII in detergent, exposing different regions. However it is more likely 
that it is due to experimental setup. The relationship between pH and activity could be 
affected by the buffer salt used. In the event that this experiment was repeated, the same 
buffer salt would be tested across a small range of pH, to rule out any effect of the 
individual buffer salts on PBP activity. 
 
! 135 
     4.9.4  The Effect of Detergent on Substrate Fluorescence in the Continuous   
               Assay 
 
Different detergents may have varying impacts on the efficiency of fluorescence of the 
dansylated-LII substrate in the continuous reaction. It is not known how each detergent 
specifically affects the levels of fluorescence and the emission spectra of the dansyl 
moiety, but this should be considered and taken in to account in future studies. 
 
      4.9.5  P. aeruginosa PBP1A and E. coli PBP1A Transglycosylase Kinetics 
 
The dependency of initial reaction rate upon substrate concentration was investigated 
using the continuous fluorometric assay for transglycosylation, generating kinetic 
constants for E. coli PBP1A and P. aeruginosa PBP1A. The data was initially fitted to 
the traditional Michaelis-Menten equation with little success as the fits were so poor. 
The dual-substrate equation (Equation 4.4) which takes each kinetic cycle and binding 
of two LII substrates, was a better fit than the Michaelis-Menten equation, but the Hill 
equation of cooperativity was the optimal fit for these kinetics. The Hill equation is a 
modified Michaelis-Menten equation that takes cooperativity of substrate binding in to 
consideration. Therefore it can be concluded that the transglycosylation kinetics of E. 
coli and P. aeruginosa PBP1A assumes cooperativity. The Hill coefficients (h) for both 
proteins with all three substrates was > 1.0, indicating positive cooperativity (Table 4.3 
and 4.5). All coefficients were between 1.7 - 3.29 and these Hill values can be used to 
estimate the number of binding sites involved in cooperativity (Segel et al., 1993). The 
S0.5 values show that the LII substrates had a marginally higher affinity for E. coli 
PBP1A over P. aeruginosa PBP1A. Although it could be argued that it is possible that 
P. aeruginosa PBP1A had fewer functional active sites than the E. coli PBP1A batch, 
and that the specific activity of the transglycosylase domain differs between the two 
proteins, as this was not assayed. 
 
The fact you do not see this behavior in the presence of 10 µM DAP-LII might indicate 
that substrate binding promotes the active conformation of the E. coli PBP1A (whether 
this is due to dimerization or whatever else that might cause this). If dimerization is the 
cause of this it suggests that the substrate decreases the Kd for subunit association. Of 
course, if there is a reciprocal relationship in that dimerization increases the turnover of 
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the enzyme, this in itself might be enough to explain the non‐Michaelis-Menten kinetics 
observed. 
 
For some transglycosylases, it has been suggested that the formation of the Lipid IV 
intermediate is the rate-limiting step of processive polymerisation (Wang et al., 2011). 
The binding of Lipid IV causes a rearrangement / reassortment of the active site of the 
enzyme, which upon completion gives an enhanced catalytic capability and promotes a 
faster reaction rate. This hypothesis could account for the initial lag phase observed in 
the assays of a range of transglycosylases in vitro (Schwartz et al., 2002, Barrett et al., 
2005, Chen et al., 2003, Wang et al., 2011). It has been shown that EcPBP1A and 
EcPBP1B (as well as S. aureus PBP2 and MGT) all lose their initial lag phase when 
pre-incubated with (a chemically blocked galactose adduct form of) Lipid IV (Wang et 
al., 2011). 
 
4.10  Conclusions 
 
All three Class A bifunctional enzymes showed transglycosylase activity using the 
continuous fluorometric assay, although PaPBP1B did not show full activity in any 
detergent tested, but potentially showed some activity in the detergent CHAPS and 
further investigation is needed with this enzyme. The two other enzymes were active in 
both TritonX-100 and CHAPS. The pH screen returned a pH optimal of pH 7.5 for 
EcPBP1A, and 7.0 for PaPBP1A.  
 
All three enzymes showed activity with different substrates, with varying carbon tail 
lengths as well as with both dansDAP-LII and the Gram-positive Lysine variant of LII. 
Kinetic data for EcPBP1A and PaPBP1A did not fit Michaelis-Menten kinetics and 
fitted more readily to the Hill equation of cooperativity, additionally, they both exhibit 
similar kinetic behaviour when investigating their dependence on enzyme 
concentration.  
 
As expected, the transglycosylation activity of EcPBP1B was stimulated in the presence 
of E. coli FtsN and EcPBP1A was stimulated in the presence of E. coli PBP2. As there 
was no DNA construct readily available for PaPBP2, the purified EcPBP2 protein was 
tested for its ability to enhance the transglycosylase activity of PaPBP1A, which 
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showed a small stimulation (10-20 %) in transglycosylase activity. E. coli PBP2 
enhanced the transglycosylase activity of EcPBP1A by 2-3 fold, but not PaPBP1A. 
Cloning PaPBP2 would be of interest to assess the stimulatory affect of PBP2 upon 
PBP1A transglycosylase activity in P. aeruginosa. 
 
4.11  Future Work 
 
     4.11.1  Optimising the Detergent for Transglycosylation Activity 
 
The detergents tested in this chapter for transglycosylase activity optimisation were all 
non-ionic (electrically neutral) detergents. The ExCy range of detergents demonstrated 
the best transglycosylation activity out of the non-ionic detergents tested. Other 
detergent families including anionic, cationic and amphoteric detergents could be tested 
for their suitability to aid transglycosylase activity. Detergents create detergent micelles; 
alternatively, membrane mimetics maintain protein solubility and stability by encasing 
the protein in a lipid bilayer. n-dodecyl phosphocholine (DPC) is an example of a 
membrane mimetic, commonly used for high-resolution NMR structures. Nanodiscs are 
another technique employed in structural characterisation studies. They are much 
smaller than detergents and have a much smaller curvature, hence they reduce light 
scattering in biophysical structural techniques. Styrene Maleic Acid co-polymer Lipid 
Particles (SMALPs) are a type of lipid bilayer nanodisc being used for activity and 
structural studies of membrane proteins (Dafforn et al., 2010).  
 
     4.11.2  Further Investigation of PaPBP1B Activity 
 
The investigation of PaPBP1B activity should be pursued further to identify the 
conditions under which PaPBP1B is active. This could include the buffer conditions 
used or another detergent entirely. The zwitterionic detergent CHAPS was the detergent 
that potentially showed some activity of PaPBP1B, so exploring zwitterionic detergents 
further would be useful for investigating PaPBP1B activity. 
 
PaPBP1B was tested for extraction and purification in to Styrene Maleic Acid co-
polymer Lipid Particles (SMALPs), but the over-expressed protein was not successfully 
extracted by the nanodisc. This method could be tried again, using a larger culture 
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growth and expression of PaPBP1B. The cloning of a range of different constructs 
would be advised, with a His6 tag at the N- and the C-terminus, separately.  
 
4.11.3  The Lack of an LpoB Protein in Pseudomonas aeruginosa. 
 
PaPBP1B did not show transglycosylase activity to the same extent as EcPBP1A or 
PaPBP1A. It is possible that this protein requires a longer substrate as a primer for 
polymerisation to proceed. PaPBP1B did not show enough activity to be able to 
continue any kinetic studies including determining its Km with LII. Optimising the 
activity of PaPBP1B will need further analysis as part of future work. Determining 
whether E. coli LpoB is capable of stimulating the transglycosylase activity of 
PaPBP1B would also be of interest. If EcLpoB were to positively enhance the 
transglycosylase activity of PaPBP1B, it may indicate the presence of an equivalent 
LpoB protein in most Pseudomonas spp. 
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 Chapter 5 
A Discontinuous Spectrophotometric Assay for 
The Detection of Transglycosylase-Dependent 
Undecaprenyl Pyrophosphate Production 
 
5.1  Transglycosylation Generates the By-Product Undecaprenyl Pyrophosphate 
(C55-PP) 
 
Structural modification of LII can interfere with activity of the enzyme and bring 
into question whether modified substrate analogues are appropriate for obtaining a 
realistic representation of the native enzyme activity 
 
In peptidoglycan polymerisation, transglycosylation forms a linear polymer from the 
monomer LII, in the presence of a transglycosylase enzyme (PBP). Each LII 
monomer harbors an undecaprenyl chain that anchors it to the bacterial membrane. 
Undecaprenyl phosphate (C55-P) is a lipid carrier that allows the transport of 
hydrophilic oligosaccharide precursors (e.g. LII) across the cytoplasmic membrane 
(Manat et al., 2014) towards the periplasm where elongation of the glycan chain 
takes place.  
 
C55-P has an important role in bacterial cells as a lipid carrier, required for the 
synthesis of bacterial cell wall components including teichoic acids, 
lipopolysaccharides and peptidoglycan. It is synthesised by the sequential addition of 
eight isoprene units on to farnesyl pyrophosphate catalysed by undecaprenyl 
pyrophosphate synthase (UppS), forming undecaprenyl pyrophosphate (C55-PP), 
before being dephosphorylated to C55-P (Touzé & Mengin-Lecreulx, 2008). 
 
During transglycosylation, upon the LII monomer being incorporated into a growing 
glycan chain, the C55-PP is cleaved off and recycled. The outer-most phosphate of 
C55-PP can be removed by an undecaprenyl pyrophosphate phosphatase (e.g. PgpB), 
which can be detected by the chromogenic nucleoside MESG in the presence of PNP 
(purine nucleoside pyrophosphatase) (Webb, 1992) and quantified 
spectrophotometrically (Figure 5.1). 
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5.2  Undecaprenyl Pyrophosphate Phosphatases Dephosphorylate C55-PP 
 
In E. coli, four undecaprenyl pyrophosphate phosphatases are involved in the 
dephosphorylation of C55-PP to C55-P + Pi: UppP (formally BacA), YbjG, YeiU and 
PgpB, with the latter three being members of the type 2 phosphatidic acid 
phosphatase (PAP2) family of enzymes (El Ghachi, 2004). These three enzymes 
have conserved, glutamate-rich sequence motifs located on the periplasmic face of 
the cytoplasmic membrane (Stukey 1997, Chang 2014) and they all contribute to the 
total C55-PP phosphatase activity in E. coli (El Ghachi, 2005). UppP has been 
suggested to generate 75% of the total cellular C55-PP phosphatase activity, whereas 
the other enzymes may account for the remaining 25% phosphatase activity (El 
Ghachi, 2004, El Ghachi 2005). All four of these proteins are integral membrane 
proteins, with PgpB (phosphatidylglycerophospate phosphatase B) and UppP being 
the most heavily studied (Touze 2008, Tatar 2014, Bickford 2013). The X-ray crystal 
structure of EcPgpB was solved in 2014 (Fan et al., 2014) and was shown to have six 
transmembrane domains and a large periplasmic loop. Over-expression of PgpB or 
UppP in vivo results in bacitracin resistance and increased levels of undecaprenyl 
pyrophosphate phosphatase activity (Siewert 1967). Bacitracin is a dodecapeptide 
antibiotic that blocks C55-P formation by binding tightly with C55-PP and preventing 
its dephosphorylation (Toscano, 1982).  
 
5.3  Phosphate Release as a Means of Quantifying Lipid II Turnover 
 
An assay was devised by Webb in 1992, exploiting the difference in absorbance 
between the nucleoside MESG (a guanosine analogue called 7-methyl-6-
thioguanosine) and it’s purine base product 7-methyl-6-guanine, when in the 
presence of inorganic phosphate and PNP (purine nucleoside pyrophosphorylase). 
(Figure 5.1) The absorbance maximum of the base product is shifted to 355 nm 
compared to 330 nm of the former nucleoside (Webb, 1992). The change in 
absorbance is directly related to the change in inorganic phosphate concentration and 
so can be used to directly quantify phosphate release. The phosphatase activity of 
EcPgpB can be examined by measuring the kinetics of inorganic phosphate release 
by coupling two enzymatic reactions: the chromogenic nucleoside MESG in the 
presence of PNP. This concept was developed by Dr. Adrian Lloyd at The University 
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of Warwick to exploit the production of the by-product C55-PP with each addition of 
LII to the glycan polymer and the subsequent inorganic phosphate release. A 
spectrophotometric assay was developed for the detection of inorganic phosphate 
release from transglycosylation.  
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Figure 5.1  A Schematic of the Coupled System for Inorganic Phosphate Detection. A phosphatase (e.g. PgpB) removes the terminal phosphate from the 
transglycosylation by-product undecaprenyl pyrophosphate (C55-PP). In the presence of this free inorganic phosphate and purine nucleoside pyrophosphorylase 
(PNP), a guanosine analogue 7-methyl-6-thioguanosine is converted to its base product 7-methyl-6-guanine. This base product has a shifted absorbance maximum 
of 355 nm, allowing the direct spectrophotometric quantification of the concentration of inorganic phosphate. Ribose-1-phosphate is generated as a result. 
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5.3.1  Advantages of this Discontinuous Assay for Transglycosylation  
             Detection 
 
The major advantage to this assay compared to the continuous fluorometric assay 
described earlier in this Chapter, is that there is no modification to the substrate. With 
the substrate being in its native form, this assay is the first transglycosylation assay with 
no LII substrate modification and is the most comparable reflection of natural 
peptidoglycan synthesis in vivo. The main undecaprenyl pyrophosphate phosphatase 
used for these studies was EcPgpB as Touzé et al., kinetically characterised the 
phosphate-specific activity of this enzyme in vitro. The phosphatase EcUppP was also 
trialed but the construct failed to show any activity.  
 
   5.3.2  Disadvantages of this Discontinuous Assay for Transglycosylation  
             Detection 
 
The disadvantage of this assay is that it is discontinuous. The assay method involves the 
incubation of PBP with non-labelled LII. Transglycosylation is ceased by heating and 
any precipitated material (aggregated PBP enzyme) is removed by centrifugation. The 
soluble transglycosylation products (including by-product undecaprenyl pyrophosphate) 
are added to the coupled, continuous assay in a cuvette for quantification 
spectrophotometrically of the total phosphate released by EcPgpB. Another 
disadvantage is that MESG has a narrow pH window in which its absorbance maximum 
is at 355 nm, pH 7.6, which overlaps with physiological pH for EcPgpB activity. The 
absorbance spectrum of MESG changes as a function of pH. In the pH range 6.5-8.5, 
there is a UV absorbance difference between the phosphorylase substrate and product - 
this feature is exploited in this assay, to quantify phosphate. 
 
5.4  Experimental Aims 
 
• To develop a spectrophotometric assay for the detection of transglycosylase 
activity 
• To express and purify E. coli PgpB 
• To establish optimal assay conditions and to kinetically characterise the 
transglycosylase activity of E. coli PBP1A and P. aeruginosa PBP1A, using the 
spectrophotometric assay 
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5.5  The Expression and Purification of E. coli PgpB 
 
The pTrc::E. coli PgpB construct was a gift from Dr. Touzé (The University Paris Sud) 
with a His6-tag on the C-terminus, an IPTG-inducible promoter and ampicillin 
resistance. The plasmid was over-expressed exactly according to Touzé et al 2008, in 
C43(DE3) cells, using 750 mL 2YT media in 2L baffled glass flasks x 4. The protein 
was extracted and solubilised in 0.04 % DDM and purified by IMAC (Figure 5.2 a). A 
sample of four fractions from the major peak in (a) were run on SDS-PAGE to assess 
the protein purity at elution from IMAC (Figure 5.2 b). Purified EcPgpB in DDM was 
characterised by CD (Figure 5.2 c), in 10 mM sodium phosphate buffer pH 7.3. 
 
 
 
 
 
 
 
Figure 5.2  The Purification of E. coli PgpB with initial Biophysical Characterisation by 
Circular Dichroism (CD). (a) EcPgpB IMAC purification chromatogram, using a 5 mL Nickel 
Fast Flow column on an ÄKTA Purifier (b) 12% SDS-PAGE coomassie-stained gel: 1 = flow 
through, 2 = 10 mM Imidazole wash, 3 = 20 mM Imidazole wash, 4 = four eluted fractions 
within the major peak in (a), with the molecular weight of 30.3 kDa. (c) CD spectrum of 5 µM 
C-His6-EcPgpB in 10 mM sodium phosphate buffer pH 7.3, containing 0.5 mM DDM. 
 
The expression of EcPgpB yielded ~2 mgs of pure protein per 750 mL cell culture. The 
over-expressed protein was extracted and solubilized efficiently with 3 x CMC (0.5 
mM) of the non-ionic detergent n-Dodecyl-β-D-maltoside (DDM), yielding sufficient 
quantities of correctly folded, active protein. TritonX-100 and CHAPS detergents were 
also tested for compatibility with EcPgpB and results were similar to DDM (Figure 
5.11). Examination of the CD spectrum of EcPgpB shows weak minima peaks at 208 
nm and 222 nm, indicating a predominantly α-helical protein. Using the fitting software 
DichroWeb, CDSSTR (Whitmore & Wallace, 2004) an α-helicity percentage of 56% 
was confirmed, 41 % β-strand and 3 % β-turn/random coil. The secondary structure 
prediction software PSIPred (Jones, 1999) returned 61.8 % α-helicity, 35 % β-strand 
and 3.2 % β-turn/random coil from the protein sequence alone.  
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5.6  The Development of a Spectrophotometric Assay for the Detection of 
Transglycosylase Activity 
 
     5.6.1  Phosphate Dose-Response Curve with the MESG-PNP Coupling System 
 
To determine the suitability of this assay system to measure the rate of inorganic 
phosphate (Pi) production, the coupled MESG system was used to determine the 
linearity of response for measuring a range of Pi concentrations (Figure 5.3) to 
determine to total change in absorbance given a specific input concentration of Pi. The 
phosphate (Pi) detection system used is illustrated in Figure 5.1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3  Correlating phosphate addition to the total change in absorbance of MESG at 355 
nm. Assay conditions were 20 mM Tris.HCI pH 7.6, 0.4 Units of PNP and 600 µM MESG to 
ensure that MESG was not rate-limiting in the assay. The amount of EcPgpB (200 nM) was 
chosen such that the reaction was complete within 10 minutes. 
 
The change in absorbance at 355 nm due to the phosphorylase-catalyzed reaction of 
MESG as a function of inorganic phosphate concentration shows a linear relationship. 
Therefore this coupling system is suitable for measuring phosphate release, and has 
been shown to be sensitive to detecting phosphate as low as 2 µM phosphate (Webb 
1992). 
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     5.6.2  Initial Rate Dependence on E. coli PgpB Concentration 
 
To study the relationship between increasing EcPgpB enzyme concentration on the 
initial reaction rate, assays were conducted with increasing concentrations of EcPgpB 
from zero to 1 µM (Figure 5.4). The UPP substrate concentration was present in excess 
at 1.8 mM to ensure the reaction was independent of substrate concentration. These 
reactions were conducted using synthesised UPP (Warwick BaCWaN Facility), rather 
than from LII. 
 
 
 
 
 
 
 
 
 
 
Figure 5.4  The Dependence of the Initial rate of Reaction upon the EcPgpB Enzyme 
Concentration. EcPgpB was present in the assay at a final concentration of 0.5 mM DDM (3 x 
CMC) of DDM. The substrate (C55-PP) concentration was present in excess at 1.8 mM. 
 
The initial rate of reaction is proportional to the concentration of EcPgpB, is 
independent of substrate concentration and follows the characteristics of a zero-order 
reaction. A variety of different substrates have been identified for EcPgpB with C55-PP 
being the native substrate and the rest, including diacylglycerol (DGPP) being non-
native substrates. 
 
     5.6.3  Comparison Between Substrates of E. coli PgpB 
 
EcPgpB has wide substrate specificity; Touzé et al. tested EcPgpB activity with a 
variety of substrates with and without different phospholipids. EcPgpB can 
dephosphorylate diacylglycerol pyrophosphate (DGPP), Phosphatidic acid (PA), 
phosphatidylglycerol phosphate (PGP) and LysoPA (Funk 1992, Dillon 1996), in 
addition to its native substrate C55-PP. However, C55-PP is dephosphorylated with much 
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lower efficiency compared to DGPP (Figure 5.5) and farnesyl pyrophosphate (C15-PP) 
(Touzé et al., 2008). DGPP is a phospholipid whereas C55-PP is an isoprenoid and their 
only structural feature in common is the pyrophosphate head group. EcPgpB activity in 
vitro is enhanced by phospholipid presence, which potentially helps with conformation 
of the long C55 carbon chain interactions with the membrane (Touzé, 2008). The 
phospholipid PE (phosphatidylethanolamine) has recently been shown to inhibit 
EcPgpB activity in vitro, and the crystal structure of EcPgpB bound to PE was solved in 
2016 (Tong et al., 2016). 
 
The presumed in vivo substrate for EcPgpB (C55-PP) and a non-native substrate DGPP 
were compared for activity with EcPgpB. The EcPgpB concentration used was 200 nM. 
EcPBP1A was used for the majority of the analysis of EcPgpB from here, as much 
analysis has previously been done on the transglycosylase activity of EcPBP1B 
(Schwartz, 2002). 
 
  
 
 
 
 
 
 
 
 
Figure 5.5  A Direct Comparison of Substrate Preference of E. coli PgpB, between the 
native substrate undecaprenyl pyrophosphate (C55-PP/UPP) and the non-native substrate 
diacyl glycerol pyrophosphate (DGPP). The initial rate of reaction for C55-PP was 0.104, and 
0.290 for DGPP. 140 µM of each substrate was used and both were resuspended in to 5 µL of a 
0.1% DDM solution (equivalent to 0.05 mM DDM in a 200 µL assay), the [DDM] in the assay 
was maintained at 3xCMC (0.5 mM). [EcPgpB] concentration = 200 nM. Continuous reaction 
conditions were 20 mM Tris.HCl pH 7.6, 10 mM MgCl2., 0.4U PNP, 600 µM. 
 
The native substrate C55-PP was turned over much slower than the non-native substrate 
DGPP, with the initial rate with DGPP being 3-fold-faster than that of C55-PP (0 of 0.29 
compared to that of 0.10). An initial lag was not seen with DGPP but was evident with 
C55-PP, even though C55-PP is the native in vivo substrate and DGPP is not. This result 
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was expected, as EcPgpB has a low specificity towards lipid pyrophosphate substrates 
compared to phospholipids such as DGPP, and PgpB has been shown to not be the sole 
pyrophosphate phosphatase in vivo. It is thought that multiple phosphatases contribute 
to the pyrophosphate pyrophosphatase activity, including YbjG and YeiU.  
 
5.6.3.1  Kinetics of Dependence of E. coli PgpB on Undecaprenyl   
             Pyrophosphate (C55-PP) and Diacylglycerol Pyrophosphate (DGPP) 
 
The phosphatase activity of EcPgpB was kinetically characterised with its native 
substrate C55-PP and the non-native substrate DGPP (Figure 5.6). The initial velocity of 
the reaction (v0) was measured at a variety of substrate concentrations from up to 1 mM 
substrate. A fixed concentration of 200 nM EcPgpB was used. 
 
 
 
 
 
 
 
 
 
Figure 5.6  Kinetics of Dependence of E. coli PgpB Phosphatase Activity with (a) its 
natural substrate undecaprenyl pyrophosphate C55-PP and (b) the non-native substrate 
DGPP. A fixed concentration of 200 nM EcPgpB was used. DGPP assays were performed in 
duplicate and C55-PP assays were conducted once only at each substrate concentration due to the 
precious, expensive and elusive nature of this substrate. 200 nM EcPgpB was used in reaction 
conditions: 20 mM Tris.HCl pH 7.6, 10 mM MgCl2. 
 
There is a hyperbolic relationship between the initial enzyme velocity (v0) and the 
substrate concentration, enabling the data to be fitted to the Michaelis-Menten equation 
(Equation 4.1) to determine Kcat and Km by non-linear regression. The kinetic 
parameters for EcPgpB with both C55-PP and DGPP (calculated using GraphPad Prism), 
are presented in Table 5.1.  
 
 
 
a 
b
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Table 5.1  A Summary of the Vmax and Km data derived from the Michaelis-Menten 
equation for the two substrates C55-PP and DGPP. The data was fitted to Equation 4.1 by 
non-linear regression, enabling kinetic constants to be derived. The lower table lists the 
equivalent data published by Touzé et al. (2008). 
Substrate Vmax (AU.s-1) Km (µM) Kcat (s-1) 
Kcat/Km  
(µM-1.s-1) 
R2 
C55-PP 0.155  153 ± 12.0 7.76 ± 0.18 0.05 ± 0.004 0.99 
DGPP 0.125  106 ± 8.8 6.26 ± 0.18 0.06 ± 0.005 0.98 
 
 Substrate 
Published 
Km (µM) 
Published 
Kcat (s-1) 
Published Kcat/Km 
(µM-1.s-1) 
 
 C55-PP 530 ± 90 9.0 ± 0.7 0.017 ± 0.003  
 DGPP 84 ± 14 280 ± 20 3.5 ± 0.7  
 
As the substrate concentration increased, the reaction velocity increased until it began to 
plateau at ~400 µM for DGPP and later for C55-PP. Increasing either substrate 
concentration from 400 µM to 1000 µM made little difference to the reaction velocity. 
The Vmax values for the two substrates are very similar but the Km data differ 
significantly. The Km for C55-PP is 1.5-fold that of DGPP, further indicating that 
EcPgpB has a higher affinity for the DGPP substrate over C55-PP, despite it being a 
non-native substrate. Previously reported Km for EcPgpB with C55-PP was 300 µM (Fan 
et al 2014). The Km value extracted for UPP/C55-PP was 153 ± 12.0, which is 3.5-fold 
lower than the published value of 530 ± 90. The Km value derived previously at The 
University of Warwick was 192 ± 17.2 (Abrahams, 2011). The Kcat/Km values derived 
from fitting the data to the Michaelis-Menten equation assess the catalytic efficiency of 
E. coli PgpB, with the values extracted similar for both DGPP (6.26 ± 0.18) and UPP 
(7.76 ± 0.18). 
 
     5.6.4  A Time-Dependent Profile for E. coli PBP1A Transglycosylation 
 
The reaction conditions for both the discontinuous polymerisation and continuous assay 
were devised from the literature and the method protocol was adapted from a previous 
PhD student, Katherine Abrahams (Abrahams, 2011). Conditions required for 
successful transglycosylation in the previous assay in this chapter included 20 mM 
Tris.HCl pH 7.6 as the buffering agent, 10 mM MgCl2 was required for 
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transglycosylase catalytic site activity and a non-ionic detergent required to solubilise 
the LII substrate. DDM was selected, as EcPgpB was shown to be active in this 
detergent, and was successful in showing the activity of S. aureus monofunctional 
glycosyl-transferase (MGT). Conditions for the continuous assay were kept constant to 
the discontinuous polymerisation, maintaining a maximum DDM concentration of 
3xCMC. An excess of detergent micelles devoid of substrate creates a crowded 
environment of ‘empty’ micelles which could interfere with PgpB activity. High 
concentrations of detergent have been documented to detrimentally affect the activity of 
PgpB (Touzé et al., 2008) and EcPBP1B (Schwartz et al., 2002).  
 
The length of time needed for the completion of transglycosylation was determined to 
ensure that the quantity of LII put in to the polymerisation, is equal to the amount of 
undecaprenyl pyrophosphate produced and also proportional to the amount of free 
inorganic phosphate generated by PgpB. The time required to polymerise LII to 
completion was determined by setting up a series of polymerisation reactions with an 
excess of DAP-LII (1.8 mM) and ceasing polymerisation at increasing time intervals 
(Figure 5.7). EcPBP1A in TritonX-100 was used as the transglycosylase to polymerise 
the LII.  
  
 
 
 
 
 
 
 
 
Figure 5.7  Time-dependence of Undecaprenyl Pyrophosphate Generation in the 
Transglycosylation Polymerisation Reaction. The average of two replicates plotted. The Vmax 
calculated using the Michaelis-Menten equation in Prism GraphPad was 103.8 ± 6.29. An 
excess of 1.8 mM DAP-LII was used in each polymerisation assay, 200 nM EcPgpB was used 
in reaction conditions: 20 mM Tris.HCl pH 7.6, 10 mM MgCl2. 
 
The majority of the LII had been consumed within 20 minutes of polymerisation at 30 
°C, as not much more undecaprenyl pyrophosphate was produced after this time point. 
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The Vmax has been calculated as 104 ± 6.29 µM.min-1, indicating that the polymerisation 
has not quite reached completion after 50 minutes, but the amount of C55-PP generated 
were the same after 20, 30 40 and 50 minutes of polymerisation. 
 
     5.6.5  Comparing the Substrate Preferences of three Class A Bifunctional PBPs 
 
Each of the three PBPs (EcPBP1A, EcPBP1B and PaPBP1A) were incubated with both 
Lys- and DAP-LII for 20 minutes and one hour before quantifying the amount of 
phosphate released via the continuous-coupled assay (Figure 5.8), a no-enzyme 
negative control was also run after leaving polymerisation for one hour. 
 
 
  
 
 
 
Figure 5.8  Comparing the Substrate Preference of EcPBP1A, EcPBP1B and PaPBP1A 
with both Lys- and DAP-LII. (a) 5 µM EcPBP1A (b) 5 µM EcPBP1B (c) 5 µM PaPBP1A.  –
– 1 hour Lys-LII polymerisation, –– 20 minute Lys-LII polymerisation, –– 20 minute DAP-LII 
polymerisation, –– no PBP enzyme negative control (polymerisation incubation for 1 hour). 80 
µM LII used. A LII polymerisation assay was conducted at 30 °C for both 20 minutes and 60 
minutes before the PBP was heat-inactivated at 60 °C. The amount of C55-PP produced by 
transglycosylation was measured via the release of the terminal inorganic phosphate and 
quantification of the free phosphate released. 200 nM EcPgpB was used in each assay and 200 
µM DAP- or Lys-LII substrate was used in reaction conditions: 20 mM Tris.HCl pH 7.6, 10 
mM MgCl2. 
 
Both DAP- and Lys-LII generate the same undecaprenyl pyrophosphate by-product 
(C55-PP) upon transglycosylation. DAP-LII was shown to be the preferred substrate by 
approximately 3-fold for all three PBP enzymes, as all of the DAP-LII had been turned-
over after just 20 minutes of polymerisation in the presence of PBP. The change in A355 
nm after 20 minutes indicated that all the DAP-LII had been consumed; therefore there 
was no need to leave the polymerisation for longer than 20 minutes. In contrast, the 
Lys-LII did not show full consumption of substrate after 20 minutes, and so was left for 
1 hour to ensure completion of polymerisation before testing the total amount of 
phosphate released. The negative control without PBP present did not show a positive 
result for free inorganic phosphate. Upon the total consumption of all the 200 µM 
a" b" c"
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substrate polymerised, the amount of phosphate released for DAP- and Lys-LII was 
comparable, but DAP-LII generated the C55-PP faster than Lys-LII. 
 
Concluding that DAP-LII is used more favourably over Lysine-LII, a range of DAP-LII 
concentrations were polymerised and assayed via phosphate release. The kinetic profile 
of EcPgpB with undecaprenyl pyrophosphate (C55-PP) generated from DAP-LII, by 
three Gram-negative Class A bifunctional PBPs was characterised below. 
 
     5.6.6  The Kinetic Profile of E. coli PgpB with C55-PP and Three Class A PBPs 
 
The amount of phosphate released was measured from increasing concentrations of 
DAP-LII. The DAP-LII was initially polymerised by a PBP, and the undecaprenyl 
pyrophosphate generated from each completed polymerisation was quantified 
continuously. The concentration of DAP-LII polymerised initially is proportional to the 
amount of C55-PP generated. The C55-PP is turned over by EcPgpB and the terminal 
phosphate released, enters in to the MESG coupling system and all free phosphate is 
quantified (Figure 5.9). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9  The Kinetic Profile of E. coli PgpB with DAP-LII generated undecaprenyl 
pyrophosphate (C55-PP) from 3 different Class A PBPs. (a) EcPBP1B, (b) and (d) EcPBP1A 
(c) and (e) P. aeruginosa PBP1A. Ec and Pa PBP1A data was fitted to the Hill equation in 
addition to the Michaelis-Menten equation, as a sigmoidal relationship was observed. Increasing 
concentrations of DAP-LII were incubated with PBP for one hour (completion). The amount of 
phosphate released was quantified as change in absorbance at 355 nm. 200 nM EcPgpB was 
used in reaction conditions: 20 mM Tris.HCl pH 7.6, 10 mM MgCl2. The final change in 
absorbance at 355 nm is when all free inorganic phosphate has been turned-over by the MESG-
coupling system. 
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P. aeruginosa PBP1A had the highest Km of the three PBPs and so turned over DAP-LII 
at a slower rate than the other two PBPs. The kinetic parameters of EcPgpB-dependent 
Pi release are presented in Table 5.2, fitted to the Michaelis-Menten equation (Equation 
4.1). The data was also fitted to the Hill equation (Equation 4.5), as the data indicates a 
sigmoidal approach to Vmax (Table 5.3). 
 
Table 5.2  The Kinetic Constants for each PBP, with data fitted to the Michaelis-Menten 
equation (Equation 4.1). LII was polymerised with each PBP, with subsequent Pi hydrolysis 
from undecaprenyl pyrophosphate by EcPgpB. 
PBP 
Vmax 
(AU/min/µg) 
Km (µM) Vmax/Km R2 
E. coli PBP1A 1.73 ± 0.44 395 ± 111 4.38 x 10-3 0.93 
E. coli PBP1B 2.41 ± 0.22 926 ± 122 2.60 x 10-3 0.96 
P. aeruginosa PBP1A 1.64 ± 0.28 313 ± 122 5.24 x 10-3 0.99 
 
Table 5.3  The Kinetic Constants for each PBP, with data fitted to the Hill equation 
(Equation 4.5). LII was polymerised with each PBP, with subsequent Pi hydrolysis from 
undecaprenyl pyrophosphate by EcPgpB. 
PBP 
Vmax 
(AU/min/µg) 
Km (µM) Vmax/Km R2 
E. coli PBP1A 1.16 ± 0.11 156 ± 27.8 7.46 x 10-3 0.98 
P. aeruginosa PBP1A 1.06 ± 0.11 152 ± 26.2 8.48 x 10-3 0.96 
 
Little is known kinetically about P. aeruginosa PBPs as there is very little published 
compared to E. coli PBPs. EcPBP1B did not reach Vmax, therefore the Km value 
extracted for this enzyme using the Michaelis-Menten equation is large, 926 ± 122 µM. 
The Km values extracted from the Michaelis-Menten fitting are much higher than 
previously defined in Chapter 4, using the continuous fluorescence assay for monitoring 
transglycosylation. The Km data derived by fitting to the Hill equation defines lower Km 
values that more closely resemble those defined by the continuous fluorescence assay, 
although the Km values in Table 5.3 are still 10-fold those defined by the continuous 
assay. The substrate measured in the fluorescence continuous assay is not identical as it 
is dansylated and the substrate used in the PgpB assay is native LII. However, the PgpB 
assay is a stopped assay and the fluorescence assay is continuous and so the derived 
kinetic values are likely to be more reliable.  
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    5.6.7  Testing Transglycosylase and Transpeptidase Active Site Mutant Activity   
              Using the Discontinuous Coupled Spectrophotometric Assay 
 
Transglycosylase (TG) and transpeptidase (TP) active site mutants were synthesised by 
site-directed mutagenesis (section 2.3.6). Active-site residues mutated are as follows: 
EcPBP1A = E86Q and S473A, EcPBP1B = E233Q and S510A, PaPBP1A = E86Q and 
S461A and PaPBP1B = E190Q and S469A. The PaPBP1B active-site mutants were 
successfully mutated confirmed by DNA sequencing, however, these mutants were 
never expressed as an active wildtype PaPBP1B protein could not be obtained as a 
positive control to compare against these active-site mutants. The activity of all other 
mutant PBPs: EcPBP1A, EcPBP1B and PaPBP1A were tested against their wildtype in 
the discontinuous DAP-LII polymerisation assay, with the (Figure 5.10). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10  The activity of both transglycosylase and transpeptidase wildtype and active 
site mutants were tested using EcPgpB. (a-c) TG active site mutant for each PBP (d-f) TP 
active site mutant for each PBP (a+d) EcPBP1A (b+e) EcPBP1B (c+f) PaPBP1A, –– Wildtype 
PBP –– active site mutant.  200 nM EcPgpB was used in each assay and 200 µM DAP-LII 
substrate was used in reaction conditions: 20 mM Tris.HCl pH 7.6, 10 mM MgCl2. 
 
The transpeptidase active site mutant (d-f) had no affect on the measurement of 
phosphate released from undecaprenyl pyrophosphate, the assays with the TP active site 
mutant were comparable to the wildtype. Assays containing the TG active site mutant 
(a-c) didn’t show any phosphate presence and therefore no transglycosylase activity. 
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The drive behind optimising this assay for transglycosylase activity was to ultimately 
develop the assay in to one that assayed both transglycosylase and transpeptidase 
activity simultaneously, giving alternative read-outs for both activity. The major factor 
preventing such a development is the kinetics of the EcPgpB enzyme and how slowly it 
turns over phosphate in the current conditions. In the continuous transglycosylase assay 
using fluorescently-labelled-LII, the principle detergent used to solubilise the LII 
substrate is decyl PEG. Adrian Lloyd used this range of detergents to optimise a 
transpeptidase assay and suggested trying this detergent and a range of similar 
detergents as a means of increasing the kinetic activity of EcPgpB and potentially the 
availability and presentation of the undecaprenyl pyrophosphate to EcPgpB and the 
coupling system.  
 
     5.6.8  Detergent Screening of E. coli PgpB Activity 
 
5.6.8.1  The Activity of E. coli PgpB when purified in TritonX-100,  
             CHAPS and DDM 
 
EcPgpB was purified in both DDM and TritonX-100 (Section 5.5) with its activity 
analysed after extraction and solubilisation in these three detergents (Figure 5.11). 
EcPgpB was extracted and purified in each detergent (0.03 % DDM, 0.5% TritonX-100 
and 1 % CHAPS. 
 
 
 
 
 
 
 
 
 
 
Figure 5.11  The activity of E. coli PgpB when extracted and purified in DDM, TritonX-
100 and CHAPS. DAP-LII was used at 200 µM in the discontinuous polymerisation with 200 
nM EcPgpB and 200 µM DAP-LII substrate and 8 µM EcPBP1A was used in reaction 
conditions: 20 mM Tris.HCl pH 7.6, 10 mM MgCl2. 
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EcPgpB was active in all three non-ionic detergents: DDM, TritonX-100, and CHAPS. 
The initial rate of reaction differed slightly with each detergent, with EcPgpB in DDM 
being the fastest, and EcPgpB in TritonX-100 being the slowest. In theory, all three 
preparations should release the same amount of phosphate from the undecaprenyl 
pyrophosphate from transglycosylation, as the same amount of LII was in the 
polymerisation, assuming that EcPBP1A went to completion in all assays. EcPgpB in 
CHAPS releases the most phosphate as the ΔA355 is greatest in this detergent, but the 
three detergents differ only marginally. 
 
5.6.8.2  E.coli PgpB Activity in Ethylene Glycol Alkyl Ether Detergents 
 
Ethylene glycol alkyl ether detergents are non-ionic surfactants with worm-like 
micelles. The micelles are analogous to real polymers but importantly different in that 
they can break and recombine like equilibrium polymers (Shirari et al 2006). Their 
micellar size is not fixed but fluctuates around an equilibrium volume (Miyake, et al 
2008). These series of detergents have a range of poly(Ethylene glycol) units and ethers, 
denoted as (ExCy) (Table 5.4). 
 
Table 5.4  A Summary of the Ethylene Glycol Ether Detergents Tested for Suitability for 
EcPgpB Activity 
 
Decyl PEG Name Abbreviation MW (g/mol) CMC (mM) 
Tetraethylene glycol 
monododecyl ether 
E4C12 334.49 0.069a 
Pentaethylene glycol 
monodecyl ether 
E5C10 406.60 0.07b 
Hexaethylene glycol 
monododecyl ether 
E6C12 450.65 0.087b 
Octaethyleneglycol 
monodecyl ether 
E8C10 538.75 0.11b 
a Fragento et al, 1996, Langmuir 12 pp477 
b Sigma Aldrich Website 
 
EcPgpB activity was tested with five of the ExCy detergents (Figure 5.12). The 
discontinuous assay was carried out as in section 2.8.4. The continuous assay was 
conducted by using assay buffer containing the ExCy detergent, conducting the 
continuous assay in a final concentration of 3xCMC of each ExCy detergent. The 
EcPgpB used was extracted and purified in CHAPS and when added to continuous 
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assay, the micellar concentration of the ExCy detergent present in the continuous assay 
buffer is at 3x its critical micellar concentration, but the CHAPS that the EcPgpB is 
delivered drops below its CMC. Therefore the EcPgpB enzyme is likely to switch from 
a CHAPS detergent micelle to a ExCy detergent micelle to maintain stability and 
solubility. EcPgpB could not be purified in these ExCy detergents individually because 
the detergents are extremely expensive and it is unknown whether they would work as a 
detergent for extraction and purification. 
 
 
 
 
 
 
 
 
 
 
Figure 5.12  E. coli PgpB activity tested in the presence of the non-ionic ethylene glycol 
alkyl ether detergents E4C12, E5C10, E6C12 and E8C10. EcPgpB was delivered to the 
continuous assay in CHAPS, but as the CHAPS became diluted it dropped below its CMC and 
the EcPgpB switched to the ExCy detergent in the continuous assay buffer. The discontinuous 
assay was carried out the same in all cases, with only the ExCy detergent in the assay buffer in 
the continuous assay differing. 200 µM DAP-LII substrate was used in the polymerisation, with 
200 nM EcPgpB in the continuous assay, in reaction conditions 20 mM Tris.HCl pH 7.6, 10 
mM MgCl2. 
 
The ethylene glycol ether detergent with the shortest and the longest ethylene glycol 
chain showed the least EcPgpB activity. When handling the detergents, it became 
apparent that the detergents with shorter ethylene glycol chain (E3, E4), the more 
viscous the detergent was. E3C10 exhibited the lowest EcPgpB activity with E4C12, 
E5C10 and E6C12 all demonstrating very good activity for EcPgpB. E6C12 has the fastest 
initial rate, and reaches a higher absorbance of all the detergents and so 
dephosphorylated more C55-PP molecules than the other detergents. 
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     5.6.9  E. coli PgpB Activity ± MgCl2, in a Variety of Non-ionic Detergents 
 
The activity of EcPgpB was tested in the presence and absence of magnesium chloride 
(MgCl2) in each detergent: DDM, TritonX-100, E3C10, E4C12, E5C10 and E8C10 (Figure 
5.13). In each case, the discontinuous assay was carried out as in section 2.8.4, with the 
polymerisation and continuous assay buffers altered to ensure the conditions were 
consistent with 3xCMC of each detergent and the correct concentration of MgCl2. The 
EcPgpB was purified in CHAPS, with the detergent being tested, present in each assay 
buffer. The concentration of CHAPS is diluted below its CMC, and the detergent 
present stabilises and maintains the solubility of EcPgpB. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13  The Activity of E. coli PgpB with and without Magnesium Chloride (MgCl2) 
in a Range of Detergents: (a) DDM (b) TritonX-100 (c) E3C10 (d) E4C12 (e) E5C10 (f) E6C12 (g) 
E3C10. –– Assay contains MgCl2,  –– No MgCl2 added to assay, only the MgCl2 delivered to the 
assay in the EcPgpB enzyme storage buffer, which is diluted 40-fold in the volume of the 
continuous assay and equates to a final MgCl2 concentration of 25 µM. 
 
In every case, the presence of > 25 µM MgCl2 enhanced the activity of EcPgpB, 
irrespective of the detergent that EcPgpB was in. When the assay was conducted in the 
ethylene glycol alkyl ether series of detergents, the presence of MgCl2 was amplified 
compared to in DDM or TritonX-100. The absence of MgCl2 (only the 25 µM donated 
from the EcPgpB storage buffer) had less of an effect on the activity of EcPgpB in the 
assays with DDM and TritonX-100 compared to the ExCy detergents. In the assays in 
the ExCy detergent series, the concentration of MgCl2 had a much greater effect on the 
activity of EcPgpB. In addition, two divalent cations (MgCl2 or CaCl2) per active site of 
a" b"
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UppS (Undecaprenyl Pyrophosphate Synthase) are shown to be absolutely required for 
UppS activity (Chang 2014). 
 
5.7  Discussion 
 
Traditionally transglycosylation has been monitored with radiolabelled or fluorescentl-
labelled substrates (Offant et al., 2010; Schwartz et al., 2002; Terrak & Nguyen-
Disteche, 2006). This assay has the advantage of using only natural substrates and 
quantifying transglycosylation discontinuously, however, the length of polymers cannot 
be determined, except for by mass spectrometry. 
 
     5.7.1  Comparing the Continuous Fluorescence Assay with the Phosphate  
               Release Spectrophotometric Assay 
 
The main advantage of the fluorometric assay is that it is continuous, with 
transglycosylation progression visualised in real-time. This assay is in contrast to the 
spectrophotometric assay, in which transglycosylation is discontinuous and is stopped 
after completion. The main disadvantage of the fluorometric assay is that it misses the 
initial rate of reaction, less so if dispensers are used to initiate the reaction, if enough 
reagents are available for dispenser priming. Another disadvantage of the continuous 
transglycosylase assay is that it is hard to quantify exactly how much LII substrate has 
been turned over at any given time, even upon reaction completion it may not be the 
case that all LII has been used up. With some further studies and standardized assays 
conducted, it could be possible to translate the change in relative fluorescence units into 
the volume of LII consumed.  
 
The main advantage of the spectrophotometric assay is that the substrate used is non-
labelled and so is as close to native as possible and is the only assay known to use 
native substrate. The main disadvantages being that is it not a continuous assay, and it is 
much less high-through put at present compared to the continuous assay as the 
spectrophotometric assay is done in a 200 µL cuvette whereas the continuous assay has 
been translated in to a plate reader format. 
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     5.7.2  Ceasing Transglycosylation Polymerisation 
 
Ceasing transglycosylation in the LII polymerisation assay was done by heating to 60 
°C for 10 minutes, which was successful at stopping polymerisation, as the PBP was 
visibly aggregated after this procedure. However, it is possible that heating the reaction 
products to 60 °C could destabilize the undecaprenyl pyrophosphate released during 
polymerisation and hence affect the true quantification of glycan chain polymerisation. 
A simple test could be conducted involving heating undecaprenyl pyrophosphate to 
different temperatures and analysing the phosphate released after exposure to each 
temperature. Also, by heating the reaction, transglycosylation does not halt 
instantaneously. With E. coli PgpB showing dependence upon divalent cations 
quenching with EDTA is possible. EDTA could be added to LII polymerisation to 
sequester the MgCl2, which this would halt transglycosylation, although this would not 
be a realistic solution, as EDTA would also affect the activity of EcPgpB in the 
subsequent continuous reaction. Quenching with EDTA was also shown to not be 100 
% effective at ceasing PgpB activity, retaining a small degree of activity (Abrahams, 
2011). 
 
     5.7.3  E. coli PgpB Activity in Different Detergents 
 
Upon determining the EcPgpB activity in different detergents, the ability of the MESG-
PNP coupling system to turn over free phosphate in the presence of each detergent 
should have been investigated initially to demonstrate that the detergent didn’t interfere 
with the coupling system. See section 5.9.3 for associated future work. 
 
5.8  Conclusions 
 
The dose-response plot of increasing concentrations of inorganic phosphate 
demonstrated that the MESG-PNP coupling system was appropriate for accurately 
measuring phosphate release and showed a linear response between phosphate and 
absorbance (Figure 5.3). The initial rate of reaction was also linear relative to EcPgpB 
concentration (Figure 5.4). PgpB gave a Km value of 154 ± 12.0 µM for its native 
substrate UPP, and 106 ± 8.7 µM for the non-native substrate DGPP. The published Km 
values by Touze et al., are 530 ± 90 µM for UPP and 80 ± 14 µM for DGPP. The 
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affinity that EcPgpB has for its native substrate was found to be 3.5-fold greater than 
previously published and similar to that published for DGPP (Table 5.2). 
 
EcPgpB is expressed and purified according to Touzé et al, 2008 in DDM is well folded 
and shows activity in this environment. Alternative detergents were tested for activity, 
including TritonX-100 and CHAPS, which showed similar activity to EcPgpB in DDM 
(CD was not carried out on EcPgpB in these additional detergents). 
The MESG-PNP coupling system showed a linear dose-response curve for the 
phosphate concentration, suggesting a stable system for phosphate detection and the rate 
of the continuous reaction was shown to be linear to EcPgpB concentration. DGPP was 
shown to be a better substrate for EcPgpB than it’s native substrate undecaprenyl 
pyrophosphate, with a lower Km and faster initial rate of reaction. DAP LII was also 
used more favourably by the PBPs compared to Lys-LII, as the rate of DAP-LII 
consumption was faster than that of Lys-LII. This is also backed-up from results using 
the continuous transglycosylase assay. All three Class A enzymes showed activity using 
this assay method, with PaPBP1A having the lowest Km of the three PBPs and so turned 
over DAP-LII the slowest. Transglycosylase active-site mutants were proven to be non-
functional in both transglycosylase assays in this chapter, while the TP active-site 
mutants did not inhibit transglycosylase activity. 
 
5.9  Future Work 
 
     5.9.1   The PgpB Assay has the Potential to Monitor Transglycosylation  
                Continuously 
 
This discontinuous assay for transglycosylation has the potential to be continuous, with 
transglycosylation occurring concurrently with PgpB cleaving the phosphate, followed 
by phosphate detection by the coupling system. The kinetic rate of the pyrophosphatase 
will need stimulation in order for a phosphate release rate to be detected. The addition 
of cytoplasmic membrane phospholipids such as cardiolipin and phosphatidyl glycerol 
has been shown to enhance the activity of E. coli PgpB by 5.4-fold (Touze et al., 2008), 
which could be incorporated in to a continuous format, providing such phospholipids  
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     5.9.2  The Stability and Activity of PgpB in Different Detergents 
 
As the kinetic speed of E. coli PgpB is a limiting factor in this assay thus far, the 
stability of this enzyme should be tested and optimised. Circular dichroism would 
indicate sufficient folding of the enzyme, but also, a thermoflour assay that measures 
changes in thermal shift and quantifies the change in thermal denaturation temperature 
of a protein, is ideal for measuring the stability of proteins in different detergents. 
 
     5.9.3  Scrutinise the Kinetic Capability of E. coli PgpB in a Wider Range of      
               Detergents 
 
EcPgpB was successfully used to indirectly visualise transglycosylation, but speeding 
up its enzymatic ability is necessary for the assay to be developed into a continuous 
format. EcPgpB could be extracted and purified in to one of the series of Ethylene 
Glycol Alkyl Ether detergents, in which PgpB exhibited good activity, however, this 
would be very expensive as a lot of detergent is required to extract and purify a protein. 
Other phosphatases such as BacA should be trialled as an alternative to PgpB. 
 
     5.9.4  Investigate Alternative Undecaprenyl Pyrophosphate Phosphatases to 
               PgpB 
 
As UppP (formally BacA) is now thought to generate 75% of the undecaprenyl 
pyrophosphate in a bacterial cell, the spectrophotometric, phosphate-release assay could 
be tried with UppP as an alternative to PgpB. UppP has been suggested to generate 75% 
of the total cellular C55-PP phosphatase activity, whereas the other enzymes may 
account for the remaining 25% phosphatase activity (El Ghachi, 2004, El Ghachi 2005). 
 
     5.9.5  The PgpB Assay and Bacitracin 
 
The PgpB assay could be conducted in the presence of bacitracin, which binds to 
undecaprenyl pyrophosphate, and showed increased levels of undecaprenyl 
pyrophosphate phosphatase activity in vivo (El Ghachi et al., 2005). Modification of 
bacitracin with a fluorophore reporter could allow indirect monitoring of 
transglycosylation (Manat et al., 2014).  
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Chapter 6 
The Study of Transpeptidation in Class A Penicillin 
Binding Proteins from E. coli and P. aeruginosa 
 
The precise catalytic mechanism of transpeptidation by PBPs is yet to be fully 
understood and assay methods are limited. The synthesis of transpeptidase donor and 
acceptor compounds in this chapter will aid in understanding specific requirements for 
these molecules and their function in transpeptidation. Efforts in developing compounds 
towards a FRET assay in this chapter aim to further observe the process of 
transpeptidation in real time, providing further enzymatic and mechanistic insights.  
 
6.1  Defining Transpeptidase Donors and Acceptors 
 
The mechanism of transpeptidation is an attractive target for antibiotics as it occurs on 
the outer face of the cytoplasmic membrane of the bacterium, and is a lethal target. If 
this system is disrupted and peptidoglycan formation is prevented, e.g. by the action of 
penicillin, the bacterial cell wall will lyse under osmotic pressure. Transpeptidation 
forms the cross-links between two adjacent pentapeptide strands to form a pentapeptide 
bridge and a mesh-like structure of high tensile strength to resist osmotic stresses. In 
transpeptidation, there is a donor substrate and an acceptor substrate (Figures 6.1 and 
Figure 1.6). The donor substrate forms an acyl-enzyme complex with the PBP (section 
1.45) and is often part of an elongating glycan chain. The acceptor substrate is part of an 
adjacent glycan strand (Lupoli et al., 2011). 
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Figure 6.1  Transpeptidase Donor and Acceptor Compounds. In the mechanism of 
transpeptidation (section 1.4.5), the active site serine of the PBP forms a covalent bond 
with the carbonyl of the penultimate D-alanine of the donor strand. This releases the C-
terminal D-alanine from the pentapeptide stem forming a PBP-seryl MurNAc-GlcNAc 
tetrapeptidyl species. The ε-amino group of the diaminopimelyl moiety of the acceptor 
displaces the PBP, forming a peptide bond constituting a 3-4 cross-link formed between 
the fourth D-alanine on the donor strand and the third mesoDAP residue on the acceptor 
strand. 
 
In order to monitor transpeptidation specifically, the requirements of a transpeptidase 
donor assay substrate are that it is able to polymerise LII, with the second requirement 
that it is not able to cross-link to any adjacent glycan strand. Most Gram-negative 
bacteria cross-link to the mesoDAP residue on the acceptor strand, so labelling the 
reactive ε-amine of the mesoDAP residue with a dansyl or fluorescamine fluorophore 
prevents the substrate from being a transpeptidase acceptor, but not in principle, a 
donor. 
 
In the transpeptidase acceptor molecule, the mesoDAP residue at position three of the 
peptide stem cross-links to the fourth residue of the transpeptidase donor. Natural 
peptide acceptors have been shown to contain reactive amine D-amino acids (Lupoli et 
al., 2011). In the case of mesoDAP, there are two stereocentres with differing 
configuration: L and D. In peptidoglycan, the L-stereocentre is incorporated into the 
peptide backbone and is not involved in DD-transpeptidase cross-linking, whereas the D-
stereocentre cross-links to the fourth amino acid of the donor strand (Pillai et al., 2006). 
 
 
Transpeptidase 
Donor Substrate Transpeptidase 
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6.2  Transpeptidase Assays in the Literature 
 
DD-Transpeptidase activity is challenging to measure and characterise, as the products 
are not easily distinguished from uncross-linked peptidoglycan, because they have 
similar chromatographic properties (Jha & de Sousa, 2006). The transpeptidase domain 
of PBPs functions as both a DD-transpeptidase as well as a DD-carboxypeptidase, both 
of which result in the release of D-alanine, but nearly all assays available do not 
distinguish between the two functions. Efforts towards the development of 
transpeptidase assays in the past have included making peptide thioester substrates as a 
means for showing transpeptidation (Grandchamps et al., 1995). However, these 
thioester substrates were not entirely representative of native in vivo peptidoglycan and 
had low affinity. Additionally, the thiolester linkage was reactive towards non-
enzymatic hydrolysis, making PBP assays with these substrates relatively insensitive 
(Adams et al., 1991).  
 
The drive to search for potential transpeptidase inhibitors resulted in assays being 
developed that relied on how well the inhibitor compound out-competed the β-lactam 
for transpeptidase active-site binding. A scintillation Proximity Assay (SPA) was 
developed to screen for potential transglycosylase and transpeptidase inhibitors, 
assaying the transpeptidase in an E. coli membrane environment (Kumar et al., 2014). 
Using Wheat Germ Aglutinin (WGA)-SPA beads, the cross-linked products were 
distinguished from the uncross-linked substrate as well as uncross-linked LII. This two-
step assay first treated the membranes with a concentration of vancomycin that inhibited 
transglycosylation, but not MraY or MurG, to accumulate LII in the E. coli membranes. 
The second step of this assay involved the addition of D-Ala-D-Ala to counter the 
presence of the vancomycin and trigger transpeptidation. The results were captured by 
scintillation counts.  
 
Assays that have used native substrates used methods including chromatography and 
spectrophotometry, mostly to detect amino acid exchange. The products of 
peptidoglycan synthesis can, after enzymatic digestion, be separated by HPLC and 
analysed quantitatively using mass spectrometry to detect and confirm the presence of 
cross-linked material, the extent of cross-linking as well as the relative abundance of the 
various muropeptides (Vinatier et al., 2009). Vollmer and colleagues developed an 
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assay using radio-labelled LII as the substrate for polymerisation by E. coli PBP1A 
(Born et al., 2006) and E. coli PBP1B (Bertsche et al., 2005), then subsequently 
digesting the polymerised products with cellosyl ready for analysis by HPLC. 
Synthesised peptidoglycan products have also been analysed by LC-MS without the 
need for radioactivity (Lebar et al., 2014). The disadvantage of all of these assays thus 
far, is that they are all stopped assays with none of them showing any kinetic activity in 
real-time (with the exception of the thiol ester substrate assays, which suffer from 
intrinsic instability of the substrate within the assay). 
 
6.2.1  The Exchange Reaction 
 
The exchange reaction is the most recent attempt at characterising the two steps of 
transpeptidation. The first step of transpeptidation is donor activation resulting in the 
release of the terminal D-alanine and the esterification of the remaining tetrapeptide to 
the transpeptidase active site of the PBP. The second step of the exchange reaction 
involves the attack by D-alanine (or for the purposes of assay, an alternative D-amino 
acyl species) of the PBP-tetrapeptide intermediate to reform the pentapeptide of the 
donor strand. In this instance, the reaction overall is a transpeptidation event, but by 
reversal of the initial acylation of the PBP with its donor substrate. To study the 
suitability of peptidoglycan donor chains as a substrate for the second step of 
transpeptidation (linking with the acceptor), Lupoli et al., trialled a variety of L and D 
amino acids (alanine, glycine, tryptophan, phenylalanine and tyrosine) as potential 
participants in the exchange reaction (Figure 6.2).  
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Figure 6.2  The D-Amino Acid Exchange Reaction 
 
The D-amino acid acted as the nucleophile and exchanged the terminal D-alanine with 
the added amino acid. Only the D-amino acids were incorporated (exchanged) in to the 
fifth position of the donor strand. This exchange reaction has been exploited to label the 
peptide with fluorescent D-amino acids (Kuru et al., 2012). 
 
6.3  Experimental Aims 
 
• To develop novel donor and acceptor substrates for the study of transpeptidation 
via a FRET assay 
• To synthesise UDP-MurNAc-L-Ala-γ-D-Gln-mesoDAP-D-Ala-D-Ala labelled 
with Fluorescamine  
• To characterise the synthesised compounds as potential transpeptidase donors 
and acceptors  
• To characterise the transpeptidase activity of P. aeruginosa and E. coli Class A 
PBPs, via a continuous spectrophotometric assay 
• To monitor the continuous, in vitro detection of the transpeptidase activity of E. 
coli PBP1A, followed by optimising the assay conditions. 
Acyl-enzyme 
intermediate 
Modified 
pentapeptide 
side chain 
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• To analyse the ability of transglycosylase and transpeptidase active site mutants 
to perform transpeptidation  
• To test the transpeptidase function of P. aeruginosa PBP1A under the conditions 
defined for E. coli PBP1A. 
 
6.4  The Development of a FRET Assay Allowing the Kinetic Characterisation of 
Class A PBPs 
 
Developing a novel transpeptidation assay will extend our understanding of the 
transpeptidase mechanism through kinetic analysis of PBPs which itself could be used 
to identify potential inhibitors.  
 
Compared to transpeptidation assays involving radioactivity, using fluorescence as a 
reporter for reaction progression is more convenient and can be visualised in real-time. 
Fluorescent labels appended to the pentapeptide stem in LII and have successfully been 
used as reporters in continuous assays for transglycosylation (Schwartz et al., 2001, 
Mohammadi, et al., 2011). The convenience of using fluorescence over radioactivity 
and the ability to already incorporate fluorophores in to peptidoglycan precursors, 
together with the opportunity to selectively label the transpeptidase donor and acceptor 
are sound justification for the choice to use FRET to study transpeptidation. 
 
          6.4.1  Definition of FRET 
 
Förster Resonance Energy Transfer (FRET) involves donors and acceptors of energy, 
which is transferred through space from a donor fluorophore to an acceptor fluorophore. 
FRET can be used to measure the relative amount of donor and acceptor fluorophore 
complexes, protein-protein interactions, protein-ligand interactions, or protein-protein 
inter-distances, usually by labelling the proteins with fluorophores. 
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6.4.2  The Förster Radius (R0)  
 
The Förster distance (radius, R0) is the critical distance at which 50% of internal 
quenching occurs. Each pair of fluorophores has their own R0 length (in Ångstroms). 
The bigger the R0 value, the larger the distance over which that emission can be 
transferred to the FRET acceptor, but the efficiency of transfer is reduced. It can be 
useful to increase the R0 to accommodate for the long undecaprenyl chain in LII, which 
is approximately 50Å (Huang et al., 2013). The Förster radius can be determined from 
the optical properties of the fluorophores used (Roy et al. 2008). 
 
6.4.3  The Pros and Cons of FRET 
 
FRET can be a convenient alternative to radioactivity assays as they continuous, 
quantitative, high throughput and can be used to determine kinetic constants such as 
inhibition constant (Ki). FRET can be a highly sensitive method that can be used to 
measure distance or changes in distance in vitro and in vivo. However, some drawbacks 
to the technique include the requirement for a low background to have a sensitive 
signal-to-background ratio for real-time enzymatic assays. FRET-pair labelling also 
needs to be bright, with the donor fluorophore completely saturated by the acceptor 
fluorophore. Occasionally, free fluorophores can mask energy transfer and fluorescence 
can be quenched. Additionally, modification of the substrate can either eliminate its 
ability to support the enzyme activity or significantly modifies the kinetics of the 
enzyme relative to that displayed by native substrates. Fluorescence is also relative, 
rather than absolute. 
 
6.5   Designing the Transpeptidase Donor and Acceptor Compounds for FRET 
 
In the specific case of this assay, the terms ‘transpeptidase acceptor’ and ‘transpeptidase 
donor’ are used to describe the substrates involved in the transpeptidase reaction. In 
addition to this terminology, donor and acceptor are also used in the FRET literature to 
indicate which fluorophore donates or accepts the fluorescence energy, i.e. donor 
fluorophore and acceptor fluorophore. In this FRET assay, the transpeptidase donor is 
labelled with the FRET acceptor fluorophore and the transpeptidase acceptor 
harbours the FRET donor fluorophore. 
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Considerations when designing the transpeptidase FRET assay included determining the 
requirements for a donor molecule and for acceptor molecules. For a molecule to be a 
donor only, the epsilon amino group on the third amino acid in the peptide stem must 
not be capable of nucleophilic attack thereby also acting as an acceptor molecule. There 
are three methods of ensuring that a peptidoglycan precursor acts as a transpeptidation 
donor only: 
 
1. Labelling the mesoDAP residue with a fluorophore attached to its ε-amine group 
shields the D-stereocentre of the DAP residue. Blocking this functional group 
prevents acceptor capability and ensures donor-only capability. Dans-LII has 
this property of only being able to serve as an acyl donor in the transpeptidase 
reaction. The large dansyl group attached to position 3 prevents the non-
proteinaceous meso-DAP from acting as an acyl-acceptor. 
2. Another requirement of the transpeptidase donor is that it must be able to be 
polymerised in to a linear glycan strand, as a polymeric fragment of 
peptidoglycan, i.e linear glycan strands without any chance of cross-linking with 
each other are required for transpeptidation to occur. 
 
Acceptor molecules need only be a single amino acid with the amine nucleophile in the 
D-configuration. L-amino acids are discriminated against (Lupoli et al,, 2011, Lebar  et 
al., 2014). 
 
6.5.1  Criteria for a Successful FRET System 
 
1) The optimum fluorescence emission of the donor molecule must overlap with 
the excitation wavelength of the acceptor (Willard et al., 2001). 
 
An overlap between the emission spectra of the donor fluorophore and the absorption 
spectrum of the acceptor fluorophore is necessary for energy transfer to occur. FRET 
efficiency (the degree to which energy is transferred), is related to the overlap between 
the respective spectra of the fluorophores, and is highly dependent on the distance 
between them (dynamic range). At the middle of the dynamic range, half of the energy 
would be transferred from donor to acceptor.  
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2) The distance between the two fluorophores, defined as the Förster Radius (R0) is 
optimal between 20-80Å, depending on the nature of the pairing (Corry et al., 
2005). 
 
There is a spectral overlap integral between the donor fluorophore emission spectrum 
and the acceptor fluorophore absorbance spectrum, which can be calculated. Using the 
calculated spectral overlap integral, the Förster radius for a specific fluorophore pair can 
then be calculated if the quantum yield of the donor in the absence of the acceptor is 
known, the dipole orientation factor, the refractive index of the solvent system and 
Avogadro’s number. FRET efficiencies (obtained by experimentation) can be used to 
estimate the separation distance between the two fluorophores. 
 
     6.5.2  Selecting the Optimum Fluorophores for Transpeptidase Donors and   
   Acceptors 
 
             6.5.2.1  Potential FRET Donor Fluorophores 
 
The intensity of emission of a fluorophore is determined primarily by its extinction 
coefficient and quantum yield, which are both dependent on the environment of the 
fluorophore. Fluorophores that could potentially be compatible with being incorporated 
in to the transpeptidase acceptor molecule are listed in Table 6.1. 
 
Table 6.1  Potential Fluorescent Amino Acids that can be Incorporated in to the 
Pentapeptide Stem of the Transpeptidase Acceptor Molecule (Molecular Probes website). 
 Absorbance Fluorescence  
FRET Donor 
Fluorophore 
Ex λ 
(nm) 
Extinction 
Coefficient* 
Em λ 
(nm) 
Quantum 
Yield** (Φf) 
Molecular 
weight (g/mol) 
D-Tryptophan 280 5,690 348 0.20  204.23 
D-7-Azatryptophan 300 5,080 390 0.03 205.21 
Tyrosine  274 1,400 303 0.14  181.19 
Phenylalanine 257 200 282 0.04 165.19 
*All extinction coefficients reported at the absorption maximum of the fluorophore 
** All quantum yields given are for an aqueous environment 
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D-Azatryptophan and D-tryptophan have very similar extinction coefficients but D-
azatryptophan has a much lower quantum yield comparatively. All potential 
fluorophores have similar spectral maxima because they are all α-amino acids. These 
properties were considered when matching this FRET donor fluorophore with an 
acceptor fluorophore See Figure 6.3 for the selected FRET acceptor fluorophores. 
 
6.5.2.2  Potential FRET Acceptor Fluorophores 
 
A variety of fluorophores were considered as FRET acceptor fluorophores including 
dansyl, Fluorescamine, Fluorescein, NBD, Rhodamine II, Biotin, and BODIPYTM. 
Which all have varying quantum yields, extinction coefficients and fluorophore size. 
The selected fluorophores are required to be able to label the DAP residue on the 
transpeptidase donor molecule. The fluorophore selected would be a FRET acceptor 
fluorophore, but would be labelling the transpeptidase donor molecule.  
 
There is a large variety in the molecular weights of the fluorophores, with BODIPYTM 
being this largest. The ‘bulkiness’ of the fluorophore needs to be considered so that it 
does not interfere with the natural transpeptidase mechanism. The excitation wavelength 
of this FRET acceptor fluorophore has to overlap significantly with the emission 
wavelength of the selected FRET donor fluorophore. After extensive research in to a 
variety of different fluorophore pairings, two sets of fluorophore pairs were chosen for 
this FRET assay.  
 
Dansyl chloride has traditionally been used to label the mesoDAP residue on the 
pentapeptide stem, for tracking transglycosylation processivity (Schwart et al., 2002; 
Liu et al., 2010). The excitation wavelength (λEx) of dansyl is 340 nm and the emission 
wavelength (λEm) of D-tryptophan is also 340 nm (Figure 6.3). Therefore the dansyl 
label on the pentapeptide stem can be the FRET acceptor fluorophore and a D-
tryptophan residue can be incorporated in to the pentapeptide stem of the transpeptidase 
acceptor. The considerations with using D-tryptophan as a fluorophore are that it is 
sensitive to solvent polarity as a fluorophore (Vivian & Callis, 2001), which is also the 
case for dansyl. Also, in the presence of a proteinaceous enzyme in an assay 
environment, any aromatic amino acids in the enzyme would also be excited at 280 nm 
and potentially interfere with FRET and contribute to background noise. An alternative 
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to D-tryptophan is D-7-azatryptophan, whose excitation spectrum is red shifted by 20 
nm but has the disadvantage that its quantum yield is lower. D-7-Azatryptophan can be 
incorporated in to the pentapeptide stem to serve as a FRET donor fluorophore. The 
cognate acceptor fluorophore is fluorescamine. The emission maximum of D-7-
azatryptophan is 360-390 nm, overlapping with the excitation maximum of 
fluorescamine. 
 
 
 
 
 
 
 
 
 
(a)  FRET Pair 1 
 λEx 
(nm) 
λEm 
(nm) 
Extinction 
Coefficient 
Quantum 
Yield (Φf) 
Donor Fluorophore D-Tryptophan 280 340 5,690 0.20 
Acceptor Fluorophore Dansyl 340 520 4,550 0.70 
(b)  FRET Pair 2      
Donor Fluorophore D-7-Azatryptophan 295 360 5,080 0.03 
Acceptor Fluorophore Fluorescamine 390 470 26,000 0.23 
 
Figure 6.3  Potential FRET Fluorophore Pairs and their Fluorometric Properties (a) The 
emission spectrum of the FRET donor fluorophore (D-tryptophan) overlaps sufficiently with the 
excitation maximum of the acceptor fluorophore (Dansyl). (b) The emission spectrum of the 
FRET donor fluorophore (D-azatryptophan) overlaps sufficiently with the excitation maximum 
of the acceptor fluorophore (Fluorescamine). 
 
Other factors in addition to overlapping spectra were considered when selecting 
fluorophores, such as quantum yield (brightness of fluorescence), the Förster distance 
between the two fluorophores, along with the size and shape of the fluorophore. The 
ability of the fluorophore to incorporate naturally in to the peptidoglycan precursor 
without disrupting transpeptidation is of paramount importance, which is another 
justification for selecting amino acids as FRET donor fluorophores, as amino acids are 
present in the pentapeptide stem of all peptidoglycan precursors naturally. A summary 
of the selected FRET fluorophore pairs is in Figure 6.5. 
 
b)  FRET Pair 2 a)  FRET Pair 1 
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6.5.2.3  Considering R0: The Förster Distance Between Rwo FRET Pairs 
 
The Förster radius (R0) for a specific FRET pair is the distance at which half the energy in 
transferred from the donor fluorophore to the acceptor fluorophore. For any specific dye 
pair, only a small measurable range of distances around R0 can be accurately quantified. 
Using the extinction coefficient of fluorescamine and the quantum yield of D-
azatryptophan, the R0 for this FRET pair was calculated to be 25.74 Å according to the 
Förster equation. The R0 for D-tryptophan and dansyl was calculated as 26.14 Å. 
 
6.5.2.4  The Selected Fluorescent Compounds to be Synthesised 
 
In the proposed FRET assay, the transpeptidase donor is labelled with the FRET 
acceptor fluorophore and the transpeptidase acceptor harbours the FRET donor 
fluorophore, clarified in Figure 6.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4  A Schematic of the Concept Behind the Proposed FRET Assay Mechanism. 
Energy transfer should occur when the third position ε-amino group of the diaminopimelyl 
moiety of the transpeptidase acceptor forms a cross-link with the carbonyl of the forth position 
D-alanyl residue of the transpeptidase polymeric donor. The transpeptidase donor is Dansyl- or 
Fluorescamine-labelled DAP-LII (F/D in figure), with the FRET acceptor fluorophore being the 
dansyl or fluorescamine label. The transpeptidase acceptor is MurNAc-L-Ala-D-Glu-mesoDAP-
D-Trp-D-Ala or MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala, with the D-trp or D-azatrp at 
the fourth position being the FRET donor fluorophore.  
 
1 
2 
3 
4 
5 
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3 
! 175 
The chemical structures of the four compounds synthesised are in Figure 6.5. 
 
Fluorescamine-labelled DAP-LII Dansyl-labelled DAP-LII 
 
 
 
 
 
 
 
 
 
 
MurNAc-LAla-DGlu-mDAP-DAzatrp-DAla MurNAc-LAla-DGlu-mDAP-DTrp-DAla 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5  The Structures of the Four Compounds Chemi-Enzymatically Synthesised to 
Function as FRET Donors and Acceptors as well as Transpeptidase Acceptors and 
Donors. 
 
These substrates were designed so that the fluorophore causes the least interference to 
the transpeptidase function and flexibility of the compound. The FRET donor 
fluorophores are amino acids that are thought to be able to be tolerated in to the native 
peptide stem on a transpeptidase acceptor (Lebar et al., 2014, Lupoli et al., 2011, 
Schouten et al., 2006). The FRET acceptor fluorophores were attached to the ε-amino 
group on the mesoDAP residue in the pentapeptide stem. 
 
7" 3"
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6.5.3  The Fluorescent Properties of the Selected Fluorophores 
 
The emission maxima for each fluorophore were tested under different pH conditions 
(Figure 6.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6  The Emission Maxima of the Four Fluorophores Dansyl, Fluorescamine, D-
Tryptophan and D-Azatryptophan were tested between pH 7.0 and 9.0. 
 
Each of the fluorophores have the same emission maximum under different pH 
conditions, although the fluorescence efficiency (quantum yield) differs slightly 
(insignificantly) under different pH conditions, with each fluorophore having a slightly 
lower quantum yield at pH 7.0 compared to pH 9.0. Assays were conducted at pH 8.5 as 
this is the optimum pH for the transpeptidase activity of E. coli PBP1B (Adrian Lloyd, 
personal communication). 
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6.6  Synthesis of the Transpeptidase Acceptor Compounds 
 
6.6.1  Synthesis of MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala 
 
Introducing an alternative acceptor in the form of D-tryptophan was recently shown 
with E. coli PBP1A (Lupoli et al., 2011). The more intrinsically fluorescent molecule, 
D-azatryptophan is used as a potential acceptor in the transpeptidase reaction in this 
FRET assay. Incorporating a non-canonical amino acid in to the pentapeptide stem at 
the fourth position involved synthesising the UDP-MurNAc-L-Ala-D-Glu-mesoDAP and 
subsequently exploiting the promiscuity of the ATP-dependent Mur ligase MurF, which 
naturally attaches the D-Ala-D-Ala dipeptide on to the UDP-MurNAc-Tripeptide. MurF 
(from the Gram-negative species P. aeruginosa) was tested to see if its specificity could 
be exploited to incorporate the unusual dipeptide at the terminus of the tripeptide.  
 
There are two ways in which D-azatryptophan could be incorporated into the 
pentapeptide: either as a residue previously ligated to D-Ala, forming a dipeptide 
substrate prior to incorporation in to the peptide stem by MurF, or by the utility of D-
alanyl-D-alanine ligase (Ddl) where two D-Ala residues are ligated together by Ddl A or 
B. However, DdlA/B is D-Ala specific (Healey et al. 2000) and would be unlikely to 
ligate D-azatryptophan to D-Ala. VanA and VanB are alternative ligases to DdlB, both 
of which ligate D-Lac to D-Ala, and VanC is a D-Ala-D-Ser ligase. D-Ala-D-X ligases all 
use zwitterionic D-Ala and proceed in a two-step reaction. Initially, a phosphoryl 
intermediate is formed proceeded by nucleophilic attack of this intermediate by the 
second substrate. VanA is a D-Ala-D-Lac ligase that requires ATP for activity and is 
known to make D-Ala-D-X dipeptides (Bugg et al., 1991). A continuous 
spectrophotometric ADP-coupled release assay, for the enzymatic analysis of VanA was 
published (Daib et al., 1988). The substrate specificity of VanA was tested to see if it 
was more promiscuous than DdlB and would attach D-Ala to D-azatryptophan (Figure 
6.7). 
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Figure 6.7  The Ligation of D-Tryptophan and D-Azatryptophan on to D-Ala by the D-Ala-
D-Lac ligase E. coli VanA. (a) The addition of 4 mM D-Lactate as a positive control for the D-
Ala-D-Lac ligase VanA (b) Testing the ability of VanA to ligate D-Ala to D-Trp (4mM or 8mM) 
or D-Azatrp (8 mM). Assay conditions: 10 mM HEPES pH 7.5, 10 mM MgCl2, 10 mM KCl, 
0.15 mM NADH, 2 mM PEP, 7.5 Units pyruvate kinase, 9 Units lactate dehydrogenase, 5 mM 
ATP, 0.1 mM D-Ala and either 4 mM or 8 mM D-Trp of D-Azatrp. A low concentration of D-
Ala was used along with a very high concentration of the D-tryptophan and D-azatryptophan, to 
promote incorporation of the unusual amino acid in to the second site of the dipeptide. 
Monitored at 340 nm as the pyridine ring of NADH absorbs light at this wavelength but the 
aromatic ring of NAD+ does not. 
 
VanA successfully ligated D-Trp to D-Ala as well as D-Azatryptophan to D-Ala. MurF 
may also incorporate these unusual dipeptides in the pentapeptide stem, resulting in D-
trp or D-azatrp at the fifth position. However, for the purposes of this FRET assay, D-trp 
and D-azatrp are needed at the forth position in the pentapeptide, so this is not a suitable 
methods for incorporating the non-canical residues into the pentapeptide stem. 
Alternatives to VanA are VanC, VanC2 or Lmdl, but in all cases the non-D-Ala amino 
acid is second in the dipeptide sequence, resulting in the terminal amino acid in the 
pentapeptide stem deviating from the canonical D-Ala. D-Azatryptophan would need to 
be first in the dipeptide in order for it to reside at position four in the pentapeptide after 
incorporation by MurF, VanA ligase does not allow for this. The substrate specificity of 
MurF may be flexible enough to incorporate a D-azatrp-D-Ala dipeptide. The dipeptide 
(-R-D-Azatrp-D-Ala-OH) was synthesised separately by ActivoTech and used to test the 
promiscuity of PaMurF with respect to ligation of D-azatrp-D-Ala to the C-terminal 
DAP carboxyl of UDP-MurNAc-L-Ala-D-Glu-mesoDAP.  
 
Both Pseudomonas aeruginosa (Pa) and S. pneumoniae (Sp) MurF were tested in a 
continuous coupled spectrophotometric assay (Figure 6.8a). ADP released upon the 
successful ligation of the dipeptide to the tripeptide is phosphorylated by pyruvate 
a b 
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kinase, with PEP regenerating the ATP consumed by MurF. The pyruvate formed from 
pyruvate kinase is reduced to lactate with the concurrent oxidation of NADH to NAD+ 
+ H+ by lactate dehydrogenase. The oxidation of NADH is observed as a decrease in 
absorbance at 340 nm, due to fewer pyridine rings from NADH, as NADH is oxidised. 
This coupled assay was utilised to see whether MurF could incorporate the unusual 
dipeptide D-azatrp-D-Ala (Figure 6.8 b-c), which was necessary to confirm before 
setting up a pentapeptide synthesis reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8  The Incorporation of Non-Canonical Dipeptides (D-Azatryp-D-Ala) at the C-
Terminus of the Pentapeptide Stem, using MurF. (a) A schematic of the continuous, coupled 
spectrophotometric assay used to test the substrate specificity of MurF with respect to ligation 
of the non-canonical dipeptide -R-D-Azatrp-D-Ala-OH to form UDP-MurNAc-L-Ala-D-Glu-
mesoDAP-D-Azatrp-D-Ala. (b) The incorporation of the non-canonical dipeptide D-Azatrp-D-
Ala, using both P. aeruginosa MurF and S. pneumoniae MurF. The native D-Ala-D-Ala 
dipeptide was the positive control, incorporated using both Pa and SpMurF. 1 mM of dipeptide 
was used in each assay and 1 µM MurF (c) The dependence of PaMurF initial velocity on D-
Azatrp-D-Ala, data fitted to Equation 4.1 by non-linear regression. 
b c 
a 
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Both Gram-negative (Pa) and Gram-positive (Sp) MurF successfully attached the 
unusual dipeptide on to the tripeptide. The affinity of PaMurF for the dipeptide D-
Azatrp-D-Ala was calculated as a Km of 96 µM ± 14. To exploit the observation that 
PaMurF could utilise D-Azatrp-D-Ala, a pentapeptide synthesis reaction of UDP-
MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala was set up (section 2.7.1) and the 
products were subsequently purified on an anion exchange Source 30Q column, upon a 
gradient from 10 mM to 1 M ammonium acetate (Figure 6.9).  
 
 
 
 
 
 
 
 
 
 
Figure 6.9  Purification of the potential transpeptidase acceptor UDP-MurNAc-L-Ala-D-
Glu-mesoDAP-D-Azatrp-D-Ala on a Source 30Q column with an ammonium acetate gradient 
from 10 mM to 1 M. 
 
The first peak to be eluted was suspected to be unwanted impurities, with the second 
peak being more likely to contain the desired organic compound with its prominent 
absorbance at A254 nm, due to the presence of the UDP group. This elution pattern is 
common from previous experience with purification of UDP-MurNAc-DAP 
pentapeptide, suggesting that the second peak was likely to be the desired compound. 
The third peak displays the typical profile of ATP, i.e. a A254 : A280 ratio of 6:1. The 
fractions in the second peak suspected to be the UDP-pentapeptide were pooled and 
lyophilised to remove the ammonium acetate.  
 
To confirm the presence of pentapeptide in this second peak a coupled, enzymatic assay 
was used. Here, the terminal D-Ala was released from the pentapeptide by the enzyme 
E. coli DacB, a low molecular weight penicillin-binding protein with DD-
carboxypeptidase activity, D-alanine was then oxidised by D-amino acid oxidase 
(DAAO), generating hydrogen peroxide which was detected by horse radish peroxidase-
Suspected 
pentapeptide 
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impurities 
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catalysed reaction with the chromogen Amplex Red, to generate the red dye resorufin 
with an intense absorbance at 555 nm (ε = 55,000M-1.cm-1). This coupled assay 
confirmed the presence of the C-terminal D-amino acid residue of the suspected 
pentapeptide. Fractions in the other peaks were also tested for the presence of 
pentapeptide, with peaks 1 and 3 testing negative for the presence of pentapeptide 
(Figure 6.10). 
 
 
 
 
 
 
 
 
Figure 6.10  Determining the presence of pentapeptide by release of the terminal D-Ala 
residue from UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala. Elution peaks in 
Figure 6.9 were analysed for pentapeptide presence. The positive control used was UDP-
MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. 
 
The second peak from the pentapeptide purification in Figure 6.9 was confirmed 
enzymatically to be pentapeptide; therefore it could be concluded that MurF 
incorporated D-Azatrp-D-Ala in to UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-
Ala. This product was then assessed for purity using a MonoQ analytical column 
developed with a gradient of 10 mM – 1 M Ammonium Acetate (Figure 6.11). 
 
 
 
 
 
 
 
 
 
 
Figure 6.11  MonoQ analysis of UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala to 
assess the purity of the pentapeptide.       
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The pentapeptide was subjected to mass spectrometry, which confirmed identity as 
UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala (Figure 6.12). The exact mass 
(m) of the compound was calculated as 1308.34 Daltons. The expected mass-to-charge 
(m/z) values of the singly, doubly and triply charged ions under nanospray-time-of-
flight (TOF) M/S conditions were (m-1)/1 = 1308.34, (m-2)/2 = 653.17, (m-3)/3 = 
435.11. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12  The mass spectrometry results of UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-
Azatrp-D-Ala. Observed: 1308.38, expected: 1308.34, observed: 653.68, expected: 653.17, 
observed: 435.45, expected: 435.11.  
 
Half of the purified UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala was stored 
at -20 °C and the rest was further modified to remove its UDP group by acid hydrolysis, 
as native transpeptidase acceptors do not have a UDP group. The acid hydrolysed 
sample was purified to remove the hydrolysed UDP group, by anion exchange on a 
Source 30Q column, over an ammonium acetate gradient (data not shown). The final 
pentapeptide product (MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala was lyophilised 
to remove the ammonium acetate before analysing its function as a transpeptidase 
acceptor. A final yield of 2.4 mgs was calculated (section 2.7.3). 
 
6.6.2  Synthesis of MurNAc-L-Ala-D-Glu-mesoDAP-D-Trp-D-Ala 
 
To establish the feasibility of synthesis of a second, non-canonical UDP-MurNAc 
pentapeptide with the amino acid D-tryptophan at the fourth position of the 
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pentapeptide, the ability of PaMurF to incorporate the dipeptide D-tryptophanyl-D-
alanine in place of D-alanyl-D-alanine was evaluated. Using the spectrophotometric-
coupled assay in Figure 6.8 the ability of PaMurF to incorporation of D-Trp-D-Ala into 
the pentapeptide stem and the affinity of this enzyme for this substrate was evaluated 
(Figure 6.13). 
 
 
 
 
 
 
 
 
 
Figure 6.13  The Incorporation of the Dipeptide D-Trp-D-Ala into the pentapeptide stem, 
using PaMurF.  (a) D-Trp-D-Ala attachment to the tripeptide  (b)  D-Ala-D-Ala attachment to 
the tripeptide.           
  
D-Trp-D-Ala was confirmed as a substrate for PaMurF and can be enzymatically 
incorporated into the tripeptide. The Km of MurF for D-Ala-D-Ala was determined using 
PRISM 6, as 20 µM ± 5. Comparing the Km values determined for PaMurF with three 
dipeptides are: D-Trp-D-Ala: 62 ± 13, D-Ala-D-Ala: 20 µM ± 5 and D-Azatrp-D-Ala 96 
µM ± 14. D-Ala-D-Ala had the best affinity for PaMurF as expected as it is the native 
substrate, with D-Trp-D-Ala being a substrate with a lower affinity for MurF and D-
Azatrp-D-Ala being the least efficient substrate. An enzymatic synthesis reaction with 
D-Trp-D-Ala was conducted to synthesise the potential transpeptidase acceptor UDP-
MurNAc-L-Ala-D-Glu-mesoDAP-D-Trp-D-Ala (Section 2.7.1). The synthesis reaction 
products were purified by anion exchange using a Source 30Q column and an 
ammonium acetate gradient from 10 mM to 1 M (Figure 6.14). 
 
 
 
 
 
 
a b 
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Figure 6.14  The purification of the reaction products of the enzymatic synthesis of UDP-
MurNAc-L-Ala-D-Glu-mesoDAP-D-Trp-D-Ala, by anion exchange Source 30Q. 
 
The first peak eluted from the Source 30Q column in Figure 6.14 was suspected to be 
the desired pentapeptide, with the second peak being ATP. Fractions from both peaks 
were tested individually for the presence of pentapeptide using DacB and DAAO, via D-
Alanine release (Figure 6.15). 
 
 
 
 
  
 
 
 
 
 
Figure 6.15  Determining the presence or absence of UDP-MurNAc-L-Ala-D-Glu-
mesoDAP-D-Trp-D-Ala in peaks from its elution profile from Source30Q Purification. A 
spectrophotometric, coupled assay testing for the presence of pentapeptide was used to identify 
the peaks from purification. Both peaks from Figure 6.14 were tested for pentapeptide presence. 
The positive control used was 1 µM UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. 
 
The first peak was positive for the presence of UDP-MurNAc-L-Ala-D-Glu-mesoDAP-
D-Trp-D-Ala. Fractions positive for the presence of pentapeptide were pooled and 
lyophilised to remove the ammonium acetate. Each fraction positive for pentapeptide 
presence was analysed separately on a 1 mL analytical MonoQ column to check its 
Suspected 
ATP 
Suspected 
5-peptide 
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purity. The pure fractions were pooled and the final purity of the combined fractions 
was again analysed by MonoQ (Figure 6.16).  
 
 
 
 
 
 
 
 
 
 
Figure 6.16  Analysis of the purity of UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Trp-D-Ala. 
MonoQ analysis of UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Trp-D-Ala purity of the 
lyophilised compound purified by Source 30Q (Figure 6.14).    
 
The final yield of UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Trp-D-Ala was quantified 
(section 2.7.3) as 1.6 mgs and analysed by mass spectroscopy (Figure 6.17).! 
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Figure 6.17  Negative Ion Nanospray mass spectroscopy analysis of UDP-MurNAc-L-Ala-
D-Glu-mesoDAP-D-Trp-D-Ala. Exact Mass = 1308.38 Daltons, expected singly charged ion = 
1307.38 Da, singly charged ion not observed. (a) The doubly-charged species. Expected doubly 
charged ion = 653.19, observed = 653.1907 (b) The triply-charged species: expected triply-
charged ion = 435.127, observed = 435.1225). 
 
The doubly charged species was present along with the triply charged species. With 
confirmation of the double and triple-charged species of the pentapeptide in the mass 
spectrometer, it can be surmised that the desired compound UDP-MurNAc-L-Ala-D-
Glu-mesoDAP-D-Trp-D-Ala has been synthesised. The final yield of this compound was 
determined in mgs and the ability of this derivative pentapeptide to serve as a 
transpeptidase acceptor was subsequently tested along with the other transpeptidase 
donor and acceptor compounds. Thus, the two acceptor compounds have been 
synthesised: UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala and UDP-
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MurNAc-L-Ala-D-Glu-mesoDAP-D-Trp-D-Ala. The transpeptidase donor compounds 
are synthesised in section 6.7. 
 
6.7  Synthesis of the Transpeptidase Donor Compounds 
 
6.7.1  Synthesis of Dansylated (mesoDAP) Lipid II 
 
Dansylated LII has the unique property of only being able to serve as an acyl donor in 
the transpeptidase reaction. The large dansyl group attached to position 3 prevents the 
non-proteinaceous mesoDAP from acting as an acyl-acceptor. UDP-MurNAc-L-Ala-D-
Glu-mesoDAP-D-Ala-D-Ala was synthesised and desalted as described in section 2.7.3 
to prepare the compound for labelling with dansyl chloride. A 42-molar excess of 
dansyl chloride added to the pentapeptide. The reaction was left over night in the dark. 
The reacted products were purified by anion exchange on a source 30Q column (Figure 
6.18 a). The major peak from this purification was run on MonoQ for test for sample 
purity (Figure 6.18 b). 
 
 
 
 
 
 
 
 
 
Figure 6.18  The Purification of dansDAP-LII (a) Anion Exchange by Source 30Q of UDP-
MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala) (b) MonoQ analysis of dansylated DAP LII.  
 
The dansylated pentapeptides eluted from the column in the second peak, with any un-
labelled material eluting earlier. Fractions from the second peak were lyophilised and a 
sample was analysed on a small analytical MonoQ column and demonstrates a single 
narrow peak. This sample was analysed by mass spectrometry and confirmed as 
dansylated-pentapeptide. The pentapeptide was synthesised in to a lipid (section 2.7.7), 
purified and analysed by TLC before using. The total yield of Fluorescamine-labelled 
DAP-LII was quantified as 1.86 mgs.  
a" b"
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     6.7.2  Synthesis of Fluorescamine-labelled Lipid II (C55-PP-MurNAc-GlcNAc-L-  
               Ala-D-Glu-(Nε-Fluorescamine)-mesoDAP-D-Ala-D-Ala 
 
Initially, UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala was synthesised and 
subsequently purified. To remove any residual ammonium acetate carried over from the 
purification of this precursor, which might prevent its modification with fluorescamine, 
and to provide a suitable medium within which the ε-amino group of the DAP of the 
pentapeptide could be acetylated, the pentapeptide was desalted by gel filtration 
(Superdex Peptide 10/300 GL) in to 0.25 M sodium bicarbonate pH 9.0 prior to 
labelling with the fluorophore, fluorescamine. Fractions from the major peak were 
pooled and introduced to the Fluorescamine fluorophore in a labelling reaction. The 
properties of Fluorescamine as a fluorophore are described next. 
 
6.7.2.1  Fluorescamine as a Primary-Amine Labelling Fluorophore 
 
Fluorescamine (4-phenylspiro [furan-2(3H),1-phthalan]-3,3-dione) a heterocyclic dione, 
is a selective fluorophore that reacts with primary amines to form a highly fluorescent 
product. It has excellent fluorescent enhancement and long fluorescent lifetimes 
(hundreds of nanoseconds) (Berezin & Achilefu, 2010). The scheme of amine-
fluorescamine reaction is shown in Figure 6.19. 
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Figure 6.19  A Schematic of Fluorescamine as a Fluorophore. The reaction of the chiral, 
non-fluorescent fluorescamine with a chiral amine begins by nucleophilic addition of the amine 
nitrogen to the C=C double bond of fluorescamine, resulting in the breakage of a C-O bond and 
loss of the chiral centre of fluorescamine (to yield the dione). Closing the 5-membered ring by a 
second nucleophilic attack of the amine nitrogen on the benzoyl ketone forms a fluorescent 
product with two chiral centres (De Bernardo et al., 1974). 
Fluorescamine is a non-fluorescent compound that reacts with primary amines at room 
temperature to yield a highly fluorescent product. The excess of reagent is destroyed by 
water to form a non-fluorescent hydrolysis product (Stein et al., 1974). The reaction of 
fluorescamine with primary amines is strongly pH dependent and the fluorescence is 
developed only in alkaline media (pH of 8.0-9.5), which disappears completely in acidic 
media (Stockhert et al., 2008). The derivatives of amines-fluorescamine are formed 
immediately and are stable for at least 1 day. The extent of the reaction between 
fluorescamine and primary amines and the fluorescent intensities of the resulting 
fluorophores, depend on pH, solvent composition, reagent concentration and the 
accessibility of the amine being labelled (Udenfriend et al., 1972). 
In previously successful dansylation labelling reactions, a 42-fold molar excess of 
dansyl chloride was used relative to the UDP MurNAc pentapeptide target. For the 
Fluorescamine-labelling reaction, two ratios of fluorescamine were trialled: UDP 
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MurNAc (DAP) pentapeptide 2:1 and 42:1, both in 50% acetonitrile. The two reactions 
were left overnight and subsequently terminated with a 10-fold molar excess of Tris 
(free base) relative to fluorescamine. As Tris is a free amine, it reacted with the ‘free-
unreacted’ fluorescamine. 
 
Fluorescamine is not fluorescent when not attached to an amine (Chen et al., 1978) and 
usually does not require separation of the product from unreacted, excess fluorescamine. 
Although to ensure purity, the sample was run down a Sepharose Q column, with an 
extra detection wavelength set to 390 nm, the excitation of fluorescamine (Figure 
6.20a). The major peak from purification was tested enzymatically for the presence of 
pentapeptide, using the DD-carboxypeptidase DacB (Figure 6.20b).  
 
 
 
 
 
 
 
 
 
 
Figure 6.20  The Purification of Fluorescamine-labelled DAP-Pentapeptide and enzymatic 
analysis of the elution products (a) The pentapeptide was purified using SepharoseQ resin. 
The absorbance at λ390 nm is the excitation wavelength of fluorescamine. (b) Determining the 
presence or absence of pentapeptide using the DD-carboxypeptidase DacB which removes the 
C-terminal D-Ala from the pentapeptide. A sample from the major peak from SepharoseQ 
purification was tested for pentapeptide presence (blue). The positive control (red) was the 
native pentapeptide UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala, the negative control 
(green) was a sample from one of the minor peaks in (a). 
 
Fluorescamine is present in the major peak in (a), confirmed spectrophotometrically 
using DacB. The suspected fluorescamine-labelled pentapeptide was sent for mass 
spectral analysis (Figure 6.21). Unlabelled pentapeptide (UDP-MurNAc-L-Ala-D-GLu-
mesoDAP-D-Ala-D-Ala) has the exact mass of 1193.33 Da, whereas the fluorescamine-
labelled compound should have an exact mass of 1471.41 Da. 
 
 
a 
 
b 
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Evidence of un-labelled pentapeptide (m-1) / 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(m-2) / 2 
  
(m-3) / 3 
 
 
 
 
 
 
 
 
Figure 6.21  Mass Spectral Analysis of Purified Fluorescamine-Labelled UDP-MurNAc-L-
Ala-D-Glu-mesoDAP-D-Ala-D-Ala (negative-ion). Fluorescamine-labelled pentapeptide has an 
exacted mass of 1471.41 Da. The singly charged species has an expected mass of (m-1)/1 = 
1470.41 Da, observed: 1470.41, the doubly charged species has an expected mass of (m-2)/2 = 
734.71 Da, observed: 734.71, the triply charged species has an expected mass of (m-3)/3 = 
489.47 Da, observed: 489.47. The Fluorescamine-labelled pentapeptide species are circled in 
green. The singly charged species is shown in (b), the doubly charged species in (a) and (c) and 
the triply-charged species is in (d). Unlabelled UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-
Ala has an exact mass of 1193.33 Da and are present in the sample, highlighted in grey. The 
singly charged species has an expected mass of (m-1)/1 = 1192.33 Da, species not observed, the 
doubly charged species has an expected mass of (m-2)/2 = 595.67 Da, observed: 595.67 Da, the 
triply charged species has an expected mass of (m-3)/3 = 396.78 Da and an observed mass of 
396.78. The doubly and triply-charged species are in (a). 
 
Mass spectral analysis indicates that there is fluorescamine-labelled pentapeptide in the 
sample, with some unlabelled pentapeptide as well. The singly charged ion was visible 
for the labelled pentapeptide, but not for the un-labelled species. The doubly and triply-
charged species for both labelled and unlabelled were visible. A lipid synthesis reaction 
was set up with the Fluorescamine-labelled pentapeptide, with the intention that the 
majority of the pentapeptides in the final lipid would be labelled with Fluorescamine. 
b 
d 
a 
c 
! 192 
The lipid synthesis (section 2.7.7) was subsequently purified using DEAE resin with a 
mobile phase of Chloroform : Methanol : Water in the ratio 2:3:1. LII species were 
eluted isocratically, by incorporating increasing concentrations of ammonium 
bicarbonate into the water component of the mobile phase. The eluted fractions were 
analysed by thin layer chromatography (TLC) (Figure 6.22, section 2.7.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.22  Thin Layer Chromatography of eluted fractions of purified Fluorescamine-
labelled LII. A sample of dansDAP-LII was run in the final lane to compare the relative 
migration of the Fluorescamine-labelled species relative to the dansDAP-LII. 
 
The chloroform : methanol 500 mM ammonium bicarbonate (2:3:1) and the chloroform 
methanol: 1M ammonium bicarbonate (2:3:1) 1M washes appeared to contain the lipid, 
with multiple bands present. Either the lipid has broken down and these were 
degradation products and/ or the sample contains impurities such as DAP-LII derived 
from the proportion of UDP-MurNAc-pentapeptide that had not originally reacted with 
fluorescamine. The chloroform : methanol 500 mM ammonium bicarbonate (2:3:1) and 
the chloroform : methanol: 1M ammonium bicarbonate (2:3:1) 1M washes were 
lyophilised and quantified using a phosphate release assay. The chloroform : methanol 
1M ammonium bicarbonate tested negative in the phosphate release assay, however, the 
chloroform : methanol 500 mM ammonium bicarbonate (2:3:1) elution contained acid-
labile phosphate at a concentration indicating the sample contained 332.74 µM LII 
species. An absorbance spectrum of both elutions is in Figure 6.23 to test the presence 
of the Fluorescamine label on the pentapeptide. 
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Figure 6.23  An Absorbance Scan of Fluorescamine-Labelled DAP-LII between 200 and 
800 nm. The expected absorption maximum of Fluorescamine is 390 nm.   
 
The pronounced absorbance at 260 nm is commonly observed in Fluorescamine spectra 
(Jameson & Reinhart, 2012) and the peak at 390 nm is the Fluorescamine moiety. 
Samples of both ammonium bicarbonate concentrations at which lipid species eluted 
were sent for mass spectral analysis, but only non-labelled DAP-LII was detected in 
both samples. It is known from previous research (Tim Bugg Personal Communication, 
Bagga, 2004), that Lipid I/II compounds labelled with fluorophores are very hard to 
analyse by electrospray mass spectrometry. Judged by the spectral properties of the 
purified lipids that absorbed at wavelengths indicative of the presence of a 
fluorescamine group, labelling DAP-LII with Fluorescamine was successful (also see 
Fluorescamine-DAP-LII polymerisation in a continuous fluorometric transglycosylase 
assay (Figure 6.24). 
 
        6.7.2.2  Enzymatic Characterisation of Fluorescamine DAP-LII as a substrate   
                     for E. coli PBP1B transglycosylation 
  
To confirm the functionality and identify of the putative fluorescamine-DAP-LII, the 
ability of this modified lipid to behave as a transpeptidase donor in the continuous 
fluorometric transglycosylase assay was assessed. The positive detection of DAP-LII 
species with the spectral signal indicative of a fluorescamine modification, albeit 
without a positive identification of fluorescamine-labelled DAP-LII by mass 
spectrometry required another means of confirmation of the formation of this potential 
substrate. Therefore, the ability of the Fluorescamine-labelled DAP-LII to polymerise in 
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to a linear glycan strand by a transglycosylase was evaluated using E. coli PBP1B, and 
with varying concentrations of Fluorescamine-LII (Figure 6.24). 
 
 
 
 
 
 
 
 
 
 
Figure 6.24  The polymerisation of Fluorescamine-labelled DAP-LII by E. coli PBP1B. 
Transglycosylase polymerisation was monitored using the continuous fluorometric assay 
(Schwartz et al., 2002), modified and adapted to monitor the spectral maxima of fluorescamine 
λEx 390 nm and λEm 470 nm. 
 
Indicated in the fall in fluorescence at λEm 470 upon transition of the fluorescamine 
label from a micellar to an aqueous environment, coupled to muramidase, 
Fluorescamine-DAP-LII was shown to be capable of polymerisation in to linear glycan 
chains in a concentration-dependent manner catalysed by EcPBP1B. EcPBP1B 
transpeptidation activity is predicted upon active transglycosylation to generate a 
polymeric transpeptidase donor (Bertsche et al., 2005). The demonstration that the 
preparation of Fluorescamine-DAP-LII was polymerisable enabled investigation of this 
substrate as a potential transpeptidase donor in a FRET assay, where it was to be used as 
a FRET acceptor. 
 
6.8  Analysis of the Activity of the Synthesised Compounds, as Functional 
       Transpeptidase Acceptors and Donors 
 
Upon the synthesis of a complete set of FRET pairs, the compounds were tested for 
activity in their expected functions. Therefore, the synthesised transpeptidase donors 
(Dansyl and Fluorescamine-labelled LII - FRET acceptors) were assayed for their 
ability to be polymerised by a transglycosylase. Also, the transpeptidase acceptors were 
tested for potential acceptor capability using a continuous coupled, spectrophotometric 
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assay, developed to monitor, quantify and visualise transpeptidase activity in real-time 
(section 2.8.5). This assay was developed by Dr. Adrian Lloyd in August 2014, which 
has been used in this thesis to test whether these synthesised compounds act as 
transpeptidase donors or acceptors, as well as testing the purified PBPs for their ability 
to function as transpeptidases. EcPBP1B was used as the enzymatic LII polymerase 
(transglycosylase) throughout the characterisation of these four compounds, as it has 
been used as the model enzyme for the majority of studies in this thesis and the wider 
field.  
 
     6.8.1  Activity of the Synthesised Compounds as Functional Transpeptidase   
               Acceptors, using L-Lysine-LII as the Transpeptidase Donor 
 
The transpeptidase acceptor that most closely resembles that found natively in vivo 
(MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala) (section 2.7.6) was initially used with 
LII with L-lysine at the third position in the pentapeptide stem (Lys-LII) as the 
transpeptidase donor. Lys-LII can only act as a transpeptidase donor and not a 
transpeptidase acceptor because the lysine does not, unlike mesoDAP (the natural 
residue replaced by lysine in Lys-LII) possess an ε-carbon amino and carboxyl group in 
the D-stereoisomeric configuration (Lupoli et al., 2014). Conversely, one of the 
requirements of a Gram-negative transpeptidase for its acceptor is that it must have a D-
stereocentre at the third position of the peptide stem, as in D,L-DAP (Lupoli et al., 
2011).  
 
All steady-state kinetic assays were conducted in a dual beam format with Lys-LII in 
one cuvette but not the other, which enables any background rate to be taken into 
consideration. The presence and absence of Lys-LII is the distinguishing feature 
between the duplicates. The reference cuvette lacking the transpeptidase donor Lys-LII 
was substituted with the solvent that Lys-LII was resuspended in, usually Hexa-ethylene 
glycol, monododecyl ether (E6C12). EcPBP1B was added to both cuvettes and its 
absorbance monitored until a stable baseline was reached before adding the acceptor to 
both cuvettes, initiating the reactions. Incubation of the donor-only Lys-LII with the 
PBP initially, accounted for any DD-carboxypeptidase activity before the addition of the 
acceptor, which allows subsequent transpeptidase activity to be kinetically tracked. 
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The transpeptidase activity of EcPBP1B with initially established using substrates that 
have exclusive activity as only either a transpeptidase donor or acceptor. Lys-LII was 
used as the transpeptidase donor and MurNAc pentapeptide DAP (L-Ala-D-Glu-
mesoDAP-D-Ala-D-Ala) as the transpeptidase acceptor, analysed for their ability to 
support EcPBP1B transpeptidase activity (Figure 6.25). This combination of 
transpeptidase donor and acceptor were expected to work together. Gram-negative 
EcPBP1B naturally uses DAP-LII in vivo, but is known to also accept Lys-LII in vitro.  
 
 
 
 
 
 
 
 
 
Figure 6.25  Analysing the Capability of Lys-LII to act as a Transpeptidase Donor with 
MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala as the Transpeptidase Acceptor. Assay 
conditions: 50 mM BisTris Propane, pH 8.5, 20 mM MgCl2, 0.1 % TritonX-100, 50 µM 
Amplex Red, 3.5 Units Rhodotorula gracalis DAAO, 5.8 Units HRP, 0.2 µM E. coli LpoB, 
transpeptidase donor: 20 mM Lys-LII in 0.1 % TritonX-100, 11 nM E. coli PBP1B in 0.2% 
TritonX-100, transpeptidase acceptor: MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. Blue: + 
Lys-LII, Orange: without Lys-LII.   
 
In the presence of Lys-LII, a positive rate was observed that is not the case in the 
absence of Lys-LII. Therefore it is likely that MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-
D-Ala can function as a transpeptidase acceptor when using Lys-LII as the 
transpeptidase donor. Next, the three synthesised compounds were tested as 
transpeptidase acceptors with the same Lys-LII donor (Figure 6.26). The three 
transpeptidase acceptor compounds tested were:  
(1) D-Trptophan at position four, with the UDP group: UDP-MurNAc-L-Ala-D-
Glu-mesoDAP-D-Trp-D-Ala  
(2) D-Azatryptophan at position four, with the UDP group: UDP-MurNAc-L-
Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala 
(3) A variant of (2) without the UDP group: MurNAc-L-Ala-D-Glu-mesoDAP-D-
Azatrp-D-Ala 
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Compound (1) contained D-tryptophan, which could act as a donor fluorophore in the 
FRET pair with dansDAP-LII. Compounds (2) and (3) contained the fluorophore D-
azatryptophan, both/either of which could be used as part of a FRET pairing with 
Fluorescamine-labelled LII. For these potential FRET pairs to work, Fluorescamine and 
Dansyl-labelled DAP-LII had to be active as transpeptidase donors, and the three 
compounds above had to function as transpeptidase acceptors. The capability of all of 
these compounds to function in these roles in support of EcPBP1B transpeptidase 
activity was then analysed using the Amplex Red assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.26  The Capability of the Three Synthesised Compounds as Transpeptidase 
Acceptors, all with Lys-LII as the Donor. (a) and (d) UDP-MurNAc-L-Ala-D-Glu-mesoDAP-
D-Trp-D-Ala as transpeptidase acceptor, (b) and (e) UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-
Azatrp-D-Ala as transpeptidase acceptor, (c) and (e) MurNAc-L-Ala-D-Glu-mesoDAP-D-
Azatrp-D-Ala as transpeptidase acceptor. (a-c) No Moenomycin (d-f) with 2 µM Moenomycin. 
Assay conditions: 50 mM BisTris Propane, pH 8.5, 20 mM MgCl2, 0.1 % TritonX-100, 50 µM 
Amplex Red, 3.5 Units Rhodotorula gracalis DAAO, 5.8 Units HRP, 0.2 µM E. coli LpoB, 
transpeptidase donor: 20 mM Lys-LII in 0.1 % TritonX-100, 11 nM E. coli PBP1B in 0.2 % 
TritonX-100, transpeptidase acceptor. Blue: + Lys-LII, Orange: without Lys-LII. 
 
The three compounds tested positive as transpeptidase acceptors when using Lys-LII as 
the transpeptidase donor. UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala (b) 
appeared to be turned over the fastest, with MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-
D-Ala second (c), and UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Trp-D-Ala (a) third. 
The negative control assays without Lys-LII were inactive, as expected. The assays with 
the transglycosylase inhibitor Moenomycin added were inhibited suggesting that as was 
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observed by Bertsche et al., (2005), transglycosylation is required for activity of the 
transpeptidase domain of EcPBP1B. 
 
     6.8.2  Activity of the Synthesised Compounds as Functional Transpeptidase   
               Acceptors, using dansylated DAP-LII as the Transpeptidase Donor 
 
Dansylated DAP-LII was tested as a transpeptidase donor because this compound is one 
of the four compounds to be used in one of the FRET pairings. MurNAc-L-Ala-D-Glu-
mesoDAP-D-Ala-D-Ala was used as the transpeptidase acceptor using the Amplex Red 
coupled assay (Figure 6.27). DansDAP-LII functions exclusively as a transpeptidase 
donor because the mesoDAP D-stereocentre of the DAP residue is shielded by the 
presence of the dansyl group appended to the ε-amine group of the mesoDAP. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.27  The Ability of dansDAP-LII to Function as a Transpeptidase Donor, using 
MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala as the Transpeptidase Acceptor. Assay 
conditions: 50 mM BisTris Propane, pH 8.5, 20 mM MgCl2, 0.1 % TritonX-100, 50 µM 
Amplex Red, 3.5 Units Rhodotorula gracalis DAAO, 5.8 Units HRP, 0.2 µM E. coli LpoB, 
transpeptidase donor: 20 mM dansDAP-LII in 0.1 % TritonX-100, 11 nM E. coli PBP1B in 0.2 
% TritonX-100, transpeptidase acceptor: MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. Blue: 
+ dansDAP-LII, Orange: without dansDAP-LII.  
 
After confirming that dansDAP-LII functioned as a transpeptidase donor with an 
acceptor (using the pentapeptide that most closely resembles the transpeptidase acceptor 
in vivo: MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala), dansDAP-LII was tested as a 
transpeptidase donor with the three synthesised transpeptidase acceptor compounds with 
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the unusual D-amino acid at the fourth position in the peptide stem using the Amplex 
Red coupled assay (Figure 6.28). 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 6.28  Evaluation of the Three Synthesised Compounds as Transpeptidase 
Acceptors, with dansDAP-LII as the Donor. (a) and (d) UDP-MurNAc-L-Ala-D-Glu-
mesoDAP-D-Trp-D-Ala as transpeptidase acceptor, (b) and (e) UDP-MurNAc-L-Ala-D-Glu-
mesoDAP-D-Azatrp-D-Ala as transpeptidase acceptor, (c) and (e) MurNAc-L-Ala-D-Glu-
mesoDAP-D-Azatrp-D-Ala as transpeptidase acceptor. (a-c) No Moenomycin (d-f) with 2 µM 
Moenomycin. Assay conditions: 50 mM BisTris Propane, pH 8.5, 20 mM MgCl2, 0.1 % 
TritonX-100, 50 µM Amplex Red, 3.5 Units Rhodotorula gracalis DAAO, 5.8 Units HRP, 0.2 
µM E. coli LpoB, transpeptidase donor: 20 mM dansDAP-LII in 0.1 % TritonX-100, 11 nM E. 
coli PBP1B in 0.2 % TritonX-100, transpeptidase acceptor. Blue: + dansDAP-LII, Orange: 
without dansDAP-LII. 
 
All three compounds were active as transpeptidase acceptors, when dansDAP-LII was 
used as the transpeptidase donor. UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-
Ala (b) appeared to be turned over the quickest (calculate turnover number), with 
MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala (c) the second best and UDP-
MurNAc-L-Ala-D-Glu-mesoDAP-D-Trp-D-Ala third (a). 
 
 
 
 
 
 
(1) UDP-MurNAc-L-Ala-D-Glu-
mesoDAP-D-Trp-D-Ala 
(2) UDP-MurNAc-L-Ala-D-Glu-
mesoDAP-D-azaTrp-D-Ala 
(3) MurNAc-L-Ala-D-Glu-
mesoDAP-D-azaTrp-D-Ala 
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     6.8.3  Activity of the Synthesised Compounds as Functional Transpeptidase   
               Acceptors, using Fluorescamine-labelled DAP-LII as the Transpeptidase   
               Donor 
 
The final compound to be tested for its capability as a potential substrate for 
transpeptidation is Fluorescamine-labelled LII as a transpeptidase donor. The most 
native transpeptidase acceptor (MurNAc DAP-pentapeptide) was initially used with 
Fluorescamine-LII (Figure 6.29). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.29  The Capability of Fluorescamine-DAP-LII to Function as a Transpeptidase 
Donor with MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala as Acceptor. Assay conditions: 
50 mM BisTris Propane, pH 8.5, 20 mM MgCl2, 0.1 % TritonX-100, 50 µM Amplex Red, 3.5 
Units Rhodotorula gracalis DAAO, 5.8 Units HRP, 0.2 µM E. coli LpoB, transpeptidase donor: 
20 mM Fluorescamine-DAP-LII in 0.1 % TritonX-100, 11 nM E. coli PBP1B in 0.2 % TritonX-
100, transpeptidase acceptor: MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. Blue: + 
Fluorescamine-labelled DAP-LII, Orange: without Fluorescamine-labelled DAP-LII. 
 
Fluorescamine-DAP-LII is likely to be a viable substrate as a transpeptidase donor, but 
as the LII may contain some unlabelled species, it cannot be proven that this positive 
rate is due to Fluorescamine-DAP-LII. The three unusual transpeptidase acceptor 
compounds with D-Trp or D-Azatrp at position four of the pentapeptide were 
subsequently tested as transpeptidase acceptors, using Fluorescamine-LII as the donor 
(Figure 6.30). 
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Figure 6.30  The Ability of the Three Synthesised Compounds as Transpeptidase 
Acceptors, all with Fluorescamine-DAP-LII as the Donor.  
(a) and (d) UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Trp-D-Ala as transpeptidase acceptor, (b) 
and (e) UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala as transpeptidase acceptor, (c) 
and (e) MurNAc-L-Ala-D-Glu-mesoDAP-D-Azatrp-D-Ala as transpeptidase acceptor. (a-c) No 
Moenomycin (d-f) with 2 µM Moenomycin. Assay conditions: 50 mM BisTris Propane, pH 8.5, 
20 mM MgCl2, 0.1 % TritonX-100, 50 µM Amplex Red, 3.5 Units Rhodotorula gracalis 
DAAO, 5.8 Units HRP, 0.2 µM E. coli LpoB, transpeptidase donor: 20 mM Fluorescamine-
DAP-LII in 0.1 % TritonX-100, 11 nM E. coli PBP1B in 0.2 % TritonX-100, transpeptidase 
acceptor. Blue: + Fluorescamine-DAP-LII, Orange: without Fluorescamine-DAP-LII. 
 
The three compounds tested positive as transpeptidase acceptors when using 
Fluorescamine-DAP-LII as the transpeptidase donor. MurNAc-L-Ala-D-Glu-mesoDAP-
D-Azatrp-D-Ala (c) appeared to be turned over the quickest, UDP-MurNAc-L-Ala-D-
Glu-mesoDAP-D-Trp-D-Ala (a) second, UDP-MurNAc-L-Ala-D-Glu-mesoDAP-D-
Azatrp-D-Ala third. The negative control assays without Fluorescamine-DAP-LII were 
inactive, as expected. The assays with the transglycosylase inhibitor Moenomycin 
added were inhibited.  
 
In summary, dansDAP-LII and potential Fluorescamine-DAP-LII were both active as 
transpeptidase donors. The UDP-MurNAc pentapeptides with D-Trp or D-Azatrp at 
position four in the pentapeptide stem were both active transpeptidase acceptors, with or 
without the UDP attached in the case of the D-Azatrp pentapeptide. Having confirmed 
that these compounds are viable transpeptidase substrates, their ability to work as part 
of a FRET pair is tested. 
 
(1) UDP-MurNAc-L-Ala-D-Glu-
mesoDAP-D-Trp-D-Ala 
(2) UDP-MurNAc-L-Ala-D-Glu-
mesoDAP-D-Azatrp-D-Ala 
(3) MurNAc-L-Ala-D-Glu-
mesoDAP-D-Azatrp-D-Ala 
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The compounds were designed as FRET fluorophore pairs, with D-Trp in the 
pentapeptide stem being the fluorophore donor to the fluorophore acceptor, Dansyl. The 
other FRET pairing being D-azatrp as the fluorophore donor to the fluorophore acceptor 
Fluorescamine (Figure 6.31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.31  Schematic of the Proposed FRET Assay. Upon 3-4 Cross-linking during 
transpeptidation, fluorescent energy should transfer from the D-Azatrp donor fluorophore, to the 
Fluorescamine acceptor fluorophore. This schematic represents one of the FRET pairs. In the 
other pairing, there is a dansyl group in the place of the Fluorescamine moiety, and the D-Azatrp 
is replaced by D-Trp. 
 
The FRET assay was attempted using the PTI Fluorimeter, but more optimisation is 
required to show FRET activity between these compounds. Due to the potential for 
contamination of the fluorescamine-DAP-LII with unlabelled lipid, it is possible that 
competition by the unlabelled lipid for the transpeptidase acceptor and donor sites 
reduced the ability of the fluorophore labelled substrates to bind sufficiently to 
eliminate any detectable FRET interactions. 
 
 
 
 
 
Lipid II DAP- 
Fluorescamine 
(+/-UDP)-MurNAc-L-Ala-D-Glu-
mesoDAP-D-Azatrp-D-Ala 
Donor Fluorophore: 
D-AzaTrp 
Acceptor Fluorophore: 
Fluorescamine 
3-4 Cross-link 
D-Ala 
Transpeptidation 
PBP 
! 203 
6.9  Enzymology of Transpeptidation: Kinetic Characterisation of the     
       Transpeptidase Activity of E. coli PBP1A and P. aeruginosa PBP1A 
 
The penicillin-binding domain of PBPs is responsible for both transpeptidase and 
carboxypeptidase activity, both of which result in the release of D-alanine. In the past, 
substrate analogues were used to mimic the donor, and single D-amino acids were used 
as acceptors in primitive monitoring of transpeptidation. The recent ability to synthesise 
native substrates de novo (Breukink et al., 2003) has encouraged the monitoring of 
transpeptidation to be detected directly, using radiolabelled peptidoglycan initially 
(Bertsche et al., 2005) and the native substrate LII more recently (Lebar et al., 2013). 
The reaction products were seaparated either chromographically or by measuring 
release of the terminal D-alanine. EcPBP1A (Born et al., 2006) and EcPBP1B (Bertsche 
et al., 2005) transpeptidase products were separated by HPLC, analysing the 
muropeptides by HPLC. The first use of monitoring D-Ala release was by Mirelman et 
al., (1972) through the incorporation of UDPMurNAc-L-Ala-D-Glu-L-Lys-D-Ala-[14C]-
D-Ala into Micrococcus luteus membranes. A more recent advancement that has 
somewhat explained previous difficulties in detecting transpeptidase activity, is the role 
of the lipoproteins E. coli LpoA and LpoB in the enhancement of transpeptidase 
activities of EcPBP1A and 1B, respectively (section 1.5.10.1). EcLpoA was shown to 
stimulate EcPBP1A catalysed cross-linking by 4.5 fold in vitro (Paradis-Bleau et al., 
2010, Typas et al., 2010). 
 
This transpeptidation assay follows the continuous release of the terminal D-Ala from 
the donor stem peptide. The presence of D-amino acid oxidase, when coupled with 
Amplex Red and Horse Radish Peroxidase (HRP) gives a quantitative continuous read 
out of transpeptidation in real time. Addition of an acceptor stimulates the release of the 
terminal D-Ala on the donor (The transpeptidase donor is esterified at the active site). 
This released D-amino acid is detected by DAAO and triggers the coupling system 
(Figure 6.32). 
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Figure 6.32  A Schematic of the Continuous Transpeptidase coupled Assay. D-Amino acid 
oxidase oxidises the released D-amino acid to pyruvate and hydrogen peroxide. Horse radish 
peroxidase (HRP) uses hydrogen peroxide to convert Amplex Red to the chromophore 
Resorufin, which absorbs strongly at 555 nm. 
 
The spectrophotometric continuous assay was developed by Dr. Adrian Lloyd at The 
University of Warwick, using E. coli PBP1B (sections 2.8.3 and Figure 6.33). In each 
assay, all components were present in the cuvette upon initiation of spectrophotometric 
monitoring, except for the PBP and the acceptor. A baseline reading was measured for a 
few minutes, before adding the PBP and finally the acceptor. Assays were monitored at 
555 nm, at 30 °C, for 40 minutes. Also, two separate assays were run in parallel, one 
with the donor present (e.g. Lys-LII, red), and one without the donor  (blue) to account 
for the background rate. This assay was further developed for E. coli PBP1A 
predominantly, as well as P. aeruginosa PBP1A subsequently.  
 
     6.9.1  The Transpeptidase Activity of E. coli PBP1B in the presence and   
               Absence of E. coli CpoB 
 
The transpeptidase activity of E. coli PBP1B with its necessary cognate stimulatory 
accessory protein E. coli LpoB is shown in Figure 6.33 a. Another accessory protein 
involved in the coordination of cell division and active in the divisome complex is E. 
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coli YbgF, which has recently been renamed in E. coli to CpoB. CpoB localises to mid-
cell at the onset of constriction, requiring a functional divisome complex. CpoB binds to 
PBP1B between the UB2H and transpeptidase domains, residues Thr751 and Thr753 of 
PBP1B. The affect of the presence of E. coli CpoB was tested during transpeptidation 
(Figure 6.33 b).  
 
 
 
 
 
 
 
 
Figure 6.33  The Continuous Spectrophotometric Detection of E. coli PBP1B 
Transpeptidase Activity. (a) E. coli PBP1B + E. coli LpoB (b) E. coli PBP1B + E. coli LpoB 
+ E. coli CpoB (formally YbgF). Assay conditions: 50 mM BisTris Propane, pH 8.5, 20 mM 
MgCl2, 0.1 % TritonX-100, 50 µM Amplex Red, 3.5 Units Rhodotorula gracalis DAAO, 5.8 
Units HRP, 0.2 µM E. coli LpoB, 0.2 µM E. coli CpoB, transpeptidase donor: 20 mM Lys-LII 
in 0.1 % TritonX-100. First addition: 11 nM E. coli PBP1B in 0.2 % TritonX-100, second 
addition (transpeptidase acceptor): MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. Red: + Lys-
LII donor, blue: no Lys-LII donor. 
 
A positive result for the transpeptidase activity of E. coli PBP1B was demonstrated in 
the presence of E. coli LpoB, shown to be necessary for transpeptidase activity. 
However, this assay does not distinguish between DD-carboxypeptidase activity and 
transpeptidation, owing to the obligation to conduct the assays in duplicate, indicating 
the comparative background rate in each case. The presence of CpoB during 
transpeptidation appeared to suppress transpeptidation. Two months before this assay 
was conducted, Gray et al., 2015 published that E. coli CpoB partially inhibited the 
stimulation of the transpeptidase activity of EcPBP1B by EcLpoB in vitro, with a 50% 
reduction in stimulation (Egan & Vollmer, 2015). 
 
Recently, both TolA and CpoB were shown to interact directly with the PBP1B-LpoB 
complex in vitro, but neither CpoB or TolA affected basal PBP1B transpeptidase 
activity (Gray et al., 2015). This effect of CpoB is reversed by TolA, which interacts 
with PBP1B at the region proximal to the membrane. CpoB also had no effect on the 
a b 
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transglycosylase activity of PBP1B, alone or in combination with LpoB (Gray et al., 
2015). 
 
     6.9.2  The Transpeptidase Activity of E. coli PBP1A 
 
The transpeptidase activity of E. coli PBP1A (no TM domain) was trialled in the 
conditions described above for EcPBP1B, with the assay buffer and PBP in 0.2% 
TritonX-100. However, the Ec1A exhibited no activity under these conditions initially. 
EcPBP1A transpeptidase activity has been shown in CHAPS (Lupoli et al., 2011). The 
use of Ethylene Glycol Alkyl Ether detergents to investigate transpeptidase activity was 
suggested by Dr. Adrian Lloyd, due to the nature of these detergents and their published 
use in the continuous fluorometric transglycosylase assay (Schwartz et al., 2002) and its 
previous success with transglycosylase activity and E. coli PgpB (section 5.6.8.2).  
 
          6.9.2.1  Comparing the Transpeptidase Activity of EcPBP1A with and   
                       without the Hexa-His tag 
 
The transpeptidase activity of E. coli PBP1A with and without the His6-tag was tested 
(Figure 6.34). The assay was also conducted in the absence of E. coli PBP1A, to 
confirm the dependency of EcPBP1A on transpeptidase activity (Figure 6.34 c).  
 
 
 
 
 
 
 
Figure 6.34  The Continuous Spectrophotometric Detection of E. coli PBP1A 
Transpeptidase Activity. (a) E. coli PBP1A (+His6-tag) + E. coli LpoA (b) E. coli PBP1A (no 
His6-tag) + E. coli LpoA (c) No E. coli PBP1A, replaced with EcPBP1A storage buffer (25 mM 
Tris pH 7.5, 10 mM MgCl2, 1M NaCl, 50% glycerol and 20 mM CHAPS). Assay conditions: 50 
mM BisTris Propane, pH 8.5, 20 mM MgCl2, 0.39 % E6C12, 50 µM Amplex Red, 3.5 Units 
Rhodotorula gracalis DAAO, 5.8 Units HRP, 1.16 µM E. coli LpoA, transpeptidase donor: 20 
µM Lys-LII in 0.026 % E6C12. Addition 1: 430 nM E. coli PBP1A in 20 mM CHAPS, addition 
2 (transpeptidase acceptor): 20 µM MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. A final ratio 
of EcPBP1A : EcLpoA was 1 : 2.7, as a 1:3 ratio advised in Typas et al., 2010) Red: + LysLII 
donor, blue: no LysLII donor. 
a b c 
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E. coli PBP1A appears to show transpeptidase activity with 430 nM EcPBP1A and 1.16 
µM EcLpoA (1 : 2.7 ratio). The profile of the activity curve for the PBP1A without a 
his6-tag is preferable to the curve observed for that with a his6-tag. Both sigmoidal and 
non-sigmoidal kinetic profiles were observed during the continuous transpeptidase 
activity monitoring of PBP1A. The his6-tag was removed from all PBP1A preparations 
for the monitoring of transpeptidation activity. 
 
          6.9.2.2  Investigating cryo-preservation and subsequent transpeptidase    
                       activity of E. coli PBP1A 
 
The concentration of EcPBP1A required to observe a continuous transpeptidation rate 
was reduced, resulting in 5 µL of a 5.75 µM protein stock, i.e. a final EcPBP1A 
concentration of 143 nm in each assay. The stability of E. coli PBP1A was tested to 
determine the optimum cryo-preservation storage method. The final step of EcPBP1A 
purification was dialysis into 50 % glycerol for long-term storage in -80. Assays in 
Figure 6.35 were conducted with freshly purified protein, before the protein had 
undergone any cryo-preservation. An aliquot of EcPBP1A was frozen at -80 °C and at -
20 °C and its activity was subsequently tested.  
 
 
 
 
 
 
 
 
Figure 6.35  The Durability and Stability of E. coli PBP1A to withstand one freeze-thaw 
cycle at -80 or -20 °C. (a) E. coli PBP1A stored at -20 °C overnight and then thawed (b) E. coli 
PBP1A stored at -80 °C overnight and then thawed. Assay conditions: 50 mM BisTris Propane, 
pH 8.5, 20 mM MgCl2, 0.39 % E6C12, 50 µM Amplex Red, 3.5 Units Rhodotorula gracalis 
DAAO, 5.8 Units HRP, 1.16 µM E. coli LpoA, transpeptidase donor: 20 µM Lys-LII in 0.026 % 
E6C12. Addition 1: 430 nM E. coli PBP1A in 20 mM CHAPS, addition 2 (transpeptidase 
acceptor): 20 µM MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. Red: + LysLII donor, blue: no 
LysLII donor. 
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E. coli PBP1A can withstand one freeze-thaw cycle from -80 °C and from -20 °C. A 
second freeze-thaw cycle was tested, which also demonstrated full activity. Activity 
became compromised after a third freeze-thaw cycle (data not shown) and no further 
testing was done, and each aliquot was thawed for single-use only. EcPBP1A can be 
stored at -20 or -80 in 50% glycerol and remain active after thawing. All 1A PBPs for 
transpeptidase assays were stored in 50% glycerol in 50 µL aliquots at -80 °C. 
 
          6.9.2.3  Determining the Dependency of a Transpeptidase Rate Upon the   
                       Presence of E. coli PBP1A and E. coli LpoA 
  
The dependency of transpeptidase activity on the presence of E. coli PBP1A was tested 
by the presence and absence of this enzyme (Figure 6.36 a). In this control, Lys-LII 
was added to both assays. The necessity to have E. coli LpoA present in all 
transpeptidase assays was also tested (Figure 6.36 b).  
 
 
 
 
 
 
 
 
Figure 6.36  The Dependency of Transpeptidase Activity upon the Presence of E. coli 
PBP1A or E. coli LpoA. (a) +/- E. coli PBP1A: LysLII added to both assays with EcPBP1A 
added to only one. (b) +/- EcLpoA. LysLII added to both assays, with EcLpoA added to only 
one. Assay conditions: 50 mM BisTris Propane, pH 8.5, 20 mM MgCl2, 0.39 % E6C12, 50 µM 
Amplex Red, 3.5 Units Rhodotorula gracalis DAAO, 5.8 Units HRP, 1.16 µM E. coli LpoA or 
EcLpoA storage buffer, transpeptidase donor: 20 µM Lys-LII in 0.026 % E6C12. Addition 1: 430 
nM E. coli PBP1A in 20 mM CHAPS or EcPBP1A storage buffer (25 mM Tris pH 7.5, 10 mM 
MgCl2, 1M NaCl, 50% glycerol and 20 mM CHAPS), addition 2 (transpeptidase acceptor): 20 
µM MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. Green: + (a) EcPBP1A / (b) EcLpoA, 
orange: no EcPBP1A in (a) or EcLpoA in (b). 
 
In the absence of E. coli LpoA the rate of transpeptidation cannot be observed, 
indicating that either EcPBP1A does not function without EcLpoA or/and the 
transpeptidation rate is so slow that it cannot be observed. Additionally, no background 
rate is present in the absence of EcLpoA. One justification for this could be that the 
a b 
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EcLpoA preparation is showing DD-carboxypeptidase activity and triggering the DAAO 
coupling system, adding to the background rate seen in the negative controls (no Lys-
LII) elsewhere. 
 
     6.9.2.4  The Sensitivity of E. coli PBP1A Transpeptidase Activity to Inhibition   
                  by Moenomycin A and Ampicillin 
 
The sensitivity of the assay was tested in the presence of two concentrations of the 
transpeptidase β-lactam inhibitor ampicillin: a concentration close to the IC50 (Figure 
6.37 a), and the other 10-fold the IC50 (Figure 6.37 b). Similarly, the potent 
transglycosylase inhibitor Moenomycin was added to test the ability of EcPBP1A to 
perform transpeptidation in the presence of a transglycosylase inhibitor (Figure 6.37 c). 
 
 
 
 
 
 
 
Figure 6.37  Sensitivity of the Transpeptidase assay to Ampicillin or Moenomycin A. (a) 
with 25 µM ampicillin (b) with 250 µM ampicillin (c) with 25 µM Moenomycin A. Assay 
conditions: 50 mM BisTris Propane, pH 8.5, 20 mM MgCl2, 0.39 % E6C12, 50 µM Amplex Red, 
3.5 Units Rhodotorula gracalis DAAO, 5.8 Units HRP, 1.16 µM E. coli LpoA, transpeptidase 
donor: 20 µM Lys-LII in 0.026 % E6C12. Addition 1: 430 nM E. coli PBP1A in 20 mM CHAPS, 
addition 2 (transpeptidase acceptor): 20 µM MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. 
Red: + LysLII donor, blue: no LysLII donor.  
 
The transpeptidase activity was diminished upon the addition of 25 µM ampicillin, 
which is close to the IC50 value for ampicillin, so 10-fold this concentration (250 µM) 
inhibited any observable transpeptidase activity. In the presence of the transglycosylase 
inhibitor Moenomycin A, transpeptidation was not observed at all. Without the 
preceding transglycosylation reaction to form glycan strands, transpeptidation cannot 
occur. Moenomycin does not affect the Amplex Red coupling reagents at the 
concentration used and also it does not inhibit DD-carboxypeptidation. 25 µM MoeA 
sufficiently inhibited the rate demonstrated in its absence, therefore indicating that the 
rate observed thus far is as a result of transpeptidase activity by EcPBP1A. 
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          6.9.2.5  The Ability of E. coli PBP1A to Utilise Structurally Diverse  
                       Transpeptidase Acceptor Compounds 
 
Thus far, the transpeptidase donor used in this section has been Lys-LII, and the 
acceptor MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. Additional acceptors have 
been tested including the tetrapeptide MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala (Figure 
6.38 b) and the tripeptide MurNAc-L-Ala-D-Glu-mesoDAP (Figure 6.38 c). 
 
 
 
 
 
 
 
Figure 6.38  The Ability of E. coli PBP1A to Utilise Non-Canonical Transpeptidase 
Acceptor Compounds. (a) Using the already tested pentapeptide acceptor 20 µM MurNAc-L-
Ala-D-Glu-mesoDAP-D-Ala-D-Ala (b) with the tetrapeptide acceptor 20 µM MurNAc-L-Ala-D-
Glu-mesoDAP-D-Ala (c) with the tripeptide acceptor 20 µM MurNAc-L-Ala-D-Glu-mesoDAP.  
Assay conditions: 50 mM BisTris Propane, pH 8.5, 20 mM MgCl2, 0.39 % E6C12, 50 µM 
Amplex Red, 3.5 Units Rhodotorula gracalis DAAO, 5.8 Units HRP, 1.16 µM E. coli LpoA, 
transpeptidase donor: 20 µM Lys-LII in 0.026 % E6C12. Addition 1: 430 nM E. coli PBP1A 20 
mM CHAPS, addition 2: chosen transpeptidase acceptor. Red: + LysLII, blue: no LysLII. 
 
The specificity of E. coli PBP1A as a transpeptidase enzyme demonstrates its ability to 
incorporate structurally diverse acceptor substrates in to peptidoglycan including a 
tetrapeptide acceptor (MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala), as well as the tripeptide 
acceptor MurNAc-L-Ala-D-Glu-mesoDAP. MurNAc-tetrapeptide was not as an efficient 
acceptor as its pentapeptide equivalent as it appears to have been incorporated at a 
slower rate. MurNAc-tripeptide was less efficient again, as the structure is deviating 
further away from that of the native acceptor in vivo. Determining which compounds 
function as plausible transpeptidase acceptors is important for elucidating further the 
mechanistic integrity of transpeptidation and could provide novel information on 
acceptor requirements. 
 
Another compound tested for its potential suitability as a potential acceptor is D-lactate 
(Figure 6.39 a), which is present naturally in the fifth position of the pentapeptide in 
a b c 
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strains resistant to vancomycin e.g. vancomycin-resistant Enterococci (VRE strains) 
(Healy et al., 2000). Substitutions in the peptidyl-D-Ala4-D-Ala5 extremity of 
peptidoglycan precursors are selected by glycopeptides because such modifications 
reduce the affinity of the antibiotics for the target (Nieto & Perkins, 1971). The 
substrate D,L(meso)-DAP-LII was trialed for its ability to function as both a donor and 
acceptor substrate concurrently (Figure 6.39 b). In sections 6.8.2 and 6.8.3, Dansyl-and 
Fluorescamine-labelled mesoDAP-LII substrates were tested for potential transpeptidase 
donor functionality. 
 
 
 
 
 
 
 
 
 
Figure 6.39  The ability of D-lactate to Function as a Transpeptidase Acceptor, and D,L-
DAP-LII to Function as both a Transpeptidase Donor and Acceptor. (a) 10 mM D-lactate 
as a transpeptidase acceptor, with 20 µM L-LysLII in 0.026 % E6C12 as the donor (b) D,L-
DAPLII as both a transpeptidase donor and acceptor simultaneously. Assay conditions: 50 mM 
BisTris Propane, pH 8.5, 20 mM MgCl2, 0.39 % E6C12, 50 µM Amplex Red, 3.5 Units 
Rhodotorula gracalis DAAO, 5.8 Units HRP, 1.16 µM E. coli LpoA. Addition 1: 430 nM E. 
coli PBP1A in 20 mM CHAPS, and in (a) only, a second addition: transpeptidase acceptor 10 
mM D-lactate. Red: + LII, blue: no LII. 
 
D-lactate did work as a transpeptidase acceptor, but only marginally and was not as 
successful as the MurNAc pentapeptides previously tested. D-lactate is a simple 
acceptor as are D-amino acid residues that can be exchanged naturally in to the fifth 
position of the pentapeptide stem (Lupoli et al., 2011), however, even with 10 mM D-
lactate it was only turned-over very slowly. The substrate D,L-DAP-LII proved to be an 
efficiently functioning donor and acceptor. 
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          6.9.2.6  Testing E. coli PBP1A Catalytic Active Site Transglycosylase and   
                       Transpeptidase Mutants in the Continuous Transpeptidase Assay 
 
E. coli PBP1A transglycosylase and transpeptidase active site mutants were tested for 
their abilities to perform as transpeptidases in the continuous assay (Figure 6.40).  
 
 
 
 
 
 
 
 
Figure 6.40  E. coli PBP1A Transglycosylase and Transpeptidase Catalytic Active Site 
Mutant Proteins Tested for Transpeptidase Activity (a) E. coli PBP1A transglycosylase 
active site mutant (b) E. coli PBP1A transpeptidase active site mutant. Assay conditions: 50 
mM BisTris Propane, pH 8.5, 20 mM MgCl2, 0.39 % E6C12, 50 µM Amplex Red, 3.5 Units 
Rhodotorula gracalis DAAO, 5.8 Units HRP, 1.16 µM E. coli LpoA. Addition 1: 430 nM E. 
coli PBP1A in 20 mM CHAPS, addition 2: transpeptidase acceptor 20 µM MurNAc-L-Ala-D-
Glu-mesoDAP-D-Ala-D-Ala. Red: + LII, blue: no LII. 
 
Transpeptidase activity was not observed at all when either the transglycosylase active 
site residue or the transpeptidase active site residue was mutated to non-catalytic 
equivalent amino acid residues. This further establishes the imperative functions of the 
catalytic active site residues in the final peptidoglycan biosynthesis step of 
transpeptidation. The mutated transglycosylase active site residue prevents glycan 
polymer formation for subsequent processing via transpeptidation. 
 
    6.9.3  The Transpeptidase Activity of P. aeruginosa PBP1A in the Presence and   
              Absence of P. aeruginosa YbgF 
 
Pseudomonas aeruginosa PBP1A was also tested for transpeptidase function, with and 
without the presence of Pseudomonas aeruginosa YbgF (renamed CpoB in E. coli) 
(Figure 6.41).  
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Figure 6.41  The Transpeptidase Activity of Pseudomonas aeruginosa PBP1A, with and 
without PaYbgF. Both assays are stimulated by the presence of PaLpoA (a) P. aeruginosa 
PBP1A transpeptidase activity (b) P. aeruginosa PBP1A transpeptidase activity with PaYbgF. 
Assay conditions: 50 mM BisTris Propane, pH 8.5, 20 mM MgCl2, 0.39% E6C12, 50 µM 
Amplex Red, 3.5 Units Rhodotorula gracalis DAAO, 5.8 Units HRP, 1.2 µM PaLpoA. 
Addition 1: 400 nM PaPBP1A in 20 mM CHAPS, addition 2: transpeptidase acceptor 20 µM 
MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. Red: + LII, blue: no LII. 
 
A kinetic rate is visible when P. aeruginosa PBP1A was tested for transpeptidase 
activity, signifying a positive observation of transpeptidase activity. No negative 
controls (apart from without the donor Lys-LII - blue curve in Figure 6.41) with 
Moenomycin A or ampicillin have been done with P. aeruginosa PBP1A thus far. 
However, the transpeptidase activity of PaPBP1A in TritonX-100 in the same 
conditions optimised for E. coli PBP1B, exhibited comparable activity to PaPBP1A in 
CHAPS with an alkyl ether detergent assay environment (data not shown).  
 
      6.9.3.1  Testing P. aeruginosa PBP1A Catalytic Transglycosylase and   
                   Transpeptidase Active-Site Mutants in the Continuous Transpeptidase  
                   Assay 
 
The PaPBP1A transglycosylase and transpeptidase active site residue mutants were also 
tested for transpeptidase activity (Figure 6.42). The transpeptidase activity of both P. 
aeruginosa mutants was not observed in this assay, suggesting that these are successful 
active site mutants, with the mutated residue having important catalytic function 
towards the transpeptidation mechanism.  
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Figure 6.42  P. aeruginosa PBP1A Transglycosylase and Transpeptidase Catalytic Active 
Site Mutant Proteins Tested for Transpeptidase Activity. PaLpoA is present in both assays 
(a) P. aeruginosa PBP1A transglycosylase mutant (b) P. aeruginosa PBP1A transpeptidase 
active site mutant. Assay conditions: 50 mM BisTris Propane, pH 8.5, 20 mM MgCl2, 0.39 % 
E6C12, 50 µM Amplex Red, 3.5 Units Rhodotorula gracalis DAAO, 5.8 Units HRP, 1.2 µM 
PaLpoA. Addition 1: 400 nM PaPBP1A in 20 mM CHAPS, addition 2: transpeptidase acceptor 
20 µM MurNAc-L-Ala-D-Glu-mesoDAP-D-Ala-D-Ala. Red: + LII, blue: no LII. 
 
A comparison between the assay buffers for the continuous transpeptidase and 
continuous transglycosylase assays are given in Table 6.2. 
 
Table 6.2  A Comparison Between Assay Buffers for Transglycosylation and 
Transpeptidation for EcPBP1A and PaPBP1A. In the continuous transglycosylase 
fluorometric assay, the dansLII substrate is resuspended directly into the assay buffer 
and is stabilised by the decyl-PEG E8C10 detergent present in the buffer, before being 
aliquoted into wells of a 96-well plate. In the continuous transpeptidase D-Ala release 
assay, the LII substrate is resuspended in detergent (Triton X-100 or EXCY) prior to 
addition to the cuvette. 
 
 E. coli PBP1a buffer P. aeruginosa PBP1a buffer 
Continuous 
Transglycosylase 
Fluorometric 
Assay 
50 mM HEPES pH 7.5 
60 mM NaCl 
10 mM MgCl2 
10 % (v/v) DMSO 
0.085 % (v/v) octa-ethylene 
glycol monodecyl ether (E8C10) 
( + 4 µg/mL muramidase) 
50 mM HEPES pH 7.0 
60 mM NaCl 
10 mM MgCl2 
10 % (v/v) DMSO 
0.085 % (v/v) octa-ethylene 
glycol monodecyl ether (E8C10) 
( + 4 µg/mL muramidase) 
Continuous 
Transpeptidase 
coupled D-Ala 
Release Assay 
50 mM BisTrisPropane pH 8.5 
20 mM MgCl2 
z % ExCy or 0.1 % TritonX-100  
( + coupling reagents: DAAO, 
HRP, Amplex Red and 
accessory protein EcLpoA) 
50 mM BisTrisPropane pH 8.5 
20 mM MgCl2 
z % ExCy or 0.1 % TritonX-100  
( + coupling reagents: DAAO, 
HRP, Amplex Red and 
accessory protein PaLpoA) 
z Each ExCy detergent has a different CMC, with the percentage used given in each case 
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The transpeptidase assay buffer did not contain NaCl or DMSO, which are both present 
in the transglycosylase assay buffer. The ExCy detergent used in the transpeptidase 
buffer was E6C12, but was E8C10 in the transglycosylase assay buffer (Schwartz et al., 
2002). 
 
6.10  Discussion 
 
Fluorescamine-DAP-pentapeptide mass spectral analysis showed some unlabelled 
species present after SepharoseQ purification. A second purification procedure should 
have been employed here to try to separate the labelled from the unlabelled species, 
such as a reverse phase column on HPLC may have worked. In light of these mass spec 
results of the fluorescamine-labelled pentapeptide, the TLC of the purified elutions of 
Fluorescamine-LII should have contained a DAP-LII (non-labelled) control. As if the 
compound being purified contained a mixture of fluorescamine labelled and non-
labelled species, it may have been easier to identity any non-labelled material on TLC if 
a sample of DAP-LII was present on the plate. There was limited space on the TLC 
plate so in retrospect, splitting these samples across two TLC plates and including 
further control samples would have been preferable. 
 
Although the Fluorescamine-DAP-LII contained some unlabelled species, but it was 
shown that it functioned as a transpeptidase donor, therefore should have seen some 
activity in the FRET assay. Or the FRET just didn’t work – it doesn’t always work. 
 
The continuous spectrophotometric D-Ala release assay was developed by Dr. Adrian 
Lloyd at The University of Warwick to demonstrate transpeptidase activity in real-time. 
The success of this assay with EcPBP1B has allowed the characterisation of P. 
aeruginosa and E. coli PBP1A transpeptidase activity continuously, for the first time. 
The rate of EcPBP1B transpeptidase activity was virtually undetectable in the absence 
of EcLpoB. 
 
6.11  Conclusions 
 
Novel transpeptidase donor and acceptor compounds have been developed to help study 
the transpeptidase mechanism. Three out of the four compounds were successfully 
! 216 
synthesised, with the Fluorescamine-DAP-LII likely to have been synthesised, indicate 
in absorbance spectroscopy data. The four synthesised compounds (two transpeptidase 
donors and two transpeptidase acceptors) were tested for transpeptidase donor and 
acceptor functionality using the D-Ala release, continuous spectrophotometric 
transpeptidase activity assay. The two synthesised acceptors showed capability as 
acceptors with both Lys-LII and dansDAP-LII. Unlabelled DAP-LII was shown to 
function as both a transpeptidase donor and acceptor simultaneously. Fluorescamine-
DAP-LII also showed ability to function as a transpeptidase donor in the continuous 
fluorometric transglycosylase assay as well as a successful donor in the continuous D-
Ala release transpeptidase assay, using the two synthesised transpeptidase acceptors. 
 
The enzymatic activity of the transpeptidase function of Class A PBPs E. coli PBP1A 
has been extensively characterised, and has begun for P. aeruginosa PBP1A. The 
transpeptidase rate exhibited of E. coli PBP1A showed sensitivity to both Moenomycin 
A and ampicillin, and also was able to utilise structurally diverse acceptors including 
MurNAc-tetrapeptide and MurNAc-tripeptide. EcPBP1A transglycosylase and 
transpeptidase active site mutants inhibited the transpeptidase rate observed when non-
active site mutants were used. P. aeruginosa PBP1A also showed a positive rate for 
transpeptidase activity, as well as its transglycosylase and transpeptidase active site 
mutants not showing a transpeptidation rate. 
 
6.12  Future Work 
 
Further synthesis work on transpeptidase donors would be useful, including 
improvements in the purity of Fluorescamine-DAP-LII. LC-MSMS characterisation of 
the products formed within a transpeptidase FRET assay to confirm the transpeptidase 
reaction followed by FRET can be detected in terms of a structural identification of the 
desired transpeptidation product. Further development of the FRET assay also, 
however, the continuous transpeptidase D-Ala release assay fulfils the requirements of 
the original brief and duplication is unnecessary. 
 
Further kinetic characterisation of the transpeptidase donors and acceptors would aid in 
the basic requirements in a transpeptidation mechanism and help in efforts to target 
transpeptidase activity. The presence of different types of acceptors (e.g. dipeptides vs 
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single D-amino acids) could have an impact on the rate in which certain donors are 
incorporated. 
 
Using the D-Ala release transpeptidase assay, investigating whether E. coli CpoB or 
PaYbgF affects the transpeptidase rate of EcPBP1B or PaPBP1B, respectively. The 
same goes for TolA. TolA is likely to influence the transpeptidation rate of PBP1B, as a 
consequence of its activation of transglycosylase activity (Gray et al., 2015). 
 
The synthesis of glycan chains through polymerisation of the LII substrate is likely be 
in close proximity to the membrane, given that transpeptidase cross-linking of these 
glycan chains must also occur in proximity to bifunctional and monofunctional 
transpeptidase (PBP) enzymes of the bacterial cell. Although Class a PBPs are 
membrane associated with a single TM domain, the transglycosylase domain is 
embedded into the membrane. 
 !!
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Chapter 7 
Discussion, Conclusions and Future Work 
 
Class A PBPs are of important relevance to fighting antibiotic resistance pathways at 
present, particularly those within the group of ESKAPE pathogens, many of which are 
multi-drug resistant and are capable of 'escaping' the biocidal action of antibiotics and 
mutually representing new paradigms in pathogenesis, transmission and resistance 
(Santajit, 2016). 
 
The disruption of the catalytic mechanism of PBPs is bacteriolytic and causes cell wall 
integrity to be compromised and the cell to lyse. Studying the enzymatic intricacies of 
bacterial cell wall synthesis is of importance, to help understand how antibiotics 
interfere with this mechanism and how future potential targets could be designed. 
 
7.1  The Continuous Fluorescence Assay for Transglycosylase Activity 
 
The assay for continuous fluorometric monitoring of real-time transglycosylase activity 
was used to measure the kinetic constants for 3 Class A bifunctional PBPs (EcPBP1B, 
EcPBP1A and PaPBP1A) with dansylated variations of LII substrate. 
 
7.1.1  Buffer Conditions for the Continuous Fluorescence Assay 
 
The conditions for optimal transglycosylase activity were determined for E. coli PBP1A 
and P. aeruginosa PBP1A. The NaCl concentration optimal for both PBP1A 
transglycosylase activities was 60 mM, with the optimal pH defined as HEPES pH 7.5 
for EcPBP1A and HEPES pH 7.0 for PaPBP1A. Transglycosylase activity for both 
PBP1A enzymes was observed in TritonX-100, CHAPS and DDM detergents, as well 
as when tested in a range of ethylene glycol detergents.  
 
7.1.2  Initial Lag-Phase Observed with Class A PBPs 
 
A pre-steady-state lag in the consumption of LII was observed with all three PBPs 
(EcPBP1B, EcPBP1A and PaPBP1A) during the monitoring of transglycosylase 
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activity. This initial lag is due to the processivity of the transglycosylase activity of the 
PBP. During the reaction steady-state, PBPs polymerise in a processive manner, adding 
LII monomers to a growing polysaccharide chain (Schwartz, 2002). Upon reaction 
initiation, there is no polymeric substrate to extend and the PBP must synthesise a short 
oligosaccharide ‘primer’ to encourage steady-state kinetics. This is a well-known 
feature of EcPBP1A and PBP1B and was observed in PaPBP1A as well, suggesting that 
PBP1A in P. aeruginosa behaves kinetically similar to E. coli PBP1A. 
 
7.1.3  The Pros and Cons of DMSO upon Transglycosylase Activity Assays  
          and Future Work 
 
Further work should be done to reduce the percentage of DMSO or omit this reagent 
entirely, as it is not necessary for transglycosylase activity in all assays. DMSO was 
included in the assay buffer for the continuous fluorometric assay because it was present 
in the published optimal buffer for this technique for E. coli PBP1B, and was shown not 
to interfere with the fluorescence properties of the dansyl reporter group on the 
pentapeptide stem of LII (Schwartz et al., 2002). The 10 % of DMSO used in the 
continuous fluorescence assays could help to maintain the low level quantity of 
synthetic detergent, TritonX-100, required for transglycosylase activity. One occasion 
where DMSO was useful and necessary was in aiding the migration of 
transglycosylation products (linear glycan polymers) through a Tris.Tricine 
polyacrylamide gel matrix to differentiate between varying glycan chain lengths 
(Figure 7.1).  
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Figure 7.1  The Effect of Increasing Percentage of DMSO upon Glycan Chain Length and 
Glycan Chain Migration when Analysed by Tris.Tricine SDS-PAGE. A specific Tris-
Tricine polyacrylamide gel and dual-buffer system is used (described in section 2.8.1). The 
dansyl moiety on the LII is visualised through a Short Pass filter. Transglycosylase assay buffer: 
10 mM HEPES, 3 mM MgCl2, 150 mM NaCl, 0.18% Triton-X100, + x % DMSO. 
 
It is unclear whether the presence of DMSO in these transglycosylation assays aids in 
the polymerisation of longer glycan chain or whether its properties means that it acts 
like a lubricant and physically separates glycan chains, allowing better separation 
through the polyacrylamide. Further investigation here would be useful to ascertain the 
involvement of DMSO in transglycosylase activity.  
 
      7.1.4  The Kinetic Constants Derived for Class A PBPs, from Transglycosylase    
                 Activity 
 
The transglycosylases tested do not require the 55 carbon undecaprenyl moiety, which 
coincides with results published in Ye et al., 2001, in which they used E. coli 
membranes for transglycosylation activity, rather than purified PBPs. In fact, a shorter 
polyprenyl chain was a preferred substrate in vitro even though the C55 chain is the 
native prenyl chain length. It can be concluded that dansLIIC35 was preferred by all 
three purified PBPs compared to dansLIIC55, most likely due to the substrate with the 
shorter prenyl chain being more soluble and therefore more accessible to the 
transglycosylase domain as not surrounded by a synthetic detergent micelle. LII-C55 has 
all the structural features required for recognition but with more desirable physical 
properties than natural LII. Therefore, it can be used to monitor transglycosylase with a 
LII only  0%     0%    10%  20%   30%    40%   50% 
 
                                              DMSO % 
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reduced requirement for synthetic detergent. This continuous fluorometric assay is 
extremely useful for rapid high-throughput screening to elucidate transglycosylase 
activity in a range of conditions for comparison, but the substrate(s) used have to report 
this activity by means of a change in fluorescence or absorbance, resulting in the use of 
modified substrates. 
 
The full conversion of LII to soluble disaccharide pentapeptide was not assumed, and 
therefore Kcat could not be extracted from the data. Full consumption of LII could be 
measured and confirmed by HPLC. Ideally the Kcat/Km measure of catalytic efficiency 
would be calculated to universally compare the affinity between a range of enzymes and 
substrates obtained through orthogonal assay methods, however, as the full 
consumption of LII could not be guaranteed with this assay, a reliable Kcat/Km value 
could not be quantified. Instead S0.5, Km and Vmax values were calculated for direct 
comparison between them under the conditions used in this project. 
 
The dependence of Class A PBP1A transglycosylase activity upon LII concentration 
demonstrated a sigmoidal approach to Vmax, culminating with a reduction of enzyme 
activity at higher substrate concentrations. This behaviour was also observed with S. 
aureus MGT (Abrahams, 2011; Bury et al., 2015). It is plausible that Class A 
bifunctional PBPs also possess two binding sites for the polymerisation of LII into 
linear glycan chains: one for the elongating glycan chain (donor site) and one for the 
incoming LII substrate (acceptor site). At time 0, both binding sites will be free of 
substrate. Upon the addition of substrate, LII binding to the donor site may induce a 
conformational change, facilitating the binding of the LII substrate at the acceptor site. 
This would be advantageous if the binding of the two substrates to the donor and 
acceptor sites occurred in an ordered manner. 
 
The catalytic efficiency values calculated for both E. coli PBP1A and P. aeruginosa 
PBP1A were measured by fitting the data to the Hill equation of cooperativity. The 
catalytic efficiency for dansDAP-LII-C35 was >2-fold greater than that for dansDAP-
LII-C55, despite the latter being the native substrate. Also this value for dansDAP-LII-
C55 was 1.5-fold that for dansLys-LII-C55 with P. aeruginosa PBP1A with no known 
published values for comparison.  
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     7.1.5  PBP Accessory Proteins and their Impact on Transglycosylase Activity 
 
The affect of the PBP accessory proteins E. coli FtsN and PBP2 on the transglycosylase 
activity of E. coli PBP1A and 1B and P. aeruginosa PBP1A were discussed in section 
4.8.2. It is known that large protein complexes form in E. coli to build multifunctional 
machinery in vivo, comprising of inter-dependent and interacting proteins (Leclercq et 
al., 2017). These initial studies provide the first evidence that the PBP accessory protein 
PBP2 (albeit the E. coli protein) interacts with P. aeruginosa PBP1A, pointing to the 
formation of similar protein complexes in P. aeruginosa in addition to E. coli. The 
cloning of the PaPBP2 construct would aid in identifying the effect of the P. 
aeruginosa PBP2 protein on the transglycosylase activity of PaPBP1A. E. coli FtsN 
stimulates the transglycosylase activity of EcPBP1B and it would be interesting to see if 
EcFtsN stimulates the same activity is PaPBP1B. There is no known FtsN protein in P. 
aeruginosa (except for in P. fluorescens F113), but searching the Pseudomonas genome 
by protein BLAST using the EcFtsN gene sequence reveals PA5052 as the only hit, 
with 28 % identity. Further work to identify the affect of EcFtsN/PA5052 upon the 
transpeptidase activity of PaPBP1B would be of interest. 
 
7.2  The Oligomeric Status of PBP1A and PBP1B in vitro 
 
Kinetic properties observed with PBP1a enzymes are that at low PBP1A concentration 
and/or low LII substrate concentration, very little transglycosylase reaction rate is 
observed. Multiple factors could contribute to this observation, including PBP1A 
requiring a substrate ‘primer’, i.e. a pre-polymerised glycan chain as a substrate, 
preferentially to the monomer unit LII substrate. Another factor at play here is that it is 
possible that PBP1a forms homodimers and so therefore a minimum concentration of 
PBP enzyme is required (KD) for optimum transglycosylase function. E. coli PBP1A 
and 1B have both been hypothesised to form independent homodimers in vivo 
(Bertsche, 2005; Born, 2006, Charpentier, 2002, King, 2016) with the KD value for 
EcPBP1B dimerisation being determined as 1.27 ± 0.96 x 10-7 M. That being said, the 
X-ray crystallography structures of EcPBP1B (King, 2016; Sung, 2009) do not 
obviously represent a ‘typical’ structure conducive to dimer formation. The dimer 
prediction software COTH (CO-THreader), a multiple-chain protein-threading 
algorithm designed to identify dimer templates and recombine protein complex 
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structures, predicted models of potential dimer formation of E. coli PBP1B homodimers 
(Figure 7.2). Although such in silico predictions are estimated guesses only and require 
experimental verification and such predictions could be tested using analytical ultra-
centrifugation (AUC) or dynamic light scattering (DLS) in solution. 
 
 
 
 
 
 
 
 
Figure 7.2  Predicted Dimer Conformations for E. coli PBP1B Enzymes Calculated using 
the COTH, models 1, 2 and 3 (Zhang et al., 2011). 
 
These models would not have the space to interact with the known interacting partners 
of the PBP, e.g. there does not appear to be the necessary space for interacting proteins 
such as EcLpoB with the UB2H domain of EcPBP1B. 
 
Many proteins are homo-oligomers in solution and monomers self-associate to form 
non-covalently bound dimers, trimers, etc. S. pneumoniae PBP2a was shown to self-
associate in vitro, TM-domain dependent (Helassa et al., 2012). SDS-PAGE analysis 
only shows the monomer because non-covalent interactions are disrupted by SDS 
detergent. However, dimeric E. coli PBP1B in particular has been observed frequently 
on SDS-PAGE and even more so in anti-His Western Blots (Figure 3.8). If dimers do 
indeed form, they are not between disulphide bridges, as potential dimers have been 
observed in an SDS (reducing) environment and after sample incubation with β-
mercaptoethanol. It is still disputed whether PBP1A and/or PBP1B form homodimers in 
vivo, and further work is need to confirm or disprove this theory. A further investigation 
of enzyme concentrations either side of the published KD for E. coli PBP1B with 
dansDAP-LII to test whether dimerisation affects cooperativity, or vice versa. 
 
 
 
1" 2" 3"
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7.3  The PgpB Assay 
 
      7.3.1  Kinetic Measurements of Transglycosylation using E. coli PgpB 
 
A continuous spectrophotometric assay using native LII substrate had been previously 
developed and optimised for use with S. aureus MGT and S. pneumoniae PBP1a by Dr. 
Kat Abrahams and Dr. Darren Braddick at The University of Warwick. This assay was 
extended for use with EcPBP1B, EcPBP1A and PaPBP1A. The phosphatase PgpB was 
used to cleave the terminal phosphate from undecaprenyl pyrophosphate that was 
generated from the transglycosylase activity of PBPs. The native substrate of E. coli 
PgpB is undecaprenyl pyrophosphate, but diacylglycerol pyrophosphate is a preferable 
substrate with the Km for UPP being 1.5-fold that for DGPP. E. coli PgpB was able to 
indirectly report the generation of undecaprenyl pyrophosphate from the capability of 
all three Class A enzymes to form linear glycan strands. The substrate preference 
between DAP- and Lys-LII was also confirmed for all three PBPs as the native, Gram-
negative substrate DAP-LII. The kinetic profile of the transglycosylase activity of all 
three proteins were generated, giving Km values for their affinity to DAP-LII, rather 
than the Km values in Chapter 4 calculated using the continuous fluorometric assay and 
dansDAP-LII. The Km values extracted from EcPgpB indirectly reporting 
transglycosylase activity were much higher than the values defined using the continuous 
fluorometric assay.  
 
      7.3.2  E. coli PgpB Detergent Screening 
 
Due to E. coli PgpB being kinetically slow in this assay, the assay conditions were 
altered to measure the affect of using different detergents. As ethylene glycol alkyl ether 
detergents were successful in the elucidation of transglycosylase activity in the 
continuous fluorometric assay as well as for transpeptidase activity in the continuous 
spectrophotometric transpeptidase assay, E. coli PgpB phosphatase activity was tested 
in the environment of these ethylene glycol alkyl ether detergents. E6C12 was found to 
be the optimum detergent from the series of ExCy range. Also, the presence and absence 
of MgCl2 with each detergent was tested and proved that MgCl2 was absolutely 
essential for E. coli PgpB activity under the conditions tested. This finding echoes and 
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confirms those of other who have extensively worked on E. coli PgpB (Touzé et al., 
2008).  
 
      7.3.3  Limitations of the Current PgpB Assay Protocol 
 
The most limiting factor in this assay is the kinetic speed of EcPgpB, but it has been 
shown that cardiolipin and phosphatidyl glycerol enhances PgpB activity (Touzé, 2008). 
At present, the assay set up involves a 15 µL LII polymerisation reaction, which is 
diluted in to a 200 µL continuous, coupled assay. The dilution of the transglycosylation 
product of interest (UPP) is unnecessary and could be improved. Reducing the volume 
of the continuous assay from 200 to 50 µL would be advantageous. Subsequently the 
assay format could be translated from a cuvette in to a plate-reader well, which would 
allow the rapid screening of a multitude of parameters and conditions optimised (NaCl, 
pH, inhibitors, divalent ion concentration, etc.).  
 
              7.3.3.1  The Development of a Continuous Assay 
 
Importantly, given that the transglycosylase activity of the Class A PBPs has shown to 
be substantial and sufficient, and that EcPgpB expresses well, this assay has the 
potential to measure transglycosylation continuously. Attempts and observing a 
continuous rate were trialled but no rate was observed. As the focus of this study with 
PgpB was on E. coli PBP1A and P. aeruginosa PBP1A and these PBPs are known to 
prefer a primer substrate for transglycosylase activity to reach steady-state kinetics, 
adding something to the assay that stimulates the transglycosylase activity of PBP1A or 
that aids in the formation of a oligosaccharide primer substrate, would be extremely 
advantageous in the advancing of this assay towards a continuous rate of simultaneous 
transglycosylation and phosphatase activity. 
 
7.4  No Activity Observed of P. aeruginosa PBP1B  
 
Thus far, an in-frame construct of PaPBP1B (W23-N744) was successfully cloned, 
expressed well in C43(DE3) E. coli cells, and purified in high quantities to a high purity 
by IMAC. The protein was shown to positively bind the BOCILLIN FLTM and also 
indicated correct folding by circular dichroism. Nonetheless this particular construct did 
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not show sufficient transglycosylase or transpeptidase activity in any conditions tested. 
Engineering an active PaPBP1B construct would be of use to compare such interactions 
between P. aeruginosa and E. coli as well as define values for kinetic constants for 
PaPBP1B, which have not been published thus far. If transglycosylase activity could be 
observed for PaPBP1B, it would be interesting to test the effect of the Lpo lipoproteins 
on the transglycosylase and transpeptidase activities of this enzyme, however, there is 
no known LpoB homologue protein in P. aeruginosa at present. 
 
      7.4.1  The Lack of LpoB in P. aeruginosa 
 
Due to the P. aeruginosa genome lacking a gene for LpoB, a ‘pull-down’ experiment 
was planned in the quest to search for the equivalent protein in Pseudomonas 
aeruginosa. An experiment to seek for a potential LpoB-like protein in P. aeruginosa 
could involve using cyanogen bromide (CNBr) resin to which PaPBP1B would bind 
and act as the ‘bait’ protein. Positive control proteins include PaPBP3 and PaYbgF, 
which are both known to bind to PBP1B. Also the putative FtsN homologue PA5052 is 
likely to positively bind to PBP1B as does FtsN to PBP1B in E. coli, if it is a true 
homologue of FtsN. Negative controls could include the proteins PaPBP1A, PaLpoA 
and FtsZ. In the hunt for a new binding partner, exploratory fractions to pass over the 
PaPBP1B-resin could include P. aeruginosa membranes and the isolated P. aeruginosa 
periplasm, as this is where LpoB resides in E. coli. 
 
7.5  The FRET Transpeptidase Assay 
 
Four compounds were synthesised, three with mass spectrometry confirmation while 
Fluorescamine-labelled LII although did not ionise readily for detection in mass 
spectrometry, the compound was polymerised by E. coli PBP1B, with the fluorescence 
emission wavelength measured for that of fluorescamine (470 nm) (Figure 5.22). The 
synthesised transpeptidase acceptor compounds were both confirmed as functional 
transpeptidase acceptors in the continuous, coupled spectrophotometric D-Ala release 
assay. 
 
Lys-LII was shown to act as a transpeptidase donor and all three synthesised 
transpeptidase acceptors were capable acceptors when using both Lys-LII and DAP-LII 
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as the transpeptidase donor. DansDAP LII was also able to function as a transpeptidase 
donor, as well as all three compounds being positive for transpeptidase acceptor ability. 
The other transpeptidase donor compound (Fluorescamine-labelled LII) was confirmed 
to be able to function as a transpeptidase donor with all three acceptor compounds. 
 
The FRET assay to elucidate transpeptidase activity was trialled using fluorescamine-
labelled LII as the transpeptidase donor and MurNAc-L-Ala-D-Glu-mesoDAP-D-
azatryptopthan-L-Ala as the transpeptidase acceptor peptide. The results observed were 
similar to those observed during a continuous fluorometric transglycosylation reaction, 
i.e. a steady decrease in fluorescence over time. The fluorescamine-labelled LII was 
likely being polymerised, but in the FRET assay conditions, there was no muramidase 
present like in a traditional transglycosylation-monitoring assay. Further optimisation of 
this technique and the relevant controls are required to progress this assay to be able to 
visualise a true FRET event between FRET fluorophore donor and acceptor. 
 
7.6  The Continuous Transpeptidation D-Ala Release Assay 
 
This is the first conclusive evidence of the continuous visualisation of transpeptidase 
activity in vitro, of PBP1A from E. coli and P. aeruginosa. There are multi-drug 
resistant (MDR) P. aeruginosa isolates that are resistant to β-lactams due to alteration 
of their PBP transpeptidase active site. Understanding the intricacies of the 
transpeptidase mechanism has been a persistent biochemical question towards which 
this assay can contribute solutions. 
 
This assay was shown to be substrate-dependent as well as enzyme-dependent and also 
demonstrated sensitivity to the inhibitors moenomycin and ampicillin. The assay 
reagents were shown not to disrupt the coupling system. The initial lag-phase observed 
in these assays is a running feature throughout Class A PBP kinetics, especially with 
PBP1A, with it having a definite preference for polymeric LII glycan chains as its 
substrate. 
 
The final reaction rate observed in this assay is a result of simultaneous DD-
carboxypeptidation and transpeptidation. The rate of DD-carboxypeptidation was 
measured upon the addition of the PBP, prior to the addition of acceptor, generating a 
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rate comprising of both transpeptidation and DD-carboxypeptidation, combined with the 
rate of transpeptidation able to be calculated by subtracting the initial DD-
carboxypeptidase rate away from the final reaction rate. 
 
The assay buffer used for transpeptidase activity did not contain NaCl or DMSO, like 
the assay buffer for the continuous fluorometric transglycosylase assay buffer. The 
transglycosylase activity of PBP1A in transpeptidase assay buffer, using the continuous 
fluorometric transglycosylase assay to determine activity, should be considered. 
However, as transglycosylation precedes transpeptidation, the PBP present in the 
transpeptidase assay is conducting transglycosylation and transpeptidation concurrently 
and this would not occur if the PBP was unstable in the buffer selected for 
transpeptidase activity. Nevertheless the transpeptidase assay buffer should be tested in 
a continuous transglycosylase format to confirm this further. Also, the assay buffer used 
for transglycosylation (the discontinuous part) of the PgpB assay is slightly different 
again (20 mM Tris.HCl pH 7.6 and 10 mM MgCl2, with the LII resuspended in 0.1 % 
DDM and the EcPgpB delivered in DDM). With confirmation that both P. aeruginosa 
and E. coli PBP1A perform transglycosylation in a few different yet specific buffer 
conditions, it is likely that continuous transglycosylase activity can be observed in the 
transpeptidase assay buffer. 
 
7.7  Thesis Summary 
 
This project involved the biochemical characterisation of the membrane-associated 
PBPs that mediate resistance to the β-lactam class of antibiotics. A number of published 
assays are limited in some way whether they are qualitative, discontinuous or use 
modified (fluorescently tagged or radiolabelled) substrate. The major component of this 
project was assay development for enzymatic characterisation of Class A PBPs. Two 
assays for transglycosylation and two for transpeptidation were developed and 
optimised using P. aeruginosa PBP1A and E. coli PBP1A. Kinetic characterisations of 
both activities of bifunctional PaPBP1A and EcPBP1A were performed and assay 
conditions optimised to emulate the environment in vivo.  
 
A previously published fluorescence assay to continuously monitor transglycosylation 
(Schwartz et al., 2002) was developed and optimised for characterisation of the PBP1A 
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enzymes. The substrate-enzyme interactions involved are paramount in elucidating the 
full mechanism of peptidoglycan biosynthesis and aiding in the search for new 
antimicrobials. Both enzymes showed preference for DAP LII over Lys-LII and also 
demonstrated preference for the non-native C35 prenyl chain length over C55. EcPBP1A 
and PaPBP1A transglycosylase kinetic data fitted for readily to a non-Michaelis-
Menten equation that accounts for two substrates: a donor substrate and an acceptor 
substrate. EcPBP1A was used as a control enzyme to compare PaPBP1A 
transglycosylase activity, which appeared to behave in the same manner as EcPBP1A 
 EcPBP2 and EcFtsN were shown to stimulate the activity of PaPBP1A, pointing to the 
formation of protein complexes in P. aeruginosa, similar to those in E. coli. 
 
Transglycosylase assay of native substrates was the first time developed for Gram-
negatives. The coupled spectrophotometric assay for transglycosylation using the 
phosphatase PgpB that is discontinuous, but uses native LII. This spectrophotometric 
assay was optimised to study the enzymology of transglycosylase activity of the PBPs 
with their natural substrate, LII.  
 
A FRET assay was developed to show transpeptidation, in which novel donor and 
acceptor transpeptidase compounds were synthesised. Non-canonical dipeptides were 
incorporated at the terminus of the pentapeptide stem, demonstrating flexible 
promiscuity of the MurF ligase. 
 
A novel spectrophotometric transpeptidase assay generated continuous data of 
transpeptidation and this thesis has the first illustration of continuously-monitored 
PBP1A transpeptidase activity. EcPBP1A and PaPBP1A demonstrated transglycosylase 
and transpeptidase activity in both TritonX-100 and CHAPS PBPs showed 
transglycosylase activity and transpeptidase activities with a range of structurally 
different substrates. EcPBP1A was able to utilise a variety of transpeptidase acceptor 
compounds. PaLpoA was shown to stimulate PaPBP1A transpeptidase activity, like 
EcLpoA stimulates EcPBP1A. 
 
Active-site mutants of transglycosylase and transpeptidase inactive domains did not 
enhance the functionality of the active domain. TP active-site mutants still underwent 
transglycosylation but transglycosylation mutants did not perform transpeptidation. 
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PaPBP1A transglycosylase and transpeptidase active-site mutants were made and 
showed a lack of activity. 
 
PaPBP1A and EcPBP1A were both subjected to crystal trials for structural 
characterisation. PaPBP1B activity was not detected at a level necessary to kinetically 
characterise the enzyme and it is possible that this PBP has an as yet undetermined 
stimulatory cofactor. 
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Appendix 1 
 
 
A table of oligos for gene synthesis or site-directed mutagenesis. Bases highlighted 
in bold are the restriction sites in the primers for gene synthesis and highlight the 
mutated codon in mutagenic primers. All sequences are 5’ ! 3’. !!
E. coli PBP1B 
58-804 
 
TTT GCG CAT ATG AAG CCT CGT GGC AAA CGC GGC TGG 
CTA TGG CTA CTG  
 
CTG TGC CAG CAG AGC GAG ATG CAG CAG CAG CCG TCA 
TAA TTT GGG GGA TCC TTA TGA CGG CTG CTG CTG CAT 
CTC GCT CTG CTG GCA CAG  
 
E. coli PBP 
1A (Full-
length) 
 
GCG TTT GCG CAT ATG ATG AAA CTA AAT GGG AAA TTT 
CCA GTG AAG TTC GTA AAG 
 
CGC TTT GCG GCG GCC GC TCA GAA CAA TTC CTG TGC 
CTC GCC ATT ATC GAT AAT 
 
Pseudomonas 
aeruginosa 
PBP 1A (Full-
length) 
 
GCG TTT GCG CAT ATG ATG CGC CTG CTG AAG TTC CTG 
TGG TGG ACT TGC GTC ACC 
 
GCG TTT GCG GCG GCC GC TCA GAA CAG GTC GAT CGG 
CGC GCC TTC GTC ATC CGG 
 
E. coli PBP1B 
TG Active 
Site Mutant: 
E233Q 
 
ACT TTG CTG GCG ACA CAG GAC CGT CAT TTT TAC 
 
GTA AAA ATG ACG GTC CTG TGT CGC CAG CAA AGT 
E. coli PBP1B 
TP Active 
Site Mutant: 
S510A 
CGT CGT TCG ATT GGT GCG CTT GCA AAA CCA GCG 
 
CGC TGG TTT TGC AAG CGC ACC AAT CGA ACG ACG 
 
 
E. coli PBP1A 
TG Active 
Site mutant: 
E94Q  
 
AGC CTT TAT CGC GAC ACA AGA CAG CCG CTT CTA CG 
TCG TAG AAG CGG CTG TCT TGT GTC GCG ATA AAG GC 
E. coli 
PBP1A TP 
Active Site 
mutant:S473A  
 
TG CGT CAG GTG GGT GCC AAC ATC AAA CCG TTC C 
AA CGG TTT GAT GTT GGC ACC CAC CTG ACG CAG TGC 
PaPBP1B TG 
Active site 
mutant E190Q 
ACC CTG GTC GCG GTC CAG GAT CGC GAC TTC TGG 
 
CCA GAA GTC GCG ATC CTG GAC CGC GAC CAG GGT 
 
PaPBP1B TP 
Active site 
mutant S468A 
GTG CGG CCG ATC GGT GCC CTG ATC AAG CCG GCG 
 
CGC CGG CTT GAT CAG GGC ACC GAT CGG CCG CAC 
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PaPBP1A TG 
Active site 
mutant: E86Q 
GCC CTG CTG TCC GCC CAG GAC GAC AAT TTC GCC 
 
GGC GAA ATT GTC GTC CTG GGC GGA CAG CAG GGC 
 
PaPBP1A TP 
Active site 
mutant S461A 
AAG CGC CAG CCG GGC GCC AGT TTC AAG CCG TTC 
 
GAA CGG CTT GAA ACT GGC GCC CGG CTG GCG CTT 
 
Pseudomonas 
aeruginosa 
PBP 1B (W23 – 
N775) 
 
GCG TTT GCG CAT ATG TGG CTC AGC TGG GCT CTC AAG 
CTC GGC CTC GTC GGC CTG  
 
GCG TTT GCG GCG GCC GC TCA ATT CAG CCA GCC ACG 
TAC CCA GTC CAT CAC CTC 
 
PaPBP1B P. 
putida 
expression 
plasmid 
pVZ101  
TTT GCG AAG CTT TAA GGA GGT TCT TGA ATG GAC CCG 
TCC GCG CTC TCC GCG TTC TCG 
 
TTT GCG TCT AGA TCA ATG ATG ATG ATG ATG ATG ATT 
CAG CCA ACC ACG AAC CCA GTC CAT 
 
E. coli PBP3 
(Full length 
gene) 
 
5’ TTT CGG GAT CCT ATG AAA GCA GCG GCG AAA ACG 
CAG AAA CCA AAA CGT 3’ 
 
5’ TTT GCG GAG CTC TTA CGA TCT GCC ACC TGT CCC 
CTC GCC TTG ATT AAT 3’ 
 
E. coli PBP3 
(no N-
terminal TM 
domain) from 
AA W44. 
5’ TTT CGG GAT CCT TGG TTA CAA GTT ATC TCC CCG 
GAT ATG CTG GTG AAA 3’ 
 
End primer is the same as the full-length gene 
PaLpoA 
 
5’ TTT GCG CAT ATG GCG ACC TCG TCC AAT TCC GGA 
CTG GGC GAA CTT CCC 3’ 
 
5’ TTT GCG GCG GCC GC TCA AAA GCT GCT GGT CCC 
CAG CGG CTG GAC CTG GCC 3’ 
 
P. aeruginosa 
PBP3 (Full 
length gene) 
 
5’ TTT CGG GAT CCT ATG AAA CTG AAT TAT TTC CAG 
GGC GCC CTC TAC CCA 3’ 
 
5’ TTT GCG GAG CTC TCA GCC ACG CCC TCC TTT TGC 
GGG CGC AGC ATT GAC 3’ 
 
P. aeruginosa 
PBP3 (no N-
terminal TM 
domain) from 
A35 
5’ TTT CGG GAT CCT GAC CTG CAC GTG ATC GAC CAT 
GAC TTC CTC AAG GGC 3’ 
 
End primer is the same as the full-length gene !
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Appendix 2 
 
 
The percentages and concentrations of each detergent used in extraction (solubilisation) 
and purification of PBPs. 
 
  Extraction Purification 
Detergent Detergent CMC 
% 
Detergent 
used 
mM 
Detergent 
used 
% 
Detergent 
used 
mM 
Detergent 
used 
CHAPS 0.49 % / 6-10 mM 0.15 % 1.5 mM 0.15 % 1.5 mM 
DDM 0.0087 % / 0.12-0.3 mM 0.04 % 0.75 mM 0.03 % 0.5 mM 
LDAO 0.023 % / 0.14-1 mM 0.07 % 2.5 mM 0.06 % 2 mM 
TritonX-100 0.02 % / 0.2-0.25 mM 1 % N/D 0.2 % N/D 
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Appendix 3 : Derivation of the ‘dual substrate’ Equation 
 
Introducing a Kinetic Model for Two transglycosylation substrates, a donor and an 
acceptor, both of which are LII. 
 
The derivation of kinetics for a two-substrate system, which takes into account the 
participation of a donor and acceptor where both are LII. A Km for both the donor 
and acceptor are derived here, KmA and KmB.  
 
 
The change in rate of product formation over time is equivalent to the initial rate of 
reaction (v0): 
 
 
When all of the substrate is bound to the total available amount of enzyme [ET], 
[ES2] = [ET]. All the catalytic sites are saturated with substrate and Vmax can be 
defined as: 
 
The two kinetic constants for transglycosylase donor and transglycosylase acceptor 
can be derived as: 
 
  
The total concentration of enzyme in the system is the sum of all bound and unbound 
catalytic sites and can be defined as: 
[ET] = [E] + [ES] + [ES2] 
 
The terms in equation (4) can be written to define [E] in terms of [ES], and [ES] in 
terms of [ES2]: 
 
 
 
Substituting [ES] in to [E], gives: 
 
 
[E]!+![S]!!!!!!!!!!!!!!!!!!!!!!!!!!!!!![ES]!!!!!!!!!!!!!!!!!!!!!!!!!!!!![ES2]!!!!!!!!!!!!!!!!!!!!!!!!!!!!![E]!!!!+!!!![P]!KmA! KmB! Kcat!+![S]!.![S]!
=!v0!=!Kcat![ES2]!dP#dt#
Vmax!=!Kcat![ET]!
[E][S]![ES]!KmA =! [ES][S]![ES2]!KmB =!
KmA![ES]![S]![E] =! KmB![ES2]![S]![ES] = 
KmA! [S]![E] =!
KmB![ES2]![S]!
(1) 
(2) 
(3a) (3b) 
(4) 
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Substituting the above equations in to equation 4, describes [ET] in terms of the 
kinetic constants [S] and [ES2]. 
 
 
 
 
 
Multiply by Kcat: 
 
 
 
Substituting equation (1) for V0 and equation (2) for Vmax in to (7), gives: 
 
 
 
Rearrange (8) to make V0 the subject: 
 
 
 
 
 
 
 
 !
KmA!KmB![ES2]![S]2![E] =!
KmA!KmB![ES]![ES2]![S]2![ET] =! KmB![ES2]![S]!+! +    [ES2]!
[ET] = [ES2]! KmB!![S]!+!KmA!KmB![S]2! +   1!
Kcat [ET] = Kcat [ES2]! KmB!![S]!+!KmA!KmB![S]2! +   1!
Vmax =  V0! KmB!![S]!+!KmA!KmB![S]2! +   1!
v0 = ! KmA!KmB![S]2!
Vmax!KmB!![S]!+! +   1!
V0 = ! Vmax![S]2!KmA KmB + KmB [S] + [S]2!
(5) 
(6) 
(7) 
(8) 
(9) 
(10) 
! 236 
 Thesis Bibliography 
 
Adam, M., Damblon, C., Jamin, M., Zorzi, W., Dusart, V., Galleni, M., el Kharroubi, A., Piras, 
G., Spratt, B. G., Keck, W. et al., (1991) Acyltransferase activities of the high-molecular mass 
essential penicillin binding proteins. Biochem J. 15 (279-Pt 2) pp601-4 
 
Arenz, S. & Wilson, D. N. (2016) Bacterial Protein Synthesis as a Target for Antibiotic 
Inhibition. Cold Spring Harb Perspect Med 6(9): pii: a025361 
 
Babu, M. (2011) Genetic interaction maps in Escherichia coli reveal functional crosstalk among 
cell envelope biogenesis pathways. PLoS Genet. 7  e1002377 
 
Bagga, S. (2004) Development of Fluorescence Assays for lipid-linked steps of Bacterial 
Peptidoglycan Biosynthesis, PhD Thesis, The University of Warwick. 
 
Barreteau, H., Kovac, A., Boniface, A., Sova, M., Gobec, S. and Blanot, D. (2008) Cytoplasmic 
steps of peptidoglycan biosynthesis FEMS Microbiol Rev 32: 168-207 
 
Barrett, D., Wang, T. S., Yuan, Y., Zhang, Y., Kahne, D., Walker, S. (2007) Analysis of glycan 
polymers produced by peptidoglycan glycosyltransferases, journal of Biological Chemistry 
282(44)pp31964 
 
Banzhaf, M, Cooperativity of peptidoglycan synthases active in bacterial cell elongation. Mol 
Microbiol, 2012. 85(1): p. 179-194. 
 
Batson, S. (2010). Structural enzymology of peptidoglycan biosynthetic D-amino 
acid dipeptide ligases. Unpublished Ph.D., University of Warwick. 
 
Berezin, M. Y. and Achilefu, S. (2010) Fluorescence Lifetime Measurements and Biological 
Imaging Chem Rev 110 (5) 2641-2684 
 
Bertsche, U., Kast, T., Wolf, B., Fraipont, C., Aarsman, M. E., Kannenberg, K., von 
Rechenberg, M., Nguyen-Disteche, M., den Blaauwen, T., Holtje, J. V., Vollmer, W. (2006) 
Interaction between two murein (peptidoglycan) synthases, PBP3 and PBP1B, in Escherichia 
coli. Mol Microbiol, 61, 675. 
 
Biboy, J., Bui, N. K., Vollmer, W. (2013) In Vitro Peptidoglycan Synthesis Assay with Lipid II 
Substrate Anne H. Delcour (ed.), Bacterial Cell Surfaces: Methods and Protocols, Methods in 
Molecular Biology, vol. 966, Springer Science New York. 
 
Bickford, J. S. Nick, H. S. Conservation of the PTEN catalytic motif in the 
bacterial undecaprenyl pyrophosphate phosphatase, BacA/UppP (2013) Microbiology 159 
2444-2455 
 
Born P, Breukink E, Vollmer W. (2006) In vitro synthesis of cross-linked murein and its 
attachment to sacculi by PBP1A from Escherichia coli. J. Biol. Chem. 281:26985-93 
 
Breukink, E., van Heusden, H. E., Vollmerhaus, P. J., Swiezewska, E., Brunner, L., (2003) 
Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. 
 
Brooks, G. Edwards, P. D., Hatto, J. D. I. Smale, T. C. Southgate, R.  (1995) Synthesis of 
Derivatives of Muramic Acid and C-1 Homologated a-D-Glucose as Potential Inhibitors of 
Bacterial Transglycosylase. Tetrahedron 51, 7999-8014 
 
! 237 
Broome-Smith, J. K. Edelman, A., Yousif, S, Spratt, BG et al., (1985) The nucleotide- 
sequences of the ponA and ponB gene encoding penicillin-binding protein 1A and 1B of 
Escherichia coli. The European Journal of biochemistry 147, 437-446. 
 
Brotz, H., Bierbaum, G., Reynolds, P.E. and Sahl, H. G. (1997) The lantibiotic  
mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur J Biochem 
246 193-199 
 
Brown, E. D. & Wright G. D. (2016) Antibacterial Drug Discovery in the Resistance Era Nature 
Rev 529 p336-343 
 
Brown, E. D. and Wright, G. D. (2005) New Targets and Screening Approaches in 
Antimicrobial drug discovery Chem Rev 105 p759-774 
 
Bugg, T. D. H. (1999) Bacterial peptidoglycan biosynthesis and its inhibition. Comprehensive 
Natural Products Chemistry 3 P41-294 
 
Bury, D., Dahmane, I., Derouaux, A., Dumbre, S., Herdewijn, P., Matagne, A.,Breukink, E., 
Mueller-Seitz, E., Petz, M., and Terrak, M., (2015). Positive Cooperativity Between Acceptor 
and Donor Sites of the Peptidoglycan Glycosyltransferase. Biochemical Pharmacology 93 (2): 
141–150. 
 
Butaye, P., Devriese, L. A., Haesebrouck, F. (2003) Antimicrobial growth promoters used in 
animal feed: effects of less well known antibiotics on gram-positive bacteria Clin Microbiol Rev 
16 p175 
 
Center for Disease Control and Prevention. Emerging Infections Program Network Active 
Bacterial Core Surveillance Report: Methicillin-Resistant Staphylococcus aureus. (2014):1-3 
 
Chang, H.-Y., Chou, C.-C., Hsu, M.-F. and Wang, A. H. J. (2014) Proposed Carrier Lipid-
binding Site of Undecaprenyl Pyrophosphate Phosphatase from Escherichia coli. Journal of 
Biological Chemistry 289 p18719-18735 
 
Charpentier, X., Chalut, C., Remy, M.-H., Masson, J.-M. (2002) Penicillin-Binding Proteins 1a 
and 1b Form Independent Dimers in Escherichia coli J. Bacteriol. 184 (13) 3749-3752 
 
Chen, W., Zhang, Y.-M. Davies, C (2017) Penicillin-Binding Protein 3 is essential for Growth 
of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 61(1) e01651-16 
 
Chen, R. F., Smith, P. D., Maly, M. (1978) The fluorescence of fluorescamine-amino acids 
Archives of Biochemistry and Biophysics 189(2) p241-250 
 
Cheng, T-J. R., Sung, M-T., Liao, H-Y., Chang, Y-F., Chen, C-W., Huang, C-Y., Chou, L-Y., 
Wu, Y. D., Chen, Y. H., Cheng, Y. S., Wong, C. H., Ma, C., Cheng, W.C., (2008). Domain 
Requirements of Moenomycin Binding to Bifunctional Transglycosylases and Development of 
High-Throughput Discovery of Antibiotics. Proc Natl Acad Sci USA 105 (2): 431–436. 
 
Cho, H., Wivagg, C. N., Kapoor, M., Barry, Z., Rohs, P. D., Suh, H., Marto, J. A., Garner, E. 
C., Bernhardt, T. G. (2016) Bacterial cell wall biogenesis is mediated by SEDS and PBPs 
polymerase families functioning semi-autonomously Nat Microbiol 1:16172  
 
Corry, B., Jayatilaka, D. and Rigby, P. (2005) A Flexible Approach to the Calculation of 
Resonance Energy Transfer Efficiency between Multiple Donors and Acceptors in Complex 
Geometries, J. Biophys. 89(6) p3822-3836 
 
! 238 
Cox, G., Sieron, A., King, A. M., De Pascale, G., Pawlowski, A. C., Koteva, K., Wright, G. D. 
(2017) A Common Platform for Antibiotic Dereplication and Adjuvant Discovery Cell Chem 
Biol 24(1) 98-109 
 
Culp, E. & Wright G (2016) Bacterial proteases, untapped antimicrobial drug targets  The 
Journal of Antibiotics 1-12 
 
Daub, E., Zawadzke, L. E., Botstein, D., and Walsh, C. T. (1988) Isolation, cloning, and 
sequencing of the Salmonella typhimurium ddlA gene with purification and characterization of 
its product, D-alanine: o-aianine ligase (ADP forming). Biochemistry 27.3701-3708.  
 
Davies, T. A., Shang, W., Bush, K. & Flamm, R. K. (2008). Affinity of doripenem and 
comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. 
Antimicrob. Agents Chemother.52, 1510–1512. 
 
De Bernardo, S., Weigele, M., Toome, V., Manhart, K., Leimgruber, W., Bohlen, P., Stein, S., 
Undenfriend, S. (1974) Studies on the reaction of fluorescamine with primary amines Archives 
of Biochemistry and Biophysics 163 (1) p390-399 
 
Delcour, A. H. (2009) Outer membrane Permeability and Antibiotic Resistance Biochem 
Biophys Acta 1794(5) 808-816 
 
Derouaux, A. Sauvage, E. Terrak, M. (2013) Peptidoglycan glycosyltransferase substrate 
mimics as templates for the design of new antibacterial drugs. Front Immunol. 4 p78 
 
Derouaux, A. & Terrak, M. (2008) The monofunctional glycosyltransferase of E. coli localises 
to the cell Division site and interacts with PBP3, and FtsN, J. Bacteriol 190(5) 1831-4 
 
Dumbre, S. Derouaux, A. Lescrinier, E., Piette, A., Joris, B., Terrak, M. and Herdewijn, P. 
(2012) Synthesis of modified peptidoglycan precursor analogues for the inhibition of 
glycosyltransferase. J. Am. Chem. Soc. 134 9343–9351 
 
Egan A.J.F., Jean, NL, Koumoutsi, A., Bougault, C. M., Biboy, J., Sassine, J., Solovyovar, A. S. 
Breukink, E., Typas, A., Vollmer W. (2014) Outer-membrane lipoprotein spans the periplasm to 
stimulate the peptidoglycan synthase PBP1B PNAS 111(22) pp8197-8202 
 
Egan, A. J.; Vollmer, W. (2013) The physiology of bacterial cell division. Annals of the New 
York Academy of Sciences, 1277, 8. 
 
El-Abadla, N., Lampilas, M., Hennig, L., Findeisen, M., Welzel, P., Müller, D., Markus, A., van 
Heijenoort, J. (1999) Moenomycin A: The Role of the Methyl Group in the Moenuronamide 
Unit and a General Discussion of Structure-Activity Relationships Tetrahedron 55 p699 
 
El Ghachi, M., Bouhss, A., Blanot D., Mengin-Lecreulx D. (2004) The bacA gene of 
Escherichia coli encodes an undecaprenyl pyrophosphate phosphatase activity. J Biol Chem 279 
(29) p30106 
 
El Ghachi, M., Derbise, A., Bouhss, A., and Mengin-Lecreulx, D. (2005) Identification of 
multiple genes encoding membrane proteins with undecaprenyl pyrophosphate phosphatase 
(UppP) activity in Escherichia coli. J. Biol. Chem. 280, 18689–18695 
 
Fagerberg L, Jonasson K, von Heijne G, Uhlen M, Berglund L (2010) Prediction of the human 
membrane proteome. Proteomics 10: 1141-1149 
 
! 239 
Farha, M.A. & E.D. Brown. 2013. Discovery of antibiotic adjuvants. Nat. Biotechnol. 31: 120–
122. 
 
Fan, J., Jiang, D., Zhao, Y., Liu, J., Zhang, X. C. (2014) Crystal Structure of lipid phosphatase 
Escherichia coli phosphatidylglycerophosphate phosphatase B PNAS 111 p7636-40 
 
Fournier, B., Zhao, X., Lu, T., Drlica, K. and Hooper, D. C. (2000) Selective Targeting of 
Topoisomerase IV and DNA gyrase in Staphylococcus aureus: Different Patterns of Quinolone-
Induced Inhibition of DNA Synthesis Antimicrob Agents Chemother 44(8) pp2160-65 
 
Fragneto, G., Lu, J. R., McDermott, D. C. and Thomas, R. K. (1996) Structure of Monolayers of 
Tetraethylene Glycol Monododecyl Ether Adsorbed on Self-Assembled Monolayers on Silicon:! 
A Neutron Reflectivity Study Langmuir, 12(2) pp477–486     
 
Fraipont, C., Alexeeva, S., Wolf, B., van der Ploeg, R., Schloesser, M., den Blaauwen, T. and 
Nguyen-Disteche, M. (2011) The integral membrane FtsW protein and peptidoglycan synthase 
PBP3 from a subcomplex in E. coli. Microbiology 157 (Pt 1) pp251-259. 
 
Funk, C. R., Zimniak, L. and Dowhan, W. (1992) The pgpA and pgpB genes of Escherichia coli 
are not essential: evidence for a third phosphatidylglycerophosphate phosphatase. J. Bacteriol 
174 p205-213 
 
Fuse, S., Tsukamoto, H., Yuan, Y., Wang, T.-S. A., Zhang, Y., Bolla, M., Walker, S., Sliz, P. 
and Kahne, D. (2010) Functional and Structural Analysis of a Key region of the cell wall 
inhibitor Moenomycin ACS Chem Biol 5(7) pp701-711 
 
Gampe, C. M., Tsukamoto, H., Wang, T. S., Walker, S., Kahne, D. (2011) Modular synthesis of 
diphospholipid oligosaccharide fragments of the bacterial cell wall and their use to study the 
mechanism of moenomycin and other antibiotics Tetrahedron 67(51) pp 9771-9778 
 
Gampe, C. M., Tsukamoto, H., Doud, E. H., Walker, S., and Kahne, D., (2013). 
Tuning the Moenomycin Pharmacophore to Enable Discovery of Bacterial Cell Wall 
Synthesis Inhibitors. Journal of the American Chemical Society 135 (10): 3776–3779. 
 
Garneau, s. L. Qiao, L. Chen, S. Walker, J.C. Vederas, (2004) Synthesis of mono- and 
disaccharide analogs of moenomycin and lipid II for inhibition of transglycosylase activity of 
penicillin-binding protein 1b. Bioorg. Med. Chem. 12 6473–6494 
 
Ghuysen, J.-M. (1991) Serine β-Lactamases and penicillin-binding proteins Annu. Rev. 
Microbiol. 45: 37-67 
 
Godfrey, A. J., Bryan, L. E. & Rabin, H. R. (1981). Beta-lactam-resistant Pseudomonas 
aeruginosa with modified penicillin-binding proteins emerging during cystic fibrosis treatment. 
Antimicrob. Agents Chemother. 19, 705–711. 
 
Goffin, C. & Ghuysen, J. M. (1998) Multimodular penicillin-binding proteins: an enigmatic 
family of orthologs and paralogs Microbiol Mol Biol Rev 62(4) 1079-93 
 
Goffin, C. & Ghuysen, J. M. (2002) Biochemistry and comparative genomics of SxxK 
superfamily acyltransferases offer a clue to the mycobacterial paradox: presence of penicillin-
susceptible target proteins versus lack of efficiency of penicillin as therapeutic agent. Microbiol 
Mol Biol Rev 66(4) 702-738 
 
Goldman, R. C. & Grange D (2000) Inhibition of transglycosylation involved in bacterial 
peptidoglycan synthesis Curr Med Chem 7(8) 801-820 
! 240 
 
Gotoh, N., Nunomura, K. & Nishino, T. (1990). Resistance of Pseudomonas aeruginosa to 
cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. 
J. Antimicrob. Chemother. 25, 513–523. 
 
Grandchamps, J., Nguyen-Disteche, M., Damblon, C., Frere, J. M., Ghuysen J.M. (1995) 
Streptomyces K15 active-site serine DD-transpeptidase: specificity profile for peptide, thiol 
ester and ester carbonyl donors and pathways of the transfer reactions Biochem J 307 Pt 2 p335-
9. 
 
Gray, A. N., Egan, A. J. F., van’t Veer, I. L., Verheul, J., Colavin, A., Koumoutsi, A., Biboy, J., 
Altelaar, M. A. F., Damen, M. J., Huang, K. C., Simorre, J.-P., Breukink, E., den Blaauwen, T., 
Typas, A. Gross, C. A., Vollmer, W. (2015) Coordination of peptidoglycan synthesis and outer 
membrane constriction during Escherichia coli cell division ELife 7(4) e07118 
 
Halliday, J., McKeveney, D, M., Muldoon, C., Rajaratnam, P. and Meutermans, E. (2006) 
Targeting the forgotten transglycosylases Biochem Pharmacol 17(7) p957-67 
 
Han, S.; Caspers, N.; Zaniewski, R. P.; Lacey, B. M.; Tomaras, A. P.; Feng, X.; Geoghegan, K. 
F.; Shanmugasundaram, V. (2011) Distinctive attributes of β-lactam target proteins in 
Acinetobacter baumannii relevant to development of new antibiotics. J. Am. Chem. Soc. 133, 
pp20536−20545. 
 
Hancock, R. E. W. & Speert, D. P. (2000) Antibiotic Resistance in Pseudomonas aeruginosa: 
mechanisms and impact on treatment. Drug Resist Update 3(4) p247-255 
 
Healy, V. L., Lessard, I. A. D., Roper, D. I., Knox, J., and Walsh, C., (2000).Vancomycin 
Resistance in Enterococci: Reprogramming of the D-Ala-D-Ala Ligases in Bacterial 
Peptidoglycan Biosynthesis. Chemistry & Biology 7 (5): 109–119. 
 
Hecker, S. J, Minich, M. L., Lackey, K. (1990) Synth Synthesis of compounds designed to 
inhibit bacterial cell wall transglycosylation. J. Org Chem. 55(16) p4902-4911 
 
van Heijenoort, Y., Derrien, M. and Van Heijenoort, J. (1978) Polymerisation by 
transglycosylation in the biosynthesis of the peptidoglycan of Escherichia coli K12 and its 
inhibition by antibiotics. FEBS Letters 89 pp141–144. 
 
Helassa, N., Vollmer, W., Breukink, E., Vernet, T. and Zapun, A. (2012) The membrane anchor 
of penicillin-binding protein PBP2a from Streptococcus pneumoniae influences peptidoglycan 
chain length The FEBS Journal 279 p2071 
 
Huang, C. Y., Shih, H. W., Lin, L. Y., Tien, Y. W., Cheng, W. C., Wong, C. H. and Ma, C. 
(2012) Crystal structure of Staphylococcus aureus transglycosylase in complex with a lipid II 
analogue and elucidation of peptidoglycan synthesis mechanism. PNAS 109 p6496 
 
Jameson, D. M. and Reinhart, G. D. (2012) Fluorescent biomolecukes: Methodologies and 
Applications Springer Science & Business Media  p75-77 
 
Jean, NL, Bougault, CM, Lodge, A, Derouaux, A, Callens, G., Egan, AJ, Ayala, I, Lewis RJ, 
Vollmer W, Simorre, JP (2014) Elongated Structure of the outer-membrane activator 
peptidoglycan synthesis LpoA: Implications for PBP1A Structure. Structure 22(7) 1047-54 
 
Jha, R. K. and de Sousa, S. M. (2006) Microplate assay for inhibitors of the transpeptidase 
activity of PBP1B of Escherichia coli. J. Biomol Screen 11 (8) p1005-14. 
 
! 241 
Johnson, J. W., Fisher, J. F., Mobashery, S (2013) Bacterial Cell Wall Recycling Annual New 
York Academy Sciences 1277 p54-75 
 
Jones DT. (1999) Protein secondary structure prediction based on position-specific scoring 
matrices. J. Mol. Biol. 292: 195-202. 
 
Kempin, U., Hennig, L., Welzel, P., Marzian, S., Müller, D., Fehlhaber, H.-W., Markus, A., van 
Heijenoort, Y. and van Heijenoort, J. (1995) Introduction of a terminal hydroxyl group into the 
lipid part of a moenomycin-type transglycosylase inhibitor suppresses antibiotic activity 
Tetrahedron 51 p8471 
 
Kim, J., Kin., H., Park, S. B., (2014) Privileged structures: efficient chemical ‘navigators’ 
toward unexplored biologically relevant chemical spaces J Am Chem Soc 136 14629-14638 
 
King, D. T., Wasney, G. A., Nosella, M., Fong, A. Strynadka, N. (2016) Escherichia coli 
Penicillin-Binding Protein 1B: Structural Insights into Inhibition, JBC In Press. 
 
Kohira N, West J, Ito A, et al. (2016) In vitro antimicrobial activity of a siderophore 
cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-
resistant strains. Antimicrob Agents Chemother. 60 (2) pp729–734 
 
Krachler, A. M., Sharma, A., Cauldwell, A., Papadakos, G. and Kleanthous, C. (2010) TolA 
Modulates the Oligomeric Status of YbgF in the Bacterial Periplasm J Mol Biol 403 p270-285 
 
Kumar, A. & Schweizer, H. P (2005) Bacterial Resistance to Antibiotics: Active Efflux and 
reduced uptake. Adv Drug Deliv Rev 57(10) pp1486-513 
 
Kumar, V. P, Basavannacharya, C. and de Sousa, S. M. (2014) A microplate assay for the 
coupled transglycosylase-transpeptidase activity of the penicillin binding proteins; a 
vancomycin-neutralizing tripeptide combination prevents penicillin inhibition of peptidoglycan 
synthesis. Biochem Biophys Res Commun 450(1) pp347-352 
 
Kuru, E., Hughes, H. V., Brown, P. J., Hall, E., Tekkam, S., Cava, F., de Pedro, M.A., Brun, Y. 
V., and VanNieuwenhze, M. S., (2012). In Situ Probing of Newly Synthesized Peptidoglycan in 
Live Bacteria with Fluorescent D-Amino Acids. Angew. Chem. Int. Ed. 51 (50): 12519–12523. 
 
Lairson, L. L. Henrissat, B., Davies, G. J. and Withers S. G. (2008) Glycosyltransferases: 
Structures, Functions and Mechanisms Annu Rev Biochem 77 pp521-55 
 
Lam, S. J., O’Brien-Simpson, N. M., Pantarat, N., Sulisto, A., Wong, E. H., Chen, Y. Y., Lenzo, 
J. C., Holden, J. A., Blencowe, A., Reynolds., E.C., Qiao, G. G. (2016) Combating multidrug-
resistant Gram-negative bacteria with structurally nano-engineered antimicrobial peptide 
polymers Nat Microbiol. 1 (11) p16162  
 
Lamers, R. & Burrows, L. (2016) Peptidoglycan aeruginosa: Targeting Cell Wall Metabolism 
for New Antibacterial Discovery and Development Future Med Chem 8 p975-92 
 
Leclercq, S., Derouaux, A., Olatunji, S., Fraipont, C., Egan, A. J., Vollmer, W., Breukink, E. 
and Terrak, M (2017) Interplay between Penicillin-binding proteins and SEDS proteins 
promotes bacterial cell wall synthesis. Sci Rep 7:43306 
 
Lewis, K. (2013) Platforms for Antibiotic Discovery Nature Reviews Drug Discovery 12, 371–
387 
 
! 242 
Liao X, Hancock RE. (1997) Susceptibility to beta-lactam antibiotics of Pseudomonas 
aeruginosa overproducing penicillin-binding protein 3. Antimicrob Agents Chemother 41 
pp1158-61 
 
Lim, D. & Strynadka, N. C. (2002) Structural basis for the beta-lactam resistance of PBP2a 
from methicillin-resistant Staphylococcus aureus. Nat Struct Biol 9(11) pp870-876 
 
Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., 
Mueller, A., et al., (2015) A New Antibiotic Kills Pathogens Without Detectable 
Resistance. Nature 517 pp455-474 
 
Lebar, M. D., Lupoli, T. J., Tsukamoto, H., May, J. M., Walker, S., and Kahne, D., 
(2013). Forming Cross-Linked Peptidoglycan From Synthetic Gram-Negative Lipid II. Journal 
of the American Chemical Society 135 (12): 4632–4635. 
 
Liu, C.Y., Guo, C. W. et al., (2010) Synthesis and evaluation of a new fluorescent 
transglycosylase substrate: lipid II-based molecule possessing a dansyl-C20 polyprenyl moiety. 
Org Lett 12(7) pp1608-11 
 
Liu, H., and Wong, C-H., (2006). Characterization of a Transglycosylase Domain of 
Streptococcus pneumoniae PBP1b. Bioorganic & Medicinal Chemistry 14 (21): 7187– 7195. 
 
Lohner, K. (2017) Membrane-Active Antimicrobial Peptides as Template Structures for Novel 
Antibiotic Agents Curr Top Med Chem 17(5) 508-519 
 
Lovering, A. J., de Castro, L. H., Lim, D. and Strynadka, N. C. (2007) Structural Insights into 
the transglycosylation step of bacterial cell wall biosynthesis Science 315(5817) 1402-5 
 
Lovering and Strynadka (2008) Structural details of the glycosyltransferase step of 
peptidoglycan assembly Curr Opin Struct Biol 18 p534 
 
Lovering, A. L., Safadi, S. S., Strynadka, N. C. J. (2012) Structural Perspective of 
Peptidoglycan Biosynthesis and Assembly Annual Review of Biochemistry 81 p451 
 
Lupoli, T. J., Hirokazu Tsukamoto, Emma H. Doud, Tsung-Shing Andrew Wang, Suzanne 
Walker, and Daniel Kahne (2011) Transpeptidase-Mediated Incorporation of D-Amino Acids 
into Bacterial Peptidoglycan JACS 133 p1074 
 
Lupoli, T. J.,  Lebar, M. D.,  Markovski, M., Berhardt, T., Kahne, D., Walker, S. (2014) 
Lipoprotein Activators Stimulate Escherichia coli Penicillin-Binding Proteins by Different 
Mechanisms JACS 136 52-55 
 
Manat G, Roure S, Auger R, Bouhss A, Barreteau H, Mengin-Lecreulx D, Touzé T. (2014) 
Deciphering the Metabolism of Undecaprenyl-Phosphate: The Bacterial Cell-wall unit carrier at 
the membrane Frontier Microb Drug Resist. 20(3) pp199-214 
 
Mark BL, Vocadlo DJ, Oliver A. (2011) Providing β-lactams a helping hand: Targeting the 
AmpC β-lactamase induction pathway. Future Microbiol. 6 p1415-1427 
 
Marr, A. K. Gooderham, W. J. and Hancock, R. E.  (2006) Antibacterial peptides for therapeutic 
use: obstacles and realistic outlook. Curr. Opin. Pharmacol 6, 468–472. 
 
Massova, I & Mobashery, S. (1998) Kinship and diversification of bacterial penicillin-binding 
proteins and beta-lactamases Antimicrob Agents Chemother 42(1) 1-17. 
 
! 243 
McGowen, J. E. (2006) Resistance in non-fermenting Gram-negative bacteria: Multidrug 
resistance to the maximum American Journal of Infection Control 34 pS29-S37 
 
Meeske, A. J., Riley, E. P., Robins, W. P., Uehara, T., Mekalanos, J. J., Kahne, D., Walker, S., 
Kruse, A. C., Bernhadt, T. G., Rudner, D. Z. (2016) SEDS Portiens are a widespread family of 
bacterial cell wall polymerises. Nature 537(7622) p634-638 
 
Meisel, U.; Holtje, J. V.; Vollmer, W. (2003) Overproduction of inactive variants of the murein 
synthase PBP1B causes lysis in Escherichia coli. J Bacteriol, 185, 5342. 
 
Mesleh, M. F., Rajaratnam, P. R., Conrad, M., Chandrasekaran, V,M Liu, C, M., Pandya, B. A., 
Hwang, Y. S., Rye, P. T., Muldoon, C., Becker, B., Zuegg, J., Meutermans, W. and Moy, T. I. 
(2016) Targeting Bacterial Cell Wall Peptidoglycan Synthesis by Inhibition of 
Glycosyltransferase Activity. Chemical Biology & Drug Design 87(2) p190-9. 
 
Miller, S. I. (2016) Antibiotic Resistance and Regulation of the Gram-Negative Bacterial Outer 
membrane Barrier by Host Innate Immune Molecules mBio 7(5) e01541-16 
 
Miller, C., Thomsen, L. F., Gaggero, C., Mosseri, R., Ingmer, H. and Cohen, S. N. (2004) SOS 
response induction by beta-lactams and bacterial defense against antibiotic lethality. Science 
305(5690) 1629-31 
 
Minasov, G., Wawrzak, Z., Shuvalova, L., Kiryukhina, O., Dubrovska, I., Grimshaw, S., Kwon, 
K., Anderson, W. F. (2017) To be published. Centre for structural Genomics of Infectious 
Diseases. H. influenzae Xtal structure Dec 2016. 
 
Miroux B, Walker JE (1996) Over-production of proteins in Escherichia coli: 
mutant hosts that allow. J Mol Biol 260: 289-298 
 
Miyake, M., Asano, A. and Einaga, Y. (2008) Size Change of the Wormlike Micelles of 
Pentaoxyethylene, Hexaoxyethylene, and Heptaoxyethylene Dodecyl Ethers with Uptake of n-
Dodecane J. Phys. Chem. B 112 pp4648 
 
Moellering R. C. J (2012) MRSA: the first half century Antimicrob Chemother 67 p4-11  
 
Mohammadi, T., van Dam, V., Sijbrandi, R., Vernet, T., Zapun, A., Bouhss, A., Diepeveen-de 
Bruin, M., Nguyen-Disteche, M., de Kruijff, B. and Breukink, E. (2011) Identification of FtsW 
as a transporter of lipid-linked cell wall precursors across the membrane J. EMBO 30(8) 
pp1452-1432 
 
Möller, U., Hobert, K., Donnerstrag, A., Wagner, P., Muller, D., Fehlhaber, H.-W., Makus, A., 
and Welzel, P. (1993) MoenomycinA – Structure activity relations synthesis of the D-
galacturonamide analogue of the smallest antibiotically active degradation product of 
Moenomycin A Tetrahedron 49 p1635 
 
Morrison, K.A.,Akram, A., Matthews, A., Khan, Z. A., Patel, J. H., Zhou, C., Hardy, D. J., 
Moore-Kelly, C., Patel, R., Odiba, V., Knowles, T. J., Javed, M. U., Chmel, N. P., Dafforn T. R. 
and Rothnie, A. (2016) Membrane Protein Extraction and purification using styrene-maleic 
(SMA) copolymer: effect  of variations in polymer structure  J Biochem 473 4349-4360 
 
Moya, B., Beceiro, A., Cabot, G., Juan, C., Zamorano, L., Alberti, S., Oliver, A (2012) Pan-β-
lactam resistace development in Pseudomonas aeruginosa clinical strains: molecular 
mechanisms, penicillin-binding protein profiles and binding affinities  Antimicrob Agents 
Chemother 56 p4771 
 
! 244 
Moya, B., Dötsch, A., Juan, C., Blázquez, J., Zamorano, L., Haussler, S. and Oliver, A. (2009) 
β-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding 
Protein PLOS Pathogens 5 e1000353 
 
Mukherjee, S. & Zhang, Y. (2011) Protein-protein complex structure predictions by multimeric 
threding and template recombination Structure 19(7) 955-966 
 
Müller, P., Ewers, C., Bertsche, U., Anstett, M., Kallis, T., Breukink, E., et al. (2007) The 
essential cell division protein FtsN interacts with the murein (peptidoglycan) synthase PBP1B in 
Escherichia coli. J Biol Chem 282: 36394-36402 
 
Münch, D., Engels, I., Müller, A., Reder-Christ, K., Falkenstein-Paul, H., Bierbaum, G., Grein, 
F., Bendas, G., Sahl, H. G., Schneider, T. (2015) Structural Variations of the cell wall precursor 
Lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic 
oritavancin Antimictob Agents Chemother 59(2) p772-81 
 
Mushtaq S, Woodford N, Hope R, et al. (2013) Activity of BAL30072 alone or combined with 
beta-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae 
and non-fermenters. J Antimicrob Chemother. 68(7) pp1601-1608 
 
National action plan for combating antibiotic-resistant bacteria. The White House, Washington 
DC, USA: March 2015:1-63. 
 
Newby ZE (2009) A general protocol for the crystallization of membrane proteins 
for X-ray. 4: 619-637 
 
Nicola, G., Tomberg, J., Pratt, R. F., Nicholas, R. A. and Davies, C. (2010) Crystal Structures of 
Covalent Complexes of B-lactam antibiotics with E. coli penicillin-binding protein 5: toward an 
understanding of antibiotic specificity Biochemistry 49 p8094-8104 
 
O'Callaghan, C. H., Acred, P., Harper, P. B., Ryan, D. M., Kirby, S. M. & Harding, S. M. 
(1980). GR20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. 
Antimicrob. Agents Chemother. 17, 876–883. 
 
Ochs, M. M., McCusker, P., Bains, M. and Hancock, R. E. W (1999) Negative Regulation of 
the Pseudomonas aeruginosa outer Membrane Porin OprD Selective for Imipenem and basic 
Amino Acids Antimicrob Agents Chemother 43(5) 1085-1090 
 
Ostash, B & Walker, S. (2005) Bacterial Transglycosylase Inhibitors Curr Opin Chem Biol 9(5) 
459-46. 
 
Ostash, B. & Walker, S. (2010) Moenomycin family antibiotics: chemical synthesis, 
biosynthesis, and biological activity Nat Prod Rep 27 p1594 
 
Ostash, B., Campbell, J., Luzhetsky A., Walker, S. (2013) MoeH5: a natural glycorandomizer 
from the moenomycin biosynthetic pathway. Mol Microbiol 90 p1324 
 
Paradis-Bleau, C. Markovski, M., Uehara, T,M Lupoli, T., Walker, S., Kahne, D. E. and 
Bernhardt T. G. (2010) Lipoprotein cofactors located in the outer membrane activate bacterial 
cell wall polymerases Cell 143(7) p1110-1120 
 
Perlstein, D. L. Wang, T.-S. A., Doud, E. H., Kahne, D. E. (2010) The Role of the Substrate 
Lipid in Processive Glycan Polymerization by the Peptidoglycan Glycosyltransferases JACS 
132 p48 
 
! 245 
Philippon A., Redjeb, S., Fournier, G. and Ben Hassen, A. (1989) Epidemiology of extended 
spectrum beta-lactamases. Infection 17(5) 347-54. 
 
Pillai, B., Cherney, M.M., Diaper, C. M., Sutherland, A., Blanchard, J. S., Vederas, J. C. and 
James, M. N. G. (2006) Structural insights into stereochemical inversion by diaminopimelate 
epimerase: An antibacterial drug target PNAS 103 (23) pp8668-8673 
 
Pinho, M. G., Kjos, M. Veening, J. W. (2013) How to get around: Mechanisms controlling 
growth and division of coccoid bacteria Nature Reviews Microbiology 11 p601-614 
 
Pollock J.J., Ghuysen J.M., Linder R., Salton M.R., Perkins H.R., Nieto M., Leyh-Bouille M., 
Frere J.M., Johnson K. (1972) Transpeptidase activity of Streptomyces d-alanyl-d 
carboxypeptidases. Proc. Natl. Acad. Sci. USA. 69 p662–666 
 
Popham, D. L. & Young, K. D. (2003) Role of penicillin-binding proteins in bacterial cell 
morphogenesis Curr Opin Microbiol 6(6) 594-599 
 
Pratt G. J. (1952) Acta Cryst. 5 770-779 Prescott, Harley & Klein’s Microbiology 7th Ed, 2008, 
authored by Willey, J., Sherwood, L. and Woolverton, C. 
 
Qiao, L. & Vederas, J. C. (1993) Synthesis of a C-phosphonate disaccharide as a potential 
inhibitor of peptidoglycan polymerization by transglycosylase J. Org. Chem., 58(13) pp 3480–
3482 
 
Rossolini GM, Arena F, Pecile P, Pollini S. (2014) Update on the antibiotic resistance crisis. 
Clin Opin Pharmacol. 18:56–60 
 
Roy, R., Hohng, S., and Ha, T. (2008). A practical guide to single-molecule FRET. Nature 
methods 5, 507-516. 
 
Santajit, S. & Indrawattana, N. (2016) Mechanisms of Antimicrobial Resistance in ESKAPE 
Pathogens Biomed Res Int. 2475067  
 
Sarkar, S. K., Dutta, M., Kumar, A., Mallik, D., and Ghosh, A. S. (2012) Sub-inhibitory 
cefsulodin sensitization of E. coli to β-lactams is mediated by PBP1B inhibition. PLoS One 7, 
e48598 
 
Sauvage, E. & Terrak. M. (2016) Glycosyltransferases and Transpeptidases/Penicillin-Binding 
Proteins: Valuable Targets for New Antibacterials Antibiotics 5(1) pii E12. 
 
Schagger, H. & von Jagow, G. (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Analytical 
Biochemistry 166 p368 
 
Schouten, J. A., Bagga, S., Lloyd, A. J., de Pascale, G., Dowson, G. D., Roper, D. I. and Bugg, 
T. D. H. (2006) Fluorescent reagents for in vitro studies of lipid-linked steps of bacterial 
peptidoglycan biosynthesis: derivatives of UDPMurNAc-pentapeptide containing D-cysteine at 
position 4 or 5  Mol. Biosyst., 2 484-491 
 
Schwartz, B., Markawalder, J. A. and Yi, W. (2001) Lipid II: Total Synthesis of the Bacterial 
Cell Wall Precursor and Utilization as a Substrate for Glycosyltransfer and Transpeptidation by 
Penicillin Binding Protein (PBP) 1b of Eschericia coli. JACS 123 11638-43 
 
Schwartz, B. J., Markwalder, A., Seitz, S. P., Wang, Y., and Stein, R. L., (2002). A 
Kinetic Characterization of the Glycosyltransferase Activity of Eschericia coli PBP1b 
! 246 
and Development of a Continuous Fluorescence Assay. Biochemistry 41: 12552–12561. 
 
Segel, I. H., (1993). Enzyme Kinetics. 2nd edn. Edited by Segel, I. John Wiley & Sons. 
 
Sham, L. T., Butler, E. K., Lebar, M. D., Kahen, D., Bernhardt, T. G., Ruiz, N (2014) Bacterial 
cell wall. MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis. Science 
345(6193) 220-222 
 
Shaw, K. J., Rather, P. N., Hare, R. S. and Miller, G. H. (1993) Molecular genetics of 
aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying 
enzymes Microbiol Rev 57(1) p138-63 
 
Shih, H. W., Chen, K. T., Cheng, T. J., Wong, C. H., Cheng, W. C. (2011) A new synthetic 
approach toward bacterial transglycosylase substrates, Lipid II and Lipid IV. Org Lett 13 p4600 
 
Shih, W. H. Chang, Y.F. Li, W.J. Meng, F.C. Huang, C.Y. Ma, C. Cheng, T.J.  
Wong, C.H. Cheng, W.C. (2012) Effect of the peptide moiety of Lipid II on bacterial 
transglycosylase. Angew. Chem. Int. Ed. Engl. 51 pp10123–10126. 
 
Shirai, S., Yoshimura, S. and Einaga, Y. (2006) Intrinsic Viscosity of Polyoxyethylene Alkyl 
Ether CiEj Micelles. Polymer Journal 38(1) pp37-43 
 
Siewert, G., and Strominger, J. L. (1967) Bacitracin: An inhibitor of the dephosphorylation of 
lipid pyrophosphate, an intermediate in the biosynthesis of the peptidoglycan cell walls PNAS 
57 767-773 
 
Silhavy, T. J., Kahne, D. K., Walker, S. (2010) The Bacterial Cell Envelope Cold Spring Harb 
Perspect Biol 2(5) 1000414 
 
Sofia, M. J. et al., (1999) Discovery of novel disaccharide antibacterial agents using a 
combinatorial library approach. J. Med Chem 42(17) 3193-3198 
 
Spratt, R. F. (2008) Substrate Specificity of bacterial DD-Peptidases (penicillin-binding 
proteins) Cell. Mol. Life Sci. 65: 2138-2155 
 
Stein, S., Bohlen, P. and Udenfriend, S. (1974) Studies on the Kinetics of Reaction and 
Hydrolysis of Fluorescamine Arch Biochem Biophys 163(1) pp400-403 
 
Starr, J., Brown, M. F., Aschenbrenner, L., Caspers, N. et al., (2014) Siderophore Receptor-
Mediated Uptake of Lactivicin Analogues in Gram-Negative Bacteria J Med Chem 57 3845-
3855 
 
Stockhert, J. C., Blazquez, A., L., Galaz, S., Juarranz, A. (2008) A mechanism for the 
fluorogenic reaction of amino groups with fluorescamine and MDPF. Acta Histochem, 110(4) 
333-340 
 
Sung, M.-T., Lai, Y.-T., Huang, C.-Y., Chou, L.-Y., Shih, H.-W., Cheng, W.-C., Wong, C.-H. 
and Ma, C. (2009) Crystal structure of the membrane-bound bifunctional transglycosylase 
PBP1B from Escherichia coli. PNAS 106(22) pp 8824-8829. 
 
Sutcliffe JA, O’Brien W, Fyfe C, et al. (2013) Antibacterial activity of eravacycline (TP-434), a 
novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 
57(11) pp5548–5558 
 
! 247 
Taylor, J. G., Li, X., Oberthür, M., Zhu, W. and Kahne, D. E. (2006) The Total synthesis of 
Moenomycin A, JACS 128(47) 15084-5. 
 
Terrak M, Ghosh TK, van Heijenoort J, Van Beeumen J, Lampilas M, et al. 1999. The catalytic, 
glycosyl transferase and acyl transferase modules of the cell wall peptidoglycan-polymerizing 
penicillin-binding protein 1b of Escherichia coli. Mol. Microbiol. 34:350–64 
 
Terrak, M. (2008) Peptidoglycan Glycosyltransferase Inhibition: New Perspectives for An Old 
Target Anti-Infective Agents Med. Chem. 7 p180–192. 
 
Testa R, Cantón R, Giani T, et al. (2015) In vitro activity of ceftazidime, ceftaroline and 
aztreonam alone and in combination with avibactam against European gram-negative and gram-
positive clinical isolates. Int J Antimicrob Agents 45(6) pp641–646.  
 
Tipper, D. J. & Strominger, J. L. (1965) Mechanism of action of penicillins: a proposal based on 
their structural similarity to acyl-D-alanyl-D-Alanine PNAS: Microbiology 54: 1133-1141 
 
Tong, S., Lin, Y., Lu, S., Wang, M., Bogdanov, M. and Zheng, L. (2016) Structural Insight into 
Substrate Selection and Catalysis of Lipid Phosphate Phosphatase PgpB in the Cell Membrane 
The Journal of Biological Chemistry 291, 18342-18352. 
 
Touze, T. and Mengin-Lecreulx D. (2008) Undecaprenyl Phosphate Synthesis EcoSal Plus. 3(1) 
 
Typas, A., Banzhaf, M.,van den Berg vab Saparoea, B., Verheul, J., Biboy, J., Nichols, R. J., 
Zietek, M., Beilharz, K., Kannenberg, K., von Rechenberge, M., Breukink, E., den Blaaauwen, 
T., Gross, C. A. and Vollmer W. (2010) Regulation of peptidoglycan synthesis by outer 
membrane proteins Cell 143(7) 1097-1109 
 
Udenfriend, S., Stein, S., Bohlen, P., Dairman, W., Leimgruber, W., Weigele, M. (1972) 
Fluorescamine: A reagent for assay of amino acids, peptides, proteins and primary amines in the 
picomole range Science, 178 (4063) p871-2 
 
van Dam, V., Sijbrandi, R., Kol, M., Swiezewska, E., de Kruijff, B., and Breukink, E., (2007). 
Transmembrane Transport of Peptidoglycan Precursors Across Model and Bacterial 
Membranes. Molecular Microbiology 64 (4): 1105–1114. 
 
Van den Berg, B., Bhamidimarri, S. P., Prajapati, J. D., Kleinekathofer, U., Winterhalter, M. 
(2015) Outer-membrane translocation of bulky small molecules by passive diffusion PNAS 
112(23) pE2991-E2999 
 
van der Ploeg, R., Verheul, J., Vischer, N. O., Alexeeva, S., Hoogendoorn, E., Postma, M., 
Banzhaf, M., Vollmer, W. & den Blaauwen, T. 2013. Colocalization and interaction between 
elongasome and divisome during a preparative cell division phase in Escherichia coli. Mol 
Microbiol 87:1074-87 
 
VanNieuwenhze, M. S., Mauldin, S. C., Zia-Ebrahimi, M., Winger, B. E., Hornback, W. J., 
Saha, S. L., Aikins, J. A., and Blaszczak, L. C., (2002). The First Total Synthesis of Lipid II: the 
Final Monomeric Intermediate in Bacterial Cell Wall Biosynthesis. Journal of the American 
Chemical Society 124 (14): 3656–3660. 
 
Vega, D. & Ayala, J. A. (2006) The DD-Carboxypeptidase activity encoded by PBP4 is not 
essential for the cell growth of Escherichia coli. Arch Microbiol 185(1) 23-7 
 
Vinatier, V., Blakey, C. B., Braddick, D., Johnson, B. R. G., Evans, S. D., and Bugg, 
T. D. H., (2009). In Vitro Biosynthesis of Bacterial Peptidoglycan Using D-Cys- 
! 248 
Containing Precursors: Fluorescent Detection of Transglycosylation and 
Transpeptidation. Chemical Communications, 27: 4037–4039. 
Vivian, J. T. & Callis, P. R. (2001) Mechanisms of Tryptophan Fluorescence Shifts in Proteins 
Biophysical Journal, 80(5) p2093-2109 
 
Vollmer, V., Blanot, D. and de Pedro, M. A. (2008) Peptidoglycan structure and architecture 
FEMS Microbiol Rev 32:149-167 
 
Vollmer, W.; von Rechenberg, M.; Holtje, J. V. (1999) Demonstration of Molecular 
Interactions between the Murein Polymerase PBP1B, the Lytic Transglycosylase MltA, and the 
Scaffolding Protein MipA of Escherichia coli. J Biol Chem, 274, 6726. 
 
Waggoner AS, Stryer L. (1970) Fluorescent probes of biological membranes. Proc. Natl. Acad. 
Sci. U S A. 67:579–589 
 
Walker, S., Heck, A. J. R., and de Kruijff, B., (2003). Lipid II Is an Intrinsic Component of the 
Pore Induced by Nisin in Bacterial Membranes. The Journal of Biological Chemistry 278 (22): 
19898–18903. 
 
Walkty A, Adam H, Baxter M, et al. (2014) In vitro activity of plazomicin against 5,015 Gram-
negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part 
of the CANWARD study, 2011–2012. Antimicrob Agents Chemother. 58(5) pp2554-2563 
 
Walsh, C. T. (1996) Bacterial Resistance to Vancomycin: five genes and one missing hydrogen 
bond tell the story. Chemistry and Biology 3(1) pp21-28 
 
Walsh, C. T. (2000) Molecular Mechanisms that confer antibacterial drug resistance Nature, 
406, 775-781 
 
Walsh, C. (2003) Antibiotics: Actions, Origins, Resistance. Washington, DC: ASM Press. 
pp345 
 
Walsh, C. T. (2004) Polyhetide and non-ribosomal peptide antibiotics: Modularity and 
Versatility. Science 202(5665) p1805-10 
 
Welzel, P. (2005) Syntheses around the Transglycosylation Step in Peptidoglycan Biosynthesis 
Chem Rev 105 p4610 
 
Welzel, P., Kunisch, F., Kruggel, F., Stein, H., Scherkenbeck, J., Hiltmann, A., Duddeck, H., 
Müller, D., Scherkenbeck, J. E. Fehlhaber, H.-W., Seibert, G., van Heijenoort, Y., van 
Heijenoort, J. (1987) Moenomycin A – Minimal Structural Requirements for Biological 
Activity Tetrahedron 43 p585-598 
 
Willard, D. M., Carillo, L. L., Jung, J. and Orden, V. (2001) Quantum Dots as Resonance 
Energy Transfer Donors in a Model Protein-Protein Binding Assay  
Nano Letters 1 p469 
 
Worthington, R.J. & C. Melander. (2013) Combination approaches to combat multidrug-
resistant bacteria. Trends Biotechnol. 31: 177–184 
 
Yang, G., Hennig, L., Findeisen, M., Oehme, R. Giesa S. and Welzel, P. (2004) Studies on the 
Synthesis of Trisaccharide Analogues of the Antibiotic Moenomycin A Helvetica Chimica Acta 
87 p1794 
 
! 249 
Yang, J.-C., van den Ent, F., Neuhaus, D., Brevier, J., Löwe, J. (2004) Solution structure and 
domain architecture of the divisome protein FtsN. Molecular Microbiology 52(3), pp651-660 
 
Yang, J. & Zhang Y. (2015) Protein Structure and Function Prediction using I-TASSER 
Current Protoc Bioinformatics 52 5.8.1-5.815 
 
Yau, W.-M., Wimley, W. C., Gawrisch, K. and White, S. H. (1998) The Preference of 
Tryptophan for Membrane Interfaces Biochemistry 37(42) pp14713-14718 
 
Ye, X.-Y., Lo, M.-C., Brunner, L., Walker, D., Kahne, D., Walker, S. (2001) Better Substrates 
for Bacterial Transglycosylases JACS 123 p3155 
 
Yim, G., Thaker, M. N., Koteva, K. and Wright, G. (2014) Glycopeptide antibiotic Biosynthesis 
The journal of Antibiotics 67 pp31-41 
 
Yuan, Y., Barrett, D., Zhang, Y., Kahne, D., Sliz, P. and Walker, S. (2007) Crystal structure of 
a peptidoglycan glycosyltransferase suggests a model for processive glycan chain synthesis. 
PNAS 104 p5348 
 
Yuan, Y., Fuse, S., Ostash, B., Sliz, P., Kahne, D. & Walker, S. (2008) Structural Analysis of 
the Contacts Anchoring Moenomycin to Peptidoglycan Glycosyltransferases and Implications 
for Antibiotic Design ACS Chem Biol 7 p429 
 
Zhang Y, Bao Q, Gagnon LA, Huletsky A, Oliver A, Jin S, Langaee T. (2010) ampG gene of 
Pseudomonas aeruginosa and its role in β-lactamase expression. Antimicrob Agents Chemother. 
54 pp4772–4779 
 
 
 
 
